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Summary 
 
The success of the pathogen Staphylococcus aureus lies in its array of virulence 
determinants, which enable pathogenesis. The recent identification of novel S. aureus 
virulence determinants led to the hypothesis that there are more to be found.  
 
In silico analysis of the S. aureus genome identified three staphylococcal superantigen-
like proteins (SSL12, SSL13 & SSL14), incorrectly annotated in the genome database 
as hypothetical proteins. Production of recombinant SSL12, 13 & 14 proteins gave a 
low yield of soluble protein, which precluded biochemical analysis. A genetic approach 
was taken and a triple gene deletion mutant constructed. No role for the 3 SSLs was 
found in an in vivo infection model, or in in vitro phagocytosis assays. However, a 
subtle reduction in growth in human blood, associated with the cellular component of 
blood was seen when compared with the wild-type.  
 
A genome-wide library of 1,920 strains each with a separate gene disrupted by a 
transposon (Tn) insertion was screened on human blood agar. Both the purine (purA and 
purB) and tetrahydrofolate (THF; pabA) synthesis pathways were found to be important 
for growth on human blood, but, in the case of the pabA disrupted strain, not on human 
plasma. THF is a single carbon donor/acceptor in many S. aureus biosynthesis 
pathways, and its synthesis is the target of sulphonamide antibiotics. The human blood 
phenotype for pabA was linked to dTTP synthesis, which is formed via a THF-
dependent pathway, or a THF-independent pathway requiring the enzyme Tdk. As the 
pabA mutant can grow on human plasma it was hypothesised that Tdk is inhibited by a 
factor in the cellular component of blood, which leads to a requirement for dTTP. This 
suggests that the activity of sulphonamide drugs is the result of inhibition of THF 
coupled with the inhibition of Tdk by an as yet unknown factor present in human blood. 
 
 
 
 
 
 
 
 
v 
 
This thesis is dedicate to my wife  
for her love and patience 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Acknowledgements 
 
I would like to thank my supervisors, Professor Simon Foster and Professor Moira 
Whyte for their support, guidance and encouragement throughout my PhD. I would like 
to thank the staff at The Royal Hallamshire Hospital, including Dr David Sammut, Dr 
Jennifer Carling-Wright and Vanessa Singleton for their help with phlebotomy. 
Particular thanks go to Dr Lynne Prince for her patient assistance with all things 
neutrophil related. I would like to thank all members past and present from the Foster 
lab including Jorge, Stephane, Felix, Alex, Beatriz, Kasia, Kathrine, Amy and Richard. 
I would also like to show my gratitude to the blood donors for making this work 
possible. Several people from the lab have aided me in accomplishing this work, 
including the fish people, Tomasz Prajsnar, Alex Williams and Gaz McVicker. I would 
like to acknowledge the very talented Dr Emma Johnson for technical advice and 
assistance. 
 
I would like to express particular thanks to my mum for her support, encouragement and 
love. This work would not have been possible without you and our walks together. I 
would also like to thank my dad and my brothers for their love and support. Separate 
thanks go to Phil for igniting my interest in science, something I will be forever grateful 
for. Thanks go to my aunt Bet, for her love and support and for her understanding when 
my visits were so rare. Special thanks go to my wife, Jacqueline, for her support and 
love and also for putting up with me throughout the writing of this thesis and in general. 
Lastly, a special dedication goes to my amazing kids for your patience when I have been 
too busy to pay you as much attention as I would have liked. 
 
This work was funded by The University of Sheffield. 
 
 
 
 
 
 
 
 
 
ix 
 
Abbreviations 
 
6-His Hexahistidine 
ABC ATP binding cassette 
ADC 4-amino-4-deoxychorismate 
AFS Ammonium ferrous sulphate 
AG Adenine and guanine 
AICAIR 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide 
AIP Autoinducing peptide 
AIR 5-amino-1-(5-phospho- -D-ribosyl)imidazole 
Amp Ampicillin 
AMPs Antimicrobial peptides 
APC Antigen presenting cell 
APS Ammonium persulphate 
attB Attachement site in the bacterial genome 
attP Attachment site in the phage genome 
BCIP 5-bromo-5-chloro-3-indolyl phosphate 
BHI Brain heart infusion 
BLAST Basic local alignment search tool 
bp Base pair 
CA Community acquired 
CAIR 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate 
Cat Chloramphenicol 
CDM Chemically defined media 
CDS Coding sequence 
CFU Colony forming unit 
CIP Calf intestinal alkaline phosphatase 
CNS Coagulase negative staphylococci 
CPS Coagulase positive staphylococci 
CVS Coagulase variable staphylococci 
DF Downstream fragment 
DHF Dihydrofolate 
DIG Digoxigenin 
DMF N,N-dimethylformamide 
DMSO Dimethyl sulphoxide 
dpf Days post fertilisation 
EB Elution buffer 
ECM Extracellular matrix 
EDTA Ethylenediamine tetra-acetic acid 
Ery Erythromycin 
ETs Enterotoxins 
FA Folic acid 
Fab Fragment antigen binding 
FAICAIR 5-formamido-1-(5-phospho-D-ribosyl)-imidazole-4-carboxamide 
FBS Foetal bovine serum 
Fc Fragment crystallisable 
FGAM 2-(formamido)-N1-(5-phospho- -D-ribosyl)acetamidine 
FGAR N2-formyl-N1-(5-phospho- -D-ribosyl)glycinamide 
FSc Forward scatter 
GAR N1-(5-phospho- -D-ribosyl)glycinamide 
HBSS Hanks balance salts solution 
x 
 
hpi Hours post infection 
IL-8 Interleukin 8 
IMP Inosine monophosphate 
IPTG  , V R S U R S \ O -D-1-thiogalactopyranoside 
IVET In vitro expression technology 
Kan Kanamycin 
LB Luria-Bertani 
LWT London wild-type 
M Molar 
MCS Multiple cloning site 
Met Methionine 
MHC Major histocompatibility complex 
MIC Minimum inhibitory concentration 
MOI Multiplicity of infection 
MRSA Methicillin resistant Staphylococcus aureus 
MSA Multiple sequence alignment 
MSCRAMM Microbial surface components recognising adhesive matrix molecules 
N5-CAIR N5-carboxyaminoimidazole ribonucleotide 
NARSA Network on Antimicrobial Resistance in Staphylococcus aureus 
NCBI National Centre for Biotechnology Information 
Neo Neomycin 
NETs Neutrophil extracellular traps 
NGS Next-generation sequencing 
Nr Non-redundant 
NTML Nebraska transposon mutagenesis library 
OD600 Optical density at 600 nm 
ORF Open reading frame 
PAMPs Pathogen associated molecular patterns 
PATRIC Pathosystems Resource Integration Centre 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFU Plaque forming units 
PI Phagocytic index 
PK Proteinase K 
PPP Platelet poor plasma 
(p)ppGpp Guanosine tetraphosphate; Guanosine pentaphosphate 
PRA 5-phospho- -D-ribosylamine 
PRP Platelet rich plasma 
PRPP 5-phospho- -D-ribose 1-diphosphate 
PRR Pattern recognition receptors 
psi Pounds per square inch 
RBC Red blood cell 
rpm Revolutions per minute 
SAF Staphylococcus aureus factor 
SAgs Superantigens 
SAICAIR 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole 
SCOTS Selective capture of transcribed sequences 
SCVs Small colony variants 
SDS-PAGE Sodium dodecyl polyacrylamide gel electrophoresis 
SNPs Single nucleotide polymorphism 
Spec Spectinomycin 
xi 
 
SS Signal sequence 
SSLs Staphylococcal superantigen-like protein 
STM Signature-tagged mutagenesis 
TAE Tris/acetate/EDTA 
TCA Tricarboxylic acid cycle 
TCR T-cell receptor 
TCS Two-component system 
TEMED N,N,N  ¶N  ¶-tetramethyl-ethylenediamine 
Tet Tetracycline 
THF Tetrahydrofolate 
TLR Toll-like receptor 
TMP Trimethoprim 
Tn Transposon 
 7 1 ).  Tumour necrosis factor alpha 
TSS Toxic shock syndrome 
UF Upstream fragment 
UV Ultraviolet 
v/v Volume for volume 
VF Virulence factor 
VitB5 Vitamin B5 
w/v Weight for volume 
-  Phage 
1 Sigma factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
Table of Contents 
 
Page number 
Title page i 
  
Summary iii 
  
Dedication v 
  
Acknowledgments vii 
  
Abbreviations ix 
  
Table of contents xiii 
  
List of figures xxi 
  
List of tables xxv 
  
  
Chapter 1: Introduction 
1- 
40 
1.1 The staphylococci 1 
1.2 Staphylococcus aureus 2 
1.2.1 S. aureus as a public health issue 2 
1.3 Virulence determinants and their genetic control 3 
1.3.1 Regulation of virulence early in infection 5 
1.3.1.1 The Fur and SaeRS regulators 5 
1.3.1.2 Repressor of toxins (rot) and other sar family members 9 
1.4 Virulence factors associated with early infection 10 
1.4.1 Adhesins 10 
1.4.1.1 Roles of adhesins in disease and colonisation 12 
1.4.1.2 Adhesins as immune evasion proteins 13 
1.4.2 Immune evasion 14 
1.5 Regulation of virulence determinants late in infection 17 
1.5.1 Destructive acquisition of nutrients 18 
1.5.2  $ O W H U Q D W L Y H  V L J P D  I D F W R U  %  1B) 20 
1.6 Virulence factors associated with late infection 21 
1.6.1 Degradative enzymes 21 
1.6.2 Secreted toxins 22 
1.6.2.1 Exfoliative toxins 23 
1.6.2.2 Enterotoxins/superantigens 23 
1.6.2.2.1 Food poisoning 23 
1.6.2.2.2 Toxic shock syndrome 24 
1.6.2.3 Haemolysins 25 
1.6.2.4 Two-component leukotoxins 26 
1.6.2.5 Phenol soluble modulins (PSMs) 27 
1.7 Regulators associated with specific environmental stimuli 27 
1.7.1 The graRS TCS 27 
1.7.2 The srrAB TCS 28 
1.8 Methods in analysis of virulence factors 29 
xiv 
 
1.8.1 Characterisation of individual virulence factors in vitro and in vivo 29 
1.8.2 Identification of virulence factors by in silico analysis 30 
1.8.3 Selective capture of transcribed sequences (SCOTS) 31  
1.8.4 In vivo expression technology (IVET) 31  
1.8.5 Signature-tagged mutagenesis (STM) 35  
1.8.6 S. aureus specific problems associated with STM and IVET 37 
1.9 Rationale and objectives 38 
  
  
Chapter 2 Materials and Methods 
41- 
84 
2.1 Media 41 
2.1.1 Baird-Parker agar 41 
2.1.2 Brain heart infusion (BHI) 41 
2.1.3 Blood and blood component agar 41 
2.1.3.1 Preparation of blood components 41 
2.1.3.1.1 Human blood collection 41 
2.1.3.1.2 Human plasma preparation 42 
2.1.3.1.3 Human serum preparation 42 
2.1.3.1.4 Non-human blood products 42 
2.1.3.2 Serum or plasma agar (50%) 42 
2.1.3.3 Human or non-human blood agar (30%) 42 
2.1.3.4 RBC homogenate agar (30%) 43 
2.1.3.5 Sheep blood agar (5%) 43 
2.1.4 Chemically defined media (CDM) 43 
2.1.4.1 CDM Solution 1 44 
2.1.4.2 CDM Solution 2 (1000x) 44 
2.1.4.3 CDM Solution 3 44 
2.1.4.4 CDM Solution 4 45 
2.1.4.5 CDM Solution 5 45 
2.1.5 Luria-Bertani media (LB) 45 
2.1.6 LK media 45 
2.1.7 RPMI-1640 media 45 
2.1.8 Tryptic soy broth 46 
2.2 Antibiotics 46 
2.3 Bacterial strains, plasmids and bacteriophage 46 
2.3.1 Maintenance, storage and culture of bacteria 46 
2.3.2 S. aureus strains 46 
2.3.3 E. coli strains 50 
2.3.4 Plasmids 50 
2.3.5 Bacteriophage 51 
2.4 Enzymes and chemicals 51 
2.5 Buffers and stock solutions 51 
2.5.1 Amino acid stock solutions 51 
2.5.2 DNA loading buffer (6x)  52 
2.5.3 Phosphate buffered saline (PBS) 52 
2.5.4 TAE (50x) 52 
2.5.5 Recombinant protein refolding buffers 52 
2.5.5.1 L-Arginine base refolding buffer (880 mM)  52 
2.5.5.2 50 mM L-Arginine, L-Glutamic acid base refolding buffer (50 
mM) 53 
xv 
 
2.5.6 E3 solution (10x) 53 
2.5.7 Methylcellulose 53 
2.5.8 HiTrap    column buffers 54 
2.5.8.1 START buffer 54 
2.5.8.2 Elution buffer 54 
2.5.9 Phage buffer 54 
2.5.10 QIAGEN buffers 54 
2.5.10.1 QIAGEN Buffer P1 54 
2.5.10.2 QIAGEN Buffer P2 54 
2.5.10.3 QIAGEN Buffer P3 55 
2.5.10.4 QIAGEN Buffer EB 55 
2.5.10.5 QIAGEN Buffer N3, QG, PB and PE 55 
2.5.11 SDS-PAGE solutions 55 
2.5.11.1 SDS-PAGE reservoir buffer (10x) 55 
2.5.11.2 SDS-PAGE loading buffer (2x)  55 
2.5.11.3 Coomassie Blue staining solution 55 
2.5.11.4 Destain solution 56 
2.5.12 Southern blotting buffers and solutions 56 
2.5.12.1 Depurination solution 56 
2.5.12.2 Denaturing buffer 56 
2.5.12.3 Neutralising buffer 56 
2.5.12.4 SSC (20x) 56 
2.5.12.5 Pre-hybridisation solution 56 
2.5.12.6 Hybridisation solution 57 
2.5.12.7 Wash solution (2x) 57 
2.5.12.8 Wash solution (0.5x) 57 
2.5.12.9 Maleic acid buffer 57 
2.5.12.10 Washing buffer 57 
2.5.12.11 Blocking solution 57 
2.5.12.12 Antibody solution 58 
2.5.12.13 Detection buffer 58 
2.5.12.14 TE buffer 58 
2.6 Determining bacterial cell density 58 
2.6.1 Spectrophotometric measurement (OD600) 58 
2.6.2 Direct cell counts (CFU) 58 
2.7 Centrifugation 59 
2.8 Growth curves 59 
2.9 Transformation techniques 60 
2.9.1 Transformation of E. coli  60 
2.9.1.1 Preparation of E. coli electrocompetent cells 60 
2.9.1.2 Transformation of E. coli electrocompetent cells 60 
2.9.2 Transformation of S. aureus 60 
2.9.2.1 Preparation of S. aureus electrocompetent cells  60 
2.9.2.2 Transformation of S. aureus by electroporation 61 
2.10 Phage techniques 61 
2.10.1 Preparation of phage lysates 61 
2.10.2 Determination of phage titres 61 
2.10.3 Phage transduction 62 
2.11 DNA purification techniques 62 
2.11.1 Gel extraction (Qiaquick) 62 
2.11.2 PCR purification (Qiaquick) 63 
xvi 
 
2.11.3 Genomic DNA preparation 63 
2.11.4 Plasmid preparation 64 
2.11.5 Ethanol precipitation of DNA 64 
2.12 In vitro DNA manipulation techniques 64 
2.12.1 Polymerase chain reaction (PCR) techniques 64 
2.12.1.1 Primer design 64 
2.12.1.2 PCR amplification 68 
2.12.1.2.1 Taq polymerase 68 
2.12.1.2.2 Phusion polymerase 69 
2.12.1.3 E. coli colony PCR 70 
2.12.2 Restriction endonuclease digestion 70 
2.12.3 Alkaline phosphatase treatment of vector DNA 70 
2.12.4 DNA ligation 70 
2.12.5 Agarose gel electrophoresis 71 
2.12.6 Plasmid sequencing 71 
2.13 Southern blotting 71 
2.13.1 Labelling of DNA probes with digoxigenin 72 
2.13.2 Quantification of DIG-labelled DNA probes 72 
2.13.3 Membrane blotting 72 
2.13.4 Fixing the DNA to the membrane 73 
2.13.5 Pre-hybridisation and hybridisation 73 
2.13.6 Colorimetric detection of DIG-labelled DNA 73 
2.14 Protein analysis 75 
2.14.1 SDS-PAGE 75 
2.14.2 Coomassie staining 76 
2.14.3 Drying gels 76 
2.15 Recombinant protein production 76 
2.15.1 Expression of recombinant proteins in E. coli BL21 76 
2.15.2 Analysis of recombinant protein solubility 77 
2.15.3 Separation of soluble and insoluble material 77 
2.15.4 Protein purification using HiTrap    column 77 
2.15.5 Protein dialysis 78 
2.15.5.1 Preparation of dialysis membrane 78 
2.15.5.2 Dialysis of recombinant protein 78 
2.16 Protein refolding by drip dilution 79 
2.17 Determining minimum inhibitory concentration (MIC) 79 
2.18 Flow cytometry analysis of neutrophil necrosis 79 
2.18.1 Neutrophil preparation 79 
2.18.2 Bacterial supernatant 80 
2.18.3 Neutrophil necrosis by S. aureus supernatant 80 
2.18.4 Flow cytometric analysis of necrosis 81 
2.18.5 Quantification of absolute neutrophil number 81 
2.19 Phagocytic index (PI) determination 81 
2.19.1 Co-culture of neutrophils and S. aureus 81 
2.19.2 Neutrophil fixation and PI calculation 82 
2.20 Whole human blood growth assay 82 
2.21 Human plasma growth assay 83 
2.22 Screening the Nebraska transposon mutagenesis library (NTML) 
on solid media 83 
2.23 Zebrafish embryo assay techniques 83 
2.23.1 Zebrafish strain 83 
xvii 
 
2.23.2 Zebrafish husbandry 83 
2.23.3 Zebrafish anaesthesia 83 
2.23.4 Microinjection of S. aureus into zebrafish embryos 84 
2.23.5 Assessment of zebrafish embryo mortality post-infection 84 
2.23.6 Determination of S. aureus growth in vivo 84 
2.23.7 Statistical analysis 84 
  
  
Chapter 3 The Search For Novel Staphylococcal Virulence Factors 
85-
162 
3.1 Introduction 85 
3.2 Results 87 
3.2.1 Is SAF an S. aureus leukotoxin? 87 
3.2.1.1 Construction of the S. aureus leukotoxin database 88 
3.2.1.2 Construction of the non-S. aureus leukotoxin database 88 
3.2.1.3 Homology search of the 645 S. aureus hypothetical proteins 90 
3.2.2 Characterisation of SAF  90 
3.2.2.1 Confirmation that SAF is a protein 93 
3.2.2.2 Growth curve of S. aureus Newman lukAB 95 
3.2.2.3 Is SAF LukAB? 95 
3.2.3 Analysis of the S. aureus genome for further novel toxins 97 
3.2.3.1 Construction of a database of known virulence factors 97 
3.2.3.2 BLAST search of the 138,811 sequence database 99 
3.2.3.3 Removing redundancy with CD-HIT and Perl 102 
3.2.3.4 BLAST of the 53,032 sequence database 102 
3.2.3.5 Removal of all non-virulence factor sequences from the non-
redundant database 105 
3.2.3.6 Analysis of all S. aureus protein sequences using the VF database 105 
3.2.3.6.1 BLAST search of the VF database using the 645 hypothetical 
proteins 106 
3.2.3.6.2 BLAST search of the VF database using the 2,110 S. aureus known 
function sequences 106 
3.2.3.7 CD-HIT clustering method 109 
3.2.3.8 Construction of a Non-redundant (Nr) Bacterial Database 109 
3.2.3.8.1 Query of Nr Bacterial Database with the 645 hypothetical protein 
sequences of S. aureus 110 
3.2.3.8.2 Query of bacterial database using 2,110 known function protein 
sequences 110 
3.2.4 Identifying the putative virulence factors 114 
3.2.4.1 Are the remaining hypothetical proteins exotoxins or SSLs? 116 
3.2.5 Characterisation of SSL12, SSL13 & SSL14 119 
3.2.5.1 The pET21d protein expression system 119 
3.2.5.2 SSL12, SSL13 & SSL14 pET21d plasmid constructs 119 
3.2.5.3 Protein overexpression of SSL12, 13 & 14 in E. coli BL21 121 
3.2.5.4 Effect of induction temperature and induction time on solubility 124 
3.2.5.5 Overexpression of the SSLs at 30
o
C in a 3 litre culture 124 
3.2.5.6 Overexpression of the SSLs at 30
o
C in 4 x 250 ml cultures 128 
3.2.5.7 Purification of insoluble SSL12, 13, 14 protein in the presence of 
8M urea 128 
3.2.5.8 Refolding of protein samples by stepwise dialysis 128 
3.2.5.9 Refolding protein by dilution in the presence of L-Arg 131 
xviii 
 
3.2.5.10 Refolding protein by dilution in the presence of L-Arg and L-Glu 133  
3.2.5.11 Construction of the SSL triplet deletion plasmid  136 
3.2.5.12 Deletion of the SSL triplet from S. aureus NewHG 139 
3.2.5.13  * U R Z W K  F K D U D F W H U L V W L F V  R I  1 H Z + *ß 6 6 / 143 
3.2.5.14  = H E U D I L V K  P R G H O  R I  V \ V W H P L F  L Q I H F W L R Q  D Q D O \ V L V  R I  1 H Z + *ß 6 6 / 143 
3.2.5.15  $ Q D O \ V L V  R I  J U R Z W K  R I  1 H Z + *ß 6 6 /  L Q  Z K R O H  K X P D Q  E O R R G 146 
3.2.5.16  $ Q D O \ V L V  R I  J U R Z W K  R I  1 H Z + *ß 6 6 / in human plasma 146 
3.2.5.17 Complementation of the SSL triplet with pGM073 plasmid system 148 
3.2.5.18 Integration of pJC001 into S. aureus RN4220 150 
3.2.5.19 Whole blood growth is restored in the complemented strain 153  
3.2.5.20 Do the SSLs affect neutrophil phagocytosis of S. aureus NewHG? 153 
3.2.5.21 Analysis of neutrophil integrity in response to NewHG and 
 1 H Z + *ß 6 6 /  V X S H U Q D W D Q W 156 
3.3 Discussion 158 
  
  
Chapter 4 Identification of S. aureus Components Involved in the    
                  Interaction with Human Blood  
163-
212 
4.1 Introduction 163 
4.2 Results 169 
4.2.1 Bioinformatic analysis of the NTML hypothetical protein sequences 169 
4.2.1.1 Identification of novel virulence determinants in the NTML by 
BLAST search of the VF database  169 
4.2.1.2 Identification of novel virulence determinants in the NTML by 
BLAST search of the non-redundant database 173 
4.2.2 Preparation for the NTML library screen 176 
4.2.2.1 Deconvolution of the NTML library 176 
4.2.2.2 Determining suitable media for the NTML screen 178 
4.2.3 Screening the NTML library 180 
4.2.3.1 Preliminary screen 180 
4.2.3.2 Screening of the NTML library on human blood, bovine serum and 
sheep blood + Columbia agar 183 
4.2.4 Confirmation of the NTML screen results 183 
4.2.4.1 Repeat screening of altered phenotype strains 183 
4.2.4.2 Transduction of Tn inserts into JE2 and SH1000 190 
4.2.4.2.1 Confirmation of successful transduction 193  
4.2.4.3 Is the JE2 phenotype linked to the Tn insertion? 193 
4.2.5 Species specificity of JE2-pabA phenotype 200 
4.2.6 Bioinformatic analysis of the 9 strains of interest 202 
4.3 Discussion 208 
  
  
Chapter 5 Characterisation of the Role of Genes Required for Growth on  
                  Human Blood 
213-
312 
5.1 Introduction 213 
5.2 Results 214 
5.2.1 Effect of Tn insertion in the 9 strains isolated from the NTML 214 
5.2.2 Analysis of the role of purA and purB in S. aureus growth 217 
5.2.3 Analysis of the purA and purB genes 217 
5.2.4 Analysis of bacterial population dynamics of purA & purB in the 
zebrafish embryo model of systemic infection 220 
xix 
 
5.2.4.1 Growth of SH-purB and SH-purA in vivo 220 
5.2.4.2 The effect of purines on SH-purA and SH-purB in vivo 222 
5.2.4.3 The effect of purines on JE2-purA and JE2-purB growth 224  
5.2.5 Analysis of the role of pabA 229 
5.2.5.1 Growth assays of JE2-pabA 229 
5.2.5.2 Why does NE821 grow poorly on blood, but not on serum? 231 
5.2.5.3 Serum concentration 233 
5.2.6 Analysis of the pab operon 233 
5.2.7 Preliminary analysis of the pab operon with the zebrafish embryo 
model of systemic infection 236 
5.2.7.1 Analysis of SH-pabB and SH-pabC pathogenicity 236 
5.2.7.2 Growth of SH-pabA in vivo 236 
5.2.7.3 The effect of folic acid on SH-pabA 236 
5.2.7.4 The effect of inosine on SH-pabA in vivo 240 
5.2.8 Analysis of pabA on CDM agar 240 
5.2.8.1 Growth of JE2-pabA on CDM agar 240 
5.2.8.2 Role of purine availability in growth of JE2-pabA 242 
5.2.8.3 The effect of glycine, serine & folic acid on JE2-pabA growth 245 
5.2.8.4 The effect of 4-aminobenzoic acid (PABA) on growth of JE2-pabA 248 
5.2.8.5 Role of PABA, serine and glycine in SH-pabA pathogenicity 251 
5.2.8.6 The role of glycine and serine in the growth of JE2-pabA 251 
5.2.8.7 Role of GlyA in virulence 257 
5.2.8.8 The role of serine, glycine, methionine & VitB5 on growth of JE2-
pabA 259 
5.2.8.9 The effect of methionine & thymine on JE2-pabA growth 262 
5.2.8.10 Role of serine, glycine, methionine & VitB5 in SH-pabA 
pathogenicity 262 
5.2.8.11 PABA complementation is associated with the pab operon 267 
5.2.9 Liquid CDM growth analysis of pabA 267 
5.2.9.1 Are purines required for full growth of JE2-pabA in CDM? 270 
5.2.9.2 Liquid CDM growth experiments 270 
5.2.9.3 Analysis of the relative importance of serine, glycine and purines to 
JE2-pabA growth 274 
5.2.9.4 Analysis of trimethoprim activity in the presence of VitB5  277 
5.2.10 Effect of inosine on SH-pabA in vivo 279 
5.2.11 Role of pabA in growth on human blood 279 
5.2.11.1 Analysis of JE2-pabA growth on human blood plus purines, glycine 
or serine 279 
5.2.11.2 Analysis of JE2-pabA growth on human blood plus methionine, 
VitB5 or thymine 282 
5.2.12 Is the JE2-pabA phenotype on human blood the result of inhibition? 282 
5.2.13 Genetic complementation of the pab operon 286 
5.2.13.1 Construction of the lipase integration plasmid pJC002 286 
5.2.13.2 Integration of pJC002 into S. aureus RN4220 288 
5.2.13.3 Analysis of the genetically complemented JE2-pabA in vitro 291 
5.2.13.4 Analysis of the genetically complemented SH-pabA in vivo 291 
5.2.14 Effect of thymidine on SH-pabA virulence 294 
5.2.15 The effect of homogenised RBCs on JE2-pabA growth 296 
5.2.16 Analysis of JE2-pabA inhibition by blood 298 
5.2.16.1 The effect of platelets on JE2-pabA growth 298 
5.2.16.2 The effect of Fe
2+
 conc. on JE2-pabA growth 298 
xx 
 
5.2.16.3 The effect of bovine haemin on JE2-pabA growth 301 
5.2.16.4 The effect of bovine haemoglobin on JE2-pabA growth 301 
5.3 Discussion 304 
5.3.1 Analysis of purA & purB 304 
5.3.2 Analysis of pabA 306 
5.3.3 The ongoing analysis of pabA 309 
5.3.4 Future work 310 
  
  
Chapter 6 General Discussion 
313-
320 
6.1 Introduction 313 
6.2 What is a virulence factor? 313 
6.2.1  9 ) V  D U H  D  E D F W H U L X P ¶ V  U H V S R Q V H  W R  L W V  H Q Y L U R Q P H Q W 314 
6.3 Success of S. aureus as a pathogen 315 
6.4 The bioinformatics toolbox 315 
6.5 Strain libraries as tools for virulence studies 317 
6.6 What is known about virulence determinants in vivo? 317 
6.7 Future directions 318 
  
  
References 
321-
350 
  
  
List of Appendices 351 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
List of Figures 
 
Figure 1.1 Representative virulence determinants of S. aureus 4 
Figure 1.2 The accessory gene regulator (agr) system of S. aureus 19 
Figure 1.3 Representation of the selective capture of transcribed sequences 
(SCOTS) methodology 32 
Figure 1.4 Representation of the in vivo expression technology (IVET) 
methodology 33 
Figure 1.5 Representation of the signature-tagged mutagenesis (STM) 
methodology 36 
   
   
Figure 2.1 Capillary transfer of DNA to nylon membranes 74 
   
   
Figure 3.1 Construction of the S. aureus (A) and non-S. aureus (B) leukotoxin 
databases, shown diagrammatically 89 
Figure 3.2 Homology search for SAF shown diagrammatically 91 
Figure 3.3 Flow cytometry assay of neutrophil necrosis, shown 
diagrammatically 92 
Figure 3.4 Flow cytometry analysis of neutrophil killing by S. aureus 
supernatant 94 
Figure 3.5 The role of lukAB in the growth of S. aureus 96 
Figure 3.6 The role of LukAB in neutrophil necrosis 98 
Figure 3.7 Homology search of the 138,811 sequences database for novel 
toxins within the 645 S. aureus hypothetical proteins, shown 
diagrammatically 100 
Figure 3.8 Homology search of the 53,032 sequences non-redundant database 
for novel toxins within the S. aureus hypothetical proteins, shown 
diagrammatically 103 
Figure 3.9 Construction and search of the Nr Bacterial Database, shown 
diagrammatically 111 
Figure 3.10 Confirmation that hypothetical proteins SAOUHSC_00191 and 
SAOUHSC_01112 are known function proteins 115 
Figure 3.11 Position of SSLs on the S. aureus 8325 genome 118 
Figure 3.12 Representative construction of the pSSL plasmids 120 
Figure 3.13 Confirmation of correct construct insert sizes for recombinant SSL 
production 122 
Figure 3.14 Overexpression and solubility of SSL12, 13 & 14 123 
Figure 3.15 Effect of temperature on SSL solubility 125 
Figure 3.16 Overexpression of SSLs at 30
o
C using a higher culture volume 127 
Figure 3.17 Overexpression of SSLs at 30
o
C using multiple low volume 
cultures 129 
Figure 3.18 Purification of urea solubilised SSL protein and elution into 
separate 1 ml samples 130 
Figure 3.19 Solubilisation of recombinant SSL protein using 880 mM L-Arg 132 
Figure 3.20 Solubilisation of recombinant SSL protein using 88 mM L-Arg 134  
Figure 3.21 Solubilisation of recombinant SSL protein using L-Arg and L-Glu 135 
Figure 3.22 Construction of the SSL deletion plasmid 137  
Figure 3.23 Confirmation of successful construction of the SSL deletion 
plasmid 138 
xxii 
 
Figure 3.24 Deletion of the SSL triplet shown diagrammatically 140 
Figure 3.25 Confirmation of deletion of the SSL triplet from S. aureus NewHG 142 
Figure 3.26 Role of SSL12, 13 & 14 in S. aureus growth 144 
Figure 3.27 Role of the SSL triplet in pathogenesis in the zebrafish embryo 
model 145  
Figure 3.28 Analysis of the role of the SSL triplet in growth in human blood 147 
Figure 3.29 Analysis of the role of the SSL triplet in growth in human plasma 147 
Figure 3.30 Construction of the complementation plasmid pJC001 149 
Figure 3.31 Site specific integration of pJC001 at the geh gene of S. aureus 
RN4220 151 
Figure 3.32 Confirming pJC001 integration into RN4220 by analysis of geh 
activity and confirmation of pJC001 & pKasbar transduction into 
the wild-type strains, SH-pabA and JE2-pabA by PCR 152 
Figure 3.33  * H Q H W L F  F R P S O H P H Q W D W L R Q  R I  W K H  1 H Z + *ß 6 6 /  S K H Q R W \ S H  L Q  K X P D Q 
blood 154 
Figure 3.34 Analysis of the role of SSLs in phagocytosis of S. aureus by 
neutrophils 155 
Figure 3.35 Analysis of the role of SSLs in neutrophil necrosis 157 
   
   
Figure 4.1 Identification of essential genes by genetic fingerprinting 166 
Figure 4.2 Construction of the NTML shown diagrammatically 167 
Figure 4.3 BLAST query of the VF database with the 44 NTML sequences, 
shown diagrammatically 171 
Figure 4.4 Construction and BLAST search of the non-redundant database, 
shown diagrammatically 174 
Figure 4.5 Deconvolution of the NTML 177 
Figure 4.6 Determination of the correct blood/serum concentrations to be used 
for the NTML screen 179 
Figure 4.7 Establishment of conditions required for the NTML screen 181 
Figure 4.8 Example plates from the preliminary screen for resistance to ery/lin 182 
Figure 4.9 Identification of mutants with altered growth, morphology or 
haemolysis on sheep blood + Columbia agar 184 
Figure 4.10 Identification of mutants with altered growth or morphology on 
bovine serum agar 185 
Figure 4.11 Identification of mutants with altered growth, morphology or 
haemolysis on human blood agar 186 
Figure 4.12 Repeat screening for mutant phenotypes 187 
Figure 4.13 Growth and haemolysis of different strains of S. aureus on human 
blood agar 191 
Figure 4.14 Diagram of the transduction of the Tn from the 46 NTML screen 
results into SH1000 and JE2 192 
Figure 4.15 Diagram showing how primers were designed to confirm Tn 
insertion by transduction 194 
Figure 4.16 Demonstration of Tn insertion site in transductants 195 
Figure 4.17 Phenotype of transductants on blood agar plates 198 
Figure 4.18 Growth analysis of JE2-pabA on sheep and horse blood agar 201 
Figure 4.19 Diagram of the methods employed to acquire information on each 
of the nine Tn inserted genes 
 
203 
Figure 4.20 Tn insertion position and surrounding genes for each of the 9 genes 
of interest 205 
xxiii 
 
Figure 5.1 The roles of THF in S. aureus metabolism 215 
Figure 5.2 Role of the isolated NTML mutants in pathogenesis in the zebrafish 
embryo model 216    
Figure 5.3 Role of purA and purB in S. aureus growth 218 
Figure 5.4 Purine de novo biosynthesis pathway 219 
Figure 5.5 Proliferation of SH-purA, SH-purB and SH1000 within zebrafish 
embryos 221 
Figure 5.6 Effect of adenine on SH-purA and SH-purB virulence 223 
Figure 5.7 Effect of adenine and inosine on SH-purB virulence 223 
Figure 5.8 Role of adenine and guanine in the growth of JE2-purA and JE2-
purB on solid media 225 
Figure 5.9 Role of adenine, guanine and inosine in the growth of JE2-purA 
and JE2-purB on solid media 228 
Figure 5.10 Role of pabA in S. aureus growth 230 
Figure 5.11 Growth of JE2-pabA on different human blood components 232 
Figure 5.12 Growth of JE2-pabA on human plasma 234 
Figure 5.13 Folate biosynthesis pathway 235 
Figure 5.14 Role of pabB and pabC in virulence 237 
Figure 5.15 Proliferation of SH-pabA within zebrafish embryos 238 
Figure 5.16 Effect of 50 µM folic acid on SH-purB virulence 239 
Figure 5.17 Effect of inosine on SH-pabA virulence 241 
Figure 5.18 Growth of JE2-pabA on CDM agar 243 
Figure 5.19 Role of purines in the growth of JE2-pabA and JE2 244 
Figure 5.20 Role of glycine, serine, folic acid and purines (AG) in the growth of 
JE2-pabA and JE2 246 
Figure 5.21 Role of glycine, serine, PABA and purines (AG) in the growth of 
JE2-pabA and JE2 249 
Figure 5.22 Effect of glycine, serine and PABA on SH-pabA virulence 252 
Figure 5.23 Diagrammatic representation of serine/glycine interconversion 253 
Figure 5.24 Role of 10x CDM concentration of glycine or serine, and 1x CDM 
concentration of glycine and serine in the growth of JE2-pabA and 
JE2 255 
Figure 5.25 Role of glyA in S. aureus pathogenesis in the zebrafish embryo 
model 258 
Figure 5.26 Role of glycine, serine, vitamin B5 and methionine in the growth of 
JE2-pabA and JE2 260 
Figure 5.27 Role of methionine and thymine in the growth of JE2-pabA and JE2 263 
Figure 5.28 Effect of addition of glycine, serine, methionine and vitamin B5 on 
SH-pabA virulence 265 
Figure 5.29  ( I I H F W  R I  D G G L W L R Q  R I  3 $ % $  R Q  1 H Z + *ßphePßsaeR pathogenesis 268 
Figure 5.30 Importance of purines to JE2-pabA growth 271 
Figure 5.31 Liquid CDM analysis of JE2-pabA growth 272 
Figure 5.32 Analysis of the JE2-pabA phenotype in liquid CDM 275 
Figure 5.33 Analysis of the effect of VitB5 concentration on trimethoprim 
activity 278 
Figure 5.34 Effect of inosine on SH-pabA virulence 280 
Figure 5.35 Analysis of the growth of JE2-pabA on human blood with various 
supplements 281 
Figure 5.36 Analysis of methionine, VitB5 and thymine on JE2-pabA growth on 
human blood 283 
Figure 5.37 Inhibition of JE2-pabA by plasma from vortexed blood 285 
xxiv 
 
Figure 5.38 Construction of the complementation plasmid pJC002 287 
Figure 5.39 Site specific integration of pJC002 at the geh gene of S. aureus 
RN4220 289 
Figure 5.40 Confirming pJC002 integration into RN4220 by analysis of geh 
activity and confirmation of pJC002 & pKasbar transduction into 
the wild-type strains, SH-pabA and JE2-pabA by PCR 290 
Figure 5.41 Growth of genetically complemented strains on 30% (v/v) human 
blood agar 292 
Figure 5.42 In vivo analysis of the genetically complemented strains 293 
Figure 5.43 Thymidine monophosphate biosynthesis in S. aureus 295 
Figure 5.44 Analysis of the effect of RBC homogenate and thymine on the 
growth of JE2-pabA 297 
Figure 5.45 Analysis of the effect of clotting factors on JE2-pabA growth 299 
Figure 5.46 Analysis of Fe concentration on the growth of JE2-pabA on RBC 
homogenate 300 
Figure 5.47 Analysis of the effect of bovine haemin on the JE2-pabA growth 
phenotype 302 
Figure 5.48 Analysis of the effect of bovine haemoglobin on the JE2-pabA 
growth phenotype 303 
Figure 5.49 Diagram of the analysis of the purA and purB genes 305 
Figure 5.50 Analysis of pabA shown diagrammatically 308 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxv 
 
List of Tables 
 
Table 1.1 Major virulence factor regulators of S. aureus and representatives 
of the genes they control 6 
Table 1.2 Interaction between sar family regulators and the agr system 11 
Table 2.1 CDM solution 1 ingredients 44 
Table 2.2 CDM solution 2 ingredients 44 
Table 2.3 CDM solution 3 ingredients 44 
Table 2.4 CDM solution 4 ingredients 45 
Table 2.5 CDM solution 5 ingredients 45 
Table 2.6 Antibiotics used in this study 46 
Table 2.7 S. aureus strains used in this study. Ery
R
, erythromycin 
resistance; Kan
R
, kanamycin resistance; Lin
R
, lincomycin 
resistance; Tet
R
, tetracycline resistance 47 
Table 2.8 E. coli strains used in this study 50 
Table 2.9 Plasmids used in this study 50 
Table 2.10 Maintenance of stock chemicals used in this study 51 
Table 2.11 Primers used in this study 65 
Table 3.1 Hypothetical proteins that aligned with virulence factors 101 
Table 3.2 Hypothetical proteins that aligned with virulence factors 104 
Table 3.3 All protein sequences returned by BLAST query of the VF 
database with the known sequences of S. aureus 8325 107 
Table 3.4 Hypothetical proteins that aligned with virulence factors of the 
non-redundant bacterial sequence database 112 
Table 3.5 NCBI BLAST of known sequences against the Nr Bacterial 
database 113 
Table 3.6 Known functions of the SSL proteins 160 
Table 4.1 Identification of novel potential virulence factors in the NTML 
by BLAST search 172 
Table 4.2 Identification of novel potential virulence factors in the NTML 
by BLAST search 175 
Table 4.3 Strains identified as having an altered phenotype on human blood 
agar 188  
Table 4.4 Transduction of Tn inserts from isolated NTML mutants into the 
JE2 and SH1000 strain background 196 
Table 4.5 Identification of strains with altered phenotype post-transduction 199    
Table 4.6 Sequence features, function and pathway information for the nine 
NTML Tn inserted genes 204 
Table 5.1 Growth analysis of JE2-purA and JE2-purB in the presence or 
absence of adenine and guanine 226 
Table 5.2 Growth analysis of JE2-purA and JE2-purB in the presence or 
absence of adenine and guanine, and in the presence of inosine 228 
Table 5.3 Analysis of the role of glycine, serine, folic acid and purines 
(AG) in the growth of JE2-pabA and JE2 247 
Table 5.4 Analysis of the role of glycine, serine, PABA and purines (AG) 
in the growth of JE2-pabA and JE2 250 
Table 5.5 Analysis of the role of 10x CDM concentration of glycine or 
serine, and 1x CDM concentration of glycine and serine in the 
growth of JE2-pabA and JE2 
 
 
256 
Table 5.6 Analysis of the role of glycine, serine, vitamin B5 and 
methionine in the growth of JE2-pabA and JE2 261 
xxvi 
 
Table 5.7 Analysis of the role of methionine and thymine in the growth of 
JE2-pabA and JE2 264 
Table 5.8 Experimental plan for the liquid CDM analysis of glycine, serine 
and VitB5 269 
Table 5.9 Composition of vortexed and non-vortexed plasma agar plates 
(by volume) 284 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 The staphylococci 
 
Staphylococci are Gram positive bacteria, forming irregular grape-like clusters first 
noted by Ogston (1881) when defining their importance in bacteraemia. Since the work 
of Ogston, 49 named staphylococci species have been identified and recorded on the 
NCBI Taxonomy database (Federhen, 2012). There are a further 2,881 unnamed 
staphylococci records, many, if not all of which, may belong to the 49 named species, 
though some may be identified as new Staphylococcus sp. Of the 49 named species, 40 
fall into the category of coagulase negative staphylococci (CNS), 7 are coagulase 
positive staphylococci (CPS) and 2 are coagulase variable staphylococci (CVS).  
 
Although CNS are commonly found in clinical samples, they were considered 
contaminants, due to their abundance on human skin (Kloos & Bannerman, 1994). 
Approximately half of the recognised staphylococci are known to inhabit the human 
body, with particular strains showing specificity for defined regions of the body 
(Longauerova, 2006; Piette & Verschraegen, 2009). S. epidermidis and S. hominis are 
the most abundant staphylococci on the trunk and limbs respectively (Gemmell, 1986), 
S. capitis on the head and S. auricularis on the external ear (von Eiff et al., 2002). A 
heightened recognition of the importance of CNS in nosocomial infections has come 
about through the increased use of indwelling devices. CNS are now known to be 
responsible for several diseases, including pneumonia, endocarditis and osteomyelitis 
and are the most common cause of venous catheter-related bacteraemia, 50-70% of 
cases are caused by S. epidermidis (Casey et al., 2007; von Eiff et al., 2002). 
 
The bacteria are able to resist the low pH and high osmolarity of the skin and possess 
extracellular enzymes including fatty acid modifying enzyme (FAME) and other 
virulence factors, including adhesins, phenol soluble modulins (PSMs) and some strains 
produce haemolysin (Longauerova, 2006). Biofilm formation allows growth of CNS 
bacteria on indwelling devices, after initial adhesin-mediated attachment (Piette & 
Verschraegen, 2009). Treatment of CNS infections is problematic due to the prevalence 
of antibiotic resistance (von Eiff et al., 2002). As the CNS are permanent residents of 
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the skin surface, there is a selective pressure to evolve mechanisms to overcome 
exposure to antibiotics. 
 
1.2 Staphylococcus aureus 
 
The species name aureus was chosen by Rosenbach in 1884 due to the golden 
pigmentation of Staphylococcus aureus colonies (aureus meaning golden in Latin), 
compared with other, non-pigmented, staphylococci (Liu et al., 2005). S. aureus lives as 
a permanent resident in the anterior nares of ~20% of the population and is a transient 
coloniser of a further ~60%, also living in the axillae, vagina and the surface of 
damaged skin. Colonised patients are at greater risk of infection; however carriers 
appear to have a reduced risk of mortality (Claassen et al., 2005; Holtfreter et al., 2009; 
Wertheim et al., 2004). Risk factors for infection include type I diabetes, surgery and 
the use of intravenous drugs. S. aureus causes a spectrum of diseases, from relatively 
mild skin rashes, to more serious diseases such as endocarditis and systemic infections 
such as septicaemia and toxic shock syndrome (Foster, 2005; Lowy, 1998; Visai et al., 
2009). 
 
1.2.1 S. aureus as a public health issue 
 
The development of resistance to commonly used antibiotics has led to difficulties in 
treating S. aureus infection. Resistance to methicillin was seen in S. aureus shortly after 
its introduction in 1961, giving rise to Methicillin Resistant S. aureus (MRSA; François 
et al., 2010). More recently resistance has been seen to vancomycin, one of the few 
remaining effective antibiotics used in the treatment of S. aureus (Jousselin et al., 
2013). MRSA in particular has developed into a serious public health concern as a 
major cause of nosocomial infection (Foster, 2005; Lowy, 1998; Mekontso-Dessap et 
al., 2005). As with other staphylococci, the use of indwelling devices, for instance 
intravenous catheters, increases the risk of S. aureus infection, as they become coated 
with serum and fibrinogen, which can be adhered to by S. aureus surface proteins such 
as clumping factor A (ClfA; Lowy, 1998). 
 
An emerging problem is the occurrence of community-acquired MRSA (CA-MRSA). 
The occurrence of CA-MRSA has caused alarm as it appears to affect healthy and non-
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immune compromised individuals (Tseng et al., 2009). CA-MRSA strains encode 
antibiotic resistance on the staphylococcal cassette chromosome (SCCmec). The 
SCCmec often encodes the regulatory phenol soluble modulin, psm-mec (Fechter et al., 
2014). The emergence of this strain may be the result of horizontal gene transfer of the 
SCCmec accompanied by the PVL toxin (Foster, 2005; Lowy, 1998).  
 
Relative to S. aureus, the CNS armoury of virulence factors is poor (Longauerova, 
2006). Genomic comparison of S. aureus and S. epidermidis, the most common cause of 
CNS-associated infection, shows that S. aureus encodes a large number of virulence 
factors, such as cytotoxins, not found in S. epidermidis (Gill et al., 2005). This suggests 
that the enhanced virulence of S. aureus compared to S. epidermidis, and other CNS, is 
the result of these additional virulence determinants.  
 
1.3 Virulence determinants and their genetic control 
 
A successful S. aureus infection relies on the pathogen  ¶s ability to colonise the initial 
infection site, adapt to the stresses of the host environment, acquire nutrients for growth, 
resist host defences and spread to other sites in the host when the nutrient levels in the 
original foci of infection are exhausted. To accomplish these stages of infection, S. 
aureus expresses multiple virulence factors from different categories, depending on the 
stage of infection (Cheung et al., 2004; Lowy, 1998). In the initial stage of infection the 
relatively low numbers of bacteria must attach to host tissues and replicate. S. aureus 
expresses multiple adhesins with specificity to host components of the extracellular 
matrix allowing firm binding (Foster & Höök, 1998). At this stage the bacteria must 
fend off host immune factors that are present at the site of infection and prevent the 
ingress of additional factors to the site of infection, by producing cell wall-associated or 
secreted immune evasion proteins (Foster, 2005). Once the bacterial load has increased, 
nutrient levels concomitantly decrease and the necessity for immune evasion 
components is less pressing than the requirement for nutrients. At this stage degradative 
enzymes and toxins are produced to allow deeper penetration of tissues and access to 
nutrients whilst adhesin expression is curtailed to allow detachment and spread (George 
& Muir, 2007). Some of the virulence factors that accomplish this are shown in Figure 
1.1. 
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Figure 1.1 Representative virulence determinants of S. aureus.  
 
Pink components are those of the host, black are S. aureus expressed factors.  
Adapted from (Nizet, 2007).  
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Clearly specific virulence factors are required at specific times during infection. The 
bacteria control gene expression in response to environmental signals recognised by a 
complex network of proteins, which trigger the appropriate gene expression. These 
regulators can themselves be classed as virulence factors, as disruption of virulence 
factor regulation has been shown to have detrimental effects on S. aureus pathogenicity. 
S. aureus has 16 two-component systems (TCS), multiple DNA binding proteins (e.g. 
the SarA family) and approximately 250 non-coding RNAs (ncRNAs) that control gene 
expression allowing adaptation to the changing environment of the host (Bronner et al., 
2004). Not all of these systems are devoted to expression of virulence genes. Some of 
these regulators and their effects on virulence factor expression are shown in Table 1.1. 
A complete discussion of all regulatory components and all virulence factors known to 
be expressed by S. aureus is beyond the scope of this work. Discussion of the major 
virulence regulatory components and many of their corresponding virulence 
determinants follows. 
 
1.3.1 Regulation of virulence early in infection 
 
1.3.1.1 The Fur and SaeRS regulators 
 
Upon entering the human host, whether orally or via an accidental/surgical wound or 
the site of an indwelling device, S. aureus encounters a hostile nutrient limiting 
environment. Humans have evolved mechanisms to sequester Fe from body tissues, due 
to its toxicity and requirement by pathogens (Johnson et al., 2011). S. aureus exploits 
the low Fe concentration upon entering the host environment, by using it as a trigger for 
gene expression. The Fur protein downregulates gene expression, by binding directly to 
a promoter region, known as the fur-box blocking transcription (Cassat & Skaar, 2012). 
In a low Fe environment, fur-box binding is alleviated, allowing expression of genes 
required for Fe acquisition. The genes controlled by Fur include the isd system, used for 
the acquisition of Fe from host proteins, including haemoglobin and haptoglobin and Fe 
chelating siderophores (Hammer & Skaar, 2011). Furthermore, this response has been 
shown to be important for nasal colonisation, as IsdA is required for binding the nasal 
epithelium in the Fe limited nares (Clarke et al., 2004). 
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Table 1.1 Major virulence factor regulators of S. aureus and representatives of the genes they control. 
Regulators arrayed along the top row, controlled virulence factor in column 1. + = upregulated. - = downregulated. 
Name Gene agr sae graRS arlRS 1B codY fur rsp sarA sarR sarT rot sarS mgrA Ref* 
Adhesins 
Autolysin aaa - + +            1, 2 
Autolysin atl - + +            1, 2 
Bone sialoprotein-
binding protein 
bbp    + +          3, 4 
Clumping factor A clfA -    +   -       3, 5, 6 
Clumping factor B clfB     +       +   7, 8 
Coagulase coa - + +  + + +  +   +   
2, 3, 9, 10, 11,  12, 
13 
Collagen-binding protein cna         -      14 
Extracellular adherence 
protein 
eap/ 
map  +     + +       5, 11, 15 
Extracellular matrix-
binding protein 
ebh    +          - 16, 17 
Extracellular fibrinogen-
binding protein 
efb       +        13 
Elastin-binding protein ebps   -  +          2, 3 
Extracellular matrix 
protein-binding protein 
emp  +     + +       5, 11, 15 
Fibronectin binding 
protein A&B 
fnbpAB - +   + +  - +      3, 5, 6, 10, 11, 12 
Iron-regulated surface 
determinant A&B 
isdAB - +     -        6, 13, 15 
Surface protein G sasG -     +  -       5, 6, 12 
Immunoglobulin-binding 
protein 
sbi - +     +        13, 15, 18 
Serine-aspartate repeat-
containing proteins 
sdrCDE -  + +    - +   +  + 2, 4, 5, 6, 17, 19, 20 
Protein A spa - +     + - -   + + - 5, 6, 9, 10, 11, 13,  14, 17 
von Willebrand factor-
binding protein 
vWbp     +          3 
Degradative Enzymes 
Enolase eno   -            2 
Hyaluronate lyase hysA +     -   -      14, 21, 22 
Lipases lip, geh +  +  -  - +    -  + 2, 3, 5, 10, 13, 17 
  
 
 
 
Table 1.1 continued 
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Name Gene agr sae graRS arlRS 1B codY fur rsp sarA sarR sarT rot sarS mgrA Ref* 
Nuclease nuc + +  + -         + 3, 4, 10, 17 
Proteases - +   - -   + -   -  + 2, 3, 5, 10, 17 
Staphylokinase sak +    -         + 3, 10, 17 
Nutrient Acquisition 
Iron-regulated surface 
determinants 
isd       -        23 
siderophores -       -     +   15, 20 
Immune Evasion 
capsule - +   +/- +    +     +/- 
2, 3, 4, 10, 12, 17, 
24 
Chemotaxis inhibitory 
protein 
chp  +     +        13, 25 
Ribitol/D-alanine 
substituting operon 
dltABCD -  +         +   2, 20, 26 
Phosphatidyl-glycerol 
lysyltransferase 
mprF   +            26 
FPRL1 inhibitor flr        +     +   8, 13 
Staphylococcal 
complement inhibitor 
scnA scnB  +     +        13, 25 
Staphylococcal 
superantigen-like 
proteins 
ssl11 - +     +     +   13, 27 
ssl10       +       + 13, 17 
ssl9 - +     +     +   13, 27 
ssl8 - +     +       + 11, 13, 14 
ssl7 - +     +     +   13, 27 
ssl6       +        13 
ssl5 - +             11 
ssl4       +        13 
ssl3       +        13 
ssl2       +        13 
ssl1 - +     +     +   13, 27 
Stress Resistance 
O-acetyltransferase oatA   -            2 
Fatty acid modifying 
enzyme (FAME) 
- +        +      14 
Catalase katA      - +        12, 28 
  
Table 1.1 continued 8 
Name Gene agr sae graRS arlRS 1B codY fur rsp sarA sarR sarT rot sarS mgrA Ref* 
Toxins 
enterotoxins - +      + + +      5, 13, 14 
Toxic shock syndrome 
toxin-1 
tst +        +      14 
exfoliative toxins - +              10 
. -haemolysin hla + +   -  -  +  - - -  3, 10, 13, 14 
 -haemolysin hlb + +  -    + +   -   4, 5, 10, 14 
/ -haemolysin hld + +  +     +  -  +  4, 10, 14 
 -haemolysin hlg +  + - -    +   -  + 2, 3, 4, 10, 17, 29 
Leukotoxins 
lukE +   -     +   -  + 4, 8, 13, 17, 29 
lukD +   -    + +   -  + 4, 8, 13, 17, 29 
lukA/G            -   8 
lukB/H            -   8 
pvl +     -   +   -   10, 29, 30 
Phenol soluble modulins psm +     -         12, 18 
* Table information was gathered from the following publications:  1. Heilmann et al., (2005); 2. Herbert et al., (2007); 3. Bischoff et al., (2004); 4. Liang et al., 
(2005); 5. Lei et al., (2011); 6. Ythier et al., (2012); 7. Hempel et al., (2010); 8. Mootz et al., (2015); 9. Hart et al., (1993); 10. Novick, (2003a); 11. Pantrangi et 
al., (2010); 12. Pohl et al., (2009); 13. Torres et al., (2010); 14. Arvidson & Tegmark, (2001); 15. Johnson et al., (2011); 16. Walker et al., (2013); 17. Luong et 
al., (2006); 18. Fechter et al., (2014); 19. Cheung et al., (2004); 20. Said-Salim et al., (2003); 21. Hart et al., (2013); 22. Ibberson et al., (2014); 23. Mazmanian 
et al., (2003); 24. Goerke et al., (2005); 25. Sun et al., (2010); 26. Joo & Otto, (2015); 27. Benson et al., (2011); 28. Horsburgh et al., (2001); 29. Bronner et al., 
(2004); 30. Montgomery et al., (2012). 
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Table 1.1 shows that along with the isd  R S H U R Q    ) X U   Q H J D W L Y H O \   U H J X O D W H V  .-haemolysin 
(hla) transcription in high Fe conditions. Hla is a homoheptameric leukotoxin that 
interacts with epithelial cells, lymphocytes, monocytes, eosinophils and red blood cells, 
leading to pore formation and necrosis (Prince et al., 2012; Vandenesch et al., 2012). As 
the majority o  I   W K H   E R G \ ¶ V   ) H   L V   K R X V H G   L Q   5 % & V    W K H   ) H-regulated expression of Hla 
early in infection is an important aspect of Fe acquisition (Hammer & Skaar, 2011). A 
large number of adhesins and immune evasion proteins are positively regulated by Fur 
(Table 1.1). In the fur mutant strains, the level of transcript for the adhesins and immune 
evasion proteins is reduced. Whether Fur controls expression of these genes directly or 
indirectly is uncertain. However, (Johnson et al., 2011) demonstrated that Fur directly 
upregulates the saeRS TCS in low Fe growth conditions. As the sae system is a known 
positive regulator of adhesins and immune evasion proteins (Table 1.1) it is possible 
that reduced expression of sae results in the reduced adhesin and immune evasion 
protein levels in the fur deletion mutant. 
 
The sae TCS consists of the saeS sensor and the saeR regulator, known to be most 
active during the exponential phase of growth, though what the sensor responds to is as 
yet unknown (Benson et al., 2012; Bronner et al., 2004). SaeR has been shown to 
positively regulate purine synthesis and amino acid transport and metabolism genes in 
the mid-exponential and early stationary phase of growth (Voyich et al., 2009). The 
importance of the sae system to pathogenicity is dependent on the type of infection. An 
saeRS mutant is non-virulent in a murine sepsis model of infection. However, no 
difference was seen between the S. aureus wild type and the S. aureus saeRS mutant in 
an abscess model (Voyich et al., 2009). Voyich et al. hypothesise that the quorum 
sensing system agr is likely more crucial for abscess formation, as a quorum is likely to 
be reached rapidly at the site of infection, resulting in toxin and degradative enzyme 
secretion. This demonstrates the dependence of S. aureus on multiple regulatory 
systems, which make it such a versatile pathogen. 
 
1.3.1.2 Repressor of toxins (rot) and other sar family members 
 
The rot gene is a member of the 11 member sar family of transcription regulators (sarA, 
sarR, sarS, sarT, sarU, rot, sarX, mgrA, sarZ, sarV and sarY). The sarA gene was the 
first sar gene discovered and each of the other 10 are homologous to sarA 
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(Cheung et al., 2008). The complex interactions between the sar family members, and 
between the sar family and agr, is shown in Table 1.2. The complexity of sar regulation 
can be seen by looking at the activity of a single member, using Table 1.2. If SarR 
activity is repressed it triggers late stage infection gene expression mediated by SarA. 
SarA promotes agr expression and represses SarT and SarV expression. 
Downregulation of the SarT activity derepresses SarT-dependent downregulation of agr 
and sarU, another positive regulator of agr, thereby indirectly enhancing the agr 
upregulation by SarA. Inhibition of SarV expression (also inhibited by MgrA, another 
positive regulator of agr) regulates autolytic activity, thereby influencing the level of 
cell wall degradation and growth (Manna et al., 2004). This suggests that SarR is active 
early during infection, preventing SarA mediated upregulation of agr activated genes. 
 
An important regulator is the sar family transcription regulator repressor of toxins (rot), 
associated with biofilm-related disease (Mootz et al., 2015). The rot protein binds to the 
promoters of S. aureus protease genes, inhibiting their expression, thereby allowing 
biofilm formation. Analysis of biofilm detachment from a polycarbonate surface has 
demonstrated that agr mediated expression of proteases is required for the dissolution of 
biofilm (Boles & Horswill, 2008). Therefore, the repression of proteases by rot 
promotes stable biofilm formation. As shown in Table 1.1 rot has dual functions being 
inhibitory to secreted proteases and extracellular toxins, while promoting expression of 
immune evasion proteins and adhesins, which are required for the establishment of 
infection. 
 
1.4 Virulence factors associated with early infection 
 
1.4.1 Adhesins 
 
To colonise and persist within its host, S. aureus expresses microbial surface 
components recognising adhesive matrix molecules (MSCRAMMs). Members of the 
MSCRAMM family allow colonisation of wounds (Foster & Höök, 1998), skin surface 
(Coates et al., 2014), the nares (Schaffer et al., 2006), indwelling devices (Hartford et 
al., 1997) and tissues within the body associated with specific diseases, such as healthy 
aortic tissue resulting in endocarditis (Hienz et al., 1996).  
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Table 1.2 Interaction between sar family regulators and the agr system. 
 
Sar Family Regulators    
agr References* 
sarA sarR sarT rot sarS mgrA sarU sarX sarZ sarV sarY 
sarA 
 -    +       1, 2, 3 
sarT 
-           - 
3 
rot 
           - 4, 5, 6 
sarS 
    + -      - 1, 2, 3, 4 
mgrA 
    +   +    + 4, 7 
sarU 
  -          
3 
sarX 
     +      - 8 
sarV 
-     -       
3 
agr +  -   + + - +    5, 8, 9, 10, 11 
* Table information was gathered from the following publications: 1. Bischoff et al., (2004); 2. Luong et al., (2006); 3. Cheung et al., (2004); 4. Herbert et al., 
(2007); 5. Liang et al., (2005); 6. Geisinger et al, (2006); 7. Ingavale et al., (2003); 8. Manna & Cheung, (2003); 9. Hart et al., (1993); 10. Bronner et al., (2004); 
11. Thoendel et al., (2011); 12. Johnson et al., (2011); 13. Said-Salim et al., (2003). 
    5 H J X O D W R U \  S U R W H L Q V  D U U D \ H G  D O Rng the top row, positively or negatively regulate those regulatory proteins in the first column. 
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The functions of adhesins have been determined by in vitro binding assays using 
purified protein and the comparison of whole bacteria deficient in a particular adherence 
protein with the wild type strain. One problem with using purified protein is that unless 
the protein is expressed along with the posttranslational modification machinery then 
the effects of posttranslational modifications are not accounted for. Isogenic mutants are 
also used to assess the importance of a particular adhesin gene to the pathogenicity of S. 
aureus, using in vivo models. These analyses can be problematic due to the high level of 
redundant function of S. aureus adhesins, for instance the extracellular matrix (ECM) 
components fibrinogen and fibronectin are bound by the autolysins Aaa and Atl 
(Heilmann et al., 2005; Hirschhausen et al., 2010), the extracellular adherence protein, 
Eap/Map (Haggar et al., 2003), extracellular fibrinogen-binding protein, Efb (Cheng et 
al., 2014; Lee et al., 2004), extracellular matrix protein-binding protein, Emp (Hussain 
et al., 2001) and the fibronectin binding protein, FnbpAB (Flock et al., 1987; Wann et 
al., 2000). These proteins also bind other ECM components and have other roles in 
infection. This redundancy may well be artefactual and a result of the methods 
employed to study S. aureus adhesins, or it may be due to differential expression of 
adhesins or an evolutionary manifestation of their importance to pathogenicity. 
 
1.4.1.1 Roles of adhesins in disease and colonisation 
 
Several S. aureus adhesins are known to be associated with specific diseases and sites in 
the host, based on the tissues they promote binding to and in vivo analyses. The 
collagen-binding protein, Cna promotes binding to the cornea promoting the 
inflammatory eye disease keratitis (Rhem et al., 2000) and is also associated with 
infective endocarditis by binding to undamaged aortic valves (Hienz et al., 1996). The 
adhesin von Willebrand binding protein, vWbp, binds to the ECM component von 
Willebrand factor and has coagulase activity (Bjerketorp et al., 2004). The importance 
of vWbp coagulase activity for bacteraemia and abscess formation has been 
demonstrated by analysis of a single vwbp mutant and a double mutant with the 
coagulase gene, coa. The Efb protein is important for postoperative wound recovery as 
it inhibits platelet aggregation at the wound site, which is important for plugging the 
wound and releasing mediators, such as growth factors, to promote wound healing 
(Shannon & Flock, 2004; Shannon et al., 2005). The plasmin sensitive, Pls, protein 
found in MRSA strains promotes binding to keratinocytes (Huesca et al., 2002), inhibits 
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fibronectin and immunoglobulin G (IgG) binding, and promotes invasion of endothelial 
cells (Hussain et al., 2009). Pls has been shown to play an important role in the 
development of sepsis and septic arthritis, using an isogenic pls mutant (Josefsson et al., 
2005). Surface protein G, SasG, promotes adhesion to desquamated nasal epithelial 
cells important for colonisation of the nares (Corrigan et al., 2007). Bacterial biofilm 
formation is important for indwelling device associated infections. SasG promotes the 
intercellular aggregation step of biofilm formation (Geoghegan et al., 2010; Kuroda et 
al., 2008). In addition to SasG, clumping factor B, ClfB and Fe regulated surface 
determinant A, IsdA promote colonisation of the nares by binding to nasal cells (Clarke 
et al., 2009; Corrigan et al., 2009) and both proteins bind loricrin and cytokeratin-10, 
components of the nasal epithelium (Clarke et al., 2009; Mulcahy et al               2 ¶ % U L H Q  
et al., 2002).  
 
1.4.1.2 Adhesins as immune evasion proteins 
 
Several adhesins of S. aureus have roles in immune evasion. The bone sialoprotein 
inhibits classical pathway complement opsonisation by binding to classical pathway 
regulators C4BP & factor H (the complement system is discussed in more detail in the 
next section; Hair et al., 2013). Eap promotes internalisation by fibroblasts, thereby 
making the bacteria undetectable to host immunity (Haggar et al., 2003). Another 
protein that uses this method of immune evasion is the serine-rich adhesin for platelets, 
SraP. This glycosylated cell wall protein mediates binding to human platelets (Siboo et 
al., 2005), adhesion and uptake by epithelial cells (Yang et al., 2014). Efb and its 
homologue Ehb bind the C3b and C3d complement fragments inhibiting complement 
activation and B-cell activation respectively (Lee et al., 2004; Ricklin et al., 2008). 
 ) Q E S $  X V H V  E R X Q G  I L E U R Q H F W L Q  W R  L Q W H U D F W  Z L W K .     L Q W H J U L Q V  R Q  W K H surface of epithelial 
cells promoting phagocytosis and intracellular evasion of immunity (Edwards et al., 
2011).  
 
The staphylococcal immunoglobulin-binding protein, Sbi, and protein A, Spa, are 
similar in sequence and function. Both proteins bind to the Fc region of IgG, presenting 
it to immune cells in the incorrect orientation, thereby blocking opsonophagocytosis 
(Atkins et al., 2008). In addition to two IgG binding domains, Sbi has two C3 binding 
domains. When bound to C3 on the surface of S. aureus complement activation is 
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inhibited; when bound away from the surface this activates the alternative pathway 
leading to futile consumption of C3 (Burman et al., 2008). The Spa adhesin binds 
keratinocytes, but it can also bind the Fab domain of IgG and IgM leading to massive 
upregulation of B-cell activity and B-cell apoptosis (Falugi et al., 2013).  
 
The complement protein C3b opsonises S. aureus, promoting recognition and 
phagocytosis by macrophages and neutrophils. Clumping factor A, ClfA, binds the 
complement regulator, factor I, promoting cleavage of the C3b opsonin to the non-
opsonin iC3b (Hair et al., 2008). ClfA is also involved in camouflaging S. aureus, 
preventing recognition by host immunity. This is done by coating the surface of the 
bacteria with fibrinogen, leading to false recognition of self by the immune response 
(Higgins et al., 2006). 
 
1.4.2 Immune evasion 
 
The presence of components of the immune system throughout the animal kingdom, 
from porifera to humans, reflects our common evolutionary heritage. The evolution of 
the immune system is estimated to have begun 600 million years ago with the first 
multicellular animals, leading to the complex protective systems seen today (Cooper & 
Herrin, 2010; Reddick & Alto, 2014). This evolution has led to innate and adaptive 
responses to infection both consisting of cellular and molecular components. Cells 
including neutrophils, macrophages and monocytes and molecules including 
antimicrobial peptides (AMPs) and complement proteins belong to the innate immune 
system (Janeway, 2001). Interaction between the innate and adaptive arms of immunity 
is clear, as many of the cells and molecules of the innate system require 
immunoglobulins (a product of adaptive immune B-cells) for their full function 
(Iwasaki & Medzhitov, 2010; Parcina et al., 2008). At the early stages of infection, S. 
aureus secretes a battery of proteins to evade innate immune factors by preventing 
recognition by host immunity, killing by host proteins such as complement and AMPs 
and migration of the primary innate cellular response to S. aureus, the neutrophil, to the 
site of infection. 
 
The first obstacles to S. aureus are pattern recognition receptors (PRRs), AMPs and 
complement. PRRs recognise pathogen associated molecular patterns (PAMPs), such as 
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peptidoglycan, lipoteichoic acid and lipoproteins. The 10 member Toll-like receptor 
(TLR) family of human PRRs were the first to be discovered (initially found in the fruit 
fly Drosophila melanogaster) and are the most studied (Medzhitov et al., 1997). NOD-
like receptors, P-type lectin receptors and RIG-I-like receptors also have important roles 
in mediating the human immune response to PAMPs. Lipoprotein recognition by 
TLR2/TLR6 complex on the surface of keratinocytes, epithelial cells and macrophages 
triggers an intracellular signalling cascade, leading to expression and secretion of 
specific cytokines and AMPs into the surrounding milieu (Iwasaki & Medzhitov, 2010; 
van Kessel et al., 2014). Askarian et al., (2014) reported a new immune evasion protein 
named TirS, which blocks the signalling cascade triggered by lipoprotein recognition by 
TLR2. Bardoel et al., (2012) and Yokoyama et al., (2012) showed using fluorescently 
labelled staphylococcal superantigen-like protein 3 (SSL3) and competition assays 
between TLR2 and monoclonal antibodies that SSL3 is a ligand of TLR2 and upon 
binding it inhibits neutrophil and macrophage activation and interleukin production. 
 
AMPs are found on the skin and tissues at all times and are expressed in response to 
PRR activation. AMPs are immune regulators promoting wound healing, neutrophil 
activity and have a direct killing effect on pathogens, by formation of pores at the 
bacterial cell surface. The positive charge of AMPs is exploited by S. aureus using two 
systems, 1. The dltABCD operon substitutes the ribitol component of teichoic acids with 
positively charged D-alanine. 2. The MprF protein adds a lysine residue to the lipids on 
the intracellular surface, and then aids flipping of the phospholipid presenting the 
positively charged lysine on the extracellular surface. The activity of the dlt operon and 
MprF give S. aureus a net positive charge leading to electrostatic repulsion of AMPs 
(Fedtke, 2004; Peschel et al., 1999; Weidenmaier et al., 2005). The regulatory 
mechanisms that control this activity are discussed in section 1.7.1. 
 
The main functions of the complement system against S. aureus are opsonisation, 
activation and attraction of neutrophils to the site of infection. The activation of the 
complement system on the surface of S. aureus is initiated via the classical, lectin or the 
alternative pathways, leading to production of the C3 convertase. The C3 convertase 
complex cleaves complement protein C3 producing the neutrophil chemoattractant C3a 
and the opsonin C3b. When the concentration of C3b reaches a threshold level, the C3 
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convertase dissociates to form the C5 convertase and C5 is cleaved to give C5a, another 
neutrophil chemoattractant, and C5b (Foster, 2005; Walport, 2001a, 2001b).  
 
S. aureus lessens the impact of the complement system via the release of several 
proteins. Host plasmin formation leads to direct Efb/Sbi-dependent plasmin cleavage of 
IgG (required for classical pathway complement activation) and the C3b opsonin. Efb 
also binds to C3b, preventing opsonisation (Koch et al             . Z L H F L V N L  et al., 2010). 
The staphylococcal complement inhibitor (SCIN) proteins, discovered relatively 
recently, are members of the S. aureus complement evasion arsenal. They bind directly 
to the C3 convertase, stabilising the complex. For their function the C3 convertases 
need to dissociate, by stabilising them SCIN inhibits activation of complement via all 
pathways (Rooijakkers et al., 2006). 
 
Neutrophils are found primarily in blood. They function by phagocytosis of S. aureus 
and killing by an array of toxic intracellular components (including reactive oxygen 
intermediates and AMPs; Rigby & DeLeo, 2012). Their chemotaxis from blood to the 
site of infection is important for clearance of S. aureus (Bestebroer et al., 2007; Li et al., 
2002). They are directed to the site of infection by chemoattractants, including C5a, 
C3a, formylated peptides and interleukin-8 (IL-8). The neutrophils move freely through 
the blood, but upon infection P-selectin and E-selectin are translocated from endothelial 
Weibel-Palade bodies to the surface of the endothelium, proximal to the site of 
infection. P-selectin glycoprotein ligand 1 (PSGL-1) expressed on the neutrophil surface 
binds to these selectins providing a weak attachment and the force imparted by the 
flowing blood breaks the attachment and the neutrophil roles along the lumen surface 
maintaining a weak attachment to the selectins. At the site of infection, IL-8 is presented 
on the surface of the endothelia on heparin sulphate proteoglycans. Neutrophil receptors 
recognise IL-8 and promote integrin expression, including Mac-1, LFA-1 and VLA-4, 
which interact with the endothelial receptors ICAM-1, ICAM-2 and VCAM-1 to give 
stable attachment to the endothelial surface. Transendothelial migration of neutrophils is 
mediated via interaction with ECM components, such as fibrinogen and fibronectin, 
between the cells of the endothelium and expression of proteases by the neutrophils to 
weaken the bonding between cells. The cells then migrate to the focus of infection along 
the concentration gradient of chemoattractants (Chavakis et al., 2007; Rigby & DeLeo, 
2012; Spaan et al., 2013). 
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The formyl peptide receptor inhibitory protein, FLIPr and FLIPr-like proteins, SSL5, 
Eap and CHIPS are secreted by S. aureus inhibiting neutrophil migration to the site of 
infection. SSL5 binds to PSGL-1 on the neutrophil, inhibiting neutrophil rolling at the 
lumen surface (Bestebroer et al., 2007). Eap binds to ICAM-1 expressed by endothelial 
cells, blocking recognition by neutrophils expressing Map-1 and LFA-1, preventing 
stable adherence of neutrophils to the lumen surface (Haggar et al., 2004). CHIPS 
competes with C5a and formylated peptides for binding to their respective chemotaxis 
receptors on the neutrophil surface (Rooijakkers et al., 2006). The FLIPr protein 
expressed by S. aureus also inhibits formylated peptide chemoattraction of neutrophils 
(Prat et al., 2009).  
 
1.5 Regulation of virulence determinants late in infection 
 
As an infection progresses and bacterial load increases, the acquisition of nutrients 
becomes a limiting factor. One method bacteria employ to overcome this is to 
 G U D P D W L F D O O \  U H G X F H  W K H L U  P H W D E R O L F  U D W H  D Q G  ‡ Z D L W  R X W  W K H  V W R U P ·   $ P L Q R  D F L G  V W D U Y D W L R Q 
leads to production of the alarmones ppGpp and pppGpp, triggering the stringent 
response. This production is triggered by an increase in uncharged tRNAs binding to the 
ribosome, leading to synthesis of the alarmones by the ribosome associated RelA/SpoT 
homologue proteins (Stenz et al., 2011). The alarmones downregulate growth related 
gene expression and upregulate genes for amino acid biosynthesis and stress tolerance 
(Gaca et al., 2015; Stenz et al., 2011).  
 
The importance of nucleotide biosynthesis enzymes to pathogenesis attests to the low 
level of nucleotides in human blood   % U R Z Q   	   6 W R F N H U           2 ¶ & D O O D J K D Q et al., 1988; 
Samant et al., 2008). The purine pathway genes purQ, purL, purF, purM and purN and 
pyrimidine synthesis genes pyrC, pyrAA, pyrF and pyrE are positively regulated by the 
cvfC operon, a four gene operon cvfC1-4. The thyA gene required for thymidylate 
synthesis in thymidine limited conditions is upregulated by CvfC3. Loss of thyA has 
been implicated in a reduction in hla expression, suggesting a role for thyA in 
upregulation of hla (Ikuo et al., 2010). The ability to acquire nutrients from the host, 
such as nucleotides and amino acids is important for bacterial growth. The cvfC operon 
demonstrates coordinated upregulation of biosynthesis genes, of particular importance 
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in the low nutrients environment of the host, with virulence genes required for the 
destructive acquisition of nutrients. 
 
1.5.1 Destructive acquisition of nutrients 
 
Control of gene expression using quorum sensing methods allows bacteria to limit the 
production of certain proteins to a time when they are required. The accessory gene 
regulator (agr) is a quorum sensing TCS of S. aureus (Figure 1.2). It is controlled from 
two promoters P2 and P3, leading to transcription of RNAII and RNAIII respectively 
(George & Muir, 2007; Novick et al., 1993). RNAII is transcribed constitutively at a 
low level and is translated to give the AgrABCD proteins (George & Muir, 2007). The 
membrane protein AgrB interacts with AgrD at the membrane, proteolytically cleaving 
AgrD to give an autoinducer peptide (AIP), which targets the transmembrane receptor 
histidine kinase AgrC (Bronner et al., 2004; Ji et al., 1995). The AIP is continuously 
processed and secreted leading to changes in gene expression when a threshold level, 
parallel with bacterial numbers, is reached. Binding of AIP to AgrC causes 
autophosphorylation of AgrC, which activates AgrA promoting increased transcription 
of RNAII from P2 and transcription of the agr effector molecule RNAIII from the P3 
promoter.  
 
The AgrA protein directly promotes transcription of phenol soluble modulins (PSMs; 
Thoendel et al., 2011). However, the complex 514 base RNAIII molecule is the primary 
regulatory molecule of the agr system. The effect of RNAIII on virulence factor 
expression is shown in Table 1.1; downregulating expression of adhesins and immune 
evasion proteins and upregulating expression of toxins and degradative enzymes. This 
regulation is carried out directly at the transcriptional and translational level and 
indirectly through inhibition of rot by binding to rot mRNA preventing recognition by 
the ribosome (George & Muir, 2007).  
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Figure 1.2 The accessory gene regulator (agr) system of S. aureus.  
 
The autoinducing peptide (AIP) is constitutively secreted by S. aureus. This is enabled 
by constitutive expression of RNAII, producing the AgrABCD proteins. AgrD is 
proteolytically cleaved by the membrane protein AgrB releasing the AIP. At a threshold 
level, AIP is recognised by the sensor protein AgrC, leading to phosphorylation of 
AgrA. Phosphorylated AgrA can then positively regulate RNAII and RNAIII 
transcription.  
 
Image modified from (Thoendel et al., 2011). 
 
 
 
 
 
 
 
 
 
20 
 
The agr system allows for coordinated gene expression at high cell density when 
nutrient levels are low. At this stage evasion of host immunity is not as pressing as the 
need for nutrients, furthermore, at the later stage of infection, secretion of proteins such 
as the SSLs to prevent movement of neutrophils to the site of infection is a less suitable 
response, as neutrophils are likely to have reached the infection and be present in high 
numbers. The liberation of toxins by high numbers of bacteria also provides a 
substantial counterattack against the immune response. The need at this stage is to 
liberate nutrients from surrounding tissues and spread to new sites of infection. Another 
benefit of controlling toxin production during the early stages is that high levels of some 
toxins are required before they are fully functional. Indeed low levels of the PSMs of S. 
aureus have been shown to promote activation and migration of neutrophils to the site 
of infection, and lysis of neutrophils at high concentrations (Berube et al., 2014; 
Kretschmer et al., 2010). 
 
If a quorum is not reached before the depletion of available nutrients, the CodY protein 
allows S. aureus to recognise and respond to the low nutrient availability. CodY 
represses its target genes by binding to their promoters, binding more effectively when 
bound to isoleucine or GTP. Decreasing nutrients and energy levels, isoleucine and 
GTP levels, respectively, leads to derepression of the CodY target genes. The sarA and 
agr promoters are CodY targets, preventing their transcription when nutrient levels are 
high enough to maintain the growing S. aureus population (Pohl et al., 2009; Stenz et 
al., 2011).  
 
1.5    $ O W H U Q D W L Y H  V L J P D  I D F W R U  %  1B) 
 
Sigma factors bind to the core polymerase allowing recognition of specific promoter 
 H O H P H Q W V    7 K H   5 V E :   S U R W H L Q   F R P S O H [ H V   Z L W K  1B preventing interaction with the 
polymerase, during exponential growth phase. Dephosphorylation of RsbV by RsbU in 
response to  H Q Y L U R Q P H Q W D O   V W U H V V   O H D G V   W R   G L V S O D F H P H Q W   R I  1B from RsbW, forming an 
 5 V E :  5 V E 9   F R P S O H [    D O O R Z L Q J  1B interaction with the polymerase (Bronner et al., 
2004; Novick, 2003a)    1 B activates adhesins and genes required for aggregation and 
biofilm formation. 
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Expression of toxins and degradative enzymes, controlled by agr, leads to destruction of 
host tissues and acute infection. S. aureus is also the cause of prolonged chronic 
infections, requiring long-term treatment. S. aureus is able to persist within the host 
intracellularly, inside phagocyti  F   F H O O V    V X F K   D V   P D F U R S K D J H V   D Q G   D   U D Q J H   R I   ‡ Q R Q-
 S U R I H V V L R Q D O   S K D J R F \ W H V ·   L Q F O X G L Q J   H S L W K H O L D O   D Q G  H Q G R W K H O L D O   F H O O V   (Olivier et al., 2009; 
Clement et al., 2005). This persistence is enabled by switching from an aggressive 
 S K H Q R W \ S H    W R   D   Q H D U   L Q D F W L Y H   U H V L V W D Q W   V W D W H    7 K H   V L J P D   I D F W R U  1B associated with 
resistance to environmental stresses, mediates this switch by downregulating the agr 
system (Tuchscherr et al., 2015). This offers an alternative response to low nutrient 
levels that can be exploited by S. aureus. 
 
1.6 Virulence factors associated with late infection 
 
1.6.1 Degradative enzymes 
 
The proteases are important degradative enzymes, as they not only degrade ECM 
components, such as collagen and fibrinogen, allowing deeper penetration of tissues and 
release of peptides and amino acids that can be assimilated (Ohbayashi et al., 2011; 
Shaw et al., 2004), but they also degrade the S. aureus surface adhesins, allowing for 
migration of the pathogen. Kolar et al., (2013) compared the growth and pathogenicity 
of MRSA USA300 Lac with the same strain deficient in its 10 secreted protease genes. 
The strains showed identical growth in defined and rich media, but the protease mutant 
demonstrated significantly reduced starvation survival in a peptide based media and 
reduced growth in pig serum, suggesting a role for nutrient acquisition in serum. In 
murine models of systemic infection and abscess formation the protease mutant CFU 
was significantly reduced compared to the wild type. However, the mortality outcome 
of systemic infections was significantly higher for the protease mutant. This was 
determined to be due to greater levels of toxins produced by the protease mutant, 
suggesting that protease activity plays a role in regulating toxin production and disease 
severity, by degrading secreted toxins. Adhesins were also found at higher levels in the 
protease mutant, supporting the role of proteases in cleaving adhesins from the bacterial 
surface. 
 
Table 1.1 shows that the nuclease gene, nuc, is upregulated by both the agr and sae 
system. Degradation of nucleic acids to nucleotides is important throughout infection, 
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supporting the evidence for poor availability of nucleotides in the human host. Nuclease 
is required for the degradation of neutrophil extracellular traps (NETs; Berends et al., 
2010). NETs are made up of the contents of neutrophils, the DNA, AMPs and histone 
proteins, ejected from the neutrophil trapping the bacteria (Berends et al., 2010; 
Schilcher et al., 2014). Nuclease has been shown to be an important virulence factor 
associated with NET-dependant clearance of respiratory tract infections (Berends et al., 
2010). 
 
Staphylokinase, Sak, activates the host protease plasmin from its inactive form, 
plasminogen. Binding of fibrin or staphylococcal enolase, Eno, to Sak/plasmin 
 F R P S O H [ H V   P D L Q W D L Q V   W K L V   D F W L Y H   V W D W H   E \   S U H Y H Q W L Q J   S O D V P L Q   L Q K L E L W L R Q   E \   W K H   K R V W  . -
antiplasmin (Mölkänen et al., 2002). The active plasmin can then attack ECM 
components and clotting factors, releasing nutrients and promoting the spread of 
 L Q I H F W L R Q    Z K L O H   L Q K L E L W L Q J   Z R X Q G   K H D O L Q J    6 D N   D O V R   E L Q G V   W R   W K H   $ 0 3   .-defensin, 
 Z K L F K  U H G X F H V  S O D V P L Q  I R U P D W L R Q    E X W  E O R F N V  W K H  D Q W L P L F U R E L D O  H I I H F W V  R I .-defensin (Jin 
et al., 2004). 
 
Hyaluronate lyase, HysA, cleaves the carbohydrate hyaluronic acid, an integral part of 
the ECM. This activity is important for virulence in an in vivo murine model of 
pulmonary infection (Ibberson et al., 2014). Isogenic mutants of the lipase genes, lip1 
and lip2 are less able to form biofilms, have reduced CFU in the liver, spleen and 
kidneys of intraperitoneally infected mice and are less able to form abscesses (Hu et al., 
2012). Lipase also inhibits phagocytosis and phagocytic killing of S. aureus by 
neutrophils in vitro (Rollof et al., 1988).  
 
1.6.2 Secreted toxins 
 
S. aureus secretes a large number of toxins, which are essential for virulence. This large 
variety of toxins allows for the range of S. aureus toxin-derived diseases, from mild 
skin infections to life-threatening systemic infections. The secreted toxins of S. aureus 
can be placed into five categories: Exfoliative toxins; enterotoxins, including the toxic 
shock syndrome toxin, TSST-1; the haemolysins; two-component leukotoxins and the 
phenol soluble modulins (PSMs). 
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1.6.2.1 Exfoliative toxins 
 
The exfoliative toxins (ETs) are the cause of staphylococcal scalded skin syndrome 
(SSSS), a disease discovered by Gottfried Ritter von Rittershain in 1878 (Bukowski et 
al., 2010). Localised blistering caused by ETs is referred to as bullous impetigo, which 
 L V   W K H Q   U H I H U U H G   W R   D V   5 L W W H U ¶ V   G L V H D V H   R U   6 6 6 6   Z K H Q   W K H   O D U J H    I O X L G   I L O O H G   E O L V W H U V   F R Y H U 
large areas of the body. The blisters are easily damaged; leading to sloughing off of the 
surface skin layers, which if untreated or not treated correctly can lead to secondary 
infections (Ladhani, 2003). The disease is most common in infants, with a low mortality 
rate of < 5%. Adults suffering from immune suppression, HIV, chronic alcoholism, 
renal failure or cancer are susceptible to SSSS, with a high mortality rate of 59%, of 
which the underlying disease is a factor (Manders, 1998). 
 
SSSS is caused by S. aureus secretion of the exfoliative toxins (ETA, ETB and ETD). 
Associating S. aureus with this disease proved difficult, as blisters are usually aseptic, 
as upon secretion of the toxins, they are transported throughout the body in the blood 
where they reach the skin surface away from the foci of infection. This spread is 
controlled by anti-toxin antibodies, explaining the frequency of infant infections, as 
infants are less likely to have been exposed to ET toxin antigens (Ladhani, 2003; 
Rogolsky, 1979). The toxins are serine proteases, but unlike others they have a very 
specific target. The ETs have been referred to as molecular scissors, cutting the bond 
between surface layer skin cells, the keratinocytes, by cleaving a specific site in 
desmoglein-1 (Dsg1), a protein bridge between the cells of the epidermis that maintains 
intercellular adhesion (Hanakawa et al., 2002; Ladhani, 2003). This cleavage only 
affects the surface epidermal layers, as in addition to Dsg1, the deeper dermal layers 
have Dsg3, which compensates for the disruption of Dsg1 (Hanakawa et al., 2002). 
 
1.6.2.2 Enterotoxins/superantigens 
 
1.6.2.2.1 Food poisoning 
 
There are 19 staphylococcal enterotoxins (SEs; SEA-SEE & SEG-SER  – SEF is now 
known as TSST-1) and several variants known as SE-like or SEl proteins, which have 
either no role in food poisoning, or have no demonstrated role (Lina et al., 2004; 
Murray, 2005). The SE genes are found on mobile genetic elements including plasmids, 
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staphylococcal pathogenicity islands and prophages potentiating their spread between S. 
aureus strains (Novick, 2003b). SEB, SEC and SED are upregulated by the agr system 
and SEH, SER and SEL are expressed post-exponentially, but the role of agr in their 
regulation has not been defined (Schelin et al., 2011). The most common cause of 
staphylococcal food poisoning is SEA, with symptoms including vomiting, diarrhoea, 
abdominal pain and nausea (Argudín et al., 2010; Schelin et al., 2011). The enterotoxins 
cause vomiting and diarrhoea by stimulating the vagus nerve and triggering the 
diarrhoea and vomiting response (Murray, 2005). 
 
1.6.2.2.2 Toxic shock syndrome 
 
All SEs and SE-like proteins are superantigens (SAgs) that can massively overstimulate 
T-cell proliferation and the release of pro-inflammatory cytokines leading to the rare, 
acute disease, toxic shock syndrome (TSS). Symptoms of TSS include fever, rash, 
shock and multiple organ failure (Argudín et al., 2010; Ortega et al., 2010). The toxic 
shock syndrome toxin 1 (TSST-1) is in a separate group from the SEs and SEls (Ortega 
et al., 2010). It has no emetic properties, but is the primary cause of menstrual TSS, 
associated with tampon use (Murray, 2005). Non-menstrual TSS occurs in association 
with a separate staphylococcal infection; it is caused by SEs, including TSST-1 and can 
lead to fatal complications in the treatment of the associated infection (Ellis et al., 2003; 
Iandolo, 1989).  
 
A normal antigen will be processed by an antigen presenting cell (APC) and displayed 
on the cell surface in the peptide binding groove of the major histocompatibility 
complex (MHC). The antigen will be recognised by the T-cell receptors (TCRs) of 0.01-
0.1% of T-cells, prompting their proliferation and release of immune mediating 
cytokines (Janeway, 2001; Manders, 1998). Staphylococcal SAgs do not require 
processing and bind directly to MHC class II on the surface of APCs, outside the 
peptide binding groove, on the outside of the MHC/II molecule (Dellabona et al., 1990). 
This allows SAgs to activate T- F H O O V   W K D W   K D Y H   D   7 & 5   F R Q W D L Q L Q J   D   9   V H J P H Q W  
stimulating proliferation and release of toxic levels of cytokines from 5  – 30% of T-
cell  V    L  H    W K R V H   W K D W   K D Y H   W K H   9   V H J P H Q W  Manders, 1998). It is this subversion of the 
adaptive immune response that leads to TSS. 
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The diseases TSS and SSSS rely on the expression of SEs and ETs, respectively. The 
remaining toxins to be discussed are not associated with a specific disease, but have 
specific activities that contribute to the virulence of S. aureus. 
 
1.6.2.3 Haemolysins 
 
The haemolysins are so named due to their ability to lyse red blood cells (RBCs). This 
 I X Q F W L R Q   L V   O L N H O \   L P S R U W D Q W   I R U   W K H   D F T X L V L W L R Q   R I   ) H    D V   a      R I   W K H   E R G \ ¶ V   ) H   L V 
associated with haemoglobin, while most of the remaining is associated as cofactors in 
other metaloproteins, or chelated by Fe storage proteins (Hammer & Skaar, 2011). As 
shown in Table 1.1, the alpha, beta and delta haemolysin genes (hla, hlb and hld, 
respectively) are expressed throughout infection, likely due to a need for Fe. However, 
hla mRNA translation to Hla is controlled by RNAIII, the agr effector molecule, and 
hld is encoded centrally on the RNAIII molecule, so hld expression must only be at a 
low level early in infection (Arvidson & Tegmark, 2001; Bronner et al., 2004). This 
may allow for low level expression of Hla for the acquisition of Fe, which increases as 
 W K H  Q H H G  I R U   ) H  L Q F U H D V H V  Z L W K  E D F W H U L D O  O R D G    7 K H   I R X U W K  K D H P R O \ V L Q -haemolysin (Hlg) 
is a two-component leukotoxin and will be discussed in the next section. 
 
Hla is a homoheptameric leukotoxin that interacts with the ADAM10 receptor on the 
surface of endothelial cells. This interaction promotes disruption of the vascular 
endothelial barrier by inhibiting production of the intercellular adherence protein 
cadherin (Gouaux et al., 1994; Powers et al., 2012). Hla also promotes pro-
inflammatory IL-      , / -18 production in monocytes by promoting formation of the 
NLRP3 inflammasome complex, a host signalling complex involved in regulating 
inflammatory cytokine production. This is followed by necrosis of monocytes in an 
NLRP3-dependent pyronecrosis, releasing the tissue damaging contents of monocytes 
(Craven et al., 2009).  
 
Hlb is a sphingomyelinase that cleaves the sphingomyelin in cell membranes making 
them permeable. The level of sphingomyelin in the membrane of different cell types 
determines their susceptibility to Hlb. Hlb is more active on sheep RBCs than human, 
but is a potent necrotic toxin of human monocytes (Walev et al., 1996). This toxin also 
has a role in immune evasion, by inhibiting production of IL-8 by endothelial cells, 
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reducing neutrophil chemotaxis to the site of infection, which may play an important 
role early in infection, suggesting a possible reason for its early expression (Tajima et 
al., 2009). 
 
Hld is now recognised as the phenol soluble modulin, PSM-/    + O G   D Q G   + O E 
synergistically promote escape from the phagosome, by Hld interaction with ceramide. 
Ceramide is one of the products of sphingomyelin cleavage by Hlb and so Hlb activity 
is required before Hld can function (Giese et al., 2011). Hld also causes mast cell 
degranulation and release of immune stimulating molecules (Nakamura et al., 2013). 
 
1.6.2.4 Two-component leukotoxins 
 
The leukotoxins are a family of S. aureus secreted toxins. They target leukocytes and 
red blood cells and are important virulence factors. The toxins consist of an F 
 F R P S R Q H Q W   D Q G   D Q   6   F R P S R Q H Q W    R U   W Z R   6   F R P S R Q H Q W V   L Q   W K H   F D V H   R I  -haemolysin. 
Individually the F and S components cannot form pores, but together form hetero-
oligomeric pores on their target cell surface. Panton-Valentine leukocidin (PVL) is 
associated with CA-MRSA strains. Initial confusion over its role in pathogenesis was 
the result of its specificity for human and rabbit neutrophils, as studies in murine models 
showed no difference in pathogenicity between isogenic PVL mutants with the wild-
type (Bubeck Wardenburg et al., 2008; Voyich et al., 2006). The toxin effectively lyses 
human and rabbit neutrophils and stimulates the release of pro-inflammatory cytokines 
IL-     D Q G   , / -18 by monocytes (Holzinger et al., 2012; Loffler et al., 2010). Hlg 
consists of two S components HlgAC and one F component HlgB, giving two active 
toxins AB and CB. Both toxins are active against RBCs, neutrophils, macrophages and 
monocytes (Dalla Serra et al., 2005).  
 
The most recently discovered leukotoxin is LukGH, also known as LukAB. This toxin 
targets monocytes, macrophages, and dendritic cells and has a potent necrotic effect on 
human neutrophils (Dumont et al., 2011; Ventura et al., 2010). LukAB/GH kills 
neutrophils extracellularly and intracellularly effecting escape after phagocytosis 
(DuMont et al., 2013). The toxin also promotes NET formation, which can lead to 
damage to host tissues (Malachowa et al., 2013). The LukED toxin is cytotoxic to T-
cells, macrophages and dendritic cells expressing the CCR5 HIV receptor and a murine 
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model negative for CCR5 expression is more resistant to S. aureus challenge (Alonzo 
III et al., 2012). The toxin also targets neutrophils and monocytes via the CXCR1 and 
CXCR2 receptors leading to their lysis (Reyes-Robles et al., 2013).The LukMF toxin is 
commonly associated with strains of S. aureus causing bovine mastitis. This leukotoxin 
is the most active of the leukotoxins against bovine neutrophils (Barrio et al., 2006; 
Rainard et al., 2003).  
 
1.6.2.5 Phenol soluble modulins (PSMs) 
 
The small peptide toxins, phenol soluble modulins (PSMs), include hld, discussed 
above, the alpha- W \ S H   3 6 0.  -4, the beta- W \ S H   3 6 0  -2 and PSM-mec. PSMs are 
cytolytic and have also been linked to regulatory roles in the expression of hla   3 6 0.  
and downregulation of agr (PSM-mec; Berube et al., 2014). PSMs promote the 
migration of neutrophils to the site of infection and it has been hypothesised that once 
an infection is well established, PSMs are upregulated under the control of agr, and 
attract neutrophils, which are then effectively lysed by high levels of PSM and other 
toxins leading to tissue damage by release of the toxic neutrophil contents (Kretschmer 
et al., 2010; Kretschmer et al., 2012). However, the chemotaxis and extracellular killing 
activity of PSMs is inhibited by human serum, suggesting that PSMs may well only 
have a role as intracellular toxins, an activity demonstrated in osteoblasts (Rasigade et 
al., 2013). 
 
1.7 Regulators associated with specific environmental stimuli 
 
1.7.1 The graRS TCS 
 
Positively charged AMPs secreted by a variety of cells and released by platelets are 
found in host tissues, within the phagolysosome and on the skin surface (Weidenmaier 
et al., 2005). AMPs, such as defensins, cathelicidins, lysozyme and thrombocidins 
attack the cell wall of S. aureus, leading to death of the pathogen (Fedtke, 2004; Kraus 
et al., 2008). The cationic AMPs are attracted to the anionic charge of the bacterial cell 
wall, imparted by negatively charged cell wall molecules such as phospholipids, 
peptidoglycan and wall teichoic acid (Fedtke, 2004; Kraus et al., 2008). The TCS graRS 
allows S. aureus to respond to the presence of AMPs, triggering expression of the 
dltABCD operon and mprF, discussed above. 
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Biofilms enhance antibiotic and immune resistance of individual bacteria within the 
biofilm. Ion chelation by sodium citrate is employed for anticoagulation in catheter 
locks. Shanks et al., (2008) showed that the graRS system is stimulated by low levels of 
sodium citrate, leading to VraFG-dependent biofilm formation. This biofilm formation 
was also dependent on SarA mediated expression of fnbpAB. Citrate is an intermediate 
of the TCA cycle and other intermediates (isocitrate, fumarate, malate and oxaloacetate) 
also stimulate biofilm formation (Shanks et al., 2008).  
 
1.7.2 The srrAB TCS 
 
The srrAB TCS downregulates toxin production in anaerobic and microaerobic 
conditions (Bronner et al., 2004). It downregulates the agr system and is itself 
downregulated by agr (Novick, 2003a; Pragman et al., 2004). The srrAB TCS is 
required for resistance to NO
.
 released by the host. NO
.
 levels are high on the skin and 
nares, making resistance important for survival in these host niches. Resistance is 
achieved by production of the flavohaemoglobin, Hmp. The hmp gene is under the 
control of SrrAB, along with genes required for anaerobic respiration and repair of 
oxidative damage. Hypoxic conditions within the biofilm result in activation of srrAB 
and this inactivation is essential for biofilm formation (Kinkel et al., 2013). 
 
The polysaccharide intercellular adhesin (PIA) is produced from the icaABCD locus. 
PIA promotes aggregation of S. aureus and biofilm formation and is commonly 
associated with cystic fibrosis S. aureus infections. Transcription from the ica locus is 
inhibited in aerobic conditions by IcaR. The anaerobic millieu associated with cystic 
fibrosis infections, leads to phosphoylation of SrrA by SrrB, which then binds the icaA 
promoter, between the IcaR binding site and the icaA gene, leading to transcription and 
biofilm formation (Ulrich et al., 2007).  
 
As discussed in section 1.6.2.2.2 toxic shock syndrome is associated with the use of 
tampons. The srr system has been implicated in tampon-associated toxic shock 
syndrome. SrrA inhibits TSST-1 in anaerobic conditions and it has been proposed that 
insertion of a tampon into the normally anaerobic vagina leads to temporary aeration 
and expression of the TSST-1 toxin (Yarwood et al., 2001). 
 
29 
 
1.8 Methods in analysis of virulence factors 
 
1.8.1 Characterisation of individual virulence factors in vitro and in vivo 
 
A frequently used method for the analysis of virulence factors is the disruption or 
deletion of a potential virulence factor encoding gene, followed by observation of the 
resulting phenotype. For an in vitro study, this may involve analysis of growth in the 
absence of a specific nutrient, or growth on tissue culture or specific host cell type. 
Alternatively, the protein product of the putative virulence factor can be overexpressed 
and purified and then its structural properties and function can be analysed in isolation. 
An important problem of in vitro analyses is that they do not mimic the host 
environment well. Inside the host a virulence factor may be released at low 
concentrations, or expressed only at certain times during infection in order to function 
correctly, while a relatively large amount of purified protein may be used in vitro over 
extended periods (Cross, 2008; Smith, 1998). This may lead to spurious conclusions as 
to the activity of the virulence factor, such as binding ligands that would not be bound 
within the host at the lower in vivo concentration and lower exposure times. In the 
majority of in vitro experiments the media used, including rich media, defined media 
and minimal media is the single source of nutrients throughout the experiment (Quinn et 
al., 1997; Smith, 1998). This does not reflect the conditions in vivo, where access to 
nutrients is changing over the course of infection, which alters the growth rate and gene 
expression of the bacteria.  
 
Complementing in vitro analyses with in vivo studies overcomes many of the above 
problems. Strains with a disrupted gene for a putative virulence factor can be used to 
infect animal models and the outcome of infection assessed. The strain will then 
encounter all the changes in nutrient availability and host immune factors that are 
missing from many in vitro studies. Putative virulence factor genes from a known 
pathogen can be inserted into avirulent or poorly virulent species and the effect can then 
be assessed in vivo. RNA interference (RNAi) can be used to knock-down the 
expression of pathogen and host gene products, to identify pathogen gene products 
required for virulence and host products required to fight infection (Burrack & Higgins, 
2007). Problems of inoculum size and the site at which the bacteria are inoculated arise 
with in vivo studies. A balance has to be found between too high a dose and too low a 
dose. Too high and the defences of the subject animals are immediately overcome, too 
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low and all subject animals recover; in both cases little is learnt. Interestingly the 
required CFU varies between infection routes, for example direct injection into the 
bloodstream may require a higher CFU than intraperitoneal infection due to the 
immediate availability of host defence cells in the blood (Cross, 2008). The category of 
virulence factor also determines the site of infection for an in vivo model. Infection by 
skin scrape is better suited to analysis of tissue degrading enzymes, whereas 
intraperitoneal infection may be better suited for analysis of virulence factors associated 
with liver abscess formation. 
 
The S. aureus 8325 genome contains 2,755 genes, according to the Patric database. Of 
these 2,755, there are 645 hypothetical genes, which have no function assigned to them. 
The remaining 2,110 contain all genes with known or predicted functions, including genes 
encoding virulence factors. However, some of these genes may well be incorrectly 
assigned and non-virulence factors may indeed be virulence factors. To assess all of 
these genes individually by in vitro and in vivo methods would be costly and slow and 
only provide full information for one strain of one species, wasting resources and time 
that could be spent using a more directed approach. Methods have been developed to 
narrow the focus of analyses to a subset of genes that have the potential to be important 
for pathogenicity. 
 
1.8.2 Identification of virulence factors by in silico analysis 
 
Advances in genome sequencing technologies have led to whole genome sequencing of 
multiple pathogenic species and strains (Buermans & Dunnen, 2014; van Dijk et al., 
2014). Bioinformatics can be used to compare the genomes of known pathogens to 
identify shared virulence factors and compare the host genome with that of the pathogen 
to identify proteins that may interact with the host. Furthermore, whole genomes can be 
searched for known promoter elements to identify genes controlled by regulators known 
to be important for virulence factor expression (Burrack & Higgins, 2007). Available 
genome sequences also allow for ordered transposon mutagenesis libraries of individual 
strains, which can be used to assess the importance of non-essential genes to the 
virulence of a pathogen (Fey et al., 2013). Bioinformatics is a powerful approach that 
can be used to identify potential targets in order to direct work in the laboratory, 
allowing for a more focused approach to characterise virulence factors. 
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1.8.3 Selective capture of transcribed sequences (SCOTS) 
 
Selective capture of transcribed sequences (SCOTS) was developed by (Graham & 
Clark-Curtiss, 1999). The SCOTS method allows comparison of transcribed genes in 
vivo with transcribed genes in vitro (see Figure 1.3). Total RNA is extracted and 
converted to cDNA, then bacterial cDNA (limited to 200-500bp) is captured by 
hybridisation to biotinylated bacterial DNA. The most common cDNA will be 
ribosomal DNA (rDNA), so the biotinylated rDNA site is blocked by an initial round of 
hybridisation with plasmid DNA encoding rDNA. Subtractive hybridisation between 
linkered cDNA from in vitro or in vivo growth, leaves enriched in vitro cDNA 
demonstrating down-regulation in vivo, or enriched in vivo cDNA, demonstrating 
upregulation in vivo (Wang et al., 2014). SCOTS can be used to determine gene 
expression changes in vitro using cell cultures (Graham & Clark-Curtiss, 1999) and 
from tissues recovered from in vivo animal models (Baltes & Gerlach, 2004). This 
method can identify genes positively or negatively regulated, but says nothing of the 
function of the genes. 
 
1.8.4 In vivo expression technology (IVET) 
 
The success of S. aureus and other pathogens results from their ability to respond to a 
change in their environment by appropriate gene expression. IVET offers a means of 
tracking the change in expression by comparison of growth in different environments. 
The basis of the IVET method was introduced by Osbourn et al., (1987) and further 
developed by Mahan et al., (1993) who coined the name IVET. The IVET method and 
modifications to the method are shown diagrammatically in Figure 1.4. 
 
The first use of IVET took advantage of a purA  P X W D Q W  V W U D L Q ¶ V   U D S L G   F O H D U D Q F H   I U R P   W K H 
host. A promoterless purA lacZY fusion, was inserted into a suicide vector and random 
genomic fragments (known as gene x) were inserted upstream. Transformation of the 
vectors into the purA mutant was then carried out, leading to homologous 
recombination and formation of a merodiploid strain library. Those strains expressing 
gene x in vivo were able to grow due to expression of purA downstream of gene x, those 
that were not did not survive. To separate those genes expressed only in vivo from those 
expressed at all times, after collection of the bacteria from host tissues, lacZY activity 
32 
 
 
Figure 1.3 Representation of the selective capture of transcribed sequences 
(SCOTS) methodology. 
 
Total RNA from in vitro and in vivo growth is extracted and reverse transcribed to 
linkered cDNA. Bacterial cDNA is extracted (barring ribosomal cDNA) by 
hybridisation to fragmented biotinylated bacterial genomic DNA, pre-hybridised with 
rDNA, and isolated with streptavidin-coated magnetic beads. Primer binding sites on 
the linker DNA are then used to amplify the cDNA and any remaining rDNA is 
removed, by further rounds of hybridisation to rDNA-blocked bacterial genomic DNA. 
The cDNA from in vitro growth is then hybridised to fragmented biotinylated bacterial 
genomic, followed by hybridisation of cDNA from in vivo growth, or vice versa, to 
enrich either in vivo transcribed cDNA or in vitro transcribed cDNA. 
 
Image modified from Wang et al., (2014). 
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Figure 1.4 Representation of the in vivo expression technology (IVET) 
methodology.  
 
Bacterial genome fragments are inserted upstream of a specific reporter gene within a 
vector. The vector is integrated into the genome of the pathogen, producing a library of 
strains each with a different genomic fragment upstream of the reporter. The strain 
library is then used to infect a model organism. The reporter is required to complement 
an existing auxotrophy in the bacteria, an antibiotic resistance marker or to perform a 
specific function. Those fragments that do not stimulate expression from the reporter 
promoter in vivo, will not be represented, due to loss of their host bacteria. The 
successful strains are then assessed for the exclusivity of their expression in vivo, by in 
vitro analysis of LacZY activity. Those strains that do not have LacZY activity in vitro 
are expressed only in vivo. 
 
Image modified from (Angelichio & Camilli, 2002). 
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was measured by growth on indicator media, those showing no lacZY activity are only 
expressed in vivo (Angelichio & Camilli, 2002). Other reporter genes used as 
alternatives to purA include purEK, panB and thyA (Rediers et al., 2005). 
 
Pathogens are required to alter their pattern of gene expression to respond to the change 
in their environment over the course of infection. At the early stages, colonisation and 
resistance to host immunity are required to establish infection. In later stages, changes 
in metabolism are required to respond to reduction in nutrient levels and expression of 
toxins and degradative enzymes are required to spread to other sites within the host. A 
purA auxotroph will likely not reach these later stages before clearance by host 
immunity; therefore, important virulence determinants required at these stages will not 
be detected. Alternatives to purA include the use of an antibiotic resistance gene, which 
allows analysis of expression at later stages of infection, by delaying antibiotic 
treatment of infected animals until an infection is well established (Angelichio & 
Camilli, 2002; Darwin, 2005). 
 
The hla gene of Listeria monocytogenes is required for escape from within the 
phagosome. Using hla as an alternative to purA, allows analysis of intracellular and 
intraphagosomal gene expression in L. monocytogenes. Other genes with known 
functions have been used in this way (Angelichio & Camilli, 2002; Rediers et al., 
2005). 
 
RIVET is a recombination-based IVET that uses a resolvase gene, in place of purA, to 
excise an antibiotic cassette previously inserted into the genome. As only low levels of 
resolvase are required for activity, RIVET can detect in vivo expressed genes required 
only for short periods during infection (Angelichio & Camilli, 2002). 
 
The IVET method has limitations that affect its results, leading to false positives and 
false negatives. IVET does not take into account gene products that are expressed both 
in vitro and in vivo, but may be only active in vivo due to posttranslational modification. 
Gene expression will vary under different in vitro conditions; therefore, a gene may be 
upregulated in vivo and downregulated in one in vitro condition, but not in another 
(Rediers et al., 2005).  
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1.8.5 Signature-tagged mutagenesis (STM) 
 
Signature-tagged mutagenesis (STM) allows analysis of multiple genes within a single 
host, to identify those genes required by the pathogen for survival in the host. STM was 
developed by Hensel et al., (1995) and the method is shown diagrammatically in Figure 
1.5. The basic STM method relies on variable tags, with identical flanking regions, 
allowing PCR of all the variable regions in a single reaction. A pool of tags are made 
and inserted into transposons (Tn). The Tn pool is then transformed into the pathogen of 
interest, giving a pool of strains with a Tn, containing a unique tag, inserted into an 
individual gene. Genomic DNA is extracted from the pool before infection (input pool) 
and from animals infected with the pool (output pool) and the tags are amplified for 
both pools. Input and output tags are then hybridised to DNA from the Tn mutant 
library. DNA that hybridises to probes from the input pool, but not the output pool is 
deemed likely to be important for virulence. 
  
As with IVET and SCOTS, there are drawbacks in the use of STM. A problem affecting 
STM results is the specificity of some virulence factors for a particular host. An 
example of this is the PVL toxin, which kills human and rabbit neutrophils, but not 
mouse neutrophils (Loffler et al., 2010). Therefore, STM would not detect the pvl gene 
in a mouse model. This can be overcome for some virulence factors, by using a variety 
of hosts, which also has the benefit of identifying genes that are central to the 
pathogenicity of a species (Shea et al., 2000). It is unlikely that STM would highlight 
the importance of PVL, as it is a secreted toxin, and the STM methodology is limited in 
that the benefits of secreted proteins by different members of the pool of strains will be 
enjoyed by all strains. Essential genes cannot be assessed by STM, as Tn disruption of 
an essential gene means that that strain cannot grow and will not be represented in the 
input pool (Autret & Charbit, 2005). 
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Figure 1.5 Representation of the signature-tagged mutagenesis (STM) 
methodology.  
 
A. DNA tags, with a variable central sequence flanked by invariable sequences are 
inserted into transposons (Tn). The tagged Tn are then used to create a bacterial strain 
library, each strain with a Tn inserted at a specific gene, containing a unique tag. 
B. Strains from a 96-well plate are pooled and then used to infect a model organism. 
Prior to infection, genomic DNA is extracted from the pool to give the input pool. 
Genomic DNA is then extracted from the host organism to give the output pool. The 
tags are amplified from primer binding sites within the invariable regions, labelled and 
the invariable tags removed. The input pool is hybridised to the Tn DNA from the 96-
well plate. Those tags that hybridise from the input pool, but not the output pool are 
considered potentially required for virulence. 
 
Image modified from (Hensel et al., 1995). 
 
A
B
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Each of the methods outlined in section 1.8.2-1.8.5 have limitations, but all provide 
targets for the more in-depth studies of isogenic mutants and functional assays. The 
potential targets that are frequently found by in vivo expression methods were assessed 
by Rediers et al., (2005), who found that a large proportion of the genes belong to those 
classes involved in nutrient acquisition and biosynthesis. These include Fe and other 
metal ion scavenging systems; upregulation of transporters for uptake of amino acids 
and sugars; amino acid synthesis and catabolism; protein synthesis and degradation; 
stress resistance genes, such as acid tolerance and osmotic stress; secretion, virulence 
factors and nucleic acid metabolism components. Purine biosynthesis is a particularly 
prevalent finding in STM screens, reflecting the low purine availability in the host 
(Shea et al., 2000). A third of genes shown to be required in vivo have no known 
function, demonstrating that there are a large number of potential virulence associated 
genes that are yet to be characterised. 
 
1.8.6 S. aureus specific problems associated with STM and IVET 
 
Work done in this laboratory by Prasjnar et al., (2012) highlights a S. aureus specific 
problem with expression technologies, relating to the dynamics of S. aureus infections. 
The observation that in a zebrafish model of systemic infection bacterial numbers 
remain static for the first 24hr post infection, and are then either cleared or grow to 
approximately 10
6
 per larvae, resulting in the death of the host, suggested a niche was 
available to avoid host clearance during this initial period. 
 
Using a mix of two isogenic strains, expressing different antibiotic resistance markers, a 
population bottleneck was seen in which low numbers of the starting inoculum 
contribute to the bacterial load seen at the end of infection. This resulted in skew 
towards one strain or the other found in larvae at the end of infection, and not the equal 
numbers of each strain at the end of infection, if the contribution of both was equal. 
Furthermore, isogenic strains with a different fluorescent label demonstrated that 
abscesses within zebrafish embryos were caused by a very low number of bacteria, if 
not a single bacterium, as many abscesses showed only a single fluorescent marker. A 
selective advantage of one strain over another was ruled out by passage of bacteria back 
through the host, leading to loss of the bias seen in the previous passage through the 
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host. This clearly demonstrated a niche were a small number of bacteria survive and go 
on to seed infection.  
 
The bottleneck effect is not associated only with zebrafish, and has been shown in a 
murine model of systemic infection (McVicker et al., 2014). Mice were intravenously 
infected with a 1:1:1 ratio of S. aureus strains, which were isogenic, apart from the 
presence of different antibiotic resistance cassettes. The numbers of bacteria in the 
kidneys, liver, spleen, heart and lungs was then measured during infection. At the early 
stage of infection no clonal bias was seen and bacterial numbers remained steady 
(similarly to the early stages of a zebrafish infection) and confined mainly to the liver 
and spleen. A high degree of clonal bias was seen later in infection when bacterial 
numbers increased in the kidneys. After 2 days, only one or two of the three strains 
(more frequently just one strain) were found in the majority of kidneys assessed. This 
clonal bias was also seen in the liver, spleen, heart and lungs at later stages of the 
infection (72 h). 
 
A limited number of strains in the mixed population would survive in vivo and this 
would not be due to the expression of required genes, but rather to the stochastic clonal 
expansion process outlined above. This demonstrates the limitations of in vivo analysis 
of gene expression and mixed mutant analyses using S. aureus strain libraries. 
 
1.9 Rationale and objectives 
 
The success of S. aureus as a pathogen is dependent on colonisation of the host, evasion 
of host defences, liberation and synthesis of nutrients, stress tolerance and the ability to 
spread through the host. These activities are enabled by an array of virulence factors 
controlled by a complex system of regulators, themselves classed as virulence 
determinants. The recent addition of the new leukotoxin, LukAB/GH (Dumont et al., 
2011; Ventura et al., 2010), to the armoury of S. aureus virulence factors raises the 
possibility that there may be further proteins, either with or without known functions 
that play important roles in pathogenesis. Two methods were used to address this, a 
bioinformatics analysis of the S. aureus genome (Chapter 3) and screening an ordered 
library of transposon mutants, the Nebraska transposon mutagenesis library (Chapter 4). 
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Attempts were then made to characterise the putative virulence determinants found and 
identify their role in S. aureus pathogenicity (Chapter 3 & Chapter 5). 
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CHAPTER 2  MATERIALS AND METHODS   2.1 Media 
 
All media was prepared using distilled H2O and autoclaved at 121oC at 15psi, unless 
otherwise stated 
 
2.1.1 Baird-Parker agar 
 
Baird-Parker Agar Base (Oxoid)     63 g l-1  
Egg Yolk Emulsion (VWR)      50 ml l-1 
 
Once cooled to 50oC after autoclaving, egg yolk emulsion was added. 
 
2.1.2 Brain heart infusion (BHI) 
 
BHI (Oxoid)        37 g l-1 
 
For BHI agar 1.5% (w/v) agar No. 1 (Oxoid) was added. 
 
2.1.3 Blood and blood component agar  2.1.3.1 Preparation of blood components  2.1.3.1.1 Human blood collection  
A 21 gauge needle was used to obtain venous blood from healthy volunteers, with their 
informed consent, at the Royal Hallamshire Hospital. The South Sheffield Ethics 
Committee approved the protocol for phlebotomy. Blood was collected in 50 ml Falcon 
tubes containing the anticoagulant sodium citrate, to give a concentration of 0.4% (w/v) 
for a full 50 ml Falcon tube. Tubes were gently rotated to ensure that the anticoagulant 
was incorporated evenly throughout the blood. Anticoagulant was added to all samples 
unless stated. Blood that was not used on the day of collection was discarded. 
 
2.1.3.1.2 Human plasma preparation 
 
Blood samples collected as in section 2.1.3.1.1 were centrifuged at 270 g for 20 min in 
50 ml Falcon tubes. This gave two phases, a lower cell rich phase and an upper platelet 
rich phase. The upper phase was collected and either used directly as platelet rich 
plasma (PRP), or centrifuged at 1155 g for 40 min to give platelet poor plasma (PPP), 
by removal of clotting factors. Plasma was stored at -20oC. 
 
2.1.3.1.3 Human serum preparation 
 
Human serum was either purchased from Millipore or prepared from blood donated as 
in section 2.1.3.1.1. Blood was collected without anticoagulant and stored at 4oC for 6 h 
to allow clotting. Once clotted, the blood was centrifuged at 5,000 rpm and the serum 
was carefully collected from the top of the pelleted clot. Serum was stored at -20oC. 
 
2.1.3.1.4 Non-human blood products 
 
Non-human animal blood was purchased from TCS Biosciences Ltd. Non-human 
animal sera were purchased from Sigma-Aldrich. Blood was stored at 4oC and sera were 
stored at -20oC. 
 
2.1.3.2 Serum or plasma agar (50%) 
 
3% (w/v) agar No. 1 (Oxoid)     30 g l-1  
 
Once the agar cooled to 55oC an equal volume of agar was added to serum or plasma, 
pre-warmed to 37oC, to give 50% (v/v) serum or 50% (v/v) plasma agar. 
 
2.1.3.3 Human or non-human blood agar (30%) 
 
2% (w/v) agar No. 1 (Oxoid)      20 g l-1 
 
Once cooled to 50oC, agar was added to human or non-human blood, pre-warmed to 
37oC, to give a final concentration of 30% (v/v) blood agar.  
2.1.3.4 RBC homogenate agar (30%) 
 
Red blood cells (RBCs) were collected as a by-product of neutrophil preparation 
(section 2.18.1). RBCs were thawed on ice, then vortexed and an equal volume of 
platelet poor plasma was added, restoring an equivalent RBC concentration to whole 
blood. Plates were then prepared with the RBC homogenate, as in section 2.1.3.3. 
 
2.1.3.5 Sheep blood agar (5%) 
 
Columbia agar (Sigma-Aldrich)    42 g l-1 
 
Once cooled to 50oC, sheep blood was added to a final concentration of 5% (v/v). 
 
2.1.4 Chemically defined media (CDM) 
 
Chemically defined media (CDM) was developed by Hussain et al., (1991). The media 
was prepared from 5 separately prepared solutions in the following ratio: 7 (solution 1) : 
1 (solution 2) : 0.5 (solution 3) : 0.1 (solution 4) : 1 (solution 5). Solution 1, 3 and 4 
were merged before autoclaving, and then cooled. Solution 2 was filter sterilised using a 
0.2 µm pore filter and added to cooled solutions 1, 3 and 4. Solution 5 was autoclaved 
separately and added to solutions 1-4 when cooled. 
 
For CDM agar 1.5% (w/v) agar No. 1 (Oxoid) was added to solutions 1, 3 and 4 before 
autoclaving.  
 
Divalent cations were removed from all glassware by acid washing overnight with 0.1M 
HCl and autoclaved prior to CDM preparation. 
 
 
 
 
 
 
 
2.1.4.1 CDM Solution 1 
 
Table 2.1 CDM solution 1 ingredients.  
Chemical Weight Chemical Weight 
Na2HPO4.2H2O 7 g L-Lysine 0.1 g 
KH2PO4 3 g L-Leucine 0.15 g 
L-Aspartic Acid 0.15 g L-Methionine 0.1 g 
L-Alanine 0.1 g L-Phenylalanine 0.1 g 
L-Arginine 0.1 g L-Proline 0.15 g 
L-Cysteine 0.05 g L-Serine 0.1 g 
Glycine 0.1 g L-Threonine 0.15 g 
L-Glutamic Acid 0.15 g L-Tryptophan 0.1 g 
L-Histidine 0.1 g L-Tyrosine 0.1 g 
L-Isoleucine 0.15 g L-Valine 0.15 g Dissolved in 700 ml of distilled water adjusted to pH 7.2 
 
2.1.4.2 CDM Solution 2 (1000x) 
 
Table 2.2 CDM solution 2 ingredients.  
Chemical Weight Chemical Weight 
Biotin (fridge) 0.02 g Pyridoxal 0.8 g 
Nicotinic Acid 0.4 g Pyridoxamine di-HCl 0.8 g 
D-Pantothenic Acid 0.4 g Riboflavin 0.4 g 
Thiamine HCL 0.4 g   Dissolved in 140 ml of distilled water. Opaque yellow colour when mixed that becomes clear yellow upon filtration  
2.1.4.3 CDM Solution 3 
 
Table 2.3 CDM solution 3 ingredients.  
Chemical Weight Chemical Weight 
Adenine Sulphate 0.02 g Guanine HCl 0.02 g Dissolved in 50 ml of 0.1M HCl 
 
 
 
 
2.1.4.4 CDM Solution 4 
 
Table 2.4 CDM solution 4 ingredients.  
Chemical Weight Chemical Weight 
CaCl2.H2O 0.01 g (NH4)2Fe(SO4)2.H2O 0.006 g Dissolved in 10 ml of 0.1M HCl 
 
2.1.4.5 CDM Solution 5 
 
Table 2.5 CDM solution 5 ingredients.  
Chemical Weight Chemical Weight 
Glucose 10 g MgSO4.7H2O 0.5 g Dissolved in 100 ml of distilled water 
 
2.1.5 Luria-Bertani media (LB) 
 
Tryptone (Oxoid)       10 g l-1  
Yeast extract (Oxoid)       5 g l-1  
NaCl         7 g l-1  
 
For LB agar 1.5% (w/v) agar No. 1 (Oxoid) was added. 
 
2.1.6 LK media 
 
Tryptone (Oxoid)       10 g l-1  
Yeast extract (Oxoid)       5 g l-1  
KCl         7 g l-1 
 
For LK top agar 1.5% (w/v) agar No. 1 (Oxoid) was added. 
For LK bottom agar 0.7% (w/v) agar No. 1 (Oxoid) was added. 
 
2.1.7 RPMI-1640 media 
 
RPMI-1640 was purchased from Sigma-Aldrich and stored in 50 ml aliquots, at 4oC. 
Before use, foetal calf serum (Sigma-Aldrich) was added to 10% (v/v). 
2.1.8 Tryptic soy broth 
 
Tryptic soya broth (Oxoid)      30 g l-1  
 
2.2 Antibiotics 
 
Table 2.6 Antibiotics used in this study. 
Antibiotic Stock concentration ( mg ml-1) 
S. aureus working concentration  ml-1) 
E. coli working concentration  ml-1) 
Solvent 
Ampicillin (Amp) 100 - 100 dH2O Chloramphenicol (Cat) 30 30 - 100% (v/v) ethanol Erythromycin (Ery) 5 5 - 100% (v/v) ethanol Kanamycin (Kan) 50 50 50 dH2O Lincomycin (Lin) 25 25 - 50% (v/v) ethanol Neomycin (Neo) 50 50 - dH2O Spectinomycin (Spec) 100 - 100 dH2O Tetracycline (Tet) 5 5 - 100% (v/v) ethanol Trimethoprim (TMP) 50 1000-0.122 - 100% (v/v) DMSO  2.3 Bacterial strains, plasmids and bacteriophage  2.3.1 Maintenance, storage and culture of bacteria 
 
Bacterial strains used in this study are given in Table 2.7 and 2.8. 
 
2.3.2 S. aureus strains 
 S. aureus strains used in this study are given in Table 2.7. Strains were inoculated onto 
BHI agar, containing a selective antibiotic where required, from -80oC Microbank stock 
vials (Pro-lab Diagnostics). Plates were placed at 4oC for short-term storage. Microbank 
vials were used for long-term storage at -80oC. For standard growth, 1 colony was used 
to inoculate 5 ml of BHI in a 25 ml Universal tube, with or without antibiotic. Cultures 
were then grown overnight at 37oC aerobically at 250 rpm on a rotary shaker. The 
overnight culture was then used to inoculate 50 ml of fresh pre-warmed media in a 
sterile 250 ml conical flask at an OD600 of 0.05-0.01. Strains were then grown to 
exponential or stationary phase at 37oC aerobically at 250 rpm on a rotary shaker. 
 
Table 2.7 S. aureus strains used in this study. EryR, erythromycin resistance; KanR, kanamycin resistance; LinR, lincomycin resistance; TetR, tetracycline resistance. 
Strain Relevant genotype/markers Source/reference 
SH1000 Functional rsbU+ derivative of 8325-4 (Horsburgh et al., 2002) 
RN4220 Restriction negative, modification positive strain (Kreiswirth et al., 1983) 
SJF4276 USA300 JE2. USA300 LAC strain cured of plasmids p01 and p03 (Fey et al., 2013) 
NewHG Functional sae derivative of Newman (Mainiero et al., 2010) 
Newman Constitutively active sae strain (Duthie & Lorenz, 1952) 
SJF3661 lukAB (unmarked deletion) Victor J. Torres (Dumont et al., 2011) 
JC001 NewHG ssl13- ssl14- ssl15- KanR This study 
JC002 JC001, pJC001 inserted at lipase  ssl13+ ssl14+ ssl15+ KanR TetR This study JC003 JC001, pKasbar inserted at lipase KanR TetR This study JC004 NewHG, pJC001 inserted at lipase TetR This study JC005 NewHG, pKasbar inserted at lipase TetR This study 
NE27-SH (SH1000) nos::Tn bursa aurealis EryR LinR This study 
NE92-SH (SH1000) qoxA::Tn bursa aurealis EryR LinR This study 
NE95-SH (SH1000) agrB::Tn bursa aurealis EryR LinR This study 
NE229-SH (SH1000) Hypothetical protein SAOUHSC_02152 disrupted by Tn bursa aurealis EryR LinR This study 
NE460-SH (SH1000) atl::Tn bursa aurealis EryR LinR This study 
NE522-SH (SH1000) purB::Tn bursa aurealis EryR LinR This study 
NE529-SH (SH1000) purA::Tn bursa aurealis EryR LinR This study 
NE573-SH (SH1000) ribBA::Tn bursa aurealis EryR LinR This study 
NE594-SH (SH1000) gltA::Tn bursa aurealis EryR LinR This study 
NE635-SH (SH1000) ribE::Tn bursa aurealis EryR LinR This study 
NE821-SH (SH1000) pabA::Tn bursa aurealis EryR LinR This study 
NE873-SH (SH1000) agrC::Tn bursa aurealis EryR LinR This study 
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Strain Relevant genotype/markers Source/reference 
NE896-SH 
(SH1000) Hypothetical protein SAOUHSC_00938 
disrupted by Tn bursa aurealis EryR LinR 
This study 
NE912-SH (SH1000) clpP::Tn bursa aurealis EryR LinR This study 
NE1048-SH (SH1000) pyrP::Tn bursa aurealis EryR LinR This study 
NE1253-SH (SH1000) murQ::Tn bursa aurealis EryR LinR This study 
NE1267-SH (SH1000) pemK::Tn bursa aurealis EryR LinR This study 
NE1296-SH (SH1000) saeS::Tn bursa aurealis EryR LinR This study 
NE1299-SH (SH1000) yjbK::Tn bursa aurealis EryR LinR This study 
NE1304-SH (SH1000) araC::Tn bursa aurealis EryR LinR This study 
NE1315-SH (SH1000) mecA::Tn bursa aurealis EryR LinR This study 
NE1354-SH (SH1000) hla::Tn bursa aurealis EryR LinR This study 
NE1391-SH (SH1000) odhB::Tn bursa aurealis EryR LinR This study 
NE1434-SH (SH1000) cyoE::Tn bursa aurealis EryR LinR This study 
NE1509-SH (SH1000) bmrA::Tn bursa aurealis EryR LinR This study 
NE1532-SH (SH1000) agrA::Tn bursa aurealis EryR LinR This study 
NE1536-SH (SH1000) gcvH::Tn bursa aurealis EryR LinR This study 
NE1604-SH 
(SH1000) Unnamed ABC transporter 
SAOUHSC_02763 disrupted by Tn bursa aurealis 
EryR LinR 
This study 
NE1622-SH (SH1000) saeR::Tn bursa aurealis EryR LinR This study 
NE1775-SH (SH1000) lipA::Tn bursa aurealis EryR LinR This study 
NE1908-SH (SH1000) ybhF_2::Tn bursa aurealis EryR LinR This study 
NE27-USA (USA300) nos::Tn bursa aurealis EryR LinR This study 
NE92-USA (USA300) qoxA::Tn bursa aurealis EryR LinR This study 
NE95-USA (USA300) agrB::Tn bursa aurealis EryR LinR This study 
NE229-USA 
(USA300) Hypothetical protein SAUSA300_1119 
disrupted by Tn bursa aurealis EryR LinR 
This study 
NE460-USA (USA300) atl::Tn bursa aurealis EryR LinR This study 
NE522-USA (USA300) purB::Tn bursa aurealis EryR LinR This study 
NE529-USA (USA300) purA::Tn bursa aurealis EryR LinR This study 
NE573-USA (USA300) ribBA::Tn bursa aurealis EryR LinR This study 
NE594-USA (USA300) gltA::Tn bursa aurealis EryR LinR This study 
NE635-USA (USA300) ribE::Tn bursa aurealis EryR LinR This study 
NE821-USA (USA300) pabA::Tn bursa aurealis EryR LinR This study 
NE873-USA (USA300) agrC::Tn bursa aurealis EryR LinR This study 
NE896-USA (USA300) Hypothetical protein SAUSA300_0903 
disrupted by Tn bursa aurealis EryR LinR 
This study 
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Strain Relevant genotype/markers Source/reference 
NE912-USA (USA300) clpP::Tn bursa aurealis EryR LinR This study 
NE1048-USA (USA300) pyrP::Tn bursa aurealis EryR LinR This study 
NE1253-USA (USA300) murQ::Tn bursa aurealis EryR LinR This study 
NE1267-USA (USA300) pemK::Tn bursa aurealis EryR LinR This study 
NE1296-USA (USA300) saeS::Tn bursa aurealis EryR LinR This study 
NE1299-USA (USA300) yjbK::Tn bursa aurealis EryR LinR This study 
NE1304-USA (USA300) araC::Tn bursa aurealis EryR LinR This study 
NE1315-USA (USA300) mecA::Tn bursa aurealis EryR LinR This study 
NE1354-USA (USA300) hla::Tn bursa aurealis EryR LinR This study 
NE1391-USA (USA300) odhB::Tn bursa aurealis EryR LinR This study 
NE1434-USA (USA300) cyoE::Tn bursa aurealis EryR LinR This study 
NE1509-USA (USA300) bmrA::Tn bursa aurealis EryR LinR This study 
NE1532-USA (USA300) agrA::Tn bursa aurealis EryR LinR This study 
NE1536-USA (USA300) gcvH::Tn bursa aurealis EryR LinR This study 
NE1604-USA 
(USA300) Unnamed ABC transporter 
SAUSA300_2407 disrupted by Tn bursa aurealis 
EryR LinR 
This study 
NE1622-USA (USA300) saeR::Tn bursa aurealis EryR LinR This study 
NE1775-USA (USA300) lipA::Tn bursa aurealis EryR LinR This study 
NE1908-USA (USA300) ybhF_2::Tn bursa aurealis EryR LinR This study 
JC006 
JE2-pabA, pJC002 inserted at lipase  – pabA+ EryR 
LinR TetR 
This study 
JC007 
JE2-pabA, pKasbar inserted at lipase EryR LinR 
TetR 
This study 
JC008 
JE2, pJC002 inserted at lipase  – pabA+ EryR LinR 
TetR 
This study 
JC009 JE2, pKasbar inserted at lipase EryR LinR TetR This study 
JC010 
SH-pabA, pJC002 inserted at lipase  – pabA+ EryR 
LinR TetR 
This study 
JC011 SH-pabA, pKasbar inserted at lipase EryR LinR TetR This study 
JC012 
SH1000, pJC002 inserted at lipase  – pabA+ EryR 
LinR TetR 
This study 
JC013 SH1000, pKasbar inserted at lipase EryR LinR TetR This study 
 
2.3.3 E. coli strains 
 
The standard growth and storage conditions of E. coli strains was that of S. aureus 
(section 2.3.2), but LB media was used alternatively to BHI. All E. coli strains from this 
study are listed in Table 2.8. 
 
Table 2.8 E. coli strains used in this study. Strain  Relevant genotype/Markers  Source  TOP10  F- (mrr-hsdRMS-mcrBC(ara-leu) 7697 galK rpsL (StrR) endA1 nupG  
Invitrogen  
BL21 (DE3)  F  ompT hsdSB (rB- mB ) gal dcm lacY1 (DE3)  Novagen   
2.3.4 Plasmids 
 
Plasmids used in this study were purified using QIAGEN kits (section 2.11.4) and 
stored at -20oC in elution buffer or nuclease free sdH2O. 
 
Table 2.9 Plasmids used in this study. Plasmid  Relevant genotype/Markers  Source  pET-21d  His6-tag overexpression vector; AmpR Novagen  pKASBAR  Hybrid vector of pCL84 and pUC18 for integration into S. aureus lipase gene (geh), attP; TetR (S. aureus), SpecR (E. coli)  
K. Wacnik and B. Salamaga, unpublished  pGM073  pKASBAR derivative with improved MCS containing ezrA-psmOrange; attP, TetR (S. aureus), AmpR (E. coli)  
G. McVicker, unpublished  
pGL485  CatR derivative of E. coli-S. aureus shuttle vector pMJ8426, containing E. coli lacI gene under the control of a constitutive promoter; SpecR (E. coli), CatR (S. aureus) , KanR 
J. Garcia-Lara, unpublished  
pOB1 Streptococcus faecalis derived shuttle vector; AmpR (E. coli), EryR (S. aureus) (Oliver et al., 1977) pOB_UF_Kan_DF ssl12, ssl13, ssl14 deletion construct derived from pOB1; AmpR, EryR, KanR This study pJC001 pGM073 containing ssl12, ssl13 and ssl14 and upstream control elements; TetR This study pJC002 pGM073 containing the pab operon, pabA, pabB and pabC and upstream control elements; TetR 
This study 
pSSL12 pET21d containing ssl12 gene, AmpR This study pSSL13 pET21d containing ssl13 gene, AmpR This study pSSL14 pET21d containing ssl14 gene, AmpR This study  
2.3.5 Bacteriophage 
 
between strains (Mani et al., 1993) -transducing phage of 
serological group B, requiring Ca2+ to establish  infection (Novick, 1991). 
 
2.4 Enzymes and chemicals 
 
The chemicals used in this study were analytical grade, purchased from Fisher 
Scientific, Roche or Sigma-Aldrich. Restriction enzymes, T4 DNA ligase, dNTPs and 
their corresponding buffers were all purchased from New England Biolabs or Promega 
and stored at -20oC. Storage and concentration of stock solutions is given in Table 2.10 
 
Table 2.10 Maintenance of stock chemicals used in this study. 
Stock solution Storage temperature Concentration Solvent 
Lysostaphin -20oC 5 mg ml-1 20 mM sodium acetate Lysozyme -20oC 10 mg ml-1 dH2O -D-1-thiogalactopyranoside (IPTG) -20
oC 1M dH2O 
 
2.5 Buffers and stock solutions 
 
All buffers and stocks solutions used in this work were prepared with dH2O and 
autoclaved if required, then stored at room temperature or 4oC, unless stated otherwise. 
Methods for the preparation of buffers and stock solutions can be found in Sambrook & 
Russell, (2001), unless otherwise stated. 
 
2.5.1 Amino acid stock solutions 
 
Stock solutions of the amino acids glycine, methionine and serine, at 100x the working 
concentration of CDM (Table 2.1) were prepared and autoclaved. 
Glycine       14.29 g l-1 
L-Methionine       14.29 g l-1 
L-Serine       14.29 g l-1 
Stock solutions were used to supplement CDM media minus the above amino acids, as 
required. 
 
2.5.2 DNA loading buffer (6x)  
 
Bromophenol blue       0.25% (w/v) 
Xylene cyanol FF       0.25% (w/v) 
Glycerol        30% (v/v) 
 
2.5.3 Phosphate buffered saline (PBS) 
 
NaCl         8 g l-1  
Na2HPO4        1.4 g l-1  
KCl         0.2 g l-1  
KH2PO4        0.2 g l-1  
 
The pH was adjusted to 7.4 using NaOH. 
 
2.5.4 TAE (50x) 
 
Trisma base        242 g l-1  
Glacial acetic acid       0.57 % (v/v)  
Na2EDTA pH 8.0       0.05M  
 
The buffer was diluted 1:50 with dH2O before use. 
 
2.5.5 Recombinant protein refolding buffers  2.5.5.1 L-Arginine base refolding buffer (880 mM)  
 
L-Arginine 1M      300 ml  
Tris-HCl pH 7.5 1M      18.76 ml  
NaCl 5M       1.43 ml  
KCl 1M       300 µl 
dH2O        19.51 ml  
Volumes of each component were adjusted depending on volume of buffer required. 
 
2.5.5.2 50 mM L-Arginine, L-Glutamic acid base refolding buffer (50 mM) 
 
L-Arginine 112 mM      150 ml  
L-Glutamic acid 112 mM     150 ml  
Tris-HCl pH 7.5 1M      18.76 ml  
NaCl 5M       1.43 ml  
KCl 1M       300 µl 
dH2O        19.51 ml  
 
Volumes of each component were adjusted depending on volume of buffer required. 
 
2.5.6 E3 solution (10x) 
 
NaCl         50 mM  
KCl         1.7 mM  
CaCl2         3.3 mM  
MgSO4        3.3 mM 
 
Methylene blue was added to a final concentration of 0.00005% (w/v) to prevent fungal 
growth (Nusslein-Volhard & Dahm, 2002). The 10x solution was diluted to 1x using 
sdH2O. 
 
2.5.7 Methylcellulose 
 
E3 solution minus methylene blue was used to dissolve methylcellulose to a 
concentration of 3% (w/v). Repeated freezing and thawing was done to aid 
methylcellulose solubility. Aliquots of 10 ml in sterile syringes were sored long-term at 
-20oC. For use and short-term storage, methylcellulose syringes were kept at 28.5oC. 
 
    
2.5.8 HiTrap  column buffers  2.5.8.1 START buffer 
 
NaPO4        0.1M  
NaCl         0.5M  
sdH2O        to 1 l  
 
8M urea or 6M guanidine was added for insoluble protein purification. 
 
2.5.8.2 Elution buffer 
 
START buffer containing:  
Imidazole        0.5M 
 
2.5.9 Phage buffer 
 
MgSO4        1 mM  
CaCl2         4 mM  
Tris-HCl pH 7.8       50 mM  
NaCl         0.6% (w/v)  
Gelatin        0.1% (w/v) 
 
2.5.10 QIAGEN buffers  2.5.10.1 QIAGEN Buffer P1 
 
Tris-HCl pH 8       50 mM  
EDTA        10 mM  
RNase A        100 µg ml-1 
 
2.5.10.2 QIAGEN Buffer P2 
 
NaOH         200 mM  
SDS         1 % (w/v) 
2.5.10.3 QIAGEN Buffer P3 
 
Potassium acetate pH 5.5      3.0M 
 
2.5.10.4 QIAGEN Buffer EB 
 
Tris-HCl pH 8.5       10 mM 
 
2.5.10.5 QIAGEN Buffer N3, QG, PB and PE 
 
Supplied with the QIAquick kit; details of solution contents not provided. 
 
2.5.11 SDS-PAGE solutions  2.5.11.1 SDS-PAGE reservoir buffer (10x) 
 
Glycine        144 g l-1  
Tris base        30.3 g l-1  
SDS         10 g l-1 
 
The buffer was diluted to 1:10 with dH2O before use. 
 
2.5.11.2 SDS-PAGE loading buffer (2x)  
 
Tris-HCl pH 6.8       0.62M 
SDS         10 % (w/v) 
Glycerol        20 % (v/v) 
Bromophenol blue       0.1 % (w/v) 
 
-mercaptoethanol was added to the buffer prior to use. 
 
2.5.11.3 Coomassie Blue staining solution 
 
Coomassie blue       0.1 % (w/v)  
Methanol        5 % (v/v)  
Glacial acetic acid       10 % (v/v) 
 
2.5.11.4 Destain solution 
 
Methanol        5 % (v/v)  
Glacial acetic acid       10 % (v/v) 
 
2.5.12 Southern blotting buffers and solutions  2.5.12.1 Depurination solution 
 
HCl         250 mM 
 
2.5.12.2 Denaturing buffer 
 
NaOH         0.5M 
NaCl         1.5M 
 
2.5.12.3 Neutralising buffer 
 
Tris-HCl (pH 7.5)       0.5M 
NaCl         3M 
 
2.5.12.4 SSC (20x) 
 
NaCl         3M 
Tri-sodium citrate·2H2O      300 mM 
 
1M NaOH was used to adjust to pH 7. All other SSC concentrations were prepared from 
20x, by dilution with sdH2O. 
 
2.5.12.5 Pre-hybridisation solution 
 
SSC         5× 
Blocking reagent (Roche)      1% (w/v) 
N-lauroylsarcosine, Na salt      0.1% (w/v) 
SDS         0.02% (w/v) 
 
2.5.12.6 Hybridisation solution 
 
Digoxigenin-labelled probes were added to pre-hybridisation solution (section 2.5.12.5) 
to 5-25 ng ml-1. 
 
2.5.12.7 Wash solution (2x) 
 
SSC         2× 
SDS         0.1% (w/v) 
 
2.5.12.8 Wash solution (0.5x) 
 
SSC         0.5× 
SDS         0.1% (w/v) 
 
2.5.12.9 Maleic acid buffer 
 
Maleic acid        0.1M 
NaCl         0.15M 
 
The pH was adjusted to 7.5 with solid NaOH. 
 
2.5.12.10 Washing buffer  
 
Maleic acid buffer containing 3% (v/v) Tween 20. 
 
2.5.12.11 Blocking solution 
 
Maleic acid buffer containing 1% (w/v) blocking reagent (Roche), dissolved by heating 
and stored at -20oC. 
 
2.5.12.12 Antibody solution 
 
 ml-1 Anti-digoxigenin-AP conjugate (Roche). 
 
2.5.12.13 Detection buffer 
 
Tris-HCl (pH 9.5)       100 mM 
NaCl         100 mM 
MgCl2·6H2O        50 mM 
 
The pH was adjusted to 7.5 using 1M NaOH. 
 
2.5.12.14 TE buffer 
 
Tris-HCl        1 mM 
EDTA        0.1 mM 
 
The pH was adjusted to 7.5 using 1M HCl before autoclaving. 
 
2.6 Determining bacterial cell density  2.6.1 Spectrophotometric measurement (OD600) 
 
Spectrophotometric measurements at 600 nm (OD600) were used to quantify bacterial 
yield. A Jenway 6100 spectrophotometer or a Biochrom WPA Biowave DNA 
spectrophotometer were used to measure OD600. Samples were diluted 1:10 with fresh 
media when necessary to reduce concentration to a measurable level. 
 
2.6.2 Direct cell counts (CFU) 
 
The bacterial CFU was determined using the method devised by Miles et al., (1938). 
Samples were serially diluted 1:10 and 10 µl drops from each dilution applied to the 
surface of well dried agar plates. Plates were incubated overnight at 37oC and the 
dilution producing visible colonies was used to determine CFU. 
 
2.7 Centrifugation 
 
The following centrifuges were used for harvesting cells or precipitated material: 
 
i. Eppendorf microfuge 5415D; max volume of 2 ml, max speed of 13,200 rpm (10,000 
x g).  
 
ii. Sigma centrifuge 4K15C; max volume of 50 ml, max speed of 5,100 rpm (5525 x g).  
 
iii. Jouan centrifuge JAC50.10; max volume of 50 ml, max speed of 13,000 rpm (10,000 
x g).  
 
iv. AvantiTM J25I (Beckman); max volumes and speeds depend on the rotor.  
JA-20; max volume of 50 ml, max speed of 20,000 rpm (48,384 x g).  
JA-10.5; max volume of 500 ml, max speed of 10,000 rpm (18,480 x g). 
 
v. Falcon 6/300R (Sanyo); max volume of 750 ml, max speed 5,600 rpm (7,047 x g). 
 
2.8 Growth curves 
 
Strains were streaked from Microbank vials onto BHI plates containing suitable 
antibiotics (section 2.3.1). A single colony was used to inoculate 5 ml BHI (no 
antibiotics) in a sterile 25 ml Universal tube, which was incubated overnight at 37oC, 
aerated by shaking at 250 rpm on a rotary shaker. The overnight culture was used to 
inoculate 50 ml of pre-warmed BHI (no antibiotics), from the same batch as the 
overnight culture, to an OD600 of 0.01. For non-CDM growth experiments triplicate 
cultures were grown at 37oC in a Grant OLS 200 water-bath with shaking equivalent to 
250 rpm. Growth was monitored by OD600 (section 2.6.1) or direct cell counts (section 
2.6.2) until stationary phase. For CDM experiments triplicate cultures were grown at 
37oC on a rotary shaker at 250rpm. Growth was monitored by OD600 (section 2.6.1) 
over 24-48 h. 
 
 
 
2.9 Transformation techniques  2.9.1 Transformation of E. coli   2.9.1.1 Preparation of E. coli electrocompetent cells 
 
E. coli Top10 or E. coli BL21 was streaked onto LB agar and incubated at 37oC 
overnight. A single colony was used to inoculate 5 ml of LB in a 25 ml sterile 
Universal, which was incubated at 37oC, aerated on a rotary shaker at 250 rpm. 400 ml 
of pre-warmed LB was inoculated using the pre-culture to an OD600 of 0.05, and 
incubated at 37oC, aerated on a rotary shaker at 250 rpm until an OD600 of 0.5-0.7 was 
reached. The culture was gently rotated by hand in ice-slurry for 15 min to cool, at 
which point the cells were harvested by centrifugation in 4x100 ml aliquots at 5,100 
rpm, at 4oC for 10 min. Cells were washed 3 times with 25 ml of ice-cold sdH2O, then 
merged into one tube. After centrifugation at 5,100 rpm, at 4oC for 10 min the pellet 
was resuspended in 10% (v/v) ice-cold glycerol. Cells were divided into 50 µl aliquots, 
snap frozen in liquid nitrogen and stored at -80oC. 
 
2.9.1.2 Transformation of E. coli electrocompetent cells 
 
50 µl aliquots of electrocompetent E. coli were thawed on ice and 5 µl (approximately 
1ng) of plasmid DNA was added. The sample was transferred to a 1 mm pre-chilled 
(Bio-Rad) electroporation cuvette. A Gene Pulser system set at 200  
µF was then used to electroporate the cells. 400 µl of room-temperature LB was 
immediately added to the cuvettes to recover the bacteria and transferred to 37oC for 60 
min. 100 µl of cells were then spread on LB agar plates containing the selective antibiotic 
and incubated at 37oC for 24 h. 
 
2.9.2 Transformation of S. aureus  2.9.2.1 Preparation of S. aureus electrocompetent cells  
 
S. aureus RN4220 was streaked onto BHI agar and incubated overnight at 37oC. A 
single colony was used to inoculate 400 ml of BHI, which was grown for 10-12 h at 
37oC, aerated on a rotary shaker at 250 rpm. The culture was then used to inoculate 400 
ml of pre-warmed BHI to an OD600 of 0.1. This culture was grown for 60-90 min at 
37oC, shaking at 250 rpm to give and OD600 of 0.4-0.6. Cells were harvested by 
centrifugation of 5,100 rpm at room temperature for 10 min in 4x100 ml aliquots. Cells 
were washed 3 times with 25 ml sdH2O, then merged into one tube. The pellet was 
resuspended in 20 ml 10% (v/v) glycerol and centrifuged for 10 min at 5,100 rpm. The 
pellet was resuspended in 10 ml 10% (v/v) glycerol and incubated at room temperature 
for 30 min. Centrifugation at 5,100 rpm at room temperature for 10 min was again used 
to harvest the cells. Cells were then resuspended in 500 µl 10% (v/v) glycerol. Cells 
were split into 50 µl aliquots and used immediately for transformation. 
 
2.9.2.2 Transformation of S. aureus by electroporation 
 
To each 50 µl aliquot of S. aureus RN4220 prepared in section 2.9.2.1, approximately 1 
µg of plasmid DNA was added. The sample was transferred to a 1 mm (Bio-Rad) 
electroporation cuvette. A Gene Pulser system set at 100 , 2.3 kV and 25 µF was then 
used to electroporate the cells. Cells were recovered by immediate addition of 1 ml BHI and 
incubation at 37oC for 3 h, at 250 rpm on a rotary shaker. Cells were spread on BHI agar 
plates, with selective antibiotic, in 200 µl aliquots and incubated for 48 h at 37oC.  
 
2.10 Phage techniques  2.10.1 Preparation of phage lysates 
 
A single colony of donor strain was used to inoculate 5 ml of BHI containing 
appropriate antibiotics and grown overnight at 37oC. Using the overnight culture, 5 ml 
of BHI was inoculated to a starting OD600 of 0.2 in a sterile 25 ml Universal tube. 5 ml 
of phage buffer and 100 µl of stock phage lysate ( 11) were added and the mixture 
incubated stationary at 25oC for 4-6 h. Once cleared, the lysate was filter sterilised through 
a 0.2 µm pore syringe filter and stored at 4oC. This method allowed for the production of 
lysates with titres of approximately 1010 plaque forming units (PFU) per ml. 
 
2.10.2 Determination of phage titres 
 
A single colony of S. aureus SH1000 was used to inoculate 5 ml of BHI, which was 
grown to an OD600 of 0.5-0.7 at 37oC, shaking at 250 rpm. Phage lysate was serially 
diluted in phage buffer, by addition of 100 µl aliquots to 900 µl aliquots of phage buffer 
and 100 µl of each dilution added to 400 µl of S. aureus SH1000 culture with 50 µl of 
1M CaCl2. The samples were then incubated stationary at room temperature for 10 min, 
and then 5 ml of LK top agar was added to each sample. The mixtures were then poured 
over LK bottom agar plates, overlaying the bottom agar, and were incubated for 48 h 
are 37oC. Plaques were then counted and multiplied by the dilution factor; a range of 
107  1010 confirmed a successful lysate. 
 
2.10.3 Phage transduction 
 
The recipient strain was grown overnight in 50 ml of LK and the cells were harvested 
by centrifugation at 5,100 rpm for 10 min. The pellet was resuspended in 1 ml of LK 
and 500 µl of cells was added to 500 µl of phage lysate and 1 ml of LK containing 10 
mM CaCl2 in a 25 ml Universal tube. A second Universal tube containing 500 µl of 
cells, 1 ml of LK containing 10 mM CaCl2, but no phage, was used as a control. The 
samples were incubated stationary for 25 min at 37oC, then for a further 15 min at 37oC 
shaking at 250 rpm. Immediately after incubation, 1 ml of ice-cold 0.02M sodium 
citrate was added and the mixtures were placed on ice for 5 min. Cells were harvested 
by centrifugation at 5,100 rpm, at 4oC for 10 min. The pellet was resuspended in ice-
cold 0.02M sodium citrate and incubated on ice for 45 min. 100 µl and 200 µl aliquots 
were spread onto LK agar plates containing 0.05% (w/v) sodium citrate, plus selective 
antibiotic. Once dry, the plates were incubated at 37oC for 24-72 h. Colonies that 
formed were patched onto BHI agar containing the appropriate antibiotic, to determine 
that colonies had the correct resistance profile. 
 
2.11 DNA purification techniques  2.11.1 Gel extraction (Qiaquick) 
 
DNA was separated on a 1% (w/v) TAE agarose gel, stained with ethidium bromide. A 
sterile scalpel blade was used to excise the required band, visualised on a UV 
transilluminator. Purification of DNA from the agarose gel slice was carried out using 
the QIAGEN QIAquick gel extraction kit. After weighing the gel slice, 3x gel slice 
volume of buffer QG were added. The gel slice was incubated at 60oC for 10-15 min 
with frequent gentle mixing, until the gel was completely dissolved. If the dissolved gel 
solution had an orange colour, the pH was above 7.5. 10 µl of 3M sodium acetate pH 5 
was added to lower the pH below 7.5 to allow binding to the silica membrane. After 
addition of 1 gel volume of isopropanol, the sample was applied to the QIAquick spin 
column and centrifuged at 13,000 rpm for 1 min, allowing binding of the DNA to the 
membrane and loss of dissolved gel. The column was washed by passing 500 µl of 
buffer QG through the column, by centrifugation at 13,000 rpm for 1 min. The column 
was washed again with 750 µl of buffer PE, passed through the column by 
centrifugation at 13,000 rpm for 1min. Residual ethanol was removed from the column 
by a further centrifugation step at 13,000 rpm for 1 min. The column was placed in a 
microcentrifuge tube and 50 µl of buffer EB was pipetted directly onto the centre of the 
column. After incubation for 1 min, the DNA was eluted by centrifugation at 13,000 
rpm for 1min. The sample was stored at -20oC. 
 
2.11.2 PCR purification (Qiaquick) 
 
DNA fragments from PCR and enzymatic reactions were purified with the QIAGEN 
QIAquick PCR purification kit. DNA samples were diluted 5x with buffer PB. The 
sample was then placed into a QIAquick spin column and centrifuged at 13,000 rpm for 
1 min. The flow through was discarded and the sample washed in 750 µl of buffer PE, 
centrifuged again at 13,000 rpm for 1 min and the column transferred to a 
microcentrifuge tube. The DNA was eluted by addition of 50 µl buffer EB, followed by 
centrifugation at 13,000 rpm. The sample was stored at -20oC. 
 
2.11.3 Genomic DNA preparation 
 
The QIAGEN DNeasyTM blood and tissue kit was used to purify S. aureus genomic 
DNA. 1 ml of overnight culture was centrifuged for 10 min at 13,000 rpm. The pellet 
was washed with 1 ml sdH2O and centrifuged at 13,000 rpm for 10 min. The cells were 
then resuspended in 180 µl of sdH2O and 10 µg ml-1 lysostaphin was added and samples 
were incubated for 1 h at 37oC. The DNA could then be purified using the 
th the DNeasy blood and tissue kit. Samples 
were stored at -20oC. 
 
 
 
2.11.4 Plasmid preparation 
 
E. coli. 3 ml of overnight culture of E. coli was centrifuged at 10,000 rpm for 1 min, to 
harvest the cells. The pellet was resuspended in 250 µl buffer P1 containing RNase A. 
Addition of buffer P2 to lyse the cells was followed by inverting the tube 4-6 times to 
ensure complete lysis. Within 5 min of starting the lysis reaction, 350 µl of neutralising 
buffer N3 was added and the tube was again inverted 4-6 times. The mixture was 
centrifuged at 13,000 rpm for 10 min to remove cellular debris, chromosomal DNA, 
precipitated protein and SDS. The supernatant was transferred to a QIAprep spin 
column and centrifuged for 1 min at 13,000 rpm. After discarding the flow-through, the 
column was washed with 750 µl buffer PE and centrifuged at 13,000 rpm for 1 min. To 
remove any remaining ethanol from the column, the column was centrifuged again at 
13,000 rpm for 1 min. The column was placed into a microcentrifuge tube and the 
plasmid DNA was eluted by pipetting 50 µl of EB buffer onto the centre of the column, 
and after 1 min incubation at room temperature, centrifuging the column for 1 min at 
13,000 rpm. The samples were stored at -20oC. 
 
2.11.5 Ethanol precipitation of DNA 
 
To enhance precipitation and aid in visualisation of the DNA pellet, 1 µl of glycogen 
(Roche) was added to DNA samples. 3M sodium acetate pH 5.2 was added to the 
purified DNA sample and 3x the sample volume of ice-cold ethanol was also added. 
The samples were then incubated at -20oC overnight to allow precipitation. Precipitated 
DNA was recovered by centrifugation for 15 min at 13,000 rpm at 4oC and the pellet 
was washed twice, without resuspension in 70% (v/v) ethanol. After air drying to 
remove any residual ethanol, the pellet was resuspended in buffer EB. 
 
2.12 In vitro DNA manipulation techniques  2.12.1 Polymerase chain reaction (PCR) techniques  2.12.1.1 Primer design 
 
The primers designed for this study are given in Table 2.11. They are short 
oligonucleotides (20-43 nucleotides) and their design was based on the genomes of S. 
aureus strains 8325-4, USA300 FPR3757 and Newman and the plasmid pGM073.  
Efficient digestion at restriction sites was permitted by addition of 6 bases (A or T) at 
-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). This tool allows the user to set the 
melting temperature of the primer to within a certain range. The tool also predicts non-
specific binding of the primers to sites outside the target site of the S. aureus genome 
and to sites within other available genomes, including Homo sapiens. The primers were 
manufactured by Eurofins MWG operon (http://www.eurofinsdna.com) and stored at 
2  
 
Table 2.11 Primers used in this study. Primer -  Application 
01124-F ATAATACCATGGCTATGTTATTACTATTAGGTACTGTATTACCTCAAAATC Amplification of each individual ssl for insertion into the pET21d overexpression plasmid   Also used to sequence the inserts 
01124-R ATAATACTCGAGATCAAAGAGGACGTCAACAGTTATTT 
01125-F ATAATACCATGGCTATGTTGTTACTATTAGGTACAGCATCTACACAA 
01125-R ATAATACTCGAGGTTTGATTTTTCGAGGATAACTTCAA 
01127-F ATAATACCATGGCTATGTTGTTACTTTTAGAAACTACATCAACACAA 
01127-R ATAATACTCGAGGTTAGATTTTTCGAGTATGACTTCAATTT 
FU CGGGCGGTACCATTTGTTGACCTATTTTCGTATCAGC Construction of the ssl deletion construct RU CGGCCGTCGACAAATCTCCTTTGCGTGAATTACC 
FD CGGCGGTCGACTGACTTATACTTCATGCACTTTAATTCC 
RD CGGGCGCATGCATGATGAGTGATTATTTTAAGAATATGTTTT 
KanF GGCGGGTCGACCAGCGAACCATTTGAGG 
KanR GGGGCGTCGACAATTCCTCGTAGGCGCTCGG 
isdA-F GATTATGAAATATCTATGACATAGG Amplify isdA, used as a control to confirm S. aureus DNA. isdA-R GTTATACGAAAATAGATGTGCTAG 
tripF ATAATAGGGCCCGCACATCGCGTTCTTGTAGA Amplify the ssl triplet for  
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Primer  6 H T X H Q F H    ¶-  ¶   Application 
tripR 
ATAATACCTCAGCTTGGGGAGTGACAAC
GAAAT 
(cont.) 
complementation 
Tset1F GCACATCGCGTTCTTGTAGA 
Sequencing 
primers for the ssl 
triplet 
Tset1R TGCGGCTGAGTGTAATATTTGAT 
Tset2F TCAAATATTACACTCAGCCGCA 
Tset2R GGAAATTGTGTAGATGCTGTACCT 
Tset3F AGGTACAGCATCTACACAATTTCC 
Tset3R TCAGAGGAATCATGATACGAGGA 
Tset4F CGCAAATACTATATTGACTTCGCTC 
Tset4R CTTGGGGAGTGACAACGAAAT 
pGM-F CGAGTCAGTGAGCGAGGAAG 
Amplify the 
pGM073 plasmid 
from either side of 
the insertion site. 
Confirms 
successful 
integration of 
plasmid backbone 
or construct 
pGM-R GTATCTGCCCTTTTTCTGCCC 
pab-F 
ATAATAGGGCCCATTGTACTGTCTTGACC
ACCACT Cloning primers 
for the pab operon 
pab-R 
ATAATACTCGAGATACGTATACAAGAATT
AACAACAGCA 
pab1-F CCACCACTAAAGACAACGATGG 
Sequencing 
primers for the 
pab operon 
pab1-R TGCACACCAAAAACCGGAAA 
pab2-F TGACGGAGCGACTTTTCCAA 
pab2-R GCCACTCTGTGATATTCTCCCT 
pab3-F CCGATGAAAGGGACAATGCC 
pab3-R CCTTGCCGTCCTCTGAAGTT 
pab4-F ACGACAGAACGAAAGCATTTAGC 
pab4-R ACGTATACAAGAATTAACAACAGCA 
NE27F TCATTCCAATAACTTTCAGCCA Each of the 
primers in this 
section was used 
to determine the 
presence of the Tn 
bursa aurealis, 
inserted in a 
specific gene in 
the strain 
corresponding to 
NE27R AAGTGATTTGCTAAGCGTGT 
NE92F CTTCTTTCACCCATTTGTCGT 
NE92R TTGCTTCTATTATTTGGCACACT 
NE95F CCATCACATCTCTGTGATCTAGT 
NE95R TGG GCA AAT GGC TCT TTG AT 
NE213F GGCCGAAAAAGATTGGTGGC 
NE213R CGTCCTGGATAGCCTTCAGC 
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Primer  6 H T X H Q F H    ¶-  ¶   Application 
NE229F CCGATATGATTATACAAGGGGCA (cont.) 
the NE number 
given in the 
primer name. 
NE229R TCTTTCCAAAACGAACCATCA 
NE460F TGTTGTAAACCACATCGCCT 
NE460R ACATGCATTTGTTGATGGGG 
NE522F ATGTTTGCGTTGATACAGGC 
NE522R TCGAGTATACATACGATAGGAGT 
NE529F TGCATTATGGTCTCGATATTGGT 
NE529R TTGCGCACCTTCGAAAAGTA 
NE573F TGTTCCGAAATCTGTAGGCA 
NE573R AGTACATTTAGAAACAGACGTTTTG 
NE594F CCTTTCAGAGAACCTACGGC 
NE594R TCATAAAGAAACAGTAAAGGGGA 
NE635F TCCACAGTAATAGACCCTTGC 
NE635R GGAACTTTGCTAGTTGAGGC 
NE821F ATGGCATTGATAAGCCCGTT 
NE821R TGCTGTAATCTTTAAGCAATTTGG 
NE873F AGAGCCATTTGCCCAATTCA 
NE873R AAGTAAGCAGTAAGATAGTCGAAA 
NE896F AAAACGAGAGAAGGGGCTTG 
NE896R CGG ACA TCC TAT GCT AAG AAA 
NE912F CGACATTGCGGGATTCTCTG 
NE912R CCTTGAGCACCACCTAATGG 
NE1048F ACTTGTCACACTTTTTGTCTCT 
NE1048R GCATCAAATTTCACAATCCCCA 
NE1253F ACGCTTAGTGCACATGACAA 
NE1253R AACTTTTCCGACACCAACCA 
NE1267F AGCTTTTTATCTTCTGTGCTAAGT 
NE1267R AGTTAGATTGCTTTTAGCATTAGGA 
NE1296F CTCATGATCCTTAGTGATTATACCA 
NE1296R TGTAAATGGTCACGAAGTCCC 
NE1299F TCGAACTCTAACTCATAATCCGT 
NE1299R ACGAGCATTTGTCCTACTTCA 
NE1304F TCCAAATTTTGCTTACTATCTTTCT 
NE1304R CACAGTCTATGAACACCGGA 
NE1315F AAGTGCTTTAATGCTTTAACTGT 
NE1315R TGACTTCTTGATCAACATGACTAT 
NE1354F CGAAGTCTGGTGAAAACCCT 
  
Table 2.11 continued 
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Primer  6 H T X H Q F H    ¶-  ¶   Application 
NE1354R TGAATCCTGTCGCTAATGCC 
 
NE1391F TTCGTAATCATGTCGTCGCC 
NE1391R ACG TAG GGG ATA GCG TAG AA 
NE1434F CTTAATTCCGGCTTTTGCGG 
NE1434R TGTGTTGCCCATTTTGTTTGA 
NE1509F ACGCTCAGTTTTATGGGAGC 
NE1509R TGTTCAAATGACAATACACCGTC 
NE1532F TCATTTGCGAAGACGATCCA 
NE1532R CCGATGCATAGCAGTGTTCT 
NE1536F AGTTGAATAGCATCTAGCCTTATG 
NE1536R CGGTTATATGCTTTTTGCTCCTT 
NE1604F ACGTGGCAGCTTGAATATCAT 
NE1604R ACAAGGGACACGTGAATCAG 
NE1622F CCCCATACAGTTGTGATGGTAT 
NE1622R GTCACTCATTGTTAAAACAGATTTC 
NE1775F ATGCCTAATTGGGAACCTGG 
NE1775R AACTTGCCAGATACCTCTGC 
NE1908F CGGGTTATCCATCGAATTTGC 
NE1908R GGTGTTGGTAAAACAACCGT 
 
2.12.1.2 PCR amplification 
 
2.12.1.2.1 Taq polymerase 
 
Taq polymerase (Promega) was used for standard PCR amplification when product 
accuracy was not required. The following components were added to 0.5 ml thin-walled 
PCR tubes 
 
Template DNA       100 - 500 ng 
Forward primer       300 nM* 
Reverse primer       300 nM* 
10x Taq PCR buffer (Promega)          O  
MgC12        1.5 - 4.5 mM* 
dNTPs        0.2 mM* 
Taq DNA polymerase            O  (2.5 Units) 
dH2O          W R       O  
*final concentration 
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Amplifications were carried out using a TC-3000 (Techne) PCR machine. The lid was 
preheated to 105
o
C for 4 min, and the following thermal cycling program was used:  
 
1 cycle Initial denaturation      95⁰C 5 min  
30 cycles Denaturation      95⁰C 30 s  
Annealing        56-60⁰C 30 s  – 1 min  
Extension        72⁰C 1 min kb-1 + 10%  
1 cycle Final extension      72⁰C 5 min  
 
 7 K H  U H D F W L R Q  S U R G X F W V  Z H U H  V W R U H G  D W  í  ⁰C.  
 
2.12.1.2.2 Phusion polymerase 
 
 ) R U   D P S O L I L F D W L R Q V   U H T X L U L Q J    ¶-  ¶   S U R R I U H D G L Q J   D F W L Y L W \    W K H   K L J K   I L G H O L W \   3 K X V L R Q 
polymerase (New England Biolabs) was used. The following master mix was prepared 
on ice: 
 
Template DNA      10-250 ng 
5x Phusion HF buffer      10 µl 
10 mM dNTPs      1 µl 
10 µM forward primer     2.5 µl 
10 µM reverse primer      2.5 µl 
Phusion polymerase      0.5 µl 
Nuclease free H2O      to 50 µl 
 
The TC-3000 (Techne) PCR machine was used, as in section 2.12.1.2.1. The lid was 
preheated to 105
o
C for 4 min, and the following thermal cycling program was used: 
 
1 cycle Initial denaturation     98
o
C 30 s 
30 cycles Denaturation     98
o
C 10 s 
Annealing       56-60⁰C 10-30 s 
Extension       72oC 30 s kb-1 
1 cycle Final extension     72
o
C 5 min 
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The reaction products were stored at -20
o
C. 
 
2.12.1.3 E. coli colony PCR 
 
Taq polymerase reaction components were added to PCR tubes (as in section 
2.12.1.2.1) minus template DNA. A single colony was then patched onto an agar plate 
using a sterile pipette tip, and added to the reaction mix. The PCR reaction was that 
used in section 2.12.1.2.1. 
 
2.12.2 Restriction endonuclease digestion 
 
Restriction enzymes were purchased from Promega, or New England Biolabs and 
 U H V W U L F W L R Q   G L J H V W L R Q   R I   ’ 1 $   Z D V   F D U U L H G   R X W   D F F R U G L Q J   W R   W K H   P D Q X I D F W X U H U ¶ V 
instructions. Digestions were performed at 37
o
C for 1-2 h, depending on the enzyme 
used. Once digestion was complete, the enzymes were immediately deactivated at 70
o
C. 
The QIAquick gel extraction kit (section 2.11.1) was used to remove the restriction 
enzymes and buffers. 
 
2.12.3 Alkaline phosphatase treatment of vector DNA 
 
To significantly reduce self-ligation of digested vector DNA, calf intestinal alkaline 
 S K R V S K D W D V H    & , 3    Z D V   X V H G   W R   U H P R Y H   W K H    ¶   3 24 group from digested vector DNA. 
CIP was added to the digestion reaction mixture, after DNA digestion and inactivation 
 R I   W K H   U H V W U L F W L R Q   H Q ] \ P H    I R O O R Z L Q J   W K H   P D Q X I D F W X U H U ¶ V   L Q V W U X F W L R Q V    , Q F Xbation at 70oC 
for 30 min was used to deactivate CIP. The QIAquick gel extraction kit (section 2.11.1) 
was used to remove the CIP and buffers. 
 
2.12.4 DNA ligation 
 
Appropriate restriction enzymes were used to digest vector DNA and insert DNA. 
Vector and insert were then ligated, at different ratios of vector to insert. Reactions were 
performed in a 10 µl volume with 1 µl of 10x T4 DNA ligase buffer and 1 µl of 3 U µl
-1
 
T4 DNA ligase (Promega). The reactions were incubated overnight at 15
o
C. Ethanol 
precipitation (Section 2.11.4) was used to purify the ligations, which were then used to 
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transform electrocompetent cells. A ligation reaction was also prepared without insert 
DNA, as a negative control. 
 
2.12.5 Agarose gel electrophoresis 
 
Separation of DNA samples was normally carried out in a 1% (w/v) agarose gel in 1x 
TAE buffer. A 0.8% (w/v) agarose gel was used for Southern blotting experiments. 
Horizontal submerged gels were poured and run using horizontal electrophoresis tanks 
(Life Technologies, Scie-Plas). 4-10 µl of ethidium bromide (10 mg ml
-1
; BioRad or 
Fisher Scientific), was added to molten gel to enable DNA visualisation by UV 
transilliuminator. 
 
One fifth the sample volume of 6x DNA loading buffer was added and samples were 
loaded into the wells of the agarose gel. Gels were run for 40-70 min at 120 V at room 
temperature. Once run the gels were visualised and photographed using an UVi Tec 
Digital camera and UVi Doc Gel documentation system. DNA fragment size was 
assessed by electrophoresis of 5 µl of DNA ladder (Fisher Scientific) in a neighbouring 
well to the sample. 
 
2.12.6 Plasmid sequencing 
 
Plasmid insert DNA sequences were determined by the Core Genetics Service, 
University of Sheffield, using the primers listed in Table 2.11. Sequencing traces were 
analysed using Finch TV software (Geospiza). Alternatively, the GATC Biotech DNA 
sequencing service was used (https://www.gatc-biotech.com/en/index.html). The 
sequence accuracy was assessed using the Geneious software package (Biomatters 
Ltd.). 
 
2.13 Southern blotting 
 
All buffers used for Southern blotting are given in section 2.5.12. 
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2.13.1 Labelling of DNA probes with digoxigenin 
 
The Southern hybridisation probe was labelled with digoxigenin (DIG) using the DNA 
labelling and detection kit (Roche). DNA template (approximately 3 µg in a 5 µl 
volume) was denatured by boiling for 10 min and chilled on ice for a further 10 min. 
Added to the denatured probe template were 2 µl of 10x hexanucleotide mixture and 2 
µl of 10x dNTP labelling mixture. The volume was adjusted to 20 µl with sdH2O and 1 
µl of Klenow polymerase was added. The reaction was incubated for 20 h and 
terminated by addition of 200 mM EDTA pH 8.0. The labelled probe was purified using 
the QIAquick PCR purification kit (section 2.11.2) and stored at -20
o
C. 
 
2.13.2 Quantification of DIG-labelled DNA probes 
 
Probe concentration was quantified by comparison to DIG labelled control DNA 
(Roche). Control DNA was diluted and 1 µl of each dilution (from 1:20 to 1:2,000,000) 
were spotted onto positively charged, nylon membranes (Roche). The DNA was fixed 
to the membrane (see section 2.13.4) and detected immunologically using anti-DIG 
antibody solution. Spot intensities of the probe could then be compared with the known 
concentration of the control DNA. 
 
2.13.3 Membrane blotting 
 
Digested genomic DNA was separated by 0.8% (w/v) gel electrophoresis, as in section 
2.12.5, without ethidium bromide. DIG labelled DNA ladder (Roche) was 
electrophoresed in one lane, to allow assessment of band sizes. The gel was soaked in 
Southern depurination solution for 10 min, in order to nick large DNA molecules aiding 
transfer of DNA during blotting. After washing in dH2O, the gel was soaked 2 times in 
Southern denaturing solution for 15 min. The gel was then neutralised by soaking 2 
times in Southern neutralising solution for 15 min. The DNA was transferred from the 
gel to the surface of a Roche positively charged, nylon membrane (Figure 2.1).  
 
Capillary transfer was used to blot the nylon membrane with gel DNA. 1-3 pieces of 
Whatman paper were soaked in 20x SSC and placed on a bridge resting in a reservoir of 
20x SSC. The gel was placed on the Whatman paper, ensuring no air bubbles between 
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the gel and the paper. Before placing the gel on the Whatman paper, the edges of the 
bridge, covered by the Whatman paper, were covered by thin strips of Parafilm, so that 
when the gel is laid on the Whatman paper, the edges of the gel are on top of the 
Parafilm. This prevents the 20x SSC from being drawn up the outsides of the gel, 
ensuring that it passes through the middle of the gel, where the DNA is found. One dry 
piece of Whatman paper was laid over the gel and a stack of paper towels, a glass or 
plastic plate and a 500 g weight was placed on top. The DNA was allowed to transfer 
overnight at room temperature. 
 
2.13.4 Fixing the DNA to the membrane 
 
Roche positively charged nylon membranes were used for all Southern procedures. 
Once DNA was transferred to the membrane it was fixed with a UV crosslinker 
(Amersham Life Sciences RPN 2500), 70 mJ cm
2-1
 for 15 s. 
 
2.13.5 Pre-hybridisation and hybridisation 
 
Before probing of membranes with DIG-labelled probes, the membranes were pre-
hybridised for 1 h at 68
o
C in pre-hybridisation solution (20 ml per 100 cm
2
 of 
membrane). The membrane was then hybridised with 5-25 ng ml
-1
 probe in 
hybridisation solution, overnight at 68
o
C. The membrane was washed twice in 2x wash 
solution for 5 min at room temperature to remove unbound probe. The membrane was 
then washed twice in 0.5x wash solution for 15 min at 68
o
C. 
 
2.13.6 Colorimetric detection of DIG-labelled DNA 
 
The hybridised and stringency washed membrane was then gently agitated for 1 min in 
washing buffer. The membrane was then blocked for 30 min by gentle agitation in 
blocking solution and then transferred to antibody solution containing 1:5000 dilution of 
stock anti-DIG antibody (Roche) for 30 min. The membrane was then washed twice by 
gentle agitation in washing buffer for 15 min. The membrane was gently agitated in 
detection buffer for 2 min, then transferred to 10 ml of colour substrate solution 
containing 66 µl nitro-blue tetrazolium at 50 mg ml
-1
 in 70% (v/v) DMF and 33 µl BCIP 
at 50 mg ml
-1
. The colour was developed in the dark, and then the membrane was 
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Figure 2.1 Capillary transfer of DNA to nylon membranes.  
 
Imaged reproduced from Sambrook & Russell, (2001) 
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washed in 1x TE buffer to stop the reaction. The membrane was dried and stored in the 
dark. 
 
2.14 Protein analysis 
 
2.14.1 SDS-PAGE 
 
Resolving gels were prepared using the following components. Ammonium persulphate 
(APS) and N,N,N  ¶N  ¶-tetramethyl-ethylenediamine (TEMED) were added immediately 
prior to pouring, to avoid gel formation before pouring: 
 
11 % (w/v) resolving gel  
 
dH2O         3.5 ml  
1.5M Tris-HCl (pH8.8)      2.5 ml  
10 % (w/v) SDS            O   
30 % (w/v) Acrylamide/Bis (37.5:1,BioRad)    4 ml  
10 % (w/v) APS            O   
TEMED            O  
 
The above components were loaded into gel casting apparatus (Bio-Rad Mini-Protean II 
gel slabs). A layer of isopropanol was pipetted onto the top of the gel, to isolate the gel 
from the air and remove any bubble that may have formed. Once the gel had set the 
isopropanol was drained and the top of the gel washed with dH2O. Components of the 
stacking gel were then mixed and poured on top as follows: 
 
dH2O         2.5 ml  
0.5M Tris-HCl (pH 6.8)      0.62 ml  
10 % (w/v) SDS           O   
30 % (w/v) Acrylamide/Bis (37.5:1BioRad)          O   
10 % (w/v) APS           O   
TEMED           O  
 
Wells were formed in the gel by inserting a Bio-Rad plastic comb, which also isolated 
the stacking gel from the air. Once the gel had formed it was transferred to a Protean II 
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protein gel running tank (Bio-Rad) and submerged in 1x SDS-PAGE reservoir buffer 
(section 2.5.11.1). The comb was removed and samples of 5-20 µl in SDS-PAGE 
loading buffer (section 2.5.11.2) were loaded into the wells. Molecular weight markers 
of known sizes were also loaded to determine the size of sample bands. The proteins 
were separated by electrophoresis at 150 V until the dye front had migrated to the base 
of the plate. 
 
2.14.2 Coomassie staining 
 
Gels were placed in Coomassie Blue stain (section 2.5.11.3) for 30 min, to allow protein 
staining. Stain was removed from the gel by submersion in destain solution (section 
2.5.11.4) overnight. The gel was then washed in dH2O. 
 
2.14.3 Drying gels 
 
The washed gel was placed between two sheets of DryEase mini cellophane 
(Invitrogen), pre-soaked in Gel-Dry
TM
 Drying solution (Invitrogen). A mini-gel drying 
frame and base (Novex) was used to hold the gel and sheets, to allow drying at room 
temperature.  Images of the gels were taken once dried. 
 
2.15 Recombinant protein production 
 
2.15.1 Expression of recombinant proteins in E. coli BL21 
 
A single colony of E. coli BL21, containing pET21d with the required insert was used 
to inoculate 5 ml of LB containing 100 µg ml
-1
 Amp, in a sterile Universal tube. After 
overnight incubation, shaking at 250 rpm at 37
o
C, the culture was used to inoculate 
either 100 ml or 2 l of LB to an OD600 of 0.05, which was incubated at 37
o
C, shaking at 
250rpm, until an OD600 of 0.4-0.6 was reached. At this point 1 ml of sample was 
removed, to give an uninduced sample (see section 2.15.2) and 1 mM IPTG was added 
to induce protein expression. The culture was re-incubated for a further 3 h, as above. 
2x 1 ml samples were removed to give two induced samples (see section 2.15.2). Cells 
were harvested by centrifugation at 5,100 rpm for 10 min at 4
o
C, and the pellet retained 
and stored at -20
o
C. 
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2.15.2 Analysis of recombinant protein solubility 
 
Uninduced and induced cells were harvested by centrifugation at 13,000 rpm for 5 min 
at room temperature and the supernatant discarded. The uninduced sample was 
resuspended in 100 µl SDS loading buffer and one of the two induced samples was 
resuspended in 250 µl SDS loading buffer. The samples were boiled for 5 min and 
centrifuged at 13,000 rpm to remove any insoluble material. Samples were compared by 
SDS-PAGE to determine overexpression of recombinant protein. To assess the 
solubility of the recombinant protein, the second induced sample was resuspended in 
250 µl of START buffer (section 2.5.8.1) with lysozyme 1 mg ml
-1
. After incubation at 
room temperature for 1 h, the sample was sonicated 3 times for 10 s (Sanyo Soniprep 
150). Soluble and insoluble material was separated by centrifugation at 13,000 rpm for 
10 min. Soluble protein, found in the supernatant, was transferred to a separate 
microfuge tube and 250 µl SDS loading buffer was added. The insoluble material in the 
pellet was resuspended in 250 µl START buffer containing 8M urea. After addition of 
250 µl of SDS loading buffer, both samples were boiled for 5 min and centrifuged at 
13,000 rpm for 3 min and assessed by SDS-PAGE. 
 
2.15.3 Separation of soluble and insoluble material 
 
The sample pellet produced in section 2.15.1 was thawed and resuspended in 5 ml or 50 
ml of START buffer minus urea. To weaken the cells, the sample was freeze-thawed 3 
times, by freezing at -80
o
C and thawing on ice. The cells were broken by sonication 10 
times for 10 s (Sanyo Soniprep 150) and then centrifuged at 10,000 rpm for 25 min at 
4
o
C. For soluble recombinant protein, the supernatant was filtered into another tube 
through a 0.45 µm pore filter and stored at 4
o
C. If the recombinant protein was 
insoluble, then the pellet was resuspended completely in 5 ml or 50 ml START buffer 
containing 8M urea or 6M guanidine and incubated overnight at 4
o
C. To remove any 
insoluble material and unbroken cells, the sample was centrifuged at 10,000 rpm for 25 
min at 4
o
C and passed through a 0.45 µm pore filter and stored at 4
o
C. 
 
2.15.4 Protein purification using HiTrap    column 
 
A 5 ml  + L 7 U D S    D I I L Q L W \   F R O X P Q    * (   + H D O W K F D U H    D Q G   % L R-Rad Econo Gradient system 
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 Z D V   H P S O R \ H G   W R   S X U L I \   U H F R P E L Q D Q W   S U R W H L Q    7 K H   + L 7 U D S    F R O X P Q   Z D V   Z D V K H G   Z L W K 
15 ml dH2O, and then charged with 20 ml of 50 mM NiSO4. Excess Ni2+ ion was 
removed by washing the column with a further 15 ml of dH2O. Tubing and pumps of 
the Econo Gradient system were flushed with START buffer (START buffer, plus 8M 
urea or 6M guanidine for insoluble protein) at a flow rate of 1.5 ml min-1. The NiSO4 
charged column was attached to the Econo Gradient system and equilibrated with 5 ml 
of START buffer. The systems spectrophotometer was zeroed, and then the supernatant 
containing the His6-tagged protein was passed through the column at a flow rate of 1 ml 
min-1. Unbound protein was washed through the column with 5% (v/v) elution buffer 
until the absorbance returned to zero. Elution of the bound His6-tagged protein was 
achieved by gradually increasing the elution buffer gradient from 5-100% (v/v) at a 
flow rate of 1 ml min-1, while 1 ml elution fractions were collected. Fractions were 
analysed by SDS-PAGE to determine which fractions contained the recombinant 
protein. Those that contained protein were pooled and stored at -20o &    7 K H   + L 7 U D S  
column was washed with 10 ml 50 mM EDTA to remove NiSO4, followed by 10 ml 
dH2O and 10 ml of 20% (v/v) ethanol, and stored at 4oC. 
 
2.15.5 Protein dialysis 
   
2.15.5.1 Preparation of dialysis membrane 
 
Size 2 dialysis membrane tubing (Medicell International Ltd.) was used for protein 
dialysis. Prior to use, tubing was boiled in 2 mM EDTA for 20 min and washed in 
dH2O. The boiled tubing was placed in 50% (v/v) ethanol and stored long-term at 4oC. 
 
2.15.5.2 Dialysis of recombinant protein 
 
Fractions eluted in section 2.15.4, solubilised in either 8M urea or 6M guanidine were 
placed in dialysis tubing and dialysed in PBS with decreasing concentrations of urea or 
guanidine, unless stated otherwise. For urea solubilised recombinant protein, starting 
dialysis was carried out at 4oC for 12 h in PBS plus 8M urea. Buffer was then replaced 
with fresh PBS containing 6M urea and dialysis was continued for 12 h at 4oC. This was 
repeated with urea concentrations of 4M, 3M, 2M, 1M, 0.5M and 0M. Similarly for 6M 
guanidine solubilised samples, starting dialysis was carried out at 4oC for 12 h in PBS 
buffer plus 6M guanidine. PBS buffer was replaced with reducing guanidine 
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concentration of 4M, 3M, 2M, 1M, 0.5M and 0M every 12 h. After dialysis was 
complete, samples were transferred to Falcon tubes and 10% (v/v) glycerol was added. 
The presence or absence of protein was determined by SDS-PAGE. 
 
2.16 Protein refolding by drip dilution 
 
L-Arginine base refolding buffer (880 mM; section 2.5.5.1), or L-Arginine, L-Glutamic 
acid base refolding buffer (50 mM; section 2.5.5.2) was poured into a sterile 500 ml 
Pyrex beaker, at 20x the volume of insoluble protein eluted in the presence of urea or 
guanidine (section 2.15.4; i.e for 5 ml of eluted protein, 100 ml of refolding buffer was 
used). The insoluble protein was dripped into the buffer by pipette, at a rate of 
approximately 1 ml min
-1
. The protein was then allowed to refold overnight at 4
o
C. The 
solution was added to 50 ml Falcon tubes and centrifuged for 20 min at 5,100rpm, at 
4
o
C to remove any insoluble material. The sample was then passed through a 0.2 µm 
pore filter and then concentrated using an Amicron Ultra Centrifugal filter. 
Concentrated samples were analysed by SDS-PAGE. 
 
2.17 Determining minimum inhibitory concentration (MIC) 
 
The sulphonamide trimethoprim (TMP) was added to 10 ml of media in a 25 ml 
Universal tube, to a concentration of 1 mg ml
-1
. This was then serially diluted 1:1 to a 
TMP concentration of 0.122 µg ml
-1
. S. aureus USA300 JE2 was then added to each 
dilution to an OD600 of 0.05. Samples were incubated at 37
o
C overnight with shaking at 
250rpm. The OD600 of each sample was then recorded. 
 
2.18 Flow cytometry analysis of neutrophil necrosis 
 
2.18.1 Neutrophil preparation 
 
Neutrophils were routinely purified by technicians and researchers at the Royal 
Hallamshire Hospital. Neutrophils were requested before preparation and provided if 
enough were collected from the donor. The following method was used to prepare 
neutrophils of a purity consistently >95%.  
 
Blood was collected and the cellular phase pelleted and platelet poor plasma (PPP) 
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prepared as in sections 2.1.3.1.1 and 2.1.3.1.2. From the cellular phase, the red blood 
cells were sedimented out from the leukocytes with 6 ml 6% (w/v) dextran (Sigma-
Aldrich) and 0.9% (w/v) saline to a final volume of 50 ml. After 20 min, an interface 
forms between the red blood cells (lower phase) and the leukocytes (upper phase). The 
leukocytes were carefully removed and centrifuged at 185 g for 6 min and the lower red 
blood cell phase was either discarded or stored at -20
o
C. The soft leukocyte pellet was 
resuspended in 1 ml of PPP and carefully layered over a discontinuous plasma-Percoll 
gradient (Amersham Pharmacia Biotech). The plasma Percoll gradient consisted of a 
lower layer of 51% (v/v) Percoll and 49% (v/v) PPP and an upper layer of 42% (v/v) 
Percoll and 58% (v/v) PPP. The neutrophils were separated through the gradient at 225 
g for 11 min. The central band of neutrophils were isolated and resuspended in 10 ml 
PPP and 30 ml Hanks Balance salts solution (HBSS) without Ca
2+
 and Mg
2+
. A 10 µl 
aliquot was used to determine cell count using a haemocytometer. The cells were 
washed twice in 10 ml PPP and 30 ml Hanks Balance salts solution by centrifugation at 
420 g for 6 min, to remove any residual Percoll. The neutrophil pellet was then 
resuspended in RPMI-1640 with 10% (v/v) foetal calf serum (Sigma-Aldrich) to give a 
cell density of 5x10
6
 neutrophils ml
-1
. Cell count was repeated to confirm neutrophil 
numbers. 
 
2.18.2 Bacterial supernatant 
 
Supernatants were prepared and used on the same day, unless otherwise stated. A single 
colony of bacteria was used to inoculate 20 ml of RPMI-1640 with 10% (v/v) foetal calf 
serum (Sigma-Aldrich) in a 250 ml conical flask and incubated for 24 h at 37
o
C shaking 
at 250rpm. Cells were removed by centrifugation for 10 min at 5,100 rpm and the 
supernatant was passed through a 0.2 µm pore filter. 
 
2.18.3 Neutrophil necrosis by S. aureus supernatant 
 
All neutrophil necrosis experiments were done in 96-well polyvinyl chloride Falcon 
Flexiwell plates (BD Biosciences) to minimise neutrophil adhesion to the well surface. 
Neutrophils were added to wells in 50 µl volumes containing approximately 2.5x10
5
 
cells. An equal volume of neat or diluted supernatant was added to the 50 µl neutrophil 
suspensions in duplicate, to give a total well volume of 100 µl. 50 µl of fresh RPMI-
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1640 with 10% (v/v) foetal calf serum was added to two wells containing 50 µl 
neutrophil suspensions, providing a control for baseline neutrophil death. The samples 
were then incubated at 37
o
C for 30 min  – 3 h, as required, to allow for neutrophil 
necrosis. 
 
2.18.4 Flow cytometric analysis of necrosis 
 
Immediately after incubation the neutrophils were pelleted by centrifugation at 400 g for 
2 min to remove bacterial supernatant and resuspended in PBS. Neutrophil necrosis was 
assessed by addition of 1:10000, final concentration, of the DNA intercalating vital dye 
To-Pro-3 (Invitrogen) to the neutrophils. Samples were analysed using a dual laser 
FACSCalibur flow cytometer (BD Biosciences). Neutrophil events were gated 
according for forward scatter (FSc) and side scatter (SSc), and fluorescence was 
measured using the FL4 channel, specific to the emission wavelength produced by To-
Pro-3, when bound to DNA. Up to 10,000 events were counted and analysed using the 
FlowJo
TM
 (TreeStar) cytometry analysis software.  
 
2.18.5 Quantification of absolute neutrophil number 
 
CountBright
TM
 absolute counting beads (Invitrogen) were used to determine absolute 
neutrophil numbers. CountBright
TM
 beads are microspheres that fluoresce intensely at a 
wide range of wavelengths, allowing analysis by flow cytometry. The concentration of 
microspheres is known per ml of supplied solution. After neutrophil recovery and 
addition of To-Pro-3 (section 2.18.4), and immediately prior to flow cytometry analysis, 
50 µl of beads were added to the sample. As the concentration is known, the absolute 
number of beads in each sample is known. The beads were appropriately gated and bead 
fluorescence was measured using a different channel to FL4 (that used to measure To-
Pro-3 fluorescence). The ratio of bead events to neutrophil events was then multiplied 
by the absolute number of beads, to give absolute neutrophil numbers in the sample. 
 
2.19 Phagocytic index (PI) determination 
 
2.19.1 Co-culture of neutrophils and S. aureus 
 
Neutrophils were prepared as in section 2.18.1 and 50 µl aliquots containing 2.5x10
5
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were added to the wells of 96-well plates. S. aureus was grown in 10 ml of RPMI-1640 
with 10% (v/v) foetal calf serum, overnight at 37
o
C, with shaking at 250rpm. Cultures 
were diluted to an OD600 of 1 in RPMI-1640 with 10% foetal calf serum, and then 12.5 
µl of this diluted culture was added to neutrophil containing wells, in triplicate, to give 
an MOI of 10. The 96-well plates were then incubated for 30 min at 37
o
C to allow for 
phagocytosis. 
 
2.19.2 Neutrophil fixation and PI calculation 
 
To determine the phagocytic index (PI) the contents of wells, prepared in section 2.19.1, 
were cytocentrifuged onto microscope slides and visualised by light microscopy. Cells 
were added to chambers and spun at 300 g for 3 min using a Shandon Cytspin 3 
(Thermo Scientific). Cells were fixed to the slides with 100% methanol and stained with 
Quick-Diff stains (Gentaur). Slides were mounted with DPX (Fisher Scientific) and 
cover slips were applied. Neutrophils were observed using a Zeiss Axioplan microscope 
using the 100x oil immersion lens. The PI was calculated according to the following 
formula: phagocytic index = (total number of engulfed bacteria/total number of counted 
neutrophils) × (number of neutrophils containing engulfed cells/total number of counted 
neutrophils) × 100. 
 
2.20 Whole human blood growth assay 
 
Whole human blood was collected, as in section 2.1.3.1.1. The blood was transferred to 
microcentrifuge tubes in 1.25 ml aliquots. A culture of S. aureus wild-type and a culture 
of S. aureus mutant strain, grown overnight in RPMI-1640 with 10% (v/v) foetal calf 
serum, at 37
o
C, shaking at 250rpm, were diluted to a CFU of 2x10
4
 ml
-1
. 62.5 µl of 
diluted culture was added to each 1.25 ml of whole human blood to give an estimated 
starting CFU of 1000. A 100 µl aliquot of the sample was removed to determine the 
actual CFU, as in section 2.6.2. Samples were then incubated for 3 h at 37
o
C with gentle 
agitation. A 100 µl sample was then removed to determine the end-point CFU, as in 
section 2.6.2. The difference in growth between mutant strains and wild-type strains 
could then be determined. Statistical analyses were done using Prism version 6.0 
(Graphpad). Significance was assumed at a p-value below 0.05. 
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2.21 Human plasma growth assay 
 
The human plasma growth assay was done exactly as that of the whole human blood 
assay (section 2.20), however, human plasma was used instead to human blood. 
 
2.22 Screening the Nebraska transposon mutagenesis library (NTML) on solid  
media 
 
The NTML consisted of twenty 96-well microtiter plates each containing S. aureus JE2 
strains with a different Tn disrupted gene. Plates were thawed on ice and the wells of 
each microtiter plate were inoculated onto solid media using a 96-pin replicator (Boekel 
Industries). Plates were incubated at 37
o
C for varied incubation times, dependent on the 
contents of the solid media. 
 
2.23 Zebrafish embryo assay techniques 
 
2.23.1 Zebrafish strain 
 
All zebrafish experiments performed in this study were done with London Wild-Type 
(LWT) zebrafish. 
 
2.23.2 Zebrafish husbandry 
 
All adult zebrafish were kept in a continuous recirculating closed aquarium system at 
28
o
C, with a day/night cycle of 14/10 h. Embryos were kept in E3 medium at 28.5
o
C. 
Zebrafish were maintained under a Project Licence awarded to the University of 
Sheffield by the UK Home Office. Zebrafish embryos used in this study were not 
protected under the Animals (Scientific Procedures) Act, as the embryos used were 
younger than 5 dpf. 
 
2.23.3 Zebrafish anaesthesia 
 
A stock solution of 0.4% (w/v) tricaine (Sigma) was prepared in 20 mM Tris-HCl, pH 7 
and stored at -20
o
C. Tricaine was added to E3 solution containing zebrafish embryos to 
a final concentration of 0.02% (w/v), 10 min before injection. 
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2.23.4 Microinjection of S. aureus into zebrafish embryos 
 
S. aureus was grown at 37
o
C in 50 ml BHI to an OD600 of approximately 1, and then 
centrifuged at 5,100 rpm for 10 min to harvest the cells. The pellet was resuspended in 4 
ml of sterile PBS and serially diluted to a CFU of 1.2x10
9
 CFU ml
-1
, then confirmed by 
plating on solid media. Anaesthetised embryos were embedded in 3% (w/v) 
methylcellulose on the surface of microscope slides. An electrode puller was used to 
obtain a fine injection tip from non-filament glass capillaries, allowing injection of 1 nl 
of bacterial suspension, of known concentration, into the bloodstream of embryos. To 
confirm the concentration, 1 nl was also injected into 100 µl PBS, and plated after serial 
dilution on BHI agar. Injections were performed using a pneumatic micropump (World 
Precision Instruments), a micromanipulator (WPI) and a dissecting microscope. The 
injected embryos were then placed into separate wells of a 96-well microtitre dish.  
 
2.23.5 Assessment of zebrafish embryo mortality post-infection 
 
Mortality was assessed several times a day, up to 120 hpi. Cessation of heart beat 
indicated mortality, and dead fish were removed and recorded. 
 
2.23.6 Determination of S. aureus growth in vivo 
 
To determine bacterial numbers over the course of infection, 5 embryos, each in 100 µl 
of E3 solution, were transferred to separate microcentrifuge tubes, and then 
mechanically homogenised using a micropestle (Eppendorf). Serial dilution of the 
homogenates, followed by plating onto BHI agar was used to determine bacterial 
numbers within zebrafish at each time-point sampled. 
 
2.23.7 Statistical analysis 
 
Survival curves were compared using the log rank (Mantel-Cox) test. Analyses were 
done using Prism version 6.0 (Graphpad). Significance was assumed at a p-value below 
0.05. 
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CHAPTER 3 
 
THE SEARCH FOR NOVEL STAPHYLOCOCCAL VIRULENCE FACTORS 
 
 
3.1 Introduction 
 
As outlined in Chapter 1, S. aureus encodes an array of virulence factors required for 
colonisation, survival and spread through the host. The genomic revolution has allowed 
for the utilisation of information from other species to potentially allow identification of 
novel virulence determinants of S. aureus. 
 
The first complete genome sequence for a living organism was determined in 1995 for 
the bacterium Haemophilus influenzae (Fleischmann et al., 1995). There are now 3,316 
bacterial, 179 eukaryotic and 202 archaeal genome sequences available on the Genome 
database of the European Bioinformatics Institute (http://www.ebi.ac.uk/genomes/bacte-
ria.html). In addition to this genomic information, sequence data from viral genomes, 
organelles, vector sequences, metagenomics and non-metagenomics studies has led to 
near exponential growth of DNA sequence data stored on freely available databases. For 
instance, the GenBank database, made available by the National Centre for 
Biotechnology Information (NCBI) in 1983, started with 606 DNA sequences 
(translated to protein sequences) totalling 680,338 DNA bases. The database now 
contains >1.85x10
8
 DNA sequences (coding sequences translated to protein) totalling 
>1.93x10
11
 DNA bases (Burks et al., 1985). The development of Next-generation 
sequencing (NGS) technologies over the last 10-15 years has been the vanguard for the 
expansion of biological sequence data. NGS has allowed for a rapid decrease in cost and 
time associated with the sequencing of large genomes (Morey et al., 2013). The varied 
uses of NGS, beyond the sequencing of genomes, and some of the commonly used NGS 
technologies are reviewed by Koboldt et al., (2013) and Morey et al., (2013). Databases 
dedicated to protein sequence data such as UniProt (created from the merger of Swiss-
Prot, TrEMBL and PIR databases), which contains >5x10
4
 protein sequences, are 
available with sequence information derived experimentally or more commonly from 
prediction based on the available DNA sequence data. Other sequence databases exist 
for specific kinds of data such as the protein domain databases Pfam (Finn et al., 2014) 
and CDD (Marchler-Bauer et al., 2015). A host of bioinformatics databases housing 
non- V H T X H Q F H   L Q I R U P D W L R Q   D O V R   H [ L V W    ( [ W U D F W L Q J   L Q I R U P D W L R Q   J H U P D Q H   W R   D Q   R U J D Q L V P ¶ V 
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phenotype from this wealth of data requires the use of computers. This has led to 
bioinformatics, a discipline at the boundary between computer science and biology. 
 
Bioinformatics can be applied to many forms of biological information, not just 
sequencing data. In general, bioinformatics analysis of biological sequence data can 
only be used for hypothesis generation, later to be corroborated or contradicted in the 
laboratory (Tang et al., 1998). Once a genome has been sequenced, the coordinates of 
potential protein coding sequences (CDSs) are determined using programs such as 
GLIMMER (Salzberg et al., 1998) and rbsfinder (Suzek et al., 2001), which identify 
sequence characteristics of CDSs, including start codons and promoter elements with an 
appropriate number of downstream codons. Once the CDSs were identified, Baba et al. 
(2002) used a protein BLAST search of the NCBI non-redundant (nr) protein sequence 
database to identify homologous genes to the CDSs of S. aureus MW2, thereby 
assigning function based on homology. This can lead to errors, as a protein may be 
homologous, but not share the same function and the nr database annotation may be 
incorrect. It has been suggested that ~30% of functional annotation is erroneous (Devos 
& Valencia, 2001; Koskinen et al., 2015). The process does allow for rapid and accurate 
classification of the majority of CDSs, but as of 2000, an estimated 30% of all CDSs 
from sequenced genomes were classed as hypothetical or unknown function genes 
(Weinstock, 2000), which increased to 40-50% by 2006 (Sivashankari & 
Shanmughavel, 2006). This demonstrates a substantial lack of knowledge of the 
proteins required for bacterial survival in their different environments.  
 
One use of genomic data is to compare genomes from related strains with different 
virulence characteristics. The genome of the hospital-acquired methicillin-resistant S. 
aureus (MRSA252) was compared to the community-acquired methicillin susceptible S. 
aureus (MSSA476; Holden et al., 2004). The methicillin resistance gene mecA is found, 
along with important virulence determinants, on the pathogenicity island SCCmec at a 
specific site on MRSA strain genomes (Fechter et al., 2014). The MSSA476 genome 
contains an SCCmec-like element (SCCfar), at the same site, with a fusidic acid 
resistance gene, rather than mecA. The hospital acquired strain MRSA252 has a greater 
number of antibiotic resistance genes, associated with transposons. This increased 
resistance profile of MRSA252 may be the result of the selective pressure to acquire 
resistance genes in a hospital environment. BLASTN comparison of the MRSA252, 
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MSSA476 and N315 genomes was used to identify regions outside of the core genome 
of these strains. Spread throughout the genome of MRSA252, in small genomic islets 
and larger regions were a large number of metabolic and transport associated genes, not 
found in the other two strains. It was hypothesised that these metabolic genes may 
benefit MRSA252 survival in the varied and often harsh hospital environment (Holden 
et al., 2004). Many of the differences between MRSA252 and MSSA476 were related 
to mobile genetic elements and insertion sequences. This analysis demonstrated the 
importance of horizontal gene transfer in the evolution of S. aureus. 
 
The aim of the following chapter was initially to identify a potential toxin (here named 
Staphylococcus aureus Factor - SAF) with potent neutrophil killing effects, identified in 
S. aureus strains SH1000 and Newman supernatant by Dr Sadia Anwar. The scope was 
then widened to search the S. aureus genome for any novel toxins or virulence factors.  
 
Results 3.2 
 
Dr Anwar used a candidate approach to determine whether one of the known toxins of 
S. aureus was responsible for the dramatic neutrophil necrosis phenotype. Phenol 
soluble modulins (PSMs) and Panton-Valentine leukocidin (PVL) were ruled out as the 
potential cause, as S. aureus SH1000 does not encode them. The haemolysins and 
LukED were considered potential candidates.  Dr Anwar developed a flow cytometry 
assay to measure neutrophil cell necrosis, the details of which are given in Chapter 2.18. 
Using this assay, hla, hlb, hld, hlg and lukED were ruled out as the cause of the 
neutrophil necrosis phenotype. This suggested that a novel toxin was responsible for the 
observed phenotype. Furthermore, activity was lost in boiled supernatant, suggesting 
that SAF is a protein. 
 
3.2.1 Is SAF an S. aureus leukotoxin? 
 
The lysis of neutrophils is the function of several characterised leukotoxins secreted by 
S. aureus, none of which are responsible for the phenotype, as determined by Dr Anwar. 
This suggested that if none of the known leukotoxins secreted by S. aureus are 
responsible for the necrotic phenotype, then it is caused by an as yet unknown secreted 
toxin. To determine this, two databases were constructed using the BLAST+ suite of 
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programs that allow database construction and execution of local Basic Local 
Alignment (BLAST) searches (Altschul et al., 1990; Camacho et al., 2009).  
 
3.2.1.1 Construction of the S. aureus leukotoxin database 
 
Construction of the database is shown diagrammatically in Figure 3.1A. Database 1 
consisted of S. aureus toxins returned by a search of the NCBI Protein database using 
the following search term: 
 
((leukotox* OR leukocid*) OR (leucotox* OR leucocid*)) AND (Staphylococcus 
aureus[Organism]) 
 
This search returned 34,323 protein sequences. A Perl program was written allowing for 
the removal of sequences with 100% identity (Appendix 3.1). Amongst these sequences 
were a large number annotated as non-toxins, hypothetical proteins or probable toxins, 
which were removed using shell commands and Excel. This left 693 S. aureus toxins 
from the haemolysin and two-component leukotoxin classes, which were used to 
construct the database. 
 
3.2.1.2 Construction of the non-S. aureus leukotoxin database 
 
Construction of the database is shown diagrammatically in Figure 3.1B. Database 2 
consisted of toxins returned with the following query of the NCBI Protein database: 
 
((leukotox* OR leukocid*) OR (leucotox* OR leucocid*)) NOT (Staphylococcus 
aureus[Organism]) 
 
This returned 2,380 protein sequences. procedure procedure identical to that used in 
section 3.2.1.1 was implemented for the removal of non-toxin sequences, based on their 
annotation. This reduced the number of sequences from 2,380 to 396 from 30 different 
species, none of which were S. aureus. As in Database 1, the sequences were from the 
haemolysin and two-component leukotoxin classes. 
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Figure 3.1 Construction of the S. aureus (A) and non-S. aureus (B) leukotoxin 
databases, shown diagrammatically. 
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3.2.1.3 Homology search of the 645 S. aureus hypothetical proteins 
 
The homology search of the hypothetical proteins of S. aureus 8325 follows the scheme 
of the flow diagram in Figure 3.2. The S. aureus 8325 hypothetical proteins were 
downloaded from the Pathosystems Resource Integration Centre (PATRIC). According 
to PATRIC there are 645 hypothetical proteins within the genome of S. aureus. A 
Protein BLAST search, using a low expectation value of 10
-10
, was used to determine 
homology between the 645 hypothetical proteins and the leukotoxin sequences of 
Database 1 and Database 2. No hits were returned for any of the hypothetical sequences 
in BLAST runs against either database. This suggests that SAF is either not present 
amongst the hypothetical proteins of S. aureus, or that SAF is present, but is not one of 
the toxin types found in Database 1 or 2. Another possibility is that SAF is a leukotoxin, 
but is so distantly related that it cannot be found using such a low e-value. If SAF is not 
a protein, then finding it by comparing protein sequences would be impossible. 
 
3.2.2 Characterisation of SAF  
 
For the following flow cytometry assays, the method designed by Dr Anwar was used 
(Chapter 2.18; shown diagrammatically in Figure 3.3). Briefly, supernatants were 
prepared from RPMI-1640 + 10% (v/v) FBS cultures as outlined in Chapter 2.18.2. 
Supernatants were either used neat or diluted as required and duplicate or triplicate 50 
µl aliquots of supernatant were added to 50 µl of neutrophils in a 96-well plate. 
Neutrophil numbers were approximately 5 x 10
6
 per ml. 50 µl of treated or untreated 
media was added to the same number of neutrophils to give a baseline death without S. 
aureus supernatant products. The 96-well plate was then incubated at 37
o
C for 0.5-3 h. 
The vital dye To-Pro-3 was used to determine the level of neutrophil necrosis, as it 
penetrates cells that have lost their membrane integrity and fluoresces red on binding to 
DNA (Dockrell et al., 2003; Van Hooijdonk et al., 1994). The contents of each well was 
transferred to test tubes for flow cytometry analysis using a dual laser FACSCalibur 
flow cytometer (BD Biosciences). To-Pro-3 and 50 µl of Countbright  
 
beads were 
added to the samples just before the analysis. Countbright  
 
beads allow for 
quantification of absolute neutrophil number within a sample (see Chapter 2.18.5 for 
detailed information). 
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Figure 3.2 Homology search for SAF shown diagrammatically. 
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Figure 3.3 Flow cytometry assay of neutrophil necrosis, shown diagrammatically. 
RPMI-1640 media was treated in parallel to supernatants, providing controls.  
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3.2.2.1 Confirmation that SAF is a protein 
 
Before further attempts to identify SAF, it was essential to confirm that SAF is a 
protein. Dr Anwar has previously shown that boiled supernatant loses SAF activity, 
suggesting that SAF is a protein. To confirm that SAF is a protein, aliquots of the same 
overnight supernatant were either boiled or treated with proteinase K (PK) to destroy 
any protein activity. The treated supernatants were then compared to an untreated 
supernatant aliquot from the same batch, using the flow cytometry assay outlined in 
section 3.2.2. Figure 3.4A clearly shows that neutrophil killing activity remains in 
untreated supernatant and this effect is dose dependent. Neutrophil numbers are reduced 
relative to the media control and a large proportion of those neutrophils that remain 
have lost membrane integrity demonstrated by the high To-Pro-3 emission. SAF activity 
is lost from PK treated supernatant, as no difference is seen between media and neat 
supernatant (Figure 3.4B). However, PK appears to promote death of neutrophils, as the 
overall neutrophil numbers are reduced from that seen in untreated media and, as the 
supernatant is diluted, neutrophil numbers increase over the PK treated media control. 
Furthermore, the To-Pro-3 activity in the control and neat supernatant was high relative 
to the diluted supernatant, demonstrating reduced cell membrane integrity of neutrophils 
incubated in conditions with higher PK levels. As shown by Dr Anwar, boiling of 
supernatant destroys the neutrophil killing activity of S. aureus supernatant (Figure 
3.4C). 
 
Figure 3.4 shows the effect of untreated, boiled and proteinase K treated supernatant on 
neutrophil necrosis, from a single replicate. However, during this work, publication of 
two research articles changed the direction of the project. Ventura et al. (2010) analysed 
the cell surface proteins of S. aureus USA300/LAC and found two proteins to be 
particularly abundant on the surface and extracellularly, encoded by SAUSA300_1974 
and SAUSA300_1975. These genes are predicted by similarity to encode the LukF and 
LukS proteins of an as yet uncharacterised two-component leukotoxin, which the group 
named LukF-G LukS-H (LukGH). These genes were not among the 645 hypothetical 
proteins used above (3.2.1), as their annotation reflects their recognition as potential 
 O H X N R W R [ L Q V   7 K H  V W U D L Q  X V H G  H Q F R G H V  3 9 /   E X W  X V L Q J ßpvl   ß lukH  D   G ßpvl/lukH strains, 
the group found that LukGH is a potent leukotoxin of neutrophils that acts 
synergistically with PVL. Furthermore, it was found that surface associated LukGH 
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Figure 3.4 Flow cytometry analysis of neutrophil killing by S. aureus supernatant. 
 
A. Untreated supernatant. 
B. Proteinase K treated supernatant. 
C. Boiled supernatant. 
Data shown is from a single replicate. 
 
A
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Boiled Supernatant
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may promote intracellular neutrophil lysis upon phagocytosis. Soon after, Dumont et al. 
(2011) reported their finding that LukGH (named LukAB in their study) was primarily 
responsible for neutrophil lysis in the S. aureus Newman background and that isogenic 
lukED, hlg and hla mutants retained this phenotype. This was particularly interesting as 
the neutrophil killing phenotype observed for SAF was shown in S. aureus Newman. 
The group also found that LukAB was important for killing monocytes, macrophages 
and dendritic cells and has a role in S. aureus survival in vivo. Since confirming that 
LukAB/GH is a leukotoxin, aspects of its neutrophil killing mechanism have been 
characterised and its importance in intracellular killing confirmed (Badarau et al., 2015; 
DuMont et al., 2013a, 2013b). 
 
3.2.2.2 Growth curve of S. aureus Newman lukAB 
 
To compare SAF activity in the wild-type S. aureus Newman and S. aureus Newman 
ßlukAB, the mutant strain was requested from Professor Victor Torres, University of 
New York and kindly supplied. It was essential to compare the growth characteristics of 
wild-type and mutant, so that supernatants from the same phase of growth could be 
compared by flow cytometry assay. Growth assays were done as in Chapter 2.8. A 
single colony of each strain was inoculated into 5 ml of bovine serum and incubated 
overnight at 37
o
C. Each overnight was then used to inoculate 3 x 50 ml of pre-warmed 
bovine serum in 250 ml conical flasks. An initial sample and hourly samples were taken 
to assess growth by optical density at 600nm (OD600; Figure 3.5A) and by colony 
forming unit (CFU; Figure 3.5B). Figure 3.5 show that the pattern of growth is the same 
for both strains. Both show no lag when added to pre-warmed media and reach the 
plateau phase at the same time. For this reason, preparation of supernatants from 
overnight cultures was considered appropriate for comparison of SAF activity using the 
two strains. 
 
3.2.2.3 Is SAF LukAB? 
 
The effect of culture supernatant of the wild-type and ß OukAB on neutrophils was 
analysed by flow cytometry using the method outlined in section 3.2.2. Supernatants 
from each strain were used fresh, as it had been previously shown that SAF is unstable 
over time (results not shown). 
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Figure 3.5 The role of lukAB in the growth of S. aureus.  
 
 y = S. aureus Newman;    = S. aureus Newman lukAB.  
 
CFU and OD600 readings for S. aureus Newman and S. aureus Newman lukAB are not  
significantly different (CFU p=0.93, OD600 p=0.86). 
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The results clearly show that LukAB is responsible for the necrosis phenotype attributed 
to SAF (Figure 3.6).  
 
3.2.3 Analysis of the S. aureus genome for further novel toxins 
 
With the discovery that SAF is LukAB/GH a decision to switch the focus of the project 
was made. The discovery of this toxin raised the possibility that other as yet 
undiscovered toxins may exist in the S. aureus genome and if so, could the method 
employed in section 3.2.1 be extended and applied to all toxins and could other 
bioinfromatics methods be developed to identify potential novel toxins from the S. 
aureus genome? An NCBI Protein BLAST was carried-out, using the same stringent e-
value as the local BLAST from section 3.2.1, using the LukA/G and LukB/H protein 
sequence. This was to confirm that if the sequence had been amongst the hypothetical 
proteins it would have hit against known leukotoxins. Both sequences returned 
 D O L J Q P H Q W V   D H U R O \ V L Q V   -haemolysins and leukotoxins ED. This suggested that the 
methodology used in section 3.2.1 is sound. 
 
3.2.3.1 Construction of a database of known virulence factors 
 
Unlike the list of toxins used in the search for SAF, the goal of this list was not to find a 
toxin with a specific function (neutrophil killing in the case of SAF), but rather to find 
any novel toxin expressed by S. aureus. The list of toxins required was larger than that 
created in section 3.2.1, as it was required to contain a greater diversity of toxins. The 
database was again created using the methodology outlined in Figure 3.1 and the 
BLAST+ programs. The toxin sequences were downloaded from the NCBI Protein 
database using the following query: 
 
 ‡ W R [ L Q   2 5    W R [ L Q   2 5   K D H P R O \ V L Q   2 5 hemolysin OR leukocidin OR "phenol soluble 
modulin" OR *cidin  2 5  S R U L Q  2 5  F \ W R O \ V L Q  2 5  O \ V L Q   2 5   O \ V L Q · 
 
This query returned 138,811 protein sequences from a diverse species background, from 
which the BLAST database was constructed.  
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Figure 3.6 The role of LukAB in neutrophil necrosis.  
 
A. Neutrophil survival is significantly increased when incubated with lukAB mutant 
culture supernatant compared to the wild-type culture supernatant, p < 0.05 at 1 h and 3 
h. 
B. To-Pro-3 activity is significantly increased for neutrophils incubated with wild-type 
supernatant compared to lukAB mutant supernatant, p < 0.001 at 1 h and 3 h. 
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3.2.3.2 BLAST search of the 138,811 sequence database 
 
The homology search of the hypothetical proteins of S. aureus 8325 follows the scheme 
of the flow diagram in Figure 3.7. Execution of BLAST runs was done using a custom 
Python script (Appendix 3.2a) that could be more easily changed and implemented than 
using the command line. The XML output file was then parsed using a custom Python 
script (Appendix 3.2b) to give tab-delimited query annotation, the annotation of the 
sequence hit by the query and the e-value. A higher e-value of 10
-7
 was used, compared 
to the e-value of 10
-10
 used in section 3.2.1.3, to allow alignment of more distantly 
related sequences. However, this e-value is still low in order to minimise false positive 
results. A BLAST search of the full 138,811 sequence database with the 645 
hypothetical proteins of S. aureus returned 98 results. Based on the annotation of the 
database sequences, 55% of the results were alignments to database sequences 
annotated as hypothetical/unnamed protein sequences and 41% of alignments were with 
non-toxin sequences. Four of the 645 hypothetical proteins aligned with database 
sequences annotated as toxins (Table 3.1). 
 
Three of the hypothetical proteins in Table 3.1 are potentially exotoxins. They may also 
be Staphylococcal superantigen-like proteins (SSLs), which are immune evasion 
proteins (see Chapter 1). Although immune evasion proteins were not the target of the 
search, they were still considered interesting to this study. Figure 3.7 shows that the 
majority of database hits were to hypothetical or non-toxin sequences within the 
138,811 database. This demonstrated that the database did not consist of just toxin 
sequences. It was hypothesised that potential toxins may have been concealed by the 
large amount of non-toxin and hypothetical protein sequences within the 138,811 
sequence database. It was decided that trimming the database of the majority of non-
toxin sequences, by removing redundant sequences, may reveal toxins amongst the 645 
hypothetical proteins. 
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Figure 3.7 Homology search of the 138,811 sequences database for novel toxins 
within the 645 S. aureus hypothetical proteins, shown diagrammatically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 645 S. aureus 
hypothetical proteins from 
the PATRIC database
138,811 sequence database
Blastp comparison
98 hypothetical protein sequences 
aligned with sequences of the 138,811 
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annotated as hypothetical 
proteins
4 of the 98 alignments were 
with database sequences 
annotated as toxins
41% were alignments to 
database sequences 
annotated with non-toxin 
functions
The 4 putative toxin 
sequences were retained for 
further analysis
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Table 3.1 Hypothetical proteins that aligned with virulence factors. 
Hypothetical 
Protein Query ID 
PATRIC ID 
Number 
of Hits 
Most Common Database 
Hit 
SAOUHSC_01124 VBIStaAur99865_1032 426 
Superantigen-like 
Proteins/Exotoxin 
SAOUHSC_01125 VBIStaAur99865_1033 500 
Superantigen-like 
Protein/Exotoxins 
SAOUHSC_01127 VBIStaAur99865_1034 500 
Superantigen-like 
Protein/Exotoxins 
SAOUHSC_01438 VBIStaAur99865_1314 9 Conserved virulence factor C 
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3.2.3.3 Removing redundancy with CD-HIT and Perl 
 
Removal of redundant sequences should result in loss of a large number of hypothetical 
and non-toxin sequences. It will also result in loss of toxin sequences; however, there 
should not be a loss in the diversity of sequences, only in quantity. Therefore, sequences 
that are homologous to toxin sequences may become more visible in the BLAST output. 
Two methods were used to remove redundant sequences, 1. The custom Perl script 
written in section 3.2.1.1 was used (see Appendix 3.1 for program and description). 
This reduced the 138,811 sequences to 53,032 protein sequences and 2. The CD-HIT 
online server, which reduced the number of database sequences to 50,048. CD-HIT is 
available to run locally or online and functions by clustering sequences based on a 
specified similarity (100% in this case). A single sequence from each cluster is then 
returned (Li et al., 2001). Although the goal of the two programs was the same, the 
results differed, but not considerably. In order to avoid missing potential toxins in the 
BLAST search, it was decided that the prudent choice would be to use the larger of the 
two databases  – i.e. the database trimmed using the Perl script. 
 
3.2.3.4 BLAST of the 53,032 sequence database 
 
The homology search of the hypothetical proteins of S. aureus 8325 follows the scheme 
of the flow diagram in Figure 3.8. The same parameters and custom scripts to those 
used in 3.2.3.2 were used to run the BLAST search of the non-redundant database. The 
search returned 48 alignments with significant hits to the database. Although this is 
considerably fewer than the 98 returned in section 3.2.3.2, only 6% of the results were 
alignments between S. aureus hypothetical proteins and database sequences annotated 
as hypothetical/unnamed proteins. However, 90% of results were alignments with 
database sequences annotated as non-toxin sequences. An additional toxin/immune 
evasion protein was found using this database (Table 3.2). This sequence did hit 
exotoxins and SSLs in the full database search, however, the majority of alignments in 
the output were to hypothetical proteins. Reducing the number of hypothetical protein 
improved the quality of the output, but the majority of results were alignments between 
hypothetical proteins and non-toxins, based on annotation. The hypothetical protein that 
aligned with conserved virulence factor C (Table 3.1) was not found, but is still 
included in Table 3.2 as it was found by the prior method. 
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Figure 3.8 Homology search of the 53,032 sequences non-redundant database for 
novel toxins within the S. aureus hypothetical proteins, shown diagrammatically. 
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Table 3.2 Hypothetical proteins that aligned with virulence factors. 
Hypothetical 
Protein Query ID 
PATRIC ID 
Number 
of Hits 
Most Common 
Hit Name 
SAOUHSC_00354
*
 VBIStaAur99865_0324 6 
superantigen-like 
protein/Exotoxin 
SAOUHSC_01124 VBIStaAur99865_1032 52 
superantigen-like 
protein/exotoxin 
SAOUHSC_01125 VBIStaAur99865_1033 90 
superantigen-like 
protein/exotoxin 
SAOUHSC_01127 VBIStaAur99865_1034 81 
superantigen-like 
protein/exotoxin 
SAOUHSC_01438 VBIStaAur99865_1314 6 
Conserved virulence factor 
C 
 * Additional sequence found by homology search of the 53,032 sequence database 
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The possibility that further toxins are present among the 645 hypothetical proteins, but 
clouded out by database sequences annotated as non-toxins still exists when using the 
non-redundant database.  
 
3.2.3.5 Removal of all non-virulence factor sequences from the non-redundant  
database 
 
For most virulence factors, and all S. aureus toxins, to perform their function they must 
be secreted and attached to the S. aureus cell surface or released into the extracellular 
environment. S. aureus uses several secretion systems to translocate proteins across the 
cell wall (Bartlett & Hulten, 2010; Hecker et al., 2010; Sibbald et al., 2006). To allow 
proteins to be targeted to the secretion pathway, secreted proteins have an N-terminal 
signal sequence, which is a short sequence motif that is removed during translocation. 
Therefore, secreted virulence factor sequences can be separated from non-secreted non- 
virulence factors present in the non-redundant database, based on the presence or 
absence of a signal sequence. The signal sequence prediction program SignalP uses a 
hidden Markov model to predict Gram-negative, Gram-positive and eukaryotic signal 
sequences and sequence cleavage site (Bendtsen et al., 2004). A custom Perl program 
was written to trim the non-redundant database sequences to their first 100 amino acids 
(Appendix 3.3). These trimmed sequences were then uploaded on to the SignalP 3.0 
server and only those sequences predicted to contain a signal sequence were retained. 
Excel, one-line shell commands and Perl scripts were then used to remove any further 
non-virulence factor sequences (based on their annotation), to give a database (herein 
named the VF database) of 860 sequences all with annotation corresponding to a 
virulence function. This database could now be used to search the hypothetical and 
known protein sequences of S. aureus for potential novel VFs. 
 
3.2.3.6 Analysis of all S. aureus protein sequences using the VF database 
 
The reason for comparing the hypothetical protein sequences of S. aureus to the VF 
database is clear. If one of the hypothetical proteins is a VF, it may be homologous to a 
known VF, the sequence of which may be present in the VF database.  A BLAST search 
would align the two sequences and the hypothetical protein could then be studied 
further in the laboratory. The known function protein sequences of S. aureus were 
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compared with the VF database for two reasons; firstly the known protein sequences 
were used as a control. The purpose of the VF database is to allow selective extraction 
of potential VFs from a list of protein sequences using the BLAST algorithm, therefore 
a BLAST using the sequences with known function should extract the known VFs of S. 
aureus. Secondly, it is possible that proteins have been incorrectly assigned to roles that 
are not virulence related. Therefore, if a protein from the sequences with assigned 
function aligns to a VF in the database, it may be incorrectly annotated. Available 
information on any such sequences should be checked before they are added to the list 
of sequences for further study (Table 3.2). 
 
3.2.3.6.1 BLAST search of the VF database using the 645 hypothetical proteins 
 
The BLAST search using the hypothetical sequences as queries was repeated for the VF 
database, using the same parameters as prior searches. No new VFs were discovered 
using the VF database and all sequences (barring conserved virulence factor C) in Table 
3.2 were present in the result. 
 
3.2.3.6.2 BLAST search of the VF database using the 2,110 S. aureus known  
function sequences 
 
The BLAST search of the VF database using the 2,110 assigned function sequences of 
S. aureus as the query returned 29 results. Of these, 11 were known S. aureus toxins and 
18 were virulence factors involved in colonisation and immune evasion, all of which are 
described in Table 3.3. 
 
Before attempts to characterise the sequences in Table 3.2, further bioinformatics 
analyses were made to identify novel VFs from the hypothetical proteins of S. aureus.  
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Table 3.3 All protein sequences returned by BLAST query of the VF database with the known sequences of S. aureus 8325. 
Known Protein 
Query ID 
PATRIC ID Name of Known Protein 
Number 
of Hits 
Most Common 
Hit Name 
Reference 
Toxins and Virulence Factors 
SAOUHSC_00988 VBIStaAur99865_0908 Exfoliative Toxin B 6 exfoliative toxin (Amagai et al., 2002) 
SAOUHSC_01121 VBIStaAur99865_1029 . -Haemolysin Precursor 133 Haemolysins, leukotoxins (Prince et al., 2012) 
SAOUHSC_02163 VBIStaAur99865_1962  -Haemolysin 4 beta-haemolysin (Tajima et al., 2009) 
SAOUHSC_02708 VBIStaAur99865_2451  -Haemolysin Component A 132 Leukotoxins and haemolysins 
(Sugawara-Tomita et al., 
2002) 
SAOUHSC_02710 VBIStaAur99865_2454  -Haemolysin Component B 132 Leukotoxins and haemolysins 
SAOUHSC_02709 VBIStaAur99865_2453  -Haemolysin Component C 133 Leukotoxins and haemolysins 
SAOUHSC_01954 VBIStaAur99865_1779 Leukotoxin LukD 132 Leukotoxins and haemolysins 
(Reyes-Robles et al., 2013) 
SAOUHSC_01955 VBIStaAur99865_1780 Leukotoxin LukE 132 Leukotoxins and haemolysins 
SAOUHSC_02241 VBIStaAur99865_2035 
Leukocidin LukF-PV  
(LukA/G) 
134 
Primarily leukotoxins. Small 
 Q X P E H U  R I .-haemolysins 
(Holzinger et al., 2012) 
SAOUHSC_02243 VBIStaAur99865_2036 
Leukocidin LukS-PV   
(LukB/H) 
132 
Primarily leukotoxins. Small 
 Q X P E H U  R I .-haemolysins 
SAOUHSC_02971 VBIStaAur99865_2680 Aureolysin 4 lambda toxin (Laarman et al., 2011) 
SAOUHSC_00383 VBIStaAur99865_0353 
Staphylococcal superantigen-
like 1 
161 
Exotoxins, superantigen-like 
proteins & superantigens 
(Patel et al., 2010) 
SAOUHSC_00384 VBIStaAur99865_0354 
Staphylococcal superantigen-
like 2 
126 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00386 VBIStaAur99865_0355 
Staphylococcal superantigen-
like 3 
127 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00389 VBIStaAur99865_0357 
Staphylococcal superantigen-
like 4 
126 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00390 VBIStaAur99865_0358 
Staphylococcal superantigen-
like 5 
144 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00391 VBIStaAur99865_0359 
Staphylococcal superantigen-
like 6 
126 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00392 VBIStaAur99865_0360 
Staphylococcal superantigen-
like 7 
142 
Exotoxins, superantigen-like 
proteins & superantigens 
 Table 3.3 continued 
1
0
8
 
Known Protein 
Query ID 
PATRIC ID Name of Known Protein 
Number 
of Hits 
Most Common 
Hit Name 
Reference 
SAOUHSC_00393 VBIStaAur99865_0361 
Staphylococcal superantigen-
like 8 
162 
Exotoxins, superantigen-like 
proteins & superantigens 
 
SAOUHSC_00394 VBIStaAur99865_0362 
Staphylococcal superantigen-
like 9 
136 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00395 VBIStaAur99865_0363 
Staphylococcal superantigen-
like 10 
146 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_00399 VBIStaAur99865_0367 
Staphylococcal superantigen-
like 11 
131 
Exotoxins, superantigen-like 
proteins & superantigens 
SAOUHSC_02706 VBIStaAur99865_2450 IgG-Binding Protein SBI 35 protein A (Burman et al., 2008) 
SAOUHSC_00069 VBIStaAur99865_0059 
Protein A, von Willebrand 
Factor Binding Protein Spa 
14 
protein A 
 
(Atkins et al., 2008) 
SAOUHSC_02169 VBIStaAur99865_1967 CHIPS 1 CHIPS (Rooijakkers et al., 2006) 
SAOUHSC_01936 VBIStaAur99865_1763 Serine Protease   SplE 3 exfoliative toxin 
(Popowicz et al., 2006; 
Reed et al., 2001) 
SAOUHSC_01939 VBIStaAur99865_1765 Serine Protease   SplC 6 exfoliative toxin 
SAOUHSC_01941 VBIStaAur99865_1766 Serine Protease   SplB 6 exfoliative toxin 
SAOUHSC_01942 VBIStaAur99865_1767 Serine Protease   SplA 6 exfoliative toxin 
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3.2.3.7 CD-HIT clustering method 
 
Sequence alignments below 25-      D U H   D W   D   O H Y H O   R I   V L P L O D U L W \   N Q R Z Q   D V   ‡ W K H   W Z L O L J K W 
 ] R Q H ·   D Q G   K R P R O R J \   L Q I H U U H G   E H W Z H H Q   V H T X H Q F H V   E H O R Z   W K L V   O H Y H O   R I   V L P L O D U L W \   L V 
tenuous in the absence of other data. The clustering method of CD-HIT was exploited to 
cluster the VF database sequences with the 71 hypothetical sequences with signal 
sequences at 30% identity. The hypothesis being that hypothetical proteins with 
homology to VFs will be found in clusters with VF sequences and those that are not 
homologous, will be in their own cluster, or cluster with other hypothetical protein 
sequences. The CD-HIT program was downloaded and run locally. Alpha-haemolysin 
was again used as a control sequence. Only two clusters of interest were produced using 
this method. Cluster 1 was the control cluster, containing 51 sequences, the control 
sequence and 50 sequences that were a mix of haemolysins, leukotoxins and cytotoxins. 
The remaining cluster consisted of 3 of the putative exotoxins/SSLs 
(SAOUHSC_01124, SAOUHSC_01125 & SAOUHSC_01127; see Table 3.2) and 30 
exotoxin or SSL sequences. The fourth putative SSL SAOUHSC_00354 was not 
present in the cluster. This method added no new VFs to Table 3.2, however, it did 
show that the putative SSLs (in particular SAOUHSC_01124-5-7) are worth further 
study. 
 
3.2.3.8 Construction of a Non-redundant (Nr) Bacterial Database 
 
The concern with the database constructed in section 3.2.3.5 was that it may not have 
been complete and all VF varieties were not in it. The sequences in the database were 
initially found using a search only for toxins; so, many VFs may not be represented in 
the database. Furthermore, many toxin types may not have been returned by the original 
search. To construct a database containing all varieties of VF, a database containing all 
varieties of bacterial sequence was constructed and reduced to a smaller size to remove 
redundancy and maintain diversity by clustering to 90% with CD-HIT. All hypothetical, 
unknown, unnamed, uncharacterised and putative sequences were also removed from 
the database. Sequences < 5 amino acids and > 5,500 amino acids were removed with 
merged and modified command line Perl programs located at the following URL 
(http://archive.sysbio.harvard.edu/csb/resources/computational/scriptome/UNIX/Tools/
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Change.html). Two different methods were employed to create this database, the 
successful methodology employed to construct the database is outline in Figure 3.9A. 
 
3.2.3.8.1 Query of Nr Bacterial Database with the 645 hypothetical protein 
sequences of S. aureus 
 
The homology search of the hypothetical proteins of S. aureus 8325 follows the scheme 
of the flow diagram in Figure 3.9B. The BLAST search was done using the same 
parameters used in section 3.2.3.2. Of the 645 hypothetical proteins, 408 successfully 
aligned with the Nr Bacterial Database. Those that aligned to VFs, based on annotation, 
are shown in Table 3.4. 98% of hypothetical proteins aligned with non-VF sequences, 
based on database sequence annotation.  The 4 Exotoxin/SSL sequences in Table 3.2 all 
aligned and two additional hypothetical protein sequences were added that aligned with 
Nr Bacterial database sequences annotated as the staphylococcal complement inhibitor 
(SCIN) and the formyl peptide receptor-like 1 inhibitory protein (FLIPr-like). These 
immune evasion proteins interact with IgG and complement/complement receptors 
inhibiting complement activation and chemotaxis (Prat et al., 2009; Rooijakkers et al., 
2006).  
 
3.2.3.8.2 Query of bacterial database using 2,110 known function protein sequences 
 
The purpose of searching the bacterial database with the known function sequences of S. 
aureus is as a control. If the database possessed the expected sequence diversity, then it 
was expected that many known virulence factors would be returned by the search. The 
same methodology used in Figure 3.9B was applied to the 2,110 S. aureus sequences 
annotated with a known function. As expected, a large number of the results returned by 
the search were between known function proteins, not related to virulence, and their 
corresponding protein in the database (95.8% of the 2,045 results). The remaining 4.2% 
were alignments between known virulence factor sequences and their corresponding 
sequence (Table 3.5). 
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Figure 3.9 Construction and search of the Nr Bacterial Database, shown 
diagrammatically.  
For scripts used for constructing the non-redundant bacterial sequence database see 
Appendix 3.4. The clustering program CD-HIT was run on the University of Sheffield 
Iceberg High Performance Computer Resource. 
Nr FASTA DB Downloaded (23.7Gb)
Historical Gis Removed
Large & Small Sequences 
Removed
Extract All Sequences Corresponding To GI 
number
Removal of any Hypothetical, Unnamed, 
Uncharacterised, Unknown or Putative (5.2Gb)
CD-HIT: Cluster 5.2Gb Database To 90%
Nr Bacterial Database. 2.3Gb size, 5.45x105
Sequences 
4x107 Bacterial Gis
Downloaded from NCBI
The 645 S. aureus 
hypothetical proteins from 
the PATRIC database
Nr Bacterial Database
Blastp comparison
408 hypothetical protein sequences aligned 
with sequences of Nr Bacterial Database
98% of alignments were to 
non-VFs, based on annotation
4 hits were to the exotoxin/SSLs 
found previously (Table 3.2)
2 new putative virulence determinants 
found, homologous to SCIN and FLIPr
immune evasion proteins
A
B
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Table 3.4 Hypothetical proteins that aligned with virulence factors of the non-
redundant bacterial sequence database. 
Query ID PATRIC ID 
Number of 
Hits 
Most Common 
Hit Name 
SAOUHSC_00191 VBIStaAur99865_0178 16 
Complement Inhibitor 
SCIN 
SAOUHSC_01112 VBIStaAur99865_1019 43 
formyl peptide receptor-
like 1 inhibitory protein 
SAOUHSC_00354 VBIStaAur99865_0324 37 Exotoxins/SSLs 
SAOUHSC_01124 VBIStaAur99865_1032 110 Exotoxins/SSLs 
SAOUHSC_01125 VBIStaAur99865_1033 110 Exotoxins/SSLs 
SAOUHSC_01127 VBIStaAur99865_1034 110 Exotoxins/SSLs 
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Table 3.5 NCBI BLAST of known sequences against the Nr Bacterial database. 
Known S. aureus Queries Total Number of Hits 
Bacterial Database 
Sequence Aligned With 
Adhesins 
ClfAB, FnbpAB, Emp, Efb, 
SagG, Map/Eap, vWbp, Sbi 
1962 
ClfAB, FnbpAB, Emp, Efb, 
SagG, Map/Eap, vWbp, Sbi 
Regulatory Proteins 
SarAS, SaeRS, ArlS, 
AgrBD, Rot 
585 
SarAS, SaeRS, ArlS, 
AgrBD, Rot 
Enzymes 
Coa, HysA, Eno, SbcCC, 
Nuc, Sak 
1118 
Coa, HysA, Eno, SbcCC, 
Nuc, Sak 
Nutrient Acquisition 
SirABC, SbnA, SbnC-I, 
IsdAB, IsdD-I, MntH, 
Ferredoxin, Iron Transport 
Protein 
2250 
SirABC, SbnA, SbnC-I, 
IsdAB, IsdD-I, MntH, 
Ferredoxin, Iron Transport 
Protein 
Immune Evasion Proteins 
Spa*, OatA, KatA, Sod, 
Chp, 16 x Capsule 
Synthesis Proteins 
2035 
Spa*, OatA, KatA, Sod, 
Chp 
Toxins 
11 x Exotoxin, Hla, 
Enterotoxin, LukED, Hlb, 
LukGH/AB, Hld, HlgABC 
1997 
11 x Exotoxin, Hla, 
Enterotoxin, LukED, Hlb, 
LukGH/AB, Hld, HlgABC 
* Spa is also an adhesin 
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3.2.4 Identifying the putative virulence factors 
 
Interestingly, FLIPr-like and SCIN proteins were not found amongst the known 
function proteins in the results of the BLAST search against the bacterial database 
(Table 3.5). This suggested that their annotation is outdated and so they were found in 
the hypothetical proteins search of the bacterial database (Table 3.4). This would rule 
them out for further study, as their functions are already well known. The SCIN protein 
sequence of the Nr Bacterial database was hit by the hypothetical protein with the ID 
SAOHSC_00191. The NCBI Protein database was queried with this ID and identical 
sequences to the result were requested.  The first identical sequence in the list returned 
was the SCIN protein from S. aureus strain 21236. To confirm their identity both 
sequences were compared with bl2Seq (Figure 3.10A). The bl2Seq result demonstrated 
that SAOUHSC_00191 is SCIN and is incorrectly categorised as a hypothetical protein 
in the PATRIC database (the source of the hypothetical protein sequences).  
 
A similar search would have been carried-out for the hypothetical protein 
SAOUHSC_01112, which aligned with the FLIPr-like protein in the Nr Bacterial 
database, but it proved unnecessary. A search of the UniProt database with the ID 
SAOUHSC_01112 returned the result shown in Figure 3.10B. This showed that the 
hypothetical protein annotation was, similarly to SCIN, out of date on the PATRIC 
website. The protein was in fact the FPRL1 inhibitory protein, which has the short name 
FLIPr. 
 
FLIPr and SCIN were ruled out as subjects for further study, as they are both well 
characterised proteins with known roles in S. aureus virulence (Prat et al., 2009; 
Rooijakkers et al., 2006). 
 
The hypothetical protein SAOUHSC_01438 aligns with the conserved virulence factor 
C (CvfC; see Table 3.3). The cvfABC operon has been shown to be a virulence factor in 
silkworm and mouse models of infection. Loss of cvfABC results in reduced expression 
 R I  . -haemolysin concomitant with downregulation of RNAII, thereby reducing 
transcription RNAIII, the primary regulator of agr controlled genes. This demonstrated 
that the cfvABC operon has a role in positive control of the agr system (Kaito et al., 
2005). SAOUHSC_01438 is a protein of 83 amino acids and aligns with the first 82 
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Figure 3.10 Confirmation that hypothetical proteins SAOUHSC_00191 and 
SAOUHSC_01112 are known function proteins. 
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amino acid residues of the 374 amino acid CvfC protein from S. aureus N315. This 
suggested that SAOUHSC_01438 is a short single domain protein and that domain is 
present at the N-terminal of CvfC.  
 
The CvfC protein sequence from S. aureus N315 and SAOUHSC_01438 were both 
used to search the Protein Family database (PFam). This database searches a protein 
sequence and highlights domains within the sequence. The N-terminal of CvfC contains 
a NifU domain and a downstream Virulence Factor domain and HEAT domain. The 
single domain encoded by the SAOUHSC_01438 protein sequence is also a NifU 
domain. Information on this domai  Q  D W  W K H  ( % , ¶ V   , Q W H U S U R  Z H E V L W H (http://www.ebi.ac.uk 
/interpro/) states that NifU domains are required for the formation of FeS clusters and 
the maturation of FeS proteins. Iron sulphur clusters are important cofactors in electron 
transfer and energy production (Pandelia et al., 2011). SAOUHSC_01438 was ruled out 
of any further study, as its similarity to a domain that is not directly associated with 
virulence does not justify inclusion. Furthermore, it is likely that it is not a secreted 
protein, as it was only found when the full list of VFs was searched in section 3.2.3.2. It 
was also not present in the results when the redundancy was removed from the list and 
when only signal sequence containing proteins were used. 
 
3.2.4.1 Are the remaining hypothetical proteins exotoxins or SSLs? 
 
The SSL protein cluster was discovered by Williams et al., (2000) and initially named 
the staphylococcal enterotoxin cluster (set cluster; Lina et al., 2004). Eleven SSL genes 
 D U H   F O X V W H U H G   R Q   W K H   J H Q R P L F   L V O D Q G   ¥ 6 D. (Smyth et al., 2007). The number of SSLs 
vary between strains from 7  – 11 and there is clear homology between the 11 genes 
(Bestebroer et al., 2007; Langley et al., 2005). This cluster is found in all strains of S. 
aureus so far tested, including isolates from 49 humans, 8 cows, 2 chickens and 2 sheep. 
Although the SSL cluster is found in all isolates, there is significant variation in gene 
number and sequence identity (Fitzgerald et al., 2003). Solved structures of SSL 
proteins show structural homology to CHIPS protein (Bestebroer et al., 2009). 
Furthermore, structures of SSL5 and SSL7 show considerable similarity to 
superantigens, however the MHC II binding site, used to trigger T-cell proliferation, has 
been lost and they do not stimulate T-cells (Arcus et al., 2002; Chung et al., 2007; 
Smyth et al., 2007). The SSL proteins contain a domain shared with superantigens, the 
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 -grasp domain, which is linked to an N- W H U P L Q D O  -barrel oligonucleotide/ 
oligosaccharide-binding fold (OB-fold; Arcus et al., 2002; Itoh et al., 2010b; Williams 
et al., 2000). As discussed in Chapter 1, the SSLs have varied roles in immune evasion 
by S. aureus. 
 
Patel et al., 2010 reported that there are 14 SSL genes, eleven in a cluster (SSL1-
SSL11) and a further triplet approximately 700kb downstream (SSL12- SL14). The 
relative positioning of the hypothetical sequence triplet to the known cluster of SSLs is 
the same as that described by Patel et al. Furthermore, SAOUHSC_00354 is found in 
close proximity to the known cluster of eleven SSLs (~23kb upstream of the SSL 
cluster; Figure 3.11). To confirm that SAOUHSC_01124-5-7 and SAOUHSC_00354 
are SSLs, it was decided to search for identical proteins using the identical proteins 
option provided by the NCBI protein database. This was unnecessary for 
SAOUHSC_01124-5-7 as entry of their protein IDs into the NCBI Protein database 
returned the updated annotation, which states that these proteins are recognised 
staphylococcal superantigen-like proteins (SSL12, 13 & 14). 
 
SAOUHSC_00354 was found to be identical to the following sequences classes: 
enterotoxins, beta-grasp domain containing proteins, hypothetical proteins, exotoxins 
and SSLs. The nomenclature history for the SSLs suggests that the enterotoxins and 
beta-grasp domain containing proteins are in fact SSLs (Lina et al., 2004).  
 
Dr Suzan Rooijakkers (University Medical School Utrecht) was contacted as an expert 
on SSLs. She xplained that the group was working with SAOUHSC_00354 and was 
attempting overexpression of the protein in Lactococcus lactis, as E. coli overexpression  
produced very little protein. The group had also found that this SSL binds to 
neutrophils. Given past experience with LukAB, it was important not to duplicate 
efforts and so it was decided to move forward with SSL12, 13 & 14 only, as their role in 
pathogenesis had not been determined. 
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Figure 3.11 Position of SSLs on the S. aureus 8325 genome. 
 
The cluster of 11 SSLs and the putative SSL15 are on the positive strand of the genome 
in relatively close proximity, ~23kb. 
SSL12, 13 & 14 are on the negative strand approximately 700kb downstream of the 
SSL cluster. 
S. aureus
NCTC 8325
Putative SSL15
363,894-364,505bp
SSL cluster
388,294-403,185bp
SSL12,13 & 14
1,078,816-1,079,532bp
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3.2.5 Characterisation of SSL12, SSL13 & SSL14 
 
3.2.5.1 The pET21d protein expression system 
 
In order to determine the activity of SSL12, 13 & 14 recombinant protein was produced 
using the pET21d system. The effectiveness of the pET21d protein overexpression 
system relies on two things, the T7 polymerase induced by IPTG in E. coli strain BL21 
and the pET21d plasmid encoding a T7 polymerase controlled promoter. The T7 
polymerase is extremely active and can produce rRNA levels of target mRNA within 
three hours of activity from its promoter (Studier & Moffatt, 1986). The open reading 
frame (ORF) of a target gene can be inserted into the pET21d plasmid downstream of 
the T7 promoter and transformed into E. coli Top10. Transformation is confirmed by 
ampicillin resistance. The plasmid is then transformed into E. coli BL21, an E. coli 
strain containing a lysogenic phage with the T7 polymerase under the control of the 
IPTG inducible lacUV5 promoter, and IPTG can be used to induce expression of the 
target protein. As E. coli does not encode T7 specific promoters, the T7 polymerase 
only acts on that encoded in the plasmid and the expression can be to such a high level 
that it makes up > 50% of the total cell protein (Studier & Moffatt, 1986). To allow 
recovery of the target protein, downstream of the target ORF the plasmid encodes a 6-
His tag, followed by a T7 transcription termination signal. The 6-His tag allows for 
purification of the protein using a nickel-affinity chromatography column. 
 
3.2.5.2 SSL12, SSL13 & SSL14 pET21d plasmid constructs 
 
Construction of the SSL pET21d plasmids is shown in Figure 3.12. As discussed in 
section 3.2.3.5, secreted proteins encode an N-terminal signal sequence that is 
recognised by the secretion system. This signal peptide is cleaved during secretion to 
give the mature protein. Therefore, the forward primers were designed so as to remove 
the signal sequences of SSL12-13-14 (for primer sequences see Chapter 2.12.1.1). NcoI 
and XhoI were designed into the forward and reverse primer allowing their restriction, 
to insert into the multiple cloning site (MCS) within the pET21d plasmid cut with the 
same enzymes (Chapter 2.12.2). As the primers were designed downstream of the ORF 
start codon, an ATG codon was inserted into the forward primer, and two residues were 
inserted upstream of the ATG, between the restriction site and start codon to keep the 
ORF in frame. The PCR product sizes were confirmed by 1% (w/v) gel electrophoresis
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Figure 3.12 Representative construction of the pSSL plasmids.  
 
The red box in the gene represents the signal sequence (SS). The thin blue region of the 
gene is the stop codon. Stop codon and SS absent from the PCR product. All steps were 
done in duplicate and repeated for each SSL gene to give pSSL12, pSSL13 and 
pSSL14. 
 
pSSLxx
SSLxx GeneSS
SSLxx PCR Product
NcoI XhoI
Stop codon
121 
 
(Chapter 2.12.5) and gel extracted with the QIAquick Gel Extraction kit (Chapter 
2.11.1). Plasmid and primer DNA was then cut with NcoI and XhoI restriction enzymes 
and purified by gel extraction again, using the QIAquick Gel Extraction kit. The cut 
PCR products were ligated into cut pET21d and ethanol precipitated (Chapter 2.12.4 & 
Chapter 2.11.5 respectively). The ligation product was then transformed into E. coli 
Top10 (Chapter 2.9.1.2). The entire process was completed in duplicate to allow for any 
PCR errors.  
 
To confirm the success of construction, plasmid DNA was extracted from the E. coli 
Top10 using the QIAprep Spin Mini kit (Chapter 2.11.4). Extracted plasmid DNA was 
digested with NcoI and XhoI and expected fragments were confirmed by gel 
electrophoresis (Figure 3.13). Plasmid inserts were sequenced at the Core Genomic 
Facility, University of Sheffield (for sequencing primers see Chapter 2.12.1.1) to 
confirm the correct sequence (see Appendix 3.5 for sequence data). One sequence from 
each duplicate was correct. This recombinant plasmid was transformed into E. coli 
BL21 from E. coli Top10 (Chapter 2.9.1.2). 
 
3.2.5.3 Protein overexpression of SSL12, 13 & 14 in E. coli BL21 
 
Cultures of E. coli BL21 containing each plasmid were prepared and protein expression 
was carried out (Chapter 2.15.1). Expression was induced for 4 h at 37
o
C in mid-
exponential cultures by addition of IPTG. Samples were taken before and after IPTG 
addition to assess the level of expression. To determine if the proteins were soluble or 
insoluble, samples were taken after IPTG induction. Cells were disrupted in both 
samples and centrifuged, the supernatant contained any soluble protein and the pellet 
contained the insoluble protein. To determine solubility, samples were assessed by 
electrophoresis on an 11% (w/v) SDS-PAGE gel, which was stained with Coomassie 
Blue (Chapter 2.14.1 and Chapter 2.14.2, respectively). Protein was found to be 
overexpressed in IPTG induced samples and found in the insoluble fraction for all SSLs 
(Figure 3.14). 
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Figure 3.13 Confirmation of correct construct insert sizes for recombinant SSL 
production. 
 
DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards (M) 
of sizes shown are in each panel. 
 
Lanes 1a, 1b and 1c are PCR products for SSL12, SSL13 and SSL14 respectively. 
Lanes 2a/3a, 2b/3b and 2c/3c are digested construct from each duplicate.  
Expected bands of ~700bp for the insert and 5,440bp for pET21d are shown. 
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Figure 3.14 Overexpression and solubility of SSL12, 13 & 14. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) of sizes shown 
are present on each gel. 
 
Lane 1. Uninduced sample.  
Lane 2. Induced sample.  
Lane 3. Insoluble protein (arrows indicate protein).  
Lane 4. Soluble protein (no overexpressed protein was found in the soluble fractions).  
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3.2.5.4 Effect of induction temperature and induction time on solubility 
 
Soluble protein is required to characterise the activity of the SSLs (e.g. binding assays 
with immune molecules or cells etc.). For this reason attempts were made to induce 
production of soluble protein. As discussed in section 3.2.5.3, cultures of E. coli BL21 
expressing SSL12, 13 or 14 were grown to mid-exponential at 37
o
C, at which point 
IPTG was added to induce protein expression and the cultures were grown for another 4 
h at 37
o
C. 37
o
C is the standard temperature for growth of E. coli. The assumption made 
from the results in section 3.2.5.3 was that as E. coli grows at this temperature it 
produces too high a level of SSL protein from the T7 promoter, and as it is rapidly 
translated it forms aggregates leading to insoluble protein. The hypothesis was that if 
the growth temperature was reduced to 30
o
C and 25
o
C then growth would slow and 
production of protein would become more manageable for the bacteria. An additional 
time point of 18 h was used allowing for slowing production of protein and the 
experiment was carried-out in 250 ml conical flasks using 100 ml culture volume 
(Figure 3.15). Soluble protein, at equivalent levels to the expressed insoluble protein, 
was found to be produced at 30
o
C after 4 h IPTG induction (Figure 3.15B, lane 4). 
 
3.2.5.5 Overexpression of the SSLs at 30
o
C in a 3 litre culture 
 
A large amount of protein was required to fully characterise the SSL proteins. Soluble 
protein was found to be produced at 30
o
C; however, the majority of protein even at this 
temperature was in the insoluble fraction (Figure 3.12, lanes 3&5). Therefore, the 
overexpression of SSLs was scaled up to 3 litre cultures grown at 30
o
C in order to 
provide enough material for protein characterisation. However, none of the 3 litre 
cultures produced soluble protein (Figure 3.16, lane 4). 
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Figure 3.15 Effect of temperature on SSL solubility. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant size shown are present on each gel. 
 
Arrows indicate soluble protein bands at 30
o
C. 
 
A. IPTG induction at 25
o
C. 
B. IPTG induction at 30
o
C. 
C. IPTG induction at 37
o
C. 
 
Lane 1. Uninduced samples.  
Lane 2. Induced sample.  
Lane 3. Insoluble protein produced after 4 h induction.  
Lane 4. Soluble protein produced after 4 h induction. 
Lane 5. Insoluble protein produced after 18 h induction. 
Lane 6. Soluble protein produced after 18 h induction. 
 
 
 
 
 
 
 
 
127 
 
 
Figure 3.16 Overexpression of SSLs at 30
o
C using a higher culture volume. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown are present on each gel. 
 
Lane 1. Uninduced sample.  
Lane 2. Induced sample.  
Lane 3. Insoluble protein (arrows indicate protein).  
Lane 4. Soluble protein (no overexpressed protein was found in the soluble fractions). 
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3.2.5.6 Overexpression of the SSLs at 30
o
C in 4 x 250 ml cultures 
 
Expression of soluble protein at 30
o
C was successful using 250 ml conical flask and 100 
ml of culture (section 3.2.4.4). However, the volume was not enough for 
characterisation and since large volume cultures did not produce soluble protein, 
attempts were made to produce enough protein for characterisation using multiple small 
cultures. Protein overexpression was done using the same condition as in section 
3.2.4.4, but with multiple conical flasks and only 4 h IPTG induction. Inconsistent 
expression of soluble protein was seen and in lanes that do show soluble protein it is 
only a small amount when compared to the insoluble protein (Figure 3.17). Therefore it 
was concluded that this method does not provide a consistent source of soluble SSL 
protein.  
 
3.2.5.7 Purification of insoluble SSL12, 13 & 14 protein in the presence of 8M urea 
 
Insoluble SSL protein, from a 100 ml culture induced with IPTG, was purified by nickel 
affinity chromatography using a nickel charged HiTrap    column (Chapter 2.15.4). 
Charging the column with nickel facilitates the interaction of the column with the C-
terminal 6-His tag added to the recombinant protein. For affinity chromatography to 
work, the protein must be soluble, therefore 8M urea was added to all buffers, which 
increases the capacity for solubilisation of protein by H2O (Bennion & Daggett, 2003). 
The protein was passed through the column in START buffer. Unbound protein was 
then removed from the column by passing elution buffer containing 5% (w/v) imidazole 
through the column. Gradually increasing imidazole concentration over a 1 h time 
period allowed for elution of the recombinant protein. Elutions were collected every 
minute in 1 ml aliquots and the presence of protein was confirmed by 11% (w/v) SDS- 
PAGE (Figure 3.18). Those elutions containing protein were pooled to give a stock of 
SSL12, SSL13 and SSL14. The approximate volume of eluted protein varied from 5-9 
ml. 
 
3.2.5.8 Refolding of protein samples by stepwise dialysis 
 
Dialysis of protein samples to gradually reduce the concentration of urea in samples was 
used to refold the insoluble proteins into a soluble form (Chapter 2.15.5.2). Initially
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Figure 3.17 Overexpression of SSLs at 30
o
C using multiple low volume cultures. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown are present on each gel. 
 
Lanes 1&5. Uninduced sample.  
Lanes 2&6. Induced sample.  
Lanes 3&7. Insoluble protein (arrows indicate protein).  
Lanes 4&8. Soluble protein (no overexpressed protein or low level overexpressed 
protein was found in the soluble fractions).  
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Figure 3.18 Purification of urea solubilised SSL protein and elution into separate 1 
ml samples. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown. 
 
Each lane contains 10 µl from 1 ml elution samples.  
Samples from lanes containing protein were retained and pooled:  
SSL12 lanes 5-9, pooled volume = ~5 ml. 
SSL13 lanes 3-8, pooled volume = ~6 ml. 
SSL14 lanes 12-20, pooled volume = ~9 ml. 
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PBS + 8M urea was used as the buffer and the aim was to remove the urea using the 
following sequence every 12 h: 6M, 4M, 3M, 2M, 1M, 0.5M, 0M urea. However, the 
protein precipitated at 3M urea concentration.  
 
An alternative means of solubilising insoluble protein is 6M guanidine. SSL13 was 
again overexpressed and purified using guanidine rather than urea. Dialysis using 
decreasing concentrations of guanidine was used starting at 4M. However, again at 3M 
guanidine the protein precipitated.  
 
3.2.5.9 Refolding protein by dilution in the presence of L-Arg 
 
Dilution is an alternative method of protein renaturation to dialysis. Whereas in dialysis 
the sample is kept separate from the buffer by dialysis tubing (Chapter 2.15.5.1), in the 
dilution method the sample is added directly to the buffer to allow refolding, then 
concentrated (Chapter 2.16). An initial attempt was made using H2O as the buffer. No 
soluble protein was found after dilution or after concentration of the diluted sample 
(data not shown).  
 
L-Arg as an additive to dilution buffers was shown to enhance refolding of Sak protein 
fragments (He et al., 2008). Using an L-Arg Base Refolding Buffer containing 880 mM 
L-Arg (Chapter 2.5.5.1), 1 ml of pooled SSL12, SSL13 and SSL14 elutions (eluted 
from the HiTrap    column as in section 3.2.5.7; Figure 3.18) were diluted 20-fold by 
slowly dripping the samples into refolding buffer. Only 1 ml of the total pooled elution 
samples was diluted, to prevent loss of the full 5-9 ml of eluted protein (Figure 3.18). 
Samples were then concentrated using an Amicron Ultra Centrifugal Filter. After 
centrifugation to remove any insoluble material, the concentrated samples were 
analysed by electrophoresis of 10 µl using an 11% (w/v) SDS-PAGE gel (Figure 
3.19A). Soluble protein was found for each SSL. 
 
As the method produced soluble protein it was repeated by dilution of 1 ml of eluted 
protein sample or 3 ml of eluted protein sample, collected as in section 3.2.5.7. This was 
done to determine if a higher soluble protein concentration could be achieved, without 
causing aggregation upon concentration with the Amicron filter. Concentrated samples 
were analysed by electrophoresis of 10 µl of each concentrated sample on an 11% (w/v)
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Figure 3.19 Solubilisation of recombinant SSL protein using 880 mM L-Arg. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown are present on each gel. 
 
A. Each lane contains 10 µl (80% of total) of soluble protein sample, produced by 
dilution refolding of 1 ml of HiTrap    eluted protein in 880 mM L-Arg buffer. 
Lane 1 = SSL12, lane 2 = SSL13, lane 3 = SSL14. 
B. Lanes 1-3 contain 10 µl (80% of total) of soluble protein sample, produced by 
dilution refolding of 1 ml of HiTrap    eluted protein in 880 mM L-Arg buffer. 
Lanes 4-6 contain 10 µl (80% of total) of soluble protein sample, produced by dilution 
refolding of 3 ml of HiTrap    eluted protein in 880 mM L-Arg buffer. 
Lane 1&4 = SSL12, lane 2&5 = SSL13, lane 3&6 = SSL14. 
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SDS-PAGE gel (Figure 3.19B). A low volume of protein was collected for each sample, 
the majority of which was loaded onto the SDS-PAGE gel. For this reason, difference in 
soluble protein yield could only be determined from the appearance of bands on the 
SDS-PAGE gel. It is clear from the image (Figure 3.19B) that dilution of 3 ml of eluted 
protein sample (lanes 4-6) produced more soluble protein than dilution of 1 ml of eluted 
protein sample (lanes 1-3). This demonstrated that higher concentrations of soluble 
protein could be acquired by dilution of higher volumes of the protein eluted from 
HiTrap   columns. 
 
The problem with using L-Arg is that the concentration of L-Arg is very high and may 
interfere with downstream SSL characterisation experiments (i.e. the purpose of 
purifying the SSLs). To that end, the above experiment was repeated using 10-fold less 
L-Arg (Figure 3.20). Considerably less protein was recovered in a soluble form at this 
L-Arg concentration. 
 
3.2.5.10 Refolding protein by dilution in the presence of L-Arg and L-Glu 
 
L-Arg and L-Glu have also been shown to enhance the performance of purification 
buffers and enhance the stability of the protein during storage (Golovanov et al., 2004). 
Enhanced refolding is thought to be due to the L-Arg/L-Glu crowding hydrophobic 
regions of the protein, allowing time for the proteins to fold in such a way that the 
hydrophobic residues are housed within the hydrophobic core of the protein. Golovanov 
used 50 mM L-Arg and 50 mM L-Glu in their buffers, therefore the same concentration 
was added to the Base Refolding Buffer (Chapter 2.5.5.2).  
 
Each SSL protein was overexpressed in a 1.5 litre culture volume. The insoluble protein 
was solubilised with 8M urea and purified by Nickel-affinity chromatography, in the 
presence of urea as in section 3.2.5.7. Approximately 7 ml of each SSL was eluted from 
the HiTrap    columns, as in Figure 3.18. The full 7 ml of each eluted SSL protein was 
drip-diluted 20-fold into 50 mM L-Arg and L-Glu buffer. Samples were stored at 4
o
C to 
allow refolding overnight, followed by concentration of the diluted samples using an 
Amicon Ultra centrifugal filter. Residual insoluble protein was removed by 
centrifugation. 10 µl of the 7 ml elution sample, 10 µl of the 20-fold diluted sample and 
10 µl of the concentrated samples were analysed for each SSL protein by  
134 
 
 
Figure 3.20 Solubilisation of recombinant SSL protein using 88 mM L-Arg. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown are present on each gel. 
 
Lanes 1-3 contain 10 µl (80% of total) of soluble protein sample, produced by dilution 
refolding of 1 ml of HiTrap    eluted protein in 88 mM L-Arg buffer. 
Lanes 4-6 contain 10 µl (80% of total) of soluble protein sample, produced by dilution 
refolding of 3 ml of HiTrap    eluted protein in 88 mM L-Arg buffer. 
Lane 1&4 = SSL12, lane 2&5 = SSL13, lane 3&6 = SSL14. 
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Figure 3.21 Solubilisation of recombinant SSL protein using L-Arg and L-Glu. 
Protein samples were separated by 11% (w/v) SDS-PAGE. Markers (M) with relevant 
size shown are present on each gel. 
 
Lane 1. 10 µl of urea solubilised SSL protein taken from the pooled HiTrap   elution 
samples. 
Lane 2. 10 µl of soluble SSL protein from the pooled HiTrap    elution samples after 
20-fold dilution in L-Arg/L-Glu refolding buffer. 
Lane 3. 10 µl (80% of total) of soluble SSL protein after Amicron concentration of the 
diluted sample. 
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electrophoresis on an 11% (w/v) SDS-PAGE gel (Figure 3.21). From the protein in 
Figure 3.21 (lane 3) for each SSL it is clear that the method of protein folding works 
and works most efficiently for SSL14. However, from a 1.5 litre culture, between 10 
and 12 µl of purified protein was produced. Indeed the volume was so low that the 
majority of it was used to prepare the SDS-PAGE gels in Figure 3.21, preventing 
quantification of protein yield. Therefore, it was decided that an alternative method of 
SSL characterisation was required. 
 
3.2.5.11 Construction of the SSL triplet deletion plasmid 
 
In order to determine a role for the SSLs in host pathogen interaction a triplet mutant 
was created. The deletion plasmid construction method is shown diagrammatically in 
Figure 3.22. A 1.2kb fragment immediately upstream of the SSL triplet (UF) was 
amplified by PCR using primers FU and RU (for PCR method and primers see Chapter 
2.12.1.2 and Chapter 2.12.1.1, respectively). The FU primer encodes a KpnI restriction 
site and RU encodes a SalI restriction site. The plasmid pOB encoding erythromycin 
resistance was used as the deletion vector. The plasmid and upstream fragment were 
digested with KpnI and SalI (Chapter 2.12.2) and ligated together (Chapter 2.12.4). 
Ligations were ethanol precipitated (Chapter 2.11.5) and transformed into E. coli Top10 
(Chapter 2.9.1.1), giving plasmid pOB-UF. Plasmid DNA was extracted using the 
QIAprep Spin Mini kit (Chapter 2.11.4) and digested with KpnI and SalI and the 
presence of the UF fragment was confirmed by 1% (w/v) gel electrophoresis (Chapter 
2.12.5; Figure 3.23A). The 1.2kb fragment immediately downstream of the SSL triplet 
(DF) was then amplified using primers FD and RD, encoding a SalI cut site in FD and a 
SphI cut site in RD. Plasmid pOB-UF and downstream fragment were digested with 
SalI and SphI and ligated as above. The precipitated ligation product was used to 
transform E. coli Top10, giving pOB-UF-DF. Plasmid DNA was extracted using the 
QIAprep Spin Mini kit and digested with SphI and SalI and the presence of the DF 
fragment was confirmed by 1% (w/v) gel electrophoresis (Figure 3.23B). 
 
The kanamycin resistance cassette from the plasmid pGL485 (Liew et al., 2011) was 
amplified with primers KanF and KanR (Chapter 2.12.1.1), both encoding a SalI 
restriction site. The Kan
R
 cassette was spliced in between the UF and DF fragments, by  
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KanR
DF
UF
Kpn1-FU
Sal1-RU
Sal1-RD
Sph1-FD
Sal1-kanF
Sal1-kanR
Figure 3.22 Construction of the SSL 
deletion plasmid.  
UF = 1.2kb PCR fragment amplified 
from immediately upstream of the SSL 
triplet. DF = 1.2kb PCR fragment 
amplified from immediately down-
stream of the SSL triplet. The Kan
R
 
cassette was amplified from pGL485. 
Primer FU, RU, FD, RD, KanF, KanR 
encode the restriction sites required to 
insert the fragments into the pOB 
plasmid. 
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Figure 3.23 Confirmation of successful construction of the SSL deletion plasmid. 
DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards (M) 
of sizes shown are in each panel. 
 
A. pOB-UF digested with KpnI and SalI. 
Arrow 1. Digested plasmid, 4,464 bp.  
Arrow 2. UF fragment 1,288 bp.  
B. pOB-UF-DF digested with SphI and SalI. 
Arrow 1. Undigested plasmid, 7,036 bp. 
Arrow 2. Digested plasmid, 5,752 bp.  
Arrow 3. DF fragment 1,284 bp.  
C. pOB-UF-Kan-DF digested with SalI. 
Arrow 1. Digested plasmid, 7,036 bp.  
Arrow 2. Kan cassette 1,473 bp. 
D. pOB-UF-Kan-DF digested with KpnI & SphI. 
Arrow 1. Undigested plasmid, 8,509 bp.  
Arrow 2. Digested plasmid, 4,464. 
Arrow 3. Full insert 4,045 bp. 
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digesting the amplified cassette and pOB-UF-DF with SalI and ligating as in Chapter 
2.12.4. The ligation product was used to transform E. coli Top10 to give the pOB-UF-
Kan-DF deletion construct. The successful integration of Kan
R
 was confirmed by 1% 
(w/v) gel electrophoresis of the purified plasmid digested with SalI (Figure 3.23C). The 
plasmid DNA was digested separately with KpnI and SphI to confirm the presence of 
the full insert (Figure 3.23D). For primer sequences see Chapter 2.12.1.1. 
 
3.2.5.12 Deletion of the SSL triplet from S. aureus NewHG 
 
The method of deletion is shown diagrammatically in Figure 3.24. The pOB-UF-Kan-
DF plasmid was extracted from E. coli Top10 and used to transform electrocompetent 
RN4220 (Chapter 2.9.2.2). RN4220 is a restriction negative modification positive strain 
of S. aureus. Single crossover homologous recombination occurs between the upstream 
or downstream region of the RN4220 copy of the triplet and the upstream or 
downstream copy on the pOB-UF-Kan-DF plasmid. The plasmid is incorporated into 
the RN4220 genome, conveying resistance to kanamycin and erythromycin (Figure 
     $     7 K H   P H U R G L S O R L G   F D Q   W K H Q   E H   U H V R O Y H G   E \   S K D J H   W U D Q V G X F W L R Q   X V L Q J  -   
bacteriophage (Chapter 2.10.3). Successful resolvant transductants will be kanamycin 
resistant, due to the Kan
R
 cassette replacing the SSLs and erythromycin sensitive, due to 
loss of the plasmid insertion. PCR (Chapter 2.12.1.2; Figure 3.24B) and Southern 
hybridisation (Chapter 2.13) were used to confirm successful SSL deletion. For the PCR 
analysis five sets of primers were used: 01124-F and 01124-R, a positive control to 
confirm the presence of SSL12 in the wild-type DNA, also confirms the absence of 
 6 6 /     L Q   1 H Z + *ß 6 6 /   ’ 1 $         -F and 01125-R; 01127-F and 01127-R, confirm 
 W K H   D E V H Q F H   R I   6 6 /     D Q G        U H V S H F W L Y H O \    L Q   1 H Z + *ß 6 6 /   ’ 1 $    L V G $-F and isdA-R 
used as a positive control for S. aureus genomic DNA, Kan-F and Kan-R confirm the 
presence of the Kan
R
  F D V V H W W H   L Q   1 H Z + *ß 6 6 /    $ P S O L I L F D W L R Q   S U R G X F W V   R I   H [ S H F W H G 
sizes were found (Figure 3.25A). For primer sequences see Chapter 2.12.1.1. The 
Southern hybridisation analysis is shown in Figure 3.25B, C & D, genomic DNA of the 
correct sizes for SSL deletion were probed. 
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Figure 3.24 Deletion of the SSL triplet shown diagrammatically. 
 
A. Integration of the pOB-UF-Kan-DF plasmid into the S. aureus RN4220. Integration 
can occur either via single crossover events between the UF or the DF fragments of the 
pOB-UF-Kan-DF plasmid and the UF or DF fragments of the RN4220 genome. 
 
B. Deletion of the SSL triplet by double crossover between either of the two possible 
integrations transduced into S. aureus NewHG. This results in loss of the Ery
R
 plasmid. 
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Figure 3.25 Confirmation of deletion of the SSL triplet from S. aureus NewHG. 
DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards (M) 
of sizes shown are in each panel. 
A. PCR confirmation of SSL deletion. Lane 1     1 H Z + *ß 6 6 /   J ’ 1 $   D P S O L I L H G   Z L W K 
Kan-  ) ¶   	   . D Q - 5 ¶   Lane 2   1 H Z + *ß 6 6 /   J ’ 1 $   D P S O L I L H G   Z L W K   L V G $- ) ¶   	   L V G A- 5 ¶  
Lane 3-5    1 H Z + *ß 6 6 /   J ’ 1 $   D P S O L I L H G   Z L W K   V V O   - ) ¶   	   V V O   - 5 ¶    V V O   - ) ¶   	   V V O   -
 5 ¶   V V O   - ) ¶  	  V V O   - 5 ¶    U H V S H F W L Y H O \ Lane 6. NewHG gDNA amplified with ssl12- ) ¶  	 
ssl12- 5 ¶   B. Southern hybridisation confirmation of SSL deletion. HpaI lane 1. 
NewHG genomic DNA cut with HpaI and probed with the UF fragment (expected 
product size 3.7 kb), HpaI lane 2     1 H Z + *ß 6 6 /   J H Q R P L F   ’ 1 $   F X W   Z L W K   + S D ,   D Q G 
probed with the UF fragment (expected product size 7.1 kb), SalI/BglI lane 1. NewHG 
genomic DNA cut with SalI/BglI and probed with the UF fragment (expected product 
size 6.6 kb), SalI/BglI lane 2,  1 H Z + *ß 6 6 /   J H Q R P L F   ’ 1 $   F X W   Z L W K   6 D O ,   % J O ,   D Q G 
probed with the UF fragment (expected product size 4.3 kb). C. HpaI restriction 
digestion shown diagrammatically. D. SalI/BglI restriction digestion shown 
diagrammatically. 
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3.2.5.13  * U R Z W K  F K D U D F W H U L V W L F V  R I  1 H Z + *ß 6 6 / 
 
Before comparison of virulence of the SSL mutant strain with the wild-type strain, it 
was essential to know that growth rate in standard conditions of growth was not affected 
by the SSL deletion. A growth curve in BHI was carried-out to compare growth of 
N H Z + *   D Q G   1 H Z + *ß 6 6 6 /     ) L J X U H       $     * U R Z W K   Z D V   D O V R   F R P S D U H G   L Q   I R H W D O 
 E R Y L Q H   V H U X P     ) L J X U H        %     * U R Z W K   R I   1 H Z + *ß 6 6 /   Z D V   F R P S D U D E O H   W R   1 H Z + *   L Q 
both media. 
 
3.2.5.14 Zebrafish model of  V \ V W H P L F  L Q I H F W L R Q  D Q D O \ V L V  R I  1 H Z + *ß 6 6 / 
 
In order to determine the role of SSL12, 13 & 14 in pathogenicity, the zebrafish embryo 
model of systemic infection was used (Prajsnar et al., 2008). This work was done in 
collaboration with Alex Williams (for methodology see Chapter 2.23). Thirty zebrafish 
embryos of strain LWT, at 1 day old, were injected with ~1,500 CFU NewHG or 1,500 
NewHGß 6 6 / . Health of the fish was monitored over 4 days and dead fish were tallied. 
After four days the remaining fish were killed. No attenuation in zebrafish killing was 
seen in the  1 H Z + *ß 6 6 /  strain (p > 0.05; Figure 3.27). Many of the VFs of S. aureus 
are human specific or have stronger or weaker effects depending on the animal host. 
Therefore, there being no attenuation in the zebrafish model did not rule out SSL12, 13 
& 14 as potentially important VFs.  
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Figure 3.26 Role of SSL12, 13 & 14 in S. aureus growth. 
 y = NewHG,    =  1 H Z + *ß 6 6 /  
A CFU and OD600 measured hourly over 9 h show comparable growth between NewHG 
 D Q G  1 H Z + *ß 6 6 /   Z K H Q  J U R Z Q  L Q  % + ,   
B OD600 measured hourly over 9 h show comparable growth between NewHG and 
 1 H Z + *ß 6 6 /  Z K H Q  J U R Z Q  L Q  ) % 6   
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Figure 3.27 Role of the SSL triplet in pathogenesis in the zebrafish embryo model.  
 
 1 H Z + *ß 6 6 /  V K R Z V  Q R  D W W H Q X D W L R Q  L Q  W K H  ] H E U D I L V K  P R G H O  R I  V \ V W H P L F  L Q I H F W L R Q 
p=0.6114.  
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          $ Q D O \ V L V  R I  J U R Z W K  R I  1 H Z + *ß 6 6 /  L Q  Z K R O H  K X P D Q  E O R R G  
 
Human blood is rich with antimicrobial proteins, immune cells and is poor in available 
nutrients. Therefore it provides an ideal medium for the analysis of potential virulence 
 I D F W R U V    * U R Z W K   R I   W K H   1 H Z + *ß 6 6 /   Z D V   D V V H V V H G   L Q   Z K R O H   K X P D Q   E O R R G   W U H D W H G   Z L W K 
sodium citrate to prevent clotting. Blood collection was done at The Royal Hallamshire 
Hospital, Sheffield (Chapter 2.1.3.1.1). Full details of the assay are given in Chapter 
2.20. The method of Lancefield (1957) was modified for use with S. aureus. 
 $ S S U R [ L P D W H O \         & ) 8   R I   1 H Z + *   D Q G   1 H Z + *ß 6 6 /   Z H U H   X V H G   D V   L Q R F X O X P   S H U   P O 
of blood. The CFU was measured immediately and the samples were incubated at 37oC 
with gentle agitation for 3 h. CFU was then measured and wild type and mutant growth 
 F R P S D U H G    ’ L I I H U H Q F H   L Q   J U R Z W K   Z D V   F D O F X O D W H G   D V   W K H   J U R Z W K   R I   1 H Z + *ß 6 6 /   U H O D W L Y H 
to the wild-type (i.e. wild-type growth was set at 100% and mutant growth was 
compared with this). There is a small, but significant difference between NewHG and 
 1 H Z + *ß 6 6 /    ) L J X U H           
 
          $ Q D O \ V L V  R I  J U R Z W K  R I  1 H Z + *ß 6 6 /  L Q  K X P D Q  S O D V P D  
 
 7 R   G H W H U P L Q H   Z K H W K H U   W K H   J U R Z W K   G L I I H U H Q F H   E H W Z H H Q   1 H Z + *   D Q G   1 H Z + *ß 6SL seen 
in Figure 3.28 were due to non-cellular factors, the whole blood assay was repeated 
using human platelet rich plasma (PRP). PRP preparation method is given in section 
2.1.3.1.2. The exact protocol was that used in 3.2.5.15, except plasma was exchanged 
for blood. No significant difference in growth was found between mutant and wild-type 
(Figure 3.29). This suggests that the SSLs interact with the cellular component of 
human blood, aiding survival of S. aureus in blood. 
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Figure 3.28 Analysis of the role of the SSL triplet in growth in human blood. 
 
 1 H Z + *  J U R Z V  V L J Q L I L F D Q W O \  E H W W H U  W K D Q  1 H Z + *ß 6 6 /  L Q  Z K R O H  K X P D Q  E O R R G    S         
 
  
Figure 3.29 Analysis of the role of the SSL triplet in growth in human plasma. 
 
Growth of  1 H Z + *  D Q G  1 H Z + *ß 6 6 /  Z D V  F R P S D U D E O H  L Q  K X P D Q  S O D V P D    S  !       
 
2.53x10 3
  4.1x102
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  3.6x102
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  7.5x102
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3.2.5.17 Complementation of the SSL triplet with pGM073 plasmid system 
 
To determine if the SSL triplet was responsible for the growth phenotype in human 
blood, NewHG ß 6 6 /   Z D V   J H Q H W L F D O O \   F R P S O H P H Q W H G   X V L Q J   W K H   S * 0    
complementation system. The pGM073 plasmid was constructed by Gareth McVicker 
from the plasmid pKasbar, by addition of the genes ezrA and PSmOrange. This plasmid 
has an attP site allowing recognition by the phage integrase enzyme. Lysogenic 
bacteriophage DNA integrates into the S. aureus genome via its attP site and the 
bacterial genome encoded attB site, mediated by the integrase enzyme. In S. aureus the 
attB recognition site is located at the gene for glycerol ester hydrolase (geh) and 
incorporation of phage DNA leads to loss of lipase activity (Lee & Iandolo, 1986). The 
pGM073 plasmid encodes an attP site, allowing integration of the plasmid at lipase in 
the presence of integrase. Primers tripF and tripR (containing ApaI and BbvCI 
restriction sites, respectively) were designed to amplify the SSL triplet and up and 
downstream control elements (Chapter 2.12.1.1).  
 
The SSL triplet and up and downstream control elements were amplified and ligated 
into pGM073 (Figure 3.30A). Primers and plasmid were cut with ApaI and BbvCI and 
ligated (Chapter 2.12.2 and Chapter 2.12.4, respectively). Successful construction was 
confirmed by purification of the plasmid from E. coli and digestion with ApaI and 
BbvCI and analysis by 1% (w/v) electrophoresis (Figure 3.30B). Cutting the plasmid 
with these enzymes removes the ezrA and PSmOrange genes. Ligation gives the 
plasmid pJC001, the pKasbar plasmid with the SSL triplet inserted. Plasmid DNA was 
sequenced by GATC Biotech, using primers Tset1F, Tset1R & Tset2F, Tset2R & 
Tset3F, Tset3R & Tset4F, Tset4R, to confirm that the correct sequence of the triplet 
was inserted (Appendix 3.6). The plasmid was then used to transform an S. aureus 
RN4220 strain containing the  S < /    ß    plasmid. This plasmid encodes the integrase 
enzyme required for geh integration (Figure 3.31).  
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Figure 3.30 Construction of the complementation plasmid pJC001. 
 
A. The SSL triplet with up and downstream control elements was amplified using 
primers with ApaI and BbvCI restriction sites designed into them, giving a PCR product 
of 3,171 bp. The pGM073 and amplified triplet were then digested with ApaI and 
BbvCI and purified. Digestion of the plasmid removes the PSmOrange and ezrA genes, 
reducing the plasmid size to 5,437bp. The triplet was then ligated into the digested 
pGM073 plasmid to give the 8,608 bp plasmid pJC001.  
B. DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards 
(M) of sizes shown. 
 
Bands corresponding in size to the undigested or partially digested plasmid (1; 8,608 
bp), digested plasmid (2; 5,864 bp) and insert (3; 3,171 bp) are indicated. 
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3.2.5.18 Integration of pJC001 into S. aureus RN4220 
 
Integration of pJC001 into RN4220 is shown diagrammatically in Figure 3.31. 
Integration of the pJC001 plasmid into geh results in loss of lipase activity. Lipase 
activity was compared with RN4220 to confirm insertion of pJC001 (Figure 3.32A). 
The pJC001 plasmid was transferred from the RN4220 genome to NewHG and 
 1 H Z + *ß 6 6 /   E \   E D F W H U L R S K D J H   W U D Q V G X F W L R Q    & K D S W H U             D O O R Z L Q J   L Q W H J U D W L R Q   L Q W R 
the genome by homologous recombination. The pKasbar backbone was also transduced 
into  1 H Z + *   D Q G   1 H Z + *ß 6 6 /  to give control strains for the integration of DNA at 
geh. PCR was carried out to confirm the successful integration of pJC001 or pKasbar 
 L Q W R   1 H Z + *ß 6 6 /   D Q G   W K H   Z L O G-type. Three sets of primers were used to determine 
correct insertion: Tset1F and Tset1R, which amplify a section of the SSL triplet in wild-
type or complemented strain DNA, or nothing in the mutant DNA; KanF and KanR, 
amplify the Kan
R
 cassette in the mutant, but nothing in the wild-type and pGM-F and 
pGM-R, amplify the insertion site on the pKasbar plasmid to confirm the integration of 
pKasbar and not pJC001. The primer combination pGM-F and Tset1R were also used to 
amplify the pJC001 plasmid from outside of the insert to within the insert, 
demonstrating the presence of pJC001 and not pKasbar (primer sequences given in 
Chapter 2.12.1.1). Amplification products of expected sizes were found for all 
genetically complemented strains (Figure 3.32B). 
 
 
 
 
 
 
 
151 
 
 
Figure 3.31 Site specific integration of pJC001 at the geh gene of S. aureus 
RN4220. 
 
The pJC001 plasmid was transformed into RN4220 carrying the integrase gene within a 
separate plasmid. The integrase mediates site specific recombination between the 
plasmid encoded attP site and the attB site within the geh gene of RN4220. This leads 
to integration of the entire plasmid into geh, disrupting lipase activity. 
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Figure 3.32 Confirming pJC001 integration into RN4220 by analysis of geh activity 
and confirmation of pJC001 & pKasbar transduction into the wild-type strains, 
SH-pabA and JE2-pabA by PCR. 
 
A 1 RN4220 disruption of geh by pJC001, 2 RN4220 disruption of geh by pJC001, 3 
RN4220 wild-type Geh activity.  
B DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards 
(M) of sizes shown. 
 
PCR confirmation of pJC001 or pKasbar integration into  1 H Z + *   D Q G   1 H Z + *ß 6 6 / . 
All bands are of expected sizes.  
Lane 1: NewHG gDNA amplified with Tset1F and Tset1R.  
Lane 2: NewHG gDNA amplified with KanF and KanR.  
Lane 3: NewHG+pJC001 gDNA amplified with pGM-F and Tset1R.  
Lane 4: NewHG+pJC001 gDNA amplified with KanF and KanR.  
Lane 5: NewHG+pKasbar gDNA amplified with pGM-F and pGM-R.  
Lane 6: NewHG+pKasbar gDNA amplified with KanF and KanR. 
Lane 7:  1 H Z + *ß 6 6 /  gDNA amplified with Tset1F and Tset1R. 
Lane 8:  1 H Z + *ß 6 6 /  gDNA amplified with KanF and KanR. 
Lane 9    1 H Z + *ß 6 6 /  S - &   1 gDNA amplified with pGM-F and Tset1R. 
Lane 10:  1 H Z + *ß 6 6 /  S - &   1 gDNA amplified with KanF and KanR. 
Lane 11    1 H Z + *ß 6 6 /  S . D V E D U  gDNA amplified with pGM-F and pGM-R. 
Lane 12:  1 H Z + *ß 6 6 /  S . D V E D U  gDNA amplified with KanF and KanR. 
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3.2.5.19 Whole blood growth is restored in the complemented strain 
 
The whole human blood assay was repeated as in 3.2.5.15. The growth of the 
complemented mutant is restored to equivalence with the wild-type. However, growth 
 R I   W K H   F R P S O H P H Q W H G   P X W D Q W   Z D V   Q R W   V L J Q L I L F D Q W O \   G L I I H U H Q W   I U R P   1 H Z + *ß 6 6 /    S     
0.17. Insertion of  W K H  S . D V E D U  Y H F W R U  G R H V  Q R W  D O W H U  W K H  1 H Z + *ß 6 6 /   S K H Q R W \ S H    ) L J X U H 
3.33). 
 
3.2.5.20 Do the SSLs affect neutrophil phagocytosis of S. aureus NewHG? 
 
 7 K H   Q H X W U R S K L O   S K D J R F \ W L F   L Q G H [   Z D V   F D O F X O D W H G   I R U   1 H Z + *   D Q G   1 H Z + *ß 6 6 /   W R 
measure variation in engulfment by neutrophils of the mutant strain in comparison to 
the wild-type (Sano et al., 2003). The method used is given in Chapter 2.19. Neutrophils 
were mixed with S. aureus in triplicate at a required MOI and phagocytosis by 
neutrophils was allowed over 30 min. Cytospins were prepared for each replicate and 
total neutrophils (a count > 300 per cytospin required for reliable results), total 
neutrophils with engulfed bacteria and total number of ingested bacteria were counted 
by light microscopy. The experiment was repeated three times and the mean value of 
 H D F K   Z D V   X V H G   W R   F R P S D U H   W K H   S K D J R F \ W L F   L Q G L F H V   R I   1 H Z + *   D Q G   1 H Z + *ß 6 6 /    ) L J X U H 
3.34). No significant difference in neutrophil phagocytosis activity was observed, p > 
0.05. 
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Figure 3.33  * H Q H W L F  F R P S O H P H Q W D W L R Q  R I  W K H  1 H Z + *ß 6 6 /  S K H Q R W \ S H  L Q  K X P D Q 
blood. 
 
 2 Q O \  1 H Z + *ß 6 6 /  D Q G  1 H Z + *ß 6 6 /  9 H F W R U  D U H  V L J Q L I L F D Q W O \  G L I I H U H Q W  F R P S D U H G 
with the wild-type, p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
p=0.03
p=0.02
p=0.17
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Figure 3.34 Analysis of the role of SSLs in phagocytosis of S. aureus by 
neutrophils. 
 
No significant difference in phagocytic index was seen between NewHG and 
 1 H Z + *ß 6 6 / , p > 0.05.  
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          $ Q D O \ V L V  R I  Q H X W U R S K L O  L Q W H J U L W \  L Q  U H V S R Q V H  W R  1 H Z + *  D Q G  1 H Z + *ß 6 6 / 
supernatant 
 
The vital dye To-Pro-3 indicates neutrophil necrosis, as it enters neutrophils that have 
lost membrane integrity, emitting fluorescence upon DNA binding. This can be 
measured by flow cytometry to show the membrane integrity of a sample of neutrophils.  
 1 H Z + *   D Q G   1 H Z + *ß 6 6 /   V X S H U Q D W D Q W V   Z H U H   S U H S D U H G   D V   S H U   & K D S W H U          
Supernatants were diluted with fresh RPMI-1640 + FBS and prepared on the day of use. 
Flow cytometry was done as in section 3.2.2. Neutrophils were incubated in neat, 1in5 
and 1in10 supernatant dilutions and at 1 h or 3 h time points the level of To-Pro-3 
activity was measured. To-Pro-3 activity was comparable between neutrophils 
 L Q F X E D W H G   Z L W K   1 H Z + *   R U   1 H Z + *ß 6 6 /   V X S H U Q D W D Q W    ) L J X U H       $     7 K H   D F W L Y L W \   Z D V 
high for both strains, likely as a result of LukAB/GH activity at these dilutions. The 
following dilutions were prepared: 1in50, 1in100, 1in500 and 1in1000. These dilutions 
were added to neutrophils with the aim of removing the LukAB/GH effect by diluting it 
out, thereby allowing any difference to be measured at the edge of supernatant toxicity 
to neutrophils. Furthermore, a 30min time point was used to replace the 3 h time point. 
The neutrophil necrotic phenotype of S. aureus was lost and the mutant and wild-type 
had comparable To-Pro-3 activity at all dilutions (Figure 3.35B). Clearly any neutrophil 
killing effect will be difficult if not impossible to resolve using this method, as 
 / X N $ %  * +   D F W L Y L W \   L V   V R   K L J K    ’ H O H W L R Q   R I   W K H   6 6 /   W U L S O H W   I U R P   D  ßlukAB/GH, may 
allow resolution of neutrophil killing activity by flow cytometry analysis. 
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Figure 3.35 Analysis of the role of SSLs in neutrophil necrosis. 
 
A. To-Pro-3 activity of neutrophils after 60 min and 180 min incubation with neat 
 1 H Z + *   R U   1 H Z + *ß 6 6 /  supernatant or supernatant diluted 1 in 5 or 1 in 10. To-Pro-3 
activity is comparable for neutrophils incubated with supernatant from either wild-type 
or mutant cultures, irrespective of dilution or length of incubation, p > 0.05.  
B. To-Pro-3 activity of neutrophils after 30 min and 60 min incubation with NewHG or 
 1 H Z + *ß 6 6 /   V X S H U Q D W D Q W   G L O X W H G      L Q            L Q            L Q         R U       L Q           7 R -Pro-3 
activity is comparable for neutrophils incubated with supernatant from either wild-type 
or mutant cultures, irrespective of dilution or length of incubation, p > 0.05.  
 
 
 
 
 
 
 
 
 
60 min 180 min
30 min 60 min
A
B
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3.3 Discussion 
 
The identification of LukAB as a cytotoxin with a potent necrotic effect on human 
neutrophils (Dumont et al., 2011; Ventura et al., 2010), allowed for rapid confirmation 
that the neutrophil necrosis phenotype associated with SAF was that of LukAB. Since 
publication by Dumont et al. and Ventura et al., studies to further characterise LukAB 
have established that it is an important virulence determinant of S. aureus.  
 
As discussed in Chapter 1, two-component leukotoxins consist of an S and F subunit. 
One subunit binds to the host cell surface promoting dimerisation with the other 
component leading to surface pore formation. Unlike other S. aureus two-component 
leukotoxins, LukAB forms a heterodimer in solution and not on the surface of its target 
cell. This is a requirement based on surface exposed hydrophobic regions, hidden by 
dimerisation (Badarau et al., 2015; DuMont et al., 2014). Neutrophil cytotoxicity is 
dependent on binding of the heterodimer to the CD11b receptor on neutrophils, 
mediated by a specific glutamic acid residue (DuMont et al., 2013a, 2014). Although 
LukAB can induce necrosis of neutrophils extracellularly, it has a greater lytic capacity 
intracellularly (DuMont et al., 2013b). The activity of LukAB has been shown to be 
concentration dependent (Badarau et al., 2015), which suggests that the increased 
LukAB activity associated with engulfed S. aureus is the results of higher concentration 
due to the closed intracellular environment. However, human monocytes are only killed 
extracellularly by LukAB (Melehani et al., 2015). Similarly to the related two-
component leukotoxin PVL, in addition to pore formation on the surface of neutrophils, 
LukAB promotes production of neutrophil extracellular traps (NETs; Malachowa et al., 
2013; Pilsczek et al., 2010). Whether this is more beneficial to host or pathogen is as yet 
unclear. 
 
In addition to LukAB, the cytotoxicity against human neutrophils of other toxins has 
been identified and added to the characterised S. aureus armoury relatively recently. 
The PVL toxin has come to prominence, due to recognition of its association with 
community-acquired MRSA (Foster, 2005). Its role as a potent human/rabbit neutrophil 
cytotoxin has since been determined (Holzinger et al., 2012; Loffler et al., 2010). The 
phenol soluble modulins (PSMs) activate and attract neutrophils and are able to lyse 
them extracellularly or intracellularly. They were discovered in 1999 in S. epidermidis 
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(Mehlin et al., 1999), but were not recognised in S. aureus until 2007 (Wang et al., 
2007). The recent identification of these novel toxins presented the possibility that other 
novel virulence determinants remain to be found. 
 
The bioinformatics approach used in this work did not identify any novel toxins 
amongst the hypothetical protein sequences of S. aureus. Four putative SSL immune 
evasion proteins were found amongst the hypothetical protein sequences of S. aureus. 
However, three of the four were the previously recognised SSLs, SSL12, SSL13 and 
SSL14 and work was ongoing by another group on the remaining SSL (putative 
SSL15). The incorrect annotation of these protein sequences, and others found in this 
work (SCIN and FLIPr), highlighted the errors associated with database annotation and 
the care required when interpreting bioinformatics data.  
 
The SSL proteins have structural similarity to superantigens, but do not overstimulate 
T-cells, due to loss of the major histocompatibility binding site (Al-Shangiti et al., 
2004; Hermans et al., 2012). Of the 15 SSLs, those with a known function in S. aureus 
virulence all have a role in immune evasion (Table 3.6). The functions of SSL12, 13 & 
14 were not known and it was decided to attempt to identify the role of these proteins in 
S. aureus virulence. SSL12, 13 & 14 proteins could only be purified in a soluble form in 
the presence of a solubilising agent (urea or guanidine). Attempts to remove the 
solubilising agent, while retaining protein solubility failed to produce an adequate 
quantity of protein for analysis. Therefore, an isogenic SSL12, 13 & 14 mutant was 
made to characterise the role of the SSLs in S. aureus pathogenicity. 
 
Species specificity is seen for several S. aureus virulence determinants (including 
SSL10, see Table 3.6). For example, the plasminogen activator staphylokinase (Sak) 
shows specificity to human, dog and baboon plasminogen, but cannot activate horse, 
mouse, cow, sheep, pig or rabbit plasminogen (Gladysheva et al., 2003). The 
chemotaxis inhibitory protein (CHIPS), discovered in 2004, inhibits neutrophil 
migration to the site of infection in response to formylated peptides and complement 
protein C5a. CHIPS is 30-fold more effective at blocking human neutrophil migration 
than mouse neutrophil migration (de Haas, 2004). The superantigen SEA, structurally 
similar to SSLs, stimulates human T-cells 1000 times more effectively than mouse T-
cells (Dohlsten et al., 1993). This species specificity provides a potential explanation for  
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Table 3.6 Known functions of the SSL proteins. 
Protein 
Name 
Function Reference 
SSL1 
The structure of SSL1 has been determined, which will likely aid identification 
of SSL1 function. 
(Dutta et al., 
2014) 
SSL2 Unknown function - 
SSL3 
SSL3 inhibits secretion of the proinflammatory cytokine TNF- .  E \ 
macrophages, neutrophils and monocytes by binding to TLR2intracellularly, 
blocking activation by S. aureus cell wall components. 
(Yokoyama et 
al., 2012; 
Bardoel et al., 
2012) 
SSL4 
SSL4 binds to sialated glycoproteins on the surface of neutrophils, 
macrophages and monocytes, promoting uptake of the SSL protein. The role of 
SSL4 once internalised is unknown.  
(Hermans et al., 
2012) 
SSL5 
 6 6 /   E L Q G V  W R  W K H  F R O O D J H Q  U H F H S W R U  * 3 9 ,  D Q G  W K H  * 3 , E.   J O \ F R S U R W H L Q  R Q  W K H 
surface of platelets leading to their activation and aggregation. 
(Hu et al., 2011; 
De Haas et al., 
2009) 
Reduces wound healing and causes thromboembolism in a murine cut-tail 
bleeding model. 
(Armstrong et 
al., 2012) 
Inhibits matrix metalloproteinase 9 of human neutrophils, a protease required 
for basement membrane degradation during transmigration of neutrophils from 
the bloodstream to the site of infection. 
(Itoh et al., 
2010a) 
SSL5 inhibits neutrophil rolling by binding to P-selectin glycoprotein ligand 
(PSGL-1) blocking binding to P-selectin. This was shown under static 
conditions and when exposed to the shearing forces of a flow chamber, to 
mimic the forces applied within blood vessels. 
(Bestebroer et 
al., 2007) 
SSL6 
SSL6 binds the host surface receptor CD47. This receptor has a role in self-
recognition, and is important for preventing activated macrophages from 
phagocytosing early haemapoietic cells. SSL6 may interfere with this process 
promoting autoimmune damage at the site of infection. 
(Fevre et al., 
2014) 
SSL7 
Binds complement protein C5, preventing its cleavage to the chemoattractant 
C5a. Has an anti-inflammatory effect in a murine inflammation model.   
(Bestebroer et 
al., 2010; 
Langley et al., 
2005) 
Binds to the surface of monocytes and a subpopulation of B-cells, via a 
specific, as yet unidentified receptor, and is found in vesicles within dendritic 
cells.  
(Al-Shangiti et 
al., 2004) 
SSL7 binds to IgA blocking recognition of IgA bound S. aureus by leukocytes. 
(Langley et al., 
2005) 
SSL8 
SSL8 binds the host wound repair protein tenascin-C, slowing wound repair by 
fibroblasts. 
(Itoh et al., 
2013a) 
SSL9 
Binds to the surface of monocytes, via a specific, as yet unidentified receptor, 
and is found in large vesicles within dendritic cells.  
(Al-Shangiti et 
al., 2004) 
SSL10 
Binds to the phospholipid phosphatidylserine expressed on apoptotic cells, 
which may interfere with their clearance. Phosphatidylserine is also found on 
the surface of activated platelets, which may also be a target of SSL10. 
(Itoh et al., 
2012) 
SSL10 binds IgG, but shows preferential binding to prothrombin over IgG. 
Binding to prothrombin prevents its cleavage to thrombin and reduces the non-
proteolytic activation of prothrombin by S. aureus coagulase, thereby acting as 
an anticoagulant.  
(Itoh et al., 
2013b) 
SSL10 binds specifically to human and non-human primate IgG via the 
constant region, blocking phagocytosis of S. aureus by neutrophils and 
complement activation via the classical (IgG-dependent) pathway. 
(Patelet al., 
2010) 
SSL11 
Binds neutrophils, monocytes via sialated glycoproteins. SSL11 also binds to 
IgA via the same sialic acid moiety as that of glycoproteins bound by SSL11 
on the surface monocytes and neutrophils, thereby preventing IgA binding to 
neutrophils. Similarly to SSL5, SSL11 binds to PSGL-1. Labelled SSL11 has 
also been shown to be internalised by neutrophils.  
(Chung et al., 
2007) 
SSL12 Unknown function - 
SSL13 Unknown function - 
SSL14 Unknown function - 
SSL15 Unconfirmed SSL - 
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why no difference in pathogenicity was seen between the SSL mutant and the wild-type 
in the zebrafish model of systemic infection. 
 
A subtle reduced growth phenotype of the SSL mutant was seen in human blood, but 
not in human plasma. This suggested that the SSLs interact with the cellular component 
of human blood. Comparison of engulfment of the SSL mutant and wild-type was 
carried out and no difference was found. Based on the known functions of SSLs (Table 
3.6) it was hypothesised that the effect would relate to immune evasion, rather than 
toxicity. However, toxicity to human neutrophils was assessed, but the results were 
clouded by the potent toxicity of other S. aureus components. 
 
The role of SSL12, 13 and 14 in human blood, may be the result of only one protein of 
the triplet or a combination of them. Potential roles include uptake by host cells and 
intracellular modification of cell activity, as with SSL3 and potentially SSL4 and SSL11 
(Table 3.6). The proteins may block specific receptors on immune cells, or disrupt the 
binding of opsonins to the bacterial surface. The effect may well be unrelated to 
immune evasion, presenting possibilities such as stress tolerance, nutrient acquisition 
and nutrient synthesis. 
 
The bioinformatics analysis used in this chapter was limited to certain classes of 
virulence determinants. Methods exist, such as those discussed in Chapter 1 (STM, 
IVET, SCOTS) that allow for analysis of a broader range of virulence determinants. 
However, this chapter has also highlighted the potential human specificity of three S. 
aureus virulence determinants. For this reason, a broader approach, in conditions 
mimicking an important human host environment, is the focus of Chapter 4. 
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CHAPTER 4 
 
IDENTIFICATION OF S. AUREUS COMPONENTS INVOLVED IN THE 
INTERACTION WITH HUMAN BLOOD 
 
 
4.1 Introduction 
 
A common approach towards understanding those bacterial components involved in the 
interaction with their environment is through the use of mutational analysis. Allelic 
replacement is used to mutate the gene of interest and the resulting phenotype is then 
compared to the parental strain. The mutant phenotype indicates the function of the 
protein encoded by the gene (Beasley et al., 2011; Bubeck Wardenburg et al., 2008; 
Giraudo et al., 1996; Palmqvist et al., 2002). Although this is a useful methodology, it is 
time consuming and laborious when applied to the full gene complement of a species. 
Transposons are a powerful molecular tool allowing for functional analysis of multiple 
genes within a single screen. Class II transposons, such as the mariner Tn, have terminal 
inverted repeats, flanking a transposase gene and genes for other functions including 
antibiotic resistance. The transposase mediates excision of the Tn by interaction with 
the inverted repeats, the transposon circularises and inserts into a random site in its host 
DNA (Hamer et al., 2001; Hayes, 2003). The standard procedure for transposon 
mutagenesis is delivery of a plasmid encoding the transposon into the species of 
interest. Transposition events mediated either by a self-encoded transposase, or a 
transposase encoded on a separate plasmid, then take place as the bacteria grows in 
media with two antibiotics (resistance to which is encoded by the transposon and the 
plasmid respectively) and the plasmid is then removed by growth in the absence of the 
plasmid resistance encoded antibiotic, at a temperature non-permissive to plasmid 
replication. The bacteria in the culture should possess a transposon stably inserted 
somewhere in their chromosome. The phenotype of the bacteria is then screened using a 
chosen condition or conditions. Identification of the transposon insertion point in the 
chromosome allows determination of the gene function. The list of biological processes 
assessed with this approach includes, identification of genes involved in virulence factor 
regulation (Shaw et al., 2006), starvation survival response in Listeria monocytogenes 
(Herbert & Foster, 2001), haem toxicity (Wakeman et al., 2012)  D Q G   U H J X O D W L R Q   R I  -
lactam resistance genes (Zscheck & Murray, 1993). Although less time-consuming and 
expensive than the individual knockout of all genes in a species, the identification of Tn 
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insertion sites is time-consuming and expensive (Chaudhuri et al., 2009) and advances 
have been made to address this. 
 
A bacterium with a Tn insertion within an essential gene will not grow. This allows Tn 
mutagenesis to be used for identification of the essential gene complement within a 
species of bacteria (Chaudhuri et al., 2009); important as essential genes may provide 
novel targets for new therapeutics or vaccines. In vitro transposition into large regions 
of Haemophilus influenzae and Streptococcus pneumoniae DNA has been used in a 
genetic fingerprinting method to assess essential genes in these species (Akerley et al., 
1998; Lampe et al., 1996). Both of these naturally competent species are transformed 
with Tn inserted DNA, which can replace the native DNA by homologous 
recombination (Figure 4.1A). Primers recognising the Tn and chromosomal sections 
along the in vitro  ’ 1 $   D U H   X V H G   W R   ‡ I L Q J H U S U L Q W ·   W K H   ’ 1 $   D V   V H F W L R Q V   F R Q W D L Q L Q J 
essential genes will be highlighted as missing bands in electrophoresis gels i.e. a 
chromosomal  primer with an essential gene downstream of its binding site will show a 
pattern of PCR products as follows: larger sized bands from transposons inserted 
downstream of the essential gene and smaller bands from Tn inserts upstream of the 
essential gene; however, bands in the middle of the gel will not be present, as Tn 
insertion into the essential gene abolishes the viability of the bacterium and it is not 
represented in the library (Akerley et al., 1998; Figure 4.1B). 
 
Modification of the transposon by introduction of a T7 promoter was used by Chaudhuri 
et al., 2009 to provide rapid identification of essential genes in S. aureus. A mutant 
library was constructed and genomic DNA was digested with a specific restriction 
enzyme, giving short fragments with/without a Tn insertion present. Transposon 
mediated differential hybridisation was then used to rapidly identify essential genes. 
Transcription from the T7 promoter was induced and the RNA fragments, bounded by 
the length of the digested fragment were hybridised to a microarray of S. aureus genes. 
Those spots on the microarray that are  ‡off ·    L  H    X Q E R X Q G  E \   5 1 $   are not downstream 
of a Tn insertion, suggesting that they are within essential genes (Chaudhuri et al., 
2009). Signature-tagged mutagenesis (STM) developed by Hensel et al. (1995) uses 
transposons modified with a unique sequence tag, primarily for in vivo studies. The 
methodology is discussed in detail in Chapter 1. Briefly, strains with a sequence-tagged 
Tn insert are mixed, giving a large heterogeneous pool of strains, which is then used in 
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an animal model. At the endpoint of the model, bacteria are collected and the surviving 
Tn insert strains are analysed by PCR of their unique sequence-tag, followed by 
Southern hybridisation to identify the strain. Those tags not present at the end of the 
infection are likely inserted into genes important for the infection model being used. 
Their importance to different stages of infection can also be assessed by taking bacterial 
samples over the course of the infection. Not only is this beneficial for measuring the 
genetic requirements of a species in the changing conditions of a living host, the same 
pool can also be used to look at different genetic requirements in different infection 
types within the same host species (Coulter et al., 1998; Mei et al., 1997). STM studies 
by Brown et al. (2000) & Coulter et al. (1998) have highlighted the importance of 
nutrient acquisition and biosynthetic pathways involved in amino acid, purine and 
tetrahydrofolate production in Aspergillus fumigatus and S. aureus, respectively. This is 
not surprising considering that although the mammalian host is nutrient rich, many 
nutrients are sequestered as a means of inhibiting pathogen growth (Prentice et al., 
2007). 
 
An ordered transposon library, in which all Tn insertion sites have been characterised is 
a valuable resource for the analysis of gene function. Screens can be done in multiple 
conditions and PCR and sequencing is not required, as the Tn insertion site is known for 
each strain in the library. Producing an ordered Tn library is a demanding and expensive 
undertaking, however it has been done in two S. aureus strain backgrounds, Newman 
(Bae et al., 2004) and the community-acquired MRSA strain USA300 JE2 (Fey et al., 
2013). Both groups used the same method to make their libraries (shown 
diagrammatically in Figure 4.2). The Mariner based bursa aurealis Tn, encoding an 
erythromycin/lincomycin (ery/lin) resistance cassette, was used to make the Nebraska 
Transposon Mutagenesis Library (NTML) in the CA-MRSA USA300 JE2 strain 
background. Strain JE2 is identical to the clinical strain isolated in the Los Angeles 
County Jail LAC, except that it has been cured of plasmids. The library consists of 
1,952 ery/lin resistant strains each with a Tn inserted in the coding sequence (CDS) of a 
non-essential gene. Each strain has undergone Sanger sequencing out from the 
transposon and the resulting sequence aligned with S. aureus strain FPR3757 
chromosomal DNA by blastn, allowing identification of 1,952 genes disrupted by Tn 
insertion. Mannitol utilisation, pigment formation, protease activity and haemolysis 
were all assessed using the library upon its completion (Fey et al., 2013). The JE2 
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Figure 4.1 Identification of essential genes by genetic fingerprinting.  
 
A. DNA that has been subjected to in vitro transposition is transformed into competent 
bacteria, where homologous recombination replaces native DNA for Tn inserted DNA. 
B. After growth and extraction of chromosomal DNA, PCR is used to determine the 
locations of putative essential genes. 
Adapted from Akerley et al. (1998). 
A
B
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EryR Tn & transposase encoded cmR and 
tetR plasmids transduced into JE2
Successful transductants were grown at 30oC for 
48 h, allowing transposition events to take 
place, imparting eryR to strains containing a Tn
A single colony was suspended in 45oC H2O. The 
45oC temperature inhibits plasmid replication
10µl were spread on TSA plates containing ery to 
select for Tn insertion and grown at 45oC for 24 h
Patching on cm, tet and ery plates 
showed the loss of plasmid DNA
EryR, tetS and cmS indicates loss of plasmids. 
Colonies with this resistance profile were arrayed 
in 96-well plates
Genomic DNA was extracted from each 
well and 18,797 strains were sequenced to 
identify the Tn position
Genomic DNA flanking the Tn was 
identified by alignment to the 
USA300 FPR3757 sequenced genome
Discarded Retained
Intergenic Tn Inserts
Inserts within last 10% of CDS
Inserts within the first 90% of CDS
1,952 strain with a unique 
Tn inserts arrayed in order 
in microtiter plates
1
2
3
4
5
6
7
8
10
9
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Figure 4.2 Construction of the NTML shown diagrammatically.  
 
Step 1: The pBursa plasmid containing the transposon sequence and chloramphenicol 
resistance cassette was transduced into JE2, which was also transduced with pFA545, 
which contains the transposase gene and tetracycline resistance. Step 2: Transductants 
were grown at 30
o
C on solid media for 48 h, allowing tranposition events to occur. Step 
3: A single colony was suspended in 45
o
C in H2O immediately heating the bacteria to 
the non-permissive temperature. Step4: Bacteria were spread on erythromycin plates to 
select for Tn insertion and grown at the non-permissive temperature to promote loss of 
the plasmids. Step 5: Colonies were patched on to tetracycline, chloramphenicol and 
erythromycin plates. Step 6: Those bacteria that were ery
R
, but tet
S
 and cm
S 
had lost the 
plasmid and had a Tn insert and were arrayed in 96-well plates. Step 7: Genomic DNA 
was extracted and sequenced out from the Tn into the neighbouring genomic DNA for 
each well of the 96-well plates. Step 8: Sequencing results were aligned with S. aureus 
USA300 FPR3757 genomic DNA to determine Tn insertion site. Step 9: Strain were 
discarded or retained depending on the Tn insertion position. Step 10: The 1,952 were 
arrayed in order in microtitre plates. 
 
Based on Bae et al. (2004) & Fey et al. (2013). 
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library is freely available to registered S. aureus researchers and a website has been 
produced to accompany the library, which includes information on the insertion site of 
each Tn and files for the visual inspection of Tn insertion sites using the GView genome 
browser. 
 
The aim of this chapter was to screen the NTML with the aim of identifying genes 
associated with S. aureus virulence. Growth and haemolysis phenotypes were assessed 
on citrated human blood agar. Growth on bovine serum agar was also assessed, as it was 
a readily available and inexpensive alternative to human serum. Haemolysis was 
measured using 5% (v/v) sheep blood with Columbia agar base, a standard method for 
measuring haemolytic activity in S. aureus (Chow et al., 1983; Vítkova & Votava, 
2005). The immune components of blood are immobilised in blood agar, so S. aureus 
will not be directly challenged by immune cells or proteins during screening. However, 
CA-MRSA strains are responsible for the majority of skin and soft tissue infections and 
20% of bacteraemias in the USA  and the ability to grow in blood is necessary to 
establish bacteraemia and systemic infections (Malachowa & DeLeo, 2011). 
Haemolysins and other toxins have been shown to be upregulated in transcription 
studies of S. aureus grown in liquid blood, which apart from their anti-immune 
function, have a likely role in liberation of nutrients. Iron acquisition proteins and other 
metal ion transport systems and amino acid metabolism genes are up and down-
regulated in blood (Malachowa et al., 2011). The Malachowa study and the studies by 
Brown et al., 2000 and Coulter et al., 1998 mentioned above, suggest that the ability to 
cause blood-borne infection is not simply a matter of immune evasion, but one of 
survival and growth by nutrient acquisition and biosynthesis.  
 
4.2 Results 
 
4.2.1 Bioinformatic analysis of the NTML hypothetical protein sequences 
 
4.2.1.1 Identification of novel virulence determinants in the NTML by BLAST 
search of the VF database 
 
It was not guaranteed that the screen of the NTML would provide targets for further 
study. Therefore, the hypothetical protein sequences, containing secretory signal 
sequences, of the NTML were subjected to the same bioinformatics analysis as used in 
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Chapter 3 for S. aureus 8325. The purpose of the bioinformatics was to provide 
alternative targets, should the screen fail to produce any interesting results and to 
highlight any strains that are of particular interest in the screen results. Furthermore, 
attempts could be made to characterise the genes while the screening process was 
ongoing. Also, following on from the analysis of the previous strain (Chapter 3), it was 
hypothesised that the analysis of JE2 sequences would identify virulence determinants 
not found in S. aureus 8325, due to the genetic background differences and the high 
virulence of the JE2 strain (Francis et al., 2005). 
 
A homology search was done against the virulence factor (VF) database created in 
Chapter 3. This database was constructed in Chapter 3 in order to identify potential VFs 
amongst the sequences annotated as hypothetical sequences in the S. aureus 8325 
genome. This same approach was applied to the sequences amongst the 1,952 NTML 
strains that are annotated as hypothetical or unknown function proteins and that contain 
a signal sequence (the method is shown diagrammatically in Figure 4.3). Signal 
sequence encoding protein sequences were extracted from the full list of 1,952 NTML 
sequences using SignalP 3.0 (Bendtsen et al., 2004). 44 of the NTML protein sequences 
were annotated as hypothetical proteins and contained an N-terminal signal sequence. 
The 44 sequences were used to BLAST the VF database created in Chapter 3.2.3.5. The 
query returned 4 alignments. The protein ID of the 4 hypothetical protein sequences 
were then used to query the NCBI Protein database in order to acquire information on 
the sequence. The returned webpage allows a search for identical proteins within the 
database. Two of the hypothetical proteins were SSL proteins identified in Chapter 3 
and two were staphylococcal complement inhibitor (SCIN) proteins (Table 4.1). This 
demonstrated that these 4 protein sequences were incorrectly annotated in the NTML. 
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Figure 4.3 BLAST query of the VF database with the 44 NTML sequences, shown 
diagrammatically. 
 
The hypothetical proteins that aligned with the VF database were incorrectly annotated 
as hypothetical proteins.  
 
 
 
 
 
 
 
 
 
 
 
1,952 NTML sequences 
Hypothetical/unknown 
proteins
Sequences with 
hypothetical/unknown 
function extracted
Signal sequence 
containing sequences 
found with SignalP
44 hypothetical/unknown 
proteins with N-terminal signal 
sequences
BLAST query of the VF 
database with the 44 
sequences
4 of the 44 
hypothetical/unknown 
sequences returned by 
BLASTProtein ID of each of the 4 
was checked on the NCBI 
Protein database to 
determine if they were 
identical to known function 
proteins All 4 showed 100% sequence 
identity to known proteins
 1
7
2
 
Table 4.1 Identification of novel potential virulence factors in the NTML by BLAST search.  
 
The protein ID and the identity assigned by the NTML are given in the Column 1 and Column 2, respectively. The most common sequence that the 
query aligned to in the BLAST analysis is shown in Column 3. The number of BLAST hits is shown in Column 4. Column 5 shows the actual 
identity of the NTML protein sequence. Column 6 provides a reference for each of the proteins. 
Query ID NTML Identity 
Aligned to in the VF 
Database 
Number of Hits Confirmed Identity Reference 
SAUSA300_1919 Hypothetical protein SCIN 1 SCIN-A 
Garcia et al., 2012 
SAUSA300_1056 Hypothetical protein SCIN 1 SCIN-B 
SAUSA300_1060 Hypothetical protein Exotoxin/SSLs 77 SSL13 
Patel et al., 2010 
SAUSA300_1061 Hypothetical protein Exotoxin/SSLs 63 SSL14 
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4.2.1.2 Identification of novel virulence determinants in the NTML by BLAST 
search of the non-redundant database 
 
The homology search in the previous section did not highlight any new potential 
virulence factors. Therefore it was decided to repeat the search using the non-redundant 
bacterial sequence database that was constructed in Chapter 3.2.3.8. The method 
employed was exactly that shown in Figure 4.3, but the non-redundant bacterial 
database was searched, rather than the VF database. 
 
The non-redundant database constructed in Chapter 3 was aimed to contain 
representatives from all varieties of VF. To do this, all known bacterial protein 
sequences with known-function annotation were used in constructing the database, 
which was then clustered to 90% identity to remove redundant and similar sequences 
(Figure 4.4A).  The database contains many non-VF sequences, but contains high VF 
diversity. BLAST was used to query the 44 hypothetical sequences from the NTML 
(section 4.2.1.1) against the non-redundant database and those that hit against database 
sequences annotated as virulence factors were retained (Figure 4.4B; Table 4.2). Again 
the two SSLs and two SCIN proteins were found. Additionally the Eap, Emp and SasF 
proteins were annotated as hypothetical protein sequences in the NTML. 
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Figure 4.4 Construction and BLAST search of the non-redundant database, shown 
diagrammatically. 
 
A. Construction of the non-redundant database 
B. BLAST query of the non-redundant database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All hypothetical proteins 
with functional annotation 
Non-redundant database
Clustered to 90% identity 
to reduce the size of the 
database, while retaining 
the sequence diversity
44 Hypothetical/unknown 
proteins with N-terminal signal 
sequences
BLAST query of the non-
redundant database with 
the 44 sequences
37 of the 44 discarded - hit 
against database sequences with 
non-VF functional annotation 
7 of the 44 queries retained  – hit 
against database sequences with 
VF functional annotation
A
B
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Table 4.2 Identification of novel potential virulence factors in the NTML by BLAST search.  
 
The protein ID and the identity assigned by the NTML are given in the Column 1 and Column 2, respectively. The most common sequence that the 
queries aligned to in the BLAST analysis are shown in Column 3. The number of BLAST hits is shown in Column 4. Column 5 shows the actual 
identity of the NTML protein sequence. Colum 6 provides a reference for each of the proteins. 
Query ID NTML Identity 
Aligned to in the VF 
Database 
Number of 
Hits 
Confirmed Identity Reference 
SAUSA300_1919 Hypothetical protein SCIN 12 
Staphylococcal 
complement inhibitor A 
(SCIN-A) 
(Garcia et al., 2012) 
SAUSA300_1056 Hypothetical protein SCIN 11 
Staphylococcal 
complement inhibitor B 
(SCIN-B) 
SAUSA300_1060 Hypothetical protein Exotoxin/SSLs 16 
Staphylococcal 
superantigen-like protein 
13 (SSL13) 
(Patel et al., 2010) 
SAUSA300_1061 Hypothetical protein Exotoxin/SSLs 16 
Staphylococcal 
superantigen-like protein 
14 (SSL14) 
SAUSA300_0775 Hypothetical protein Coagulase 20 
Extracellular Matrix 
Binding Protein (Emp) 
(Johnson, Cockayne, & 
Morrissey, 2008) 
SAUSA300_0883 Hypothetical protein Map Protein 48 
Extracellular Adherence 
Protein (Eap) 
(Haggar et al., 2003) 
SAUSA300_2581 Hypothetical protein 
Cell Wall Anchor 
Protein 
13 
Surface associated protein 
(SasF) 
(Kwiecinski, Jin, & 
Josefsson, 2014) 
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4.2.2 Preparation for the NTML library screen 
 
4.2.2.1 Deconvolution of the NTML library 
 
The Nebraska Transposon Mutagenesis Library (NTML) was received from Dr Kenneth 
Bayles, University of Nebraska Medical Centre. Only 1,920 of the 1,952 strains were 
received in 5 x 384-well microtitre plates.  The remaining 32 were not supplied, as the 
Tn i  Q V H U W V   Z H U H   F O R V H   W R   W K H    ¶   H Q G V   R I   W K H V H   J H Q H V   D Q G  P D \   Q R W  F R P S O H W H O \   G L V U X S W  J H Q H 
function. However, these genes were available on request if required. For screening and 
for long-term propagation the library needed to be deconvoluted into 96-well plates, and 
into individual strain stocks for long-term usage (Figure 4.5A). Deconvolution to 96-
well plates was required for screening purposes, as the screen is an agar based screen 
and the strains will be transferred to agar using a 96-pin replicator (Boekel Industries). 
Although 384-pin replicators are available, the ability to resolve differences in 
haemolysis and growth between such closely inoculated strains would be difficult if not 
impossible. The 1,920 strains were also added to separate bead stocks to allow easy 
access to individual strains within the library. Spare copies of the library were also 
made for future screening experiments and storage. Strains were transferred from the 
384-well plate to 96-well plates using the 96-pin replicator (for details of the library, 
including identity of strains in each well of the plate, see Appendix 4.1). As the strains 
were transferred they were also used to inoculate BHI agar plates to determine if any 
obvious contaminants were present (e.g. fungal growth). This screen was also used to 
highlight any pitfalls associated with the screening method. Example plate images from 
the contamination screen are shown in Figure 4.5B; all plate images are included in 
Appendix 4.2.  No obvious contaminants were found to be present when grown on BHI. 
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Figure 4.5 Deconvolution of the NTML.  
 
A Diagram showing the deconvolution of the NTML strains, transferred from 384-well 
format to 96-well format, separation of the library into bead stocks and the contaminant 
screen.  
B Example plates from the contaminant screen of the NTML, carried out during 
deconvolution of the library. By appearance there were no obvious contaminants found 
in the library, as each pin-inoculation had the appearance of S. aureus. 
 
 
 
 
 
A
B
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4.2.2.2 Determining suitable media for the NTML screen 
 
Defining suitable concentrations of human blood and bovine serum was required before 
screening. As discussed in section 4.1 the plan was to screen the library on human blood 
agar, in which the only nutrient source is human blood, bovine serum agar, in which 
serum provides the nutrients and 5% (v/v) sheep blood with Columbia agar base, the 
Columbia agar providing a rich nutrient source. Small scale experiments using the wild-
type, JE2, were performed to determine suitable blood and serum concentrations for the 
screen. Initial experiments were carried-out using standard Petri dishes (Figure 4.6). The 
method of preparation of human blood agar, sheep blood agar and bovine serum agar is 
given in Chapter 2.1.3. No growth was seen at 5, 10 and 20% (v/v) serum agar 
concentrations after 24 h (Figure 4.6A). Barely visible growth was seen on 20% (v/v) 
human blood agar after 24h and no growth was seen at the lower concentrations tested 
(Figure 4.6B; the poor growth on 20% (v/v) human blood could not be visualised by 
photography). Using 5 or 10% (v/v) sheep blood plus Columbia agar made no 
difference to the quality of haemolytic plates (Figure 4.6C).  
 
The aim was to screen the library by applying the inoculum from a 96-well plate to 
rectangular OmniTray agar plates (Nunc) using a 96-pin replicator (Boekel Industries). 
Therefore, it was decided that further experiments to determine the correct serum and 
blood concentration would be done using the replicator and OmniTrays, thereby 
mimicking the conditions of the screen. The incubation period was also increased to 48 
h and growth in aerobic and anaerobic conditions was assessed. A 96-well microtitre 
plate containing JE2 in each well was prepared. This was used to inoculate 30% (v/v) 
and 50% (v/v) human blood agar plates, which were then incubated under aerobic or 
anaerobic conditions for 48 h. Anaerobic growth was performed in anaerobic chambers 
using Anaerogen sachets (Thermo Scientific). Growth of JE2 on 30% (v/v) human 
blood in aerobic conditions was visible, but poor in comparison to growth under 
anaerobic conditions for 48 h (Figure 4.7A 1&2 respectively). Growth on 50% (v/v) 
human blood, in either aerobic or anaerobic conditions, was more apparent than growth 
on 30% (v/v) human blood grown anaerobically (Figure 4.7B).  
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Figure 4.6 Determination of the correct blood/serum concentrations to be used for 
the NTML screen.  
 
A1, A2 and A3 show 5% (v/v), 10% (v/v) and 20% (v/v) bovine serum agar plates 
respectively. No growth was seen after 24 h incubation at 37
o
C.  
B1, B2 and B3 show 5% (v/v), 10% (v/v) and 20% (v/v) human blood agar plates 
respectively. A small amount of growth was seen on 20% plates (could not be visualised 
on the photograph), and no growth was seen on 5 and 10% (v/v) human blood agar after 
24 h incubation at 37
o
C.  
C1 and C2 show 5% (v/v) and 10% (v/v) sheep blood with Columbia agar respectively, 
incubated at 37
o
C for 24 h followed by 6 h at 4
o
C. Both give healthy colonies with clear 
halos of haemolysis. 
 
 
 
A B
C
1
2
3
1 2
3
1 2
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Growth on 30% (v/v) human blood in anaerobic conditions was deemed suitable for the 
screen, as the growth is clear and this concentration minimises the requirement for 
blood donors. Growth on bovine serum at 50% (v/v) was clear, as was growth and 
haemolysis using 5% (v/v) sheep blood plus Columbia agar (Figure 4.7C 1&2 
respectively). However, it was decided to reduce the incubation period for sheep blood 
plates, as haemolysis was nearly complete across the whole plate after 24 h growth at 
37
o
C and 6 h at 4
o
C (Figure 4.7C2). The large black spots seen on human blood plates 
are the result of clotting due to slow collection from donors. The blood collection 
procedure is outlined in Chapter 2.1.3.1.1. Only blood that was quickly collected and 
aliquoted into Falcon tubes containing anticoagulant within 5 min of collection would 
be used for the screen. 
 
4.2.3 Screening the NTML library 
 
4.2.3.1 Preliminary screen 
 
A preliminary screen of the library was done on BHI +ery/lin, to confirm the presence 
of the Tn, which encodes an ery/lin
R
 cassette (Example plate images are shown in 
Figure 4.8, see Appendix 4.3 for all plate images). Bacteria from the wells of each 96-
well plate of the library were transferred to solid media using a 96-pin replicator 
(Boekel Industries). Growth was seen for all wells of the NTML 96-well plates except 
for well G5 on the final plate, corresponding to the strain with the NARSA ID NE1901 
(see arrow Figure 4.8). When tested for contaminants in section 4.2.2.1, this strain grew 
poorly compared to all other strains. The growth seen during the contaminant screen 
was either a contaminant, or NE1901 had such poor growth due to a growth defect 
resulting from Tn insertion that it did not grow enough to carry-over to the 96-well 
plates. The gene disrupted in NE1901 codes for the enzyme acetyl-CoA 
acetyltransferase (thiolase). Analysis of the Kegg and Biocyc databases revealed that 
this enzyme has roles in metabolism of fatty acids, butanoate, propanoate and pyruvate 
and in the catabolism of specific amino acids. Therefore, poor growth of this strain is 
potentially the result of diminished energy production. Any growth or lack of growth 
from this strain was not considered when analysing the screen results. 
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Figure 4.7 Establishment of 
conditions required for the 
NTML screen.  
 
All plates were incubated at 
37
o
C for 48 h unless stated. 
 
A1 JE2 grown aerobically on 
30% (v/v) human blood agar.  
 
A2 JE2 grown anaerobically on 
30% (v/v) human blood agar.  
 
B1 JE2 grown aerobically on 
50% (v/v) human blood agar.  
 
B2 JE2 grown anaerobically on 
50% (v/v) human blood agar.  
 
C1 JE2 grown aerobically on 
50% (v/v) bovine serum agar.  
 
C2 JE2 grown aerobically on 
5% (v/v) sheep blood + 
Columbia agar, for 24 h. 
182 
 
Figure 4.8 Example plates from the preliminary screen for resistance to ery/lin.  
 
Arrow indicates no growth for well G5 on plate 5D, corresponding to the strain 
NE1901.  
 
Growth was seen for all NTML strains other than NE1901. 
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4.2.3.2 Screening of the NTML library on human blood, bovine serum and sheep 
blood + Columbia agar 
 
The NTML was screened on 30% (v/v) human blood, 50% (v/v) bovine serum and 5% 
(v/v) sheep blood + Columbia agar base. Before implementing the screen, it was 
decided strains would be selected visually based on alterations in growth, colony 
morphology and, where possible, haemolysis, in all media conditions. Altered 
phenotypes were judged based on the surrounding strains on the plate.  
 
The full screening procedure is given in Chapter 2.22. A 96-pin replicator was used to 
inoculate the library on to each screen condition. Sheep blood + Columbia agar plates 
were incubated for 16 h at 37
o
C then chilled at 4
o
 &   I R U      K   W R   D O O R Z   I R U  -haemolysis 
(Figure 4.9). 50% (v/v) bovine serum agar plates were incubated at 37
o
C for 48 h 
aerobically (Figure 4.10). 30% (v/v) human blood agar plates were incubated at 37
o
C 
for 48 h anaerobically (Figure 4.11). Figures 4.10-4.12 show example plate images for 
each screen condition; all plate images are given in Appendices 4.4, 4.5 & 4.6. 
 
4.2.4 Confirmation of the NTML screen results 
 
4.2.4.1 Repeat screening of altered phenotype strains 
 
Of the 1,920 strains screened, 100 had an altered phenotype on one or more of the 
growth conditions, when compared to their nearest neighbours on the plate. Of the 100, 
72 had an altered phenotype on human blood only or human blood plus one or both of 
the other conditions. To confirm the phenotype, each of the 100 strains was patched 
back on to the three conditions to see if the phenotype was retained (Figure 4.12). Sixty 
eight of the patched strains retained the phenotype observed in the screen. However, the 
primary goal of the screen was to find strains whose growth is altered when grown on 
human blood. The other conditions were used to give an indication why the growth is 
altered, for example low haemolysis on sheep blood may indicate that this strain cannot 
liberate nutrients from red blood cells, or good growth on serum but poor growth on 
blood may indicate an inhibitory component in human blood. Therefore, only those that 
retained their phenotype on human blood alone, or human blood and one or both of the 
other conditions were taken forward for further analysis. This gave 46 strains of interest 
resulting from the screen and patching confirmation (Table 4.3).  
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A
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Figure 4.9 Identification of 
mutants with altered growth, 
morphology or haemolysis on 
sheep blood + Columbia agar.  
 
Arrows indicate example strains of 
interest. 
 
A Strains with altered morphology 
were selected for further study. 
 
B Strains with increased or reduced 
haemolysis were selected for 
further study. 
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Figure 4.10 Identification of 
mutants with altered growth or 
morphology on bovine serum 
agar.  
 
Arrows indicate example strains of 
interest. 
 
Strains showing no growth, reduced 
growth or altered pigmentation or 
morphology were selected for 
further study 
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A
B
Figure 4.11 Identification of 
mutants with altered growth, 
morphology or haemolysis on 
human blood agar.  
 
Arrows indicate example strains of 
interest. 
 
A Strains with reduced growth and 
altered morphology were chosen for 
further study.  
 
B Haemolysis was difficult to see 
on human blood agar plates, due to 
the high concentration of blood. 
However, strains showing a clear 
difference in haemolysis were 
selected. 
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Figure 4.12 Repeat screening for mutant phenotypes.  
 
 - (   V W U D L Q  L V  S D W F K H G  D W  W K H     R ¶ F O R F N  S R V L W L R Q  R Q  H D F K  S O D W H. 
 
Arrows indicate example strains that retained their mutant phenotype 
 
A Bovine serum.  
B Human blood.  
C Sheep blood + Columbia agar.  
 
68 of the strains retained their phenotype when patched back on to their corresponding 
screen condition. 
Growth
Growth
Growth
Haemolysis
Haemolysis
A
B
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Table 4.3 Strains identified as having an altered phenotype on human blood agar.  ------ = No altered phenotype found. 
NARSA 
Strain ID 
Gene ID 
Gene 
Name 
Description 
SH1000 
identity 
(%) 
Screen Conditions 
30% Human Blood Agar 
5% Sheep Blood + Columbia 
Agar 
50% Bovine Serum 
Agar 
NE27 SAUSA300_1895 nos nitric oxide synthase oxygenase 100 Slightly reduced growth ------ ------ 
NE92 SAUSA300_0963 qoxA 
quinol oxidase, 
subunit II 
99 Reduced growth. No haemolysis ------ ------ 
NE95 SAUSA300_1989 agrB 
accessory gene regulator protein 
B 
100 No haemolysis. Opaque pigmentation No haemolysis ------ 
NE229 SAUSA300_1119 - hypothetical protein 100 Reduced growth and haemolysis 
Highly reduced haemolysis 
 
------ 
NE427 SAUSA300_1801 fumC fumarate hydratase class II 100 No haemolysis. Opaque pigmentation ------ ------ 
NE460 SAUSA300_0955 atl autolysin 99 Opaque pigmentation ------ ------ 
NE522 SAUSA300_1889 purB adenylosuccinate lyase 100 Reduced growth Reduced haemolysis and growth Highly reduced growth 
NE529 SAUSA300_0017 purA adenylosuccinate synthetase 100 Reduced growth Increased haemolysis Highly reduced growth 
NE547 SAUSA300_1306 odhA 
2-oxoglutarate dehydrogenase E1 
component 
100 Reduced growth ------ ------ 
NE552 SAUSA300_2408 nikD 
oligopeptide ABC transporter 
ATP-binding protein 
100 Slightly reduced growth ------ ------ 
NE573 SAUSA300_1713 ribBA riboflavin biosynthesis protein 100 Slightly reduced growth ------ 
White opaque 
pigmentation 
NE594 SAUSA300_1641 gltA citrate synthase II 100 Slightly reduced growth ------ ------ 
NE635 SAUSA300_1714 ribE riboflavin synthase subunit alpha 100 Reduced growth ------ ------ 
NE821 SAUSA300_0698 pabA 
para-aminobenzoate synthase, 
glutamine amidotransferase, 
component II 
100 Reduced growth ------ ------ 
NE857 SAUSA300_2346 nirB 
nitrite reductase [NAD(P)H], 
large subunit 
100 Opaque pigmentation ------ ------ 
NE873 SAUSA300_1991 agrC 
accessory gene regulator protein 
C 
99 No haemolysis. Opaque pigmentation No haemolysis ------ 
NE884 SAUSA300_2409 nikC 
oligopeptide ABC transporter 
permease 
100 
Reduced haemolysis and slightly 
reduced growth 
------ ------ 
NE896 SAUSA300_0903 - hypothetical protein 100 No haemolysis ------ ------ 
NE912 SAUSA300_0752 clpP 
ATP-dependent Clp protease 
proteolytic subunit 
100 Reduced growth Reduced haemolysis and growth 
Reduced growth. White 
opaque pigmentation 
NE945 SAUSA300_0188 brnQ 
branched-chain amino acid 
transport system II carrier protein 
100 
Highly reduced haemolysis. Opaque 
pigmentation 
------ ------ 
NE1048 SAUSA300_1092 pyrP uracil permease  No haemolysis ------ Slightly reduced growth 
NE1063 SAUSA300_0699 pabB 
chorismate-binding domain-
containing protein 
100 
Increased haemolysis and reduced 
growth 
------ ------ 
NE1236 SAUSA300_0338 - glyoxalase family protein 100 Increased haemolysis ------ ------ 
 
 
 
 
 
Table 4.3 continued 
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NARSA 
Strain ID 
Gene ID 
Gene 
Name 
Description 
SH1000 
identity 
(%) 
Screen Conditions 
30% Human Blood Agar 
5% Sheep Blood + Columbia 
Agar 
50% Bovine Serum 
Agar 
NE1253 SAUSA300_0193 murQ 
N-acetylmuramic acid-6-
phosphate etherase 
100 Increased haemolysis ------ ------ 
NE1260 SAUSA300_1731 pckA 
phosphoenolpyruvate 
carboxykinase 
100 Increased haemolysis ------ ------ 
NE1267 SAUSA300_0391 - hypothetical protein 100 Increased haemolysis Increased haemolysis ------ 
NE1296 SAUSA300_0690 saeS sensor histidine kinase 100 No haemolysis Highly reduced haemolysis ------ 
NE1299 SAUSA300_0905 - hypothetical protein 100 Increased haemolysis ------ ------ 
NE1304 SAUSA300_2326 araC transcription regulatory protein 100 No haemolysis ------ ------ 
NE1315 SAUSA300_0899 mecA adaptor protein 100 Increased haemolysis ------ ------ 
NE1354 SAUSA300_1058 hla alpha-hemolysin 100 No haemolysis Highly reduced haemolysis ------ 
NE1391 SAUSA300_1305 odhB 
dihydrolipoamide 
succinyltransferase 
100 Reduced growth Highly increased haemolysis ------ 
NE1404 SAUSA300_1605 mreC rod shape-determining protein 100 
Highly reduced haemolysis. Opaque 
pigmentation 
------ ------ 
NE1434 SAUSA300_1016 ctaB protoheme IX farnesyltransferase 99 No haemolysis. Reduced growth ------ ------ 
NE1509 SAUSA300_0630 abcA 
ABC transporter ATP-binding 
protein 
100 
Reduced haemolysis. Opaque 
pigmentation 
------ ------ 
NE1532 SAUSA300_1992 agrA 
accessory gene regulator protein 
A 
100 No haemolysis. Opaque pigmentation None haemolysis ------ 
NE1536 SAUSA300_0791 gcvH 
glycine cleavage system protein 
H 
100 Reduced growth Increased haemolysis ------ 
NE1543 SAUSA300_0961 qoxC quinol oxidase, subunit III 100 
No haemolysis. Slightly reduced 
growth 
------ ------ 
NE1604 SAUSA300_2407 nikE 
oligopeptide ABC transporter 
ATP-binding protein 
100 Slightly reduced growth ------ ------ 
NE1610 SAUSA300_0996 lpdA dihydrolipoamide dehydrogenase 99 Highly reduced growth 
Reduced growth and reduced 
haemolysis 
Reduced growth 
NE1622 SAUSA300_0691 saeR DNA-binding response regulator 100 No haemolysis Highly reduced haemolysis ------ 
NE1659 SAUSA300_0195 - transcriptional regulator 100 Highly increased haemolysis Highly increased haemolysis ------ 
NE1751 SAUSA300_0979 - hypothetical protein 100 Highly reduced growth ------ Slightly reduced growth 
NE1770 SAUSA300_1139 sucD 
succinyl-CoA synthetase subunit 
alpha 
100 Highly reduced growth Reduced growth ------ 
NE1775 SAUSA300_0320 lipA triacylglycerol lipase 99 
Highly increased haemolysis. Slightly 
reduced growth 
Increased haemolysis ------ 
NE1908 SAUSA300_1911 - 
ABC transporter ATP-binding 
protein 
100 None haemolysis. Opaque pigmentation No haemolysis 
White opaque 
pigmentation 
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4.2.4.2 Transduction of Tn inserts into JE2 and SH1000 
 
Each of the 46 Tn inserts were transduced back into JE2 and into SH1000. This was 
done in the JE2 background to establish that the mutant phenotype was associated with 
the Tn insertion. Strains of choice would also be studied in SH1000 to demonstrate the 
effect of the mutations in an independent genetic background (see Chapter 5). SH1000 
was chosen, as it is a common laboratory S. aureus strain (Horsburgh et al., 2002). 
Furthermore, when grown on human blood agar aerobically and anaerobically it had 
similar growth and haemolysis characteristics to JE2 (Figure 4.13).  
 
The Tn inserts were transduced back into JE2 to show that the phenotype is linked to 
the Tn insertion, and not the result of non-linked genome changes. The transduction 
procedure is shown diagrammatically in Figure 4.14. A total of 92 transductions were 
carried out (i.e. each of the 46 Tn inserts transduced into JE2 and each of the 46 
transduced into SH1000) and 33 of the 46 Tn transductions in each background gave 
colonies for both strains (JE2 and SH1000). For the transduction method see Chapter 
2.10.3. Although repeated attempts were made, the remaining 15 Tn inserts could not 
be transduced into either background. 
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Figure 4.13 Growth and haemolysis of different strains of S. aureus on human blood agar.  
 
Again haemolysis was difficult to visualise on 30% (v/v) human blood agar. However, strains NewHG and Newman appear to have higher 
haemolytic activity on human blood than JE2 and SH1000.  
 
SH1000
Newman
NewHG
JE2
Aerobic Anaerobic
SH1000
Newman
NewHG
JE2
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Figure 4.14 Diagram of the transduction of the Tn from the 46 NTML screen 
results into SH1000 and JE2.  
 
Attempts were made to transduce all 46 Tn insertions into SH1000 and JE2. Only 33 of 
the 46 transductions gave colonies on ery/lin for both strain backgrounds. Colonies were 
checked for the presence of the Tn by PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 NTML strains with confirmed phenotypes
JE2 SH1000
Tn Transduced Tn Transduced
33 of the 46 
transductions gave 
colonies on ery/lin
33 of the 46 transductions 
gave colonies on ery/lin
Presence of Tn
confirmed by PCR
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4.2.4.2.1 Confirmation of successful transduction 
 
The NTML database provides the exact insertion site for every Tn in the library. 33 sets 
of primers were designed against the S. aureus USA300 FPR3757 genome, 400bp 
upstream and 400bp downstream of the insertion sites given in the database (for primer 
sequences see Chapter 2.12.1.1). If the Tn was present in any of the transduction 
colonies, then the primers would amplify the full transposon giving a PCR product of 
~4kb. If the transduction failed, the transposon would not be present and only a small 
region of 800bp maximum size would be amplified (Figure 4.15). The PCR products 
were assessed by 1% (w/v) gel electrophoresis (Chapter 2.12.5), which showed that 31 
of the 33 strains that gave colonies after transduction were successful transductants 
(Figure 4.16; Table 4.4). 
 
4.2.4.3 Is the JE2 phenotype linked to the Tn insertion? 
 
Strains were streaked on different media to confirm that the phenotype is linked to the 
Tn insertion. As all 31 strains were originally selected on human blood, they were tested 
on 30% (v/v) human blood agar to confirm the phenotype (an example plate is given in 
Figure 4.17 A1, all plates for all conditions in Figure 4.17 are given in Appendix 4.7 a, 
b, c & d). As seen in the screen results (Figure 4.11) and when growing the wild-type 
strains (Figure 4.13), disparity in haemolysis was particularly difficult to observe on 
human blood plates containing 30% (v/v) blood. This was no different when the 31 
strains were grown as single colonies on 30% (v/v) blood. Therefore, it was decided that 
only variations in growth would be assessed on these plates (Figure 4.17 A1). 
Additionally, rabbit blood agar was inoculated with the 31 transductant strains to 
determine any difference in growth between human blood and rabbit blood (Figure 4.17 
A2). To assess haemolysis, the strains were grown on Columbia agar containing 5% 
(v/v) sheep blood or 5% (v/v) human blood (Figure 4.17 B1 and B2 respectively). The 
resulting growth and haemolysis phenotypes are shown in Table 4.5. 
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Figure 4.15 Diagram showing how primers were designed to confirm Tn insertion 
by transduction.  
 
Successful transductions have the Tn inserted between the primer sites and so the full 
Tn will amplify. Failed transductions will not have the Tn present, so the short region 
containing the insertion site will be amplified. 
 
 
 
 
WT
Transposon 
inserted
Primer 1F
Primer 1F
Primer 2R
Primer 2R
PCR product sizes
Failed transduction
Successful transduction
~700bp
~4kb
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Figure 4.16 Demonstration of Tn insertion site in transductants.  
 
DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards (M) 
of sizes shown are in each panel. 
 
The top row gels are the SH1000 PCR products. Lane 25 shows a PCR product 
corresponding to the size of the insertion site without the Tn insert. The bottom row gels 
are JE2 PCR products. Lanes 16 and 25 show PCR products of sizes corresponding to 
failed transductions. The first gel on both rows appears to show a lot of weak bands. 
These are the result of non-specific binding at the 56
o
C annealing temperature used for 
the PCR. Increasing the temperature for the PCRs removes the faint bands. From the 
above images 31 of the 33 transductions that gave colonies on ery/lin containing solid 
media have the Tn inserted in the gene corresponding to the library strain. 
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Figure 4.17 Phenotype of transductants on blood agar plates. 
 
A1. Growth phenotypes on 30% (v/v) human blood agar.  
A2. Growth phenotypes on 30% (v/v) rabbit blood agar.  
B1. Haemolysis on 5% sheep blood + Columbia agar.  
B2. Haemolysis on 5% human blood + Columbia agar. 
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Table 4.5 Identification of strains with altered phenotype post-transduction. ------ = no difference to the wild-type. 
Category 
NARSA 
Strain ID 
Strain Name 
Growth Phenotype Haemolysis Phenotype 
Human Blood Rabbit Blood 
5% Human Blood + 
Columbia Agar 
5% Sheep Blood + 
Columbia Agar 
A1 
NE522 JE2-purB Reduced Growth Reduced Growth Increased Haemolysis Reduced Haemolysis 
NE529 JE2-purA Reduced Growth Reduced Growth Increased Haemolysis 
Slightly Increased 
Haemolysis 
NE821 JE2-pabA Highly Reduced Growth Slightly Reduced Growth ------ ------ 
A2 
NE460 JE2-atl Opaque Colony Opaque Colony Increased Haemolysis ------ 
NE1253 JE2-murQ ------ ------ Increased Haemolysis Increased Haemolysis 
NE1304 JE2-araC ------ ------ Reduced Haemolysis ------ 
NE1315 JE2-mecA ------ ------ Reduced Haemolysis 
Slightly Reduced 
Haemolysis 
NE1391 JE2-odhB Slightly Reduced Growth Slightly Reduced Growth Increased Haemolysis Increased Haemolysis 
NE1775 JE2-lipA Slightly Reduced Growth ------ Increased Haemolysis ------ 
B 
NE95 JE2-agrB ------ ------ ------ Reduced Haemolysis 
NE873 JE2-agrC ------ ------ Slightly Reduced No Haemolysis 
NE1296 JE2-saeS ------ ------ ------ No Haemolysis 
NE1354 JE2-hla ------ ------ ------ No Haemolysis 
NE1532 JE2-agrA ------ ------ Reduced Haemolysis No Haemolysis 
NE1622 JE2-saeR ------ ------ ------ No Haemolysis 
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Category A1 in Table 4.5 shows all strains that gave a clear growth phenotype when 
grown on human blood agar. Category A2 shows those strains that gave a clear 
haemolysis phenotype on 5% (v/v) human blood plus Columbia agar. Some strains in 
category A2 gave a growth phenotype, however, this was only slight when compared 
with the growth defect of category A1 strains. Category B strains are those strains that 
gave a clear phenotype, but are the in-built controls within the screen. When screening 
on human blood, it was expected that virulence gene regulator proteins and toxins such 
 D V  .-haemolysin would be found amongst the positive results. The strains in category B 
provided confidence in the screen results, but their role in pathogenicity is well 
characterised and they were not taken forward for further study.  
 
4.2.5 Species specificity of JE2-pabA phenotype 
 
Interestingly the pabA mutant strain, JE2-pabA, showed highly reduced growth on 
human blood, but only a subtle reduction in growth was seen when grown on rabbit 
blood (Figure 4.17). Furthermore, when screening the NTML, strain NE821 (the NTML 
pabA mutant) showed highly reduced growth on human blood and normal growth on 
bovine serum. This suggested that the phenotype was specific to human blood, or the 
blood of a subset of species. Growth of JE2-pabA was compared to that of JE2 on 30% 
(v/v) sheep blood agar and 30% (v/v) horse blood agar (Figure 4.18 A & B, 
respectively). Growth of JE2-pabA was comparable to JE2 on sheep blood and only 
slightly reduced on horse blood. This demonstrated that the pabA phenotype is strain 
specific. 
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Figure 4.18 Growth analysis of JE2-pabA on sheep and horse blood agar. 
 
A. Growth phenotypes on 30% (v/v) sheep blood agar.  
B. Growth phenotypes on 30% (v/v) horse blood agar.  
Plates were incubated for 48 h at 37
o
C. 
JE2
JE2-pabA
Sheep blood Horse blood
JE2
JE2-pabA
A B
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4.2.6 Bioinformatic analysis of the 9 strains of interest 
 
The IDs of the disrupted genes in the nine strains of interest were used for bioinformatic 
analysis in order to obtain known information for these genes. The method used is 
shown diagrammatically in Figure 4.19. Sequence features including protein 
description, function and gene/protein length were confirmed using the Uniprot and 
NCBI Protein databases. The Kegg (linked to from Uniprot) and Biocyc databases were 
searched to give the known pathways that each gene has a role in. Information for each 
strain is given in Table 4.6. Atl and MurQ are involved in peptidoglycan degradation 
and recycling, both have roles in muropeptide turnover and recycling. PurA and PurB 
catalyse steps in the de novo purine biosynthesis pathway. PabA catalyses a step in 
tetrahydrofolate metabolism. The OdhB protein has a role in energy production via the 
tricarboxylic acid cycle (TCA). LipA is a lipase with a role in the triacylglycerol 
degradation pathway. All 9 genes were present in all S. aureus strains currently 
sequenced and all genes, apart from lipA, have homologous genes in other 
Staphylococcus sp. 
 
Tn insertion site for each gene was obtained from the NARSA website, which is the 
companion website of the NTML. The website hosts the free genome viewer, GView 
(Petkau et al., 2010), which was used to identify the genome position and flanking 
genes for each of the nine NTML results. Genome position, flanking genes and Tn 
insertion sites are displayed in Figure 4.20 A-I. Analysis of the flanking genes 
suggested that eight of the nine genes may be part of an operon Figure 4.20 A-H. It was 
essential to confirm this, as if the genes had to be complemented in future work, then 
the entire operon would have to be used to complement the strain, due to potential polar 
effects. The operonic structure for pabA, murQ, araC and odhB (Figure 4.20 D, E, F & 
H respectively) has been further verified by transcriptomics (Broeke-Smits et al., 2010).
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Figure 4.19 Diagram of the methods employed to acquire information on each of 
the nine Tn inserted genes.  
 
NCBI Protein and Uniprot were used to confirm sequence features. Pathway 
information was obtained from the Kegg and Biocyc databases. NCBI protein BLAST 
was used to assess level of conservation of each gene. Genome position, Tn insertion 
site and surrounding gene information was found on the NARSA website accompanying 
the NTML. 
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Table 4.6 Sequence features, function and pathway information for the nine NTML Tn inserted genes. 
NARSA 
Strain 
ID 
Protein ID 
Protein 
Length 
(aa) 
Gene 
Length 
(bp) 
Description 
Gene 
Name 
Function Pathway 
NE460 SAUSA300_0955 1256 3771 Autolysin atl 
Peptidoglycan degradation 
& recycling 
Peptidoglycan metabolism 
NE522 SAUSA300_1889 431 1296 Adenylosuccinate lyase purB 
Catalyses 2 steps in purine 
biosynthesis 
Purine biosynthesis 
 
NE529 SAUSA300_0017 427 1284 Adenylosuccinate synthetase purA 
Catalyses 1 step in purine 
biosynthesis 
Purine biosynthesis 
NE821 
SAUSA300_0698 
 
197 594 
Paraaminobenzoate synthase, 
glutamine amidotransferase, 
component_II 
pabA 
Catalyses 1 step in the 
production of p-
aminobenzoic acid from 
chorismate. Essential in 
tetrahydrofolate production 
Folate biosynthesis pathway 
NE1253 SAUSA300_0193 298 897 
N-acetylmuramic acid-6-phosphate 
esterase* 
murQ 
Peptidoglycan degradation 
& recycling 
Peptidoglycan metabolism 
NE1304 SAUSA300_2326 701 2106 Transcription regulatory protein araC 
Contains HTH domain. A 
domain primarily observed 
in positive regulators of 
transcription 
------ 
NE1315 SAUSA300_0899 239 720 Adaptor protein mecA 
Targets unfolded/aggregated 
proteins for ClpP 
degradation 
------ 
NE1391 SAUSA300_1305 422 1269 
Dihydrolipoamide 
succinyltransferase 
odhB 
Conversion of 2-
oxoglutarate to succinyl-
CoA and CO2 
Tricarboxylic acid cycle 
NE1775 SAUSA300_0320 690 2073 Triacylglycerol lipase precursor lipA 
Converts triglycerides to 
diglycerides in fatty acid 
metabolism 
Triacylglycerol degradation 
* Annotated in the NTML library as a conserved hypothetical protein. Uniprot, BLAST and NCBI Protein give the description in the table. 
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Region: 1,041,080-1,050,541bp; atl: 1,044,219-1,047,989bp; Tn Insertion: 1,046,792bpNE460A
purB
Tn
Region: 2,051,651-2,057,653bp; purB: 2,052,926-2,054,221bp; Tn Insertion: 2,053,923bpNE522B
Tn
purA
Region: 18,345-28,819bp; purA: 22,465-23,748bp; Tn Insertion: 22,754bpNE529C
Tn
pabA pabB pabC
Region: 770,120-775,683bp; pabA: 772,277-772,870bp; 
pab Operon: 772,277-774,613bp; Tn Insertion: 772,327bp
NE821D
atl
Tn
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murQ
Tn
Region: 219,419-231,736bp; murQ: 225,019-225,915bp; 
mur Operon: 223,964-228,259; Tn Insertion: 225,272bp
NE1253E
araC
Tn
Region: 2,496,801-2,506,227bp; araC: 2,501,327-2,503,432bp; 
ara Operon: 2,501,327-2,503,925bp; Tn Insertion: 2,501,453bp
NE1304F
Tn
mecA
Region: 984-763-991,417bp; mecA: 987,736-988,455bp; Tn Insertion: 987,925bpNE1315G
Tn
odhB
Region: 1,433,301-1,442,269bp; odhB: 1,435,894-1,437,162bp;
odh Operon: 1,435,894-1,439,974bp; Tn Insertion: 1,436,724bp
NE1391H
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Figure 4.20 Tn insertion position and surrounding genes for each of the 9 genes of 
interest.  
 
The Tn inserts within the first third of each gene except lipA, in which the Tn is inserted 
75% into the gene sequence. The pabA gene (D) is in an operon with two downstream 
genes. There are four genes in the murQ operon (E), one upstream of murQ, and two 
downstream genes. The araC gene (F) is in an operon with a downstream hypothetical 
protein. The odhB gene (H) is transcribed from the promoter of the gene just upstream 
from it. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Region: 368,949-377,016bp; lipA: 372,415-374487bp; Tn Insertion: 373,968bpNE1775I
Tn
lipA
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4.3 Discussion 
 
The NTML provides a valuable resource for the S. aureus research community. It 
allows for rapid identification of genes important for S. aureus growth and survival in 
any environment that is testable in a laboratory setting. For S. aureus to cause severe 
diseases such as endocarditis and sepsis, it must be able to survive and replicate in 
human blood (Alonzo et al., 2012; Zheng et al., 2015). Survival and growth is not 
simply a matter of immune evasion, the bacteria needs to access available nutrients and 
synthesise the nutrients that are not freely available (Brown et al., 2000 & Coulter et al., 
1998). Therefore, the importance of 1,920 of the NTML genes was assessed for growth 
using human blood as the sole nutrient source.  
 
Before screening, the NTML hypothetical proteins were analysed bioinformatically to 
determine if any were homologous to known virulence factors. The sequence files and 
databases constructed in Chapter 3 were used for the analysis. Two of the four 
staphylococcal superantigen-like proteins found in Chapter 3 were found amongst the 
NTML hypothetical proteins. Similarly, several of the hypothetical proteins of the 
NTML proved to be genes with known functions (Table 4.2 & 4.3). Indeed one of the 
nine genes found above, to be subjected to further study, was annotated in the NTML as 
a hypothetical protein, and was in fact N-acetylmuramic acid-6-phosphate esterase 
(murQ; Table 4.6). No potential virulence factors, other than two of those found 
previously in Chapter 3, were found bioinformatically.  
 
Screening the NTML returned 100 strains with an interesting phenotype, 72 of which 
had an altered growth or haemolysis phenotype on human blood. The 100 results 
included 30 genes annotated as transporters (1 sugar transporter, 1 Fe transporter, 12 
ABC transporter permeases, 7 amino acid transporters and 9 genes simply annotated as 
transporters). Genes involved in biosynthetic pathways, including nucleotide, amino 
acid and cofactor biosynthesis had 19 representatives in the screen results. These results 
are in agreement with Brown et al. (2000) & Coulter et al. (1998), highlighting the 
importance of nutrient acquisition and biosynthesis for pathogen growth in human 
blood. 
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After confirming the phenotype of each of the 100, there were 46 strains remaining with 
an interesting phenotype on human blood. Repeated attempts to transduce the Tn from 
these strains into the SH1000 and JE2 strain backgrounds gave 31 strains of interest. 
Transduction of the Tn insert from the remaining 15 NTML strains was unsuccessful 
potentially due to inefficient phage lysis of these strains, or slow growth of the strains 
resulting in low phage titre. After repeated attempts, these strains were not concentrated 
on further, as 31 strains had given colonies in both backgrounds and their Tn insertions 
had been confirmed. After transduction, only 9 of the 31 strains retained the altered 
phenotype seen in the screen. This confirmed linkage of the phenotype to the transposon 
insertion for the 9 strains and suggested that the phenotype seen for the other 22 strains 
was the result of unlinked genomic events (e.g. point mutations in other regions of the 
genome). The following Tn disrupted genes are found in these 9 strains: autolysin (atl), 
adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), paraaminobenzoate 
synthase, glutamine amidotransferase, component_II (pabA), N-acetylmuramic acid-6-
phosphate esterase (murQ), transcription regulatory protein (araC), adaptor protein 
(mecA), dihydrolipoamide succinyltransferase (odhB) and a triacylglycerol lipase 
precursor (lipA). 
 
Two of the above genes are involved in peptidoglycan degradation and recycling (atl 
and murQ). Disruption of the atl gene produced a strain with an unusual opaque colony 
morphology on human and rabbit blood and increased haemolysis on human blood. The 
Atl protein is a large protein that is secreted and proteolytically cleaved extracellularly 
to give two active forms, an amidase (AM) and a glucosaminidase (GL; Bose et al., 
2012). Both proteins have DNA binding activity, but their primary function is in 
peptidoglycan degradation (Grilo et al., 2014). AM cleaves the amide bond between N-
acetylmuramic acid and the L-alanine of the crosslinking peptide in peptidoglycan. The 
GL protein cleaves the bond between N-acetyl- -D-glucosamine and N-acetyl muramic 
acid. This activity is important for release of peptidoglycan from the surface of S. 
aureus, and for release of the daughter cell upon cell division (Bose et al., 2012; Foster, 
1995). Loss of Atl activity results in formation of clusters of attached S. aureus cells. 
This may explain the unusual colony morphology seen in the screen. However, the 
increased haemolysis phenotype conflicts with the results of the study by Pasztor et al. 
(2010), which found that atl  S O D \ V   D   U R O H   L Q   V H F U H W L R Q   R I   S U R W H L Q V   Y L D   ‡ Q R Q F O D V V L F D O 
 S U R W H L Q  V H F U H W L R Q ·  D Q G  V H F U H W R P H  D Q D O \ V L V  R I   D Q atl mutant strain found reduced levels of 
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. -haemolysin. Disruption of the murQ gene produced a strain with increased 
haemolysis on human blood agar. In E. coli and Haemophilus influenzae, hydrolysed 
peptidoglycan is internalised and degraded further by a series of enzymes. The MurQ 
enzyme converts MurNAc 6P to GlcNAc 6P by cleavage of an ether bond, which can 
then be used for glycolysis (Hadi et al., 2008; Hadi et al., 2013). It is unclear why 
disruption of this enzyme would produce an increased haemolysis phenotype. 
 
The araC family of transcriptional regulators have roles in pathogenesis, sugar 
metabolism and response to stress. JE2-araC had a reduced haemolysis phenotype on 
human blood. The araC gene from JE2 is identical to the araC family gene rsp from S. 
aureus MW2. Deletion of this gene was found to radically alter the secreted protein 
profile of S. aureus MW2 (Lei et al., 2011). This secretion of different proteins in the 
rsp- background indicates that the reduced haemolysis phenotype seen for the araC 
strain may occur at the transcription, translation, protein-tur over or secretion level, 
thereby altering the amount of haemolytic proteins released by JE2-araC. 
 
The mecA gene is related to mecA from Bacillus subtilis, which is involved in 
glycopeptide antibiotic resistance, including teicoplanin and vancomycin (Jousselin et 
al., 2013; Renzoni et al., 2009). JE2-mecA had a reduced haemolysis phenotype on 
human blood agar. The mecA gene is upregulated by the Spx protein, the gene for which 
is just upstream from mecA (Figure 4.20G). MecA is an adapter protein, which aids Clp 
chaperones in the delivery of proteins to the ClpP and ClpQ protease, which then 
proteolytically degrade them, allowing control of protein levels during normal growth 
and in response to a changing environment (Donegan et al., 2014). The observed 
reduced haemolysis phenotype for this strain may result from extended survival of 
regulators that downregulate haemolytic toxin production. 
 
The odhB gene is a tricarboxylic acid cycle (TCA) enzyme, a system for aerobic 
respiration. TCA cycle mutants were not expected in the results on human blood, as the 
human blood plates were grown anaerobically. JE2-odhB showed increased haemolytic 
activity on human blood. OdhB is part of an enzyme complex of three proteins, well 
studied in Bacillus subtilis. The complex catalyses oxidative decarboxylation of 2-
oxoglutarate to succinyl coenzyme A, in the TCA cycle (Carlsson & Hederstedt, 1989). 
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Triacylglycerol lipase proteins are required for resistance to fatty acids. JE2-lipA 
showed an increased haemolysis phenotype on human blood agar. Triglycerides are 
antimicrobial fatty acids secreted with other fatty acids from the sebaceous glands on 
skin. This cocktail of fatty acids is known as sebum. Lipases degrade the fatty acids 
allowing colonisation of the skin (Cadieux et al., 2014). Lipases likely have an 
important role in blood, as lipase mutants have reduced bacterial loads in the liver, 
kidney and spleen of mice.  
 
The purA and purB genes are involved in the biosynthesis of purines and the mutants 
had reduced growth on human blood and bovine serum. Serum based analysis of an E. 
coli mutant library identified nucleotide biosynthesis as essential for growth of E. coli in 
serum (Samant et al., 2008). In the same study, Salmonella enterica and Bacillus 
anthracis nucleotide synthesis mutants could not grow in serum and the B. anthracis 
strain was highly attenuated in a murine infection model. McFarland & Stocker, 1987 
found that 10
7
 CFU of a Salmonella dublin purA mutant could not kill mice on 
intraperitoneal infection, whereas 10 CFU of the wild-type was found to be deadly. 
They also found that in S. enteria subspecies enterica serovar typhimurium, the lethal 
dose was 2.5x10
3
 for the wild-type in mice and a purA or purB mutant caused no death 
in mice infected with 2.5x10
7
. This attenuation was also seen in humans who 
voluntarily drank 10
8
-10
10
 CFU of a purA mutant of S. typhi with no ill effects (Stocker, 
1988). The results of the above studies tally with the findings of the NTML screen for 
the purA and purB mutants.  
 
PabA, along with PabB and PabC produce 4-aminobenzoic acid (PABA) from 
chorismate and L-glutamine, a necessary step in the synthesis of folates (Neidhardt et 
al., 1996; Tran & Nichols, 1991; Wegkamp et al., 2007). The NTML pabA mutant 
showed an unusual altered phenotype in that it grew poorly on human blood, but had 
normal growth on bovine serum. Like the purine synthesis genes, the pabA gene has 
been shown to be attenuated in S. typhi (Brown & Stocker, 1987). The importance of 
folate for virulence has been known for many years. The sulphonamide antimicrobials 
are known to act on enzyme steps downstream of PABA (Proctor, 2008; Projan, 2002). 
Attempts have also been made to find antimicrobials using chorismate analogues in E. 
coli, which were found to competitively inhibit pabB activity (Payne et al., 2009; 
Ziebart et al., 2010).  
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Attempts to define the importance to pathogenicity of the 9 genes of interest and 
characterise those that have a demonstrable role in pathogenicity are the primary 
objectives of the next chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5  CHARACTERISATION OF THE ROLE OF GENES REQUIRED FOR GROWTH ON HUMAN BLOOD   5.1 Introduction 
 
In addition to the armoury of toxins and immune evasion proteins that S. aureus and 
other pathogens possess, physiological dynamics is essential for their ability to cause 
disease. This may involve switching off, or severely reducing the activity of, aspects of 
metabolism in order to persist in the presence of antibiotics (Amato et al., 2014), 
upregulating proteins for the acquisition of nutrients sequestered by the host (Hammer 
& Skaar, 2012; Weinberg, 1974) and the upregulation of de novo biosynthetic pathways 
to produce essential products not readily available in the environment (Autret & 
Charbit, 2005; Heroven & Dersch, 2014; McFarland & Stocker, 1987; Shea et al., 
2000). A review of the literature on antibiotics highlights the importance of metabolism 
to infection. The majority of antimicrobials function by disrupting essential metabolic 
processes, thereby killing the pathogen (bacteriocidal antibiotics) or inhibiting their 
growth (bacteriostatic antibiotics; Kohanski et al., 2010). Common antimicrobial targets 
include peptidoglycan synthesis (Labischinski, 1992), protein synthesis (Mast & 
Wohlleben, 2014), nucleic acid synthesis (Chernyshev et al., 2007; Hartmann et al., 
1968; Rottman & Guarino, 1964) and synthesis of tetrahydrofolate (THF) by the 
sulphonamide PABA analogues (Brain et al., 2008) and the dihydrofolate reductase 
(DHFR) inhibitors (Laue et al., 2007; Proctor, 2008).  
 
The THF synthesis inhibitors are of particular relevance to this chapter. THF is an 
important cofactor in many metabolic reactions, acting as a donor and acceptor of single 
carbon units (Figure 5.1). Serine is converted to glycine reversibly by the enzyme GlyA, 
using THF as methylene acceptor, in a process known as serine/glycine interconversion 
(Appling, 1991; Basset et al., 2004; Wegkamp et al., 2007; Figure 5.1A). Serine/glycine 
interconversion releases 5,10-methylene-THF, which can then be used in the 
biosynthesis of panothenate (vitamin B5; Figure 5.1B), which itself is a precursor of 
coenzyme A, a cofactor for many reactions in central metabolism (Ernst & Downs, 
2015). 5,10-methylene-THF is also required for deoxythymidine triphosphate (dTTP) 
synthesis from deoxyuridine monophospate (dUMP) (Figure 5.1C). 5,10-methylene-
THF can be converted by MetF to 5-methyl-THF, a cofactor for the remethylation of L-
homocysteine to methionine (Figure 5.1 D & E). THF is converted to 10-formyl-THF 
by the enzyme Fhs in the presence of ATP and formate. 10-formyl-THF is the formyl 
donor for the synthesis of fMet and purines (Friso & Choi, 2005; Harvey, 1973; Projan, 
2002); Figure 5.1 F, G & H).  
 
The apparent loss of THF synthesis, in the NTML strain NE821, due to disruption of the 
pab operon, resulted in a severe growth defect when grown on human blood agar. 
Characterising the phenotype associated with this strain is the main topic of this chapter. 
The phenotypes of two other strains isolated in the NTML screen (Chapter 4) involved 
in de novo purine biosynthesis are also examined.  
 
5.2 Results  5.2.1 Effect of Tn insertion in the 9 strains isolated from the NTML 
 
The importance of the nine mutations identified in Chapter 4 (Table 4.6) in 
pathogenicity was assessed using the zebrafish embryo model of systemic infection  
(Prajsnar et al., 2008). All zebrafish assays were done in collaboration with Dr Emma 
Johnson M.D. For the full zebrafish infection assay protocol, see Chapter 2.23. All 9 
strains were first assayed in the USA300 JE2 background and those that were attenuated 
were then assayed in the SH1000 background to confirm that the phenotype is not strain 
specific. Thirty zebrafish embryos of strain LWT, at 1 day old, were injected with 
~1,500 CFU S. aureus USA300 JE2, SH1000 or each of the 9 NTML mutants in the 
respective strain backgrounds. Survival of the fish was monitored over 4 days and then 
the remaining fish were culled (Figure 5.2). Previous analyses have shown that USA300 
JE2 is more virulent than SH1000 in the zebrafish embryo model (data not shown). JE2 
kills approximately 60-80% of the embryos, whereas SH1000 kills approximately 40-
50% of embryos.  
 
None of the NTML strains with a haemolysis phenotype in the JE2 background 
(Chapter 4, Table 4.5A2) were attenuated in the zebrafish embryo model of systemic 
infection, p > 0.05 (Figure 5.2A), as over a 4 day period an equivalent number of 
embryos to those infected with JE2 died. The 3 strains that showed a growth defect in 
the screen (Chapter 4, Table 4.5A1) were highly attenuated over the 4 day analysis p <
 2
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Figure 5.1 The roles of THF in S. aureus metabolism.  
 
Dashed lines indicate that 1 or more steps are not shown. A. Serine/glycine interconversion. B. Vitamin B5 biosynthesis. C. Synthesis of dTTP from dTMP. D. 
Conversion of 5,10-methylene-THF to 5-methyl-THF. E. Remethylation of L-homocysteine in the synthesis of methionine. F. 10-formyl-THF production from 
THF. G. Use of 10-formyl-THF to formylate L-methionine charged tRNA. H. 10-formyl-THF-dependent conversion of AICAIR to FAICAIR in the purine de 
novo biosynthesis pathway. I. Glycine cleavage pathway. Cleavage of glycine to CO2, ammonia and a methyl group. Abbreviations: AICAIR, 5-amino-1-(5- 
phospho-D-ribosyl)imidazole-4-carboxamide; FAICAIR, 5-formamido-1-(5-phospho-D-ribosyl)-imidazole-4-carboxamide. 
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Figure 5.2 Role of the isolated NTML mutants in pathogenesis in the zebrafish 
embryo model.  
 
*The data points overlap.  
 
A Survival of embryos injected with strains JE2-atl, JE2-murQ, JE2-araC, JE2-mecA, 
JE2-odhB and JE2-lipA was not significantly different compared to embryos injected 
with JE2, p > 0.05.  
 
B1 Survival of embryos injected with JE2-purB, JE2-purA and JE2-pabA was 
significantly improved compared to JE2, p < 0.0001. 
 
B2 Survival of embryos injected with SH-purB, SH-purA and SH-pabA was 
significantly improved compared to SH1000, p < 0.0001.  
 
 
A
B
1 2
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0.0001, with >70% survival of embryos infected with the mutant strains in the JE2 
background, compared to 25% survival of embryos infected with JE2; and for the 
SH1000 background, there was 90-100% embryo survival when injected with the 
mutant strains, compared to 60% survival of embryos injected with SH1000 (Figure 5.2 
B1 & B2). The pathogenesis screen was used as a cut-off to define those strains that 
would be taken on for further analysis. The SH1000 background was used for the 
ensuing zebrafish infection experiments, as it is a well-established strain background for 
host-pathogen interaction studies using the zebrafish embryo model (McVicker et al., 
2014; Prajsnar et al., 2012). As in Chapter 4 (Table 4.4) mutant strains in the SH1000 
background are named SH- followed by the gene name. 
 
5.2.2 Analysis of the role of purA and purB in S. aureus growth 
 
Growth curves of JE2-purB and JE2-purA were carried out (see Chapter 2.8 for growth 
curve method). In the original screen, the NTML strains NE522 and NE529 had reduced 
growth on human blood agar and bovine serum agar. Their growth was comparable to 
the wild-type on 5% (v/v) sheep blood with the nutrient rich Columbia agar base. The 
results suggested that their growth was reduced by a nutrient limitation in bovine serum 
and human blood that was supplied in the nutrient rich Columbia agar. It was expected 
that growth of the strain would be comparable to the wild-type in BHI and poor in 
bovine or human serum. Growth characteristics of JE2-purB and JE2-purA matched 
expectations (Figure 5.3). Therefore, the purA and purB mutants likely have a nutrient 
requirement for growth.  
 
5.2.3 Analysis of the purA and purB genes 
 
Strain JE2-purA has a Tn inserted in the purA gene, which encodes adenylosuccinate 
synthetase that catalyses 1 step in the biosynthesis of ATP in the purine pathway 
(Figure 5.4). The purB gene, disrupted by a Tn insertion in strain JE2-purB encodes 
adenylosuccinate lyase, which has two roles in the purine biosynthesis pathway (Figure 
5.4). Inosine monophosphate (IMP) in the purine pathway (Figure 5.4) is a branch-point 
leading to GTP synthesis, or ATP synthesis. PurB has a role in ATP synthesis after IMP 
branching in the pathway and a role before branching. Therefore, purA is likely 
essential for ATP synthesis only and purB is likely essential for both ATP and GTP
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Figure 5.3 Role of purA and purB in S. aureus growth.  
 
 y = JE2,    = JE2-purB,  c  = JE2-purA 
 
A In BHI both strains have comparable growth to JE2 measured by optical density at 
600nm (OD600) or CFU.  
B JE2-purB and JE2-purA show reduced growth in bovine serum relative to JE2.  
C Growth in human serum is reduced for JE2-purB and JE2-purA relative to JE2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B C
BHI                                                                                       BHI
Bovine Serum                                                                       Human Serum
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Figure 5.4 Purine de novo biosynthesis pathway.  
 
The PurA and PurB enzymes are coloured red, all other enzymes are green. PurB has two roles in the pathway, one before IMP branching and one after branching 
leading to ATP synthesis. Abbreviations: PRPP, 5-phospho-. -D-ribose 1-diphosphate; PRA, 5-phospho- -D-ribosylamine; GAR, N1-(5-phospho- -D-
ribosyl)glycinamide; FGAR, N2-formyl-N1-(5-phospho- -D-ribosyl)glycinamide; FGAM, 2-(formamido)-N1-(5-phospho- -D-ribosyl)acetamidine; AIR, 5-amino-1-(5-
phospho- -D-ribosyl)imidazole; N5-CAIR, N5-carboxyaminoimidazole ribonucleotide; CAIR, 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate; SAICAIR, 5'-
phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole; AICAIR, 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; FAICAIR, 5-formamido-1-(5-
phospho-D-ribosyl)-imidazole-4-carboxamide; IMP, inosine monophosphate, Adenylo-succ, N6-(1,2-dicarboxyethyl)-AMP; AMP, adenosine-monophosphate. Pathway 
information was acquired from the Kegg and Biocyc websites, and molecule images were obtained from ChemSpider. 
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synthesis. The purA and purB genes are at positions 22,465 bp and 2,054,221 bp on the 
JE2 genomes, respectively, whereas the other pur genes, encoding the enzymes shown 
in green in Figure 5.4, are in an operon at position 1,059,510  – 1,070,681 bp on the JE2 
genome. The pur genes are in approximate positions on the SH1000 genome. 
 
5.2.4 Analysis of bacterial population dynamics of purA & purB in the zebrafish 
 
embryo model of systemic infection 
 
5.2.4.1 Growth of SH-purB and SH-purA in vivo 
 
As SH-purA and SH-purB have an apparent growth defect in liquid culture, attenuation 
in the zebrafish model could be due to an inability to grow and divide. In vivo growth 
analysis was carried out to determine the growth of SH-purB and SH-purA over the 
course of infection. In order to track the growth of SH-purA and SH-purB in vivo, 
bacterial numbers, defined as CFU per embryo, were determined over 92 h, the standard 
time for a zebrafish embryo experiment. The full method used for determining bacterial 
numbers in vivo is given in Chapter 2.23.6. At 10-12 h time points, bacteria were 
harvested from all dead embryos and 6 live embryos. The bacterial numbers were then 
determined by serial dilution and compared to SH1000 (Figure 5.5). Growth of SH-
purA and SH-purB was arrested in zebrafish embryos and their numbers slowly 
declined over the 92 h experiment. This suggested that attenuation of the purA and purB 
mutant strains was the result of an inability to grow within zebrafish embryos.  
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Figure 5.5 Proliferation of SH-purA, SH-purB and SH1000 within zebrafish embryos. 
 
|       O L Y H   H P E U \ R V           G H D G   H P E U \ R V    2 Y H U   W K H   F R X U V H   R I   L Q I H F W L R Q   6 +-purA and SH-purB were unable to multiply and bacterial numbers slowly 
declined, no embryo death was seen. At each time point 6 live embryo and any dead embryos were collected and CFU per embryo determined.  
 
 
 
 
 
 
SH1000                                                       purA purB
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5.2.4.2 The effect of purines on SH-purA and SH-purB in vivo 
 
Based on assessment of the purine biosynthesis pathway (Figure 5.4) it was 
hypothesised that SH-purA might be complemented in vivo with adenine, whereas SH-
purB would require both adenine and guanine for in vivo complementation. Attempts 
were made to use adenine and guanine as they can be converted directly to AMP and 
GMP respectively (Houlberg & Jensen, 1983). In the zebrafish embryo model, upon 
injection with ~1,500 CFU bacteria, the embryos are incubated in E3 solution, pH7.4 
(for E3 preparation see Chapter 2.5.6). In the complementation experiments, the aim 
was to dissolve guanine and adenine in the E3 solution allowing diffusion of the purines 
into the embryos. However, stock guanine (Sigma-Aldrich) is dissolved in 5M HCl and 
when added to E3 it precipitated. As inosine is the branch-point in the purine 
biosynthesis pathway (Figure 5.4) leading to ATP or GTP synthesis and is soluble in 
water, it was decided that inosine would be used as an alternative to guanine in vivo. 
SH-purA and SH-purB remained highly attenuated in embryos incubated in E3 + 300 
µg ml
-1
 adenine (Figure 5.6). Addition of 400 µg ml
-1
 inosine and 300 µg ml
-1 
adenine 
to E3 solution did not restore the pathogenicity of SH-purB in vivo (Figure 5.7). 
 
The reason why adenine and inosine did not restore SH-purA and SH-purB virulence in 
vivo was uncertain. It was considered that adenine and inosine may not be what is 
required by SH-purA and SH-purB, or that adenine and inosine (or adenine alone as 
both strains were thought to require adenine for growth) could not diffuse into embryos, 
to allow their use by the bacteria. If the latter possibility was the case, then an 
alternative method for assessing the importance of purines to the purA and purB 
mutants was required. 
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Figure 5.6 Effect of adenine on SH-purA and SH-purB virulence.  
* Data points overlap. 
 
Abbreviation: A, adenine 300 µg ml
-1
. Addition of adenine to E3 solution did not 
restore virulence to SH-purA or SH-purB mutants, compared to SH1000, p < 0.0001. 
 
 
Figure 5.7 Effect of adenine and inosine on SH-purB virulence.  
* Data points overlap. 
 
Abbreviations: A, adenine 300 µg ml
-1
; I, inosine 400 µg ml
-1
. Addition of adenine and 
inosine to E3 solution did not restore virulence to SH-purB compared to SH1000, p < 
0.0001. 
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5.2.4.3 The effect of purines on JE2-purA and JE2-purB growth 
 
Chemically defined media (CDM) was used to determine the importance of adenine and 
guanine/inosine in restoring the ability of JE2-purA and JE2-purB to grow. Details on 
the preparation of CDM agar are given in Chapter 2.1.4. CDM contains adenine and 
guanine, allowing their removal to determine their importance to the purA and purB 
mutants. CDM agar was made with the following combinations of adenine (A) and 
guanine (G):  
 
1. +A & +G 
2.  –A &  –G 
3. +A &  –G 
4.  –A & +G 
 
Based on the purine biosynthesis pathway (Figure 5.4) JE2-purA should only be able to 
grow on purine combinations 1 and 3 (i.e. in the presence of adenine). For the growth of 
JE2-purB, combination 1 would be the only purine combination that would support 
growth in this experiment (i.e. both adenine and guanine would be required). Figure 5.8 
and Table 5.1 show that growth met expectations for both strains. JE2 was able to grow 
in all conditions tested. JE2-purB growth was comparable to JE2 on full CDM, but did 
not grow when adenine & guanine or either adenine or guanine was not added to CDM. 
JE2-purA growth was only seen in the presence of adenine. Aeration conditions did not 
affect the relative growth of the purA and purB mutants compared to JE2. 
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Figure 5.8 Role of adenine and guanine in the growth of JE2-purA and JE2-purB on 
solid media. 
 
JE2 can grow in the absence of purines. JE2-purA requires addition of adenine for growth, 
whereas JE2-purB requires both adenine and guanine. Varying oxygen availability does not 
alter the results. Plates were incubated at 37
o
C for 24 h. 
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Table 5.1 Growth analysis of JE2-purA and JE2-purB in the presence or absence of 
adenine and guanine. 
Strain 
Chemically Defined Media 
+Adenine 
+Guanine 
-Adenine 
-Guanine 
+Adenine 
-Guanine 
-Adenine 
+Guanine 
Aerobic Growth 
JE2 + + + + 
purB + - - - 
purA + - + - 
Microaerobic Growth 
JE2 + + + + 
purB + - - - 
purA + - + - 
Anaerobic Growth 
JE2 + + + + 
purB + - - - 
purA + - + - 
+ = Growth  
- = No Growth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
CDM was also used to confirm that inosine could be used as a valid alternative to 
guanine. As above, CDM agar was prepared with different combinations of adenine (A), 
guanine (G) and inosine (I): 
 
1. +I &  –A &  –G 
2. +I & +A &  –G 
3. +I &  –A & +G 
 
Neither the purA mutant nor the purB mutant should be complemented by combination 
1 or 3, as both require adenine. JE2-purA would be expected to grow on combination 2, 
as it only requires adenine. However, JE2-purB should only grow on combination 2, if 
inosine replaces the requirement for guanine. Figure 5.9 and Table 5.2 show the growth 
results for both strains. Both strains had comparable growth to JE2 on condition 2. This 
showed that inosine was able to replace the guanine requirement of JE2-purB. 
 
The results of the CDM experiments tallied with the known pathway information for S. 
aureus. Therefore, it was determined that to go any further with these strains would 
only lead to confirmation of what is already known about the importance of purine 
biosynthesis to bacterial growth and pathogenicity (Baxter-Gabbard & Pattee, 1970; 
McFarland & Stocker, 1987; Stocker, 1988). 
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Figure 5.9 Role of adenine, guanine and inosine in the growth of JE2-purA and 
JE2-purB on solid media. 
 
Inosine can be used to complement JE2-purB as an alternative to guanine. Inosine does 
not replace the requirement for adenine by both strains. Plates were incubated at 37
o
C 
for 48 h. 
 
Table 5.2 Growth analysis of JE2-purA and JE2-purB in the presence or absence of 
adenine and guanine, and in the presence of inosine. 
Strain 
Chemically Defined Media 
-Adenine 
-Guanine 
+Inosine 
+Adenine 
-Guanine 
+Inosine 
-Adenine 
+Guanine 
+Inosine 
Aerobic Growth 
JE2 + + + 
purB - + - 
purA - + - 
 
 
 
 
 
CDM Agar Minus Adenine & Guanine Unless Stated
+Adenine +Guanine
+Inosine +Inosine +Inosine
+Adenine +Guanine
+Inosine   +Inosine +Inosine
purA
JE2
purB
JE2
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5.2.5 Analysis of the role of pabA 
 
5.2.5.1 Growth assays of JE2-pabA 
 
Growth curves of JE2-pabA were carried out in order to confirm that growth of the 
pabA mutant on bovine serum (Sigma-Aldrich) was comparable to JE2, as seen in the 
initial screen of the NTML (Chapter 4). JE2-pabA growth was also assessed in human 
serum (Millipore) to determine if its growth remained comparable to JE2 using human 
serum as a nutrient source. See Chapter 2.8 for growth curve method. JE2-pabA showed 
comparable growth to JE2 in BHI, measured by OD600 and CFU, bovine serum and 
human serum, measured by CFU (Figure 5.10 A, B & C respectively).  
 
In the original screen, the NTML strain NE821 showed reduced growth on human blood 
and normal growth on bovine serum. When JE2-pabA was inoculated on rabbit blood 
agar (Chapter 4, Figure 4.17A2), sheep blood agar and horse blood agar (Chapter 4, 
Figure 4.18A & B, respectively), only a slight reduction in growth or comparable 
growth to JE2 was seen. This disparity between blood from different species suggested 
the possibility that bovine serum was either richer in nutrients than human blood or 
richer in a specific nutrient required by NE821. Figure 5.10C demonstrates that this is 
not the case, as JE2-pabA growth was comparable to JE2 in human serum. If greater 
nutrient availability in bovine serum was the cause of the disparity in growth between 
human blood and bovine serum, then it would be expected that human serum would not 
sustain growth of JE2-pabA to the same level as JE2.  
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Figure 5.10 Role of pabA in S. aureus growth.   
 
z     - (  -pabA        - (    
 
A In BHI JE2-pabA shows comparable growth to JE2 measured by OD600 or CFU.  
 
B JE2-pabA shows comparable growth to JE2 in bovine serum.  
 
C JE2-pabA shows slightly better growth than JE2 in human serum. Confirming that 
growth was not reduced in JE2-pabA in human serum. 
 
 
 
 
 
 
 
 
 
 
 
A
B C
BHI                                                                                       BHI
Bovine Serum                                                                       Human Serum
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5.2.5.2 Why does NE821 grow poorly on blood, but not on serum? 
 
It was hypothesised that nutrients are released from the cellular component of blood 
during preparation of serum, allowing JE2-pabA to grow on serum, but not human 
blood. Furthermore, this was thought to account for the comparable growth seen on 
animal blood, which was purchased from TCS Biosciences and may lyse in transit to the 
university releasing nutrients. The bovine serum and the human serum used in section 
5.2.5.1 were prepared off-clot. After clotting of blood, the clot, including the clumped 
red blood cells, was harvested after centrifugation and the serum supernatant was 
carefully removed. The hypothesis was that the clotting process leads to lysis of blood 
cells, liberating cell contents that can be used as a nutrient source by JE2-pabA allowing 
growth on human or bovine serum. Blood was collected at The Royal Hallamshire 
Hospital and off-clot serum was made and plasma was prepared by centrifugation to 
minimise cell disruption (see Chapter 2.1.3.1.2 and Chapter 2.1.3.1.3 for preparation of 
plasma and serum respectively).  
 
Using the serum and plasma prepared above, 50% (v/v) serum agar and 50% (v/v) 
plasma agar was made. 30% (v/v) human blood agar was also prepared, using blood 
from the same pooled blood donations. Growth of JE2-pabA was compared with JE2 on 
each medium in aerobic, microaerobic and anaerobic conditions. If nutrients leak from 
blood cells during serum preparation, then growth would be expected on human serum, 
but not on human plasma or human blood agar. Figure 5.11 shows that growth was seen 
on human serum and human plasma agar, but was highly reduced on human blood. This 
demonstrated that nutrients released from blood cells, during preparation of human 
serum, was not the cause of the growth disparity between JE2-pabA and JE2 when 
grown on human blood and human serum. The different aeration conditions did not alter 
the results. 
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Figure 5.11 Growth of JE2-pabA on different human blood components.  
 
 - (    L V   D W   W K H       R ¶ F O R F N   S R V L W L R Q   R Q all plates. JE2-pabA grows poorly on 30% (v/v) 
human blood agar relative to JE2. Growth of JE2-pabA on 50% (v/v) human plasma and 
50% (v/v) human serum is equivalent to JE2. Plates were incubated at 37
o
C for 24 h. 
 
 
 
 
Anaerobic Growth
Microaerobic Growth
Aerobic Growth
Serum  Plasma      Blood
Serum                                   Plasma      Blood
Serum  Plasma       Blood
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5.2.5.3 Serum concentration 
 
It was unclear whether the JE2-pabA phenotype was caused by the relatively low serum 
concentration in human blood agar. In a normally hydrated blood donor, ~50% (v/v) of 
blood consists of plasma, with the remaining 50% (v/v) consisting primarily of red 
blood cells (RBCs), therefore, JE2-pabA is growing on only 15% (v/v) plasma when 
grown on 30% (v/v) blood agar. If JE2-pabA requires a limiting nutrient found in 
human serum or plasma, then the strain is receiving less of this nutrient when grown on 
30% (v/v) blood agar, compared to when it is grown on 50% (v/v) serum or 50% (v/v) 
plasma agar. To determine whether this was the cause of the poor growth of this strain 
on 30% (v/v) human blood and comparable growth to JE2 on 50% (v/v) plasma, growth 
of JE2-pabA was compared with JE2 when grown on plasma agar increasing in 
concentration from 10% (v/v) to 50% (v/v) (Figure 5.12). At the lower concentrations of 
10% (v/v) and 15% (v/v) (15% being the approximate plasma concentration in 30% 
(v/v) blood agar) growth of JE2-pabA was poor, but comparable to JE2 which also 
displayed poor growth at this concentration. It was therefore concluded that the reduced 
growth on human blood was not a result of lower serum levels in human blood agar. 
 
5.2.6 Analysis of the pab operon 
 
Strain NE821 has a Tn inserted in the pabA gene, the first member of a 3 gene operon 
with pabB and pabC (Chapter 4, Figure 4.20D). These 3 genes catalyse two steps in the 
folate pathway, to produce 4-aminobenzoic acid (PABA; Figure 5.13). PABA is 
essential for the synthesis of tetrahydrofolate (THF), a cofactor in many cellular 
reactions (Figure 5.1). Without the pab operon, S. aureus growth is severely inhibited 
on human blood agar (Figure 5.11). 
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Figure 5.12 Growth of JE2-pabA on human plasma.  
 
JE2-pabA growth was comparable to that of JE2 at all plasma concentrations. Plates 
were incubated at 37
o
C for 48 h. 
 
 
 
 
 
 
 
 
JE2
JE2
JE2
pabA
pabA
pabA
10% (v/v)                                    15% (v/v)                                  20% (v/v)
Plasma                                        Plasma Plasma
40% (v/v)                                    45% (v/v)                                  50% (v/v)
Plasma                                        Plasma Plasma
25% (v/v)                                    30% (v/v)                                  35% (v/v)
Plasma                                        Plasma Plasma
 2
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Figure 5.13 Folate biosynthesis pathway.  
The pab operon encoded enzymes are shown in red; all other enzymes are shown in green. Pathway information was acquired from the Kegg and 
Biocyc websites. Molecule images were obtained from ChemSpider. 
Dihydrofolate
(DHF)
[NH3]
.
Glutamine
Glutamate
Chorismate
4-amino-4-
deoxychorismate
(ADC)
Pyruvate
4-aminobenzoic 
acid
(PABA)
7,8-
Dihydropterin 
pyrophosphate
Dihydropteroate
PabA, PabB PabB PabC
FolPFolC
FolA
Tetrahydrofolate
(THF)
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5.2.7 Preliminary analysis of the pab operon with the zebrafish embryo model of 
systemic infection 
5.2.7.1 Analysis of SH-pabB and SH-pabC pathogenicity 
 
To determine if the other members of the pab operon show reduced virulence in the 
zebrafish embryo model of systemic infection, the Tn inserts from NTML strains 
NE1063 and NE108 were transduced into S. aureus SH1000 to give SH-pabB and SH-
pabC respectively. Transductions were carried out as in Chapter 2.10.3 and confirmed 
by analysis of PCR products on 1% (w/v) electrophoresis gels (data not shown). Both 
SH-pabB and SH-pabC were attenuated in the zebrafish model (Figure 5.14). 
Interestingly NE1063 (the pabB mutant) was shown to have reduced growth on human 
blood in the NTML screen, but was not successfully transduced into both JE2 and 
SH1000 backgrounds. NE108 (the pabC mutant) was not isolated in the original screen, 
but a re-examination of the original screen plates showed that it did appear to have 
slightly reduced growth, but not as reduced as the pabA or pabB mutant. 
 
5.2.7.2 Growth of SH-pabA in vivo 
 
In vivo growth analysis was carried out to determine the growth of SH-pabA in 
zebrafish embryos over the course of infection. Experiments were carried out as in 
section 5.2.4.1 (full details in Chapter 2.23.6). SH-pabA can grow in zebrafish embryos 
resulting in embryo death (Figure 5.15). However, the frequency in which this occurs is 
reduced compared to SH1000.  
 
5.2.7.3 The effect of folic acid on SH-pabA 
 
The enzymes of the pab operon catalyse synthesis of PABA, a precursor in THF 
synthesis (Figure 5.13). As folic acid can be converted to THF, catalysed by the Fol 
enzymes of S. aureus (Bailey, 2009), it was used in the zebrafish model to attempt to 
complement the pabA mutant (Figure 5.16). Folic acid did not alter the virulence of 
SH1000, or restore virulence to the pabA mutant (Figure 5.16 A & B respectively). As 
with in vivo addition of purines (section 5.2.4.2), it was uncertain whether folic acid 
could not diffuse into the embryos, or if it could not be used by SH-pabA to 
complement the disruption of the pab operon. 
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Figure 5.14 Role of pabB and pabC in virulence. 
 
A. SH-pabB was attenuated in the zebrafish model, compared to SH1000, p < 0.0001. 
 
B. SH-pabC was attenuated in the zebrafish model, compared to SH1000, p < 0.01. 
 
 
 
 
 
 
 
 
A 
B 
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Figure 5.15 Proliferation of SH-pabA within zebrafish embryos. 
|      O L Y H  H P E U \ R V        G H D G  H P E U \ R V   
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Figure 5.16 Effect of 50 µM folic acid on SH-purB virulence.  
 
A. Survival of zebrafish embryos injected with ~1,500 CFU of SH1000 was not 
significantly altered by addition of 50 µM folic acid, p > 0.05.  
 
B. Survival of zebrafish embryos injected with ~1,500 CFU of SH-pabA was not 
significantly altered by addition of 50 µM folic acid, p > 0.05.  
 
 
SH1000 
pabA 
A 
B 
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5.2.7.4 The effect of inosine on SH-pabA in vivo 
 
Analysis of the purine de novo biosynthesis pathway showed that 10-formyl-THF is a 
cofactor in the conversion of AICAIR to FAICAIR by the purine pathway enzyme PurH 
(Figure 5.4). PurH activity occurs earlier in the pathway than the IMP branch point 
leading to GTP and ATP production. Therefore, it was hypothesised that incubation of 
zebrafish embryos injected with ~1,500 CFU of SH-pabA in E3 solution plus inosine 
may restore pathogenicity (Figure 5.17). Analysis of the purA and purB mutants 
demonstrated that adenine could not complement in the zebrafish embryo model, but it 
was still a possibility that inosine could diffuse into the embryos and be used by the 
bacteria. However, addition of inosine did not restore virulence to SH-pabA (Figure 
5.17). Again it was uncertain whether inosine did not diffuse into the embryos or 
whether it was unable to phenotypically complement the pabA mutation. 
 
5.2.8 Analysis of pabA on CDM agar 
 
Although it was not possible to complement the purA and purB mutants in vivo with 
purines, the CDM and screen results (Figure 5.8 and Chapter 4, Table 4.5, respectively) 
for these two strains suggested that purines are not freely available in zebrafish embryos 
and on human blood agar. Disruption of pabA blocks synthesis of THF, which has a role 
in the conversion of AICAIR to FAICAIR in the de novo purine biosynthesis pathway. 
Therefore, it was hypothesised that the lack of available purines in blood and zebrafish 
embryos explains the poor growth of the pabA mutant on blood and attenuation in the 
zebrafish model. However, this does not explain why JE2-pabA grows on human serum 
or plasma. It was hypothesised that the bioavailability of purines may be increased in 
serum and plasma and would be investigated further if purines were found to be a 
requirement for growth on CDM and complemented JE2-pabA growth on human blood. 
 
5.2.8.1 Growth of JE2-pabA on CDM agar 
 
The synthesis of deoxythymidine monophosphate (dTMP) requires either exogenous 
thymidine or the THF-dependent conversion of dUMP to dTMP (Figure 5.1C). As 
CDM does not contain pyrimidines, it was necessary to confirm that CDM is a viable 
means of assessing growth requirements of JE2-pabA, by determining whether the
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Figure 5.17 Effect of inosine on SH-pabA virulence.  
 
A1. Embryos incubated in E3 soln. were injected with ~1,500 CFU of SH-pabA or 
SH1000. SH-pabA was attenuated compared to SH1000, p < 0.0001. A2. Embryos 
incubated in E3 soln. plus 300 µg ml
-1
 inosine were infected with ~1,500 CFU SH-pabA 
or SH1000. SH-pabA remained attenuated compared to SH1000, p = 0.0001.  
 
B1. Embryos incubated in E3 soln. were infected with ~1,500 CFU of SH-pabA or 
SH1000. SH-pabA was attenuated compared to SH1000, p < 0.0001. B2. Embryos 
incubated in E3 soln. plus 1 mg ml
-1
 inosine were infected with ~1,500 CFU SH-pabA 
or SH1000. SH-pabA remained attenuated compared to SH1000, p = 0.0002. 
 
 
 
 
 
 
 
 
A1 A2
B1 B2
E3 soln. Inosine 300 µg ml-1
E3 soln. Inosine 1 mg ml-1
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strain has equivalent growth to JE2 on CDM. Growth of JE2-pabA was comparable to 
JE2 on CDM agar (Figure 5.18). Addition of folic acid to the agar did not enhance 
growth of either JE2-pabA or JE2. CDM agar was incubated in aerobic, microaerobic 
and anaerobic conditions, to determine the role of oxygenation conditions in the JE2-
pabA growth phenotype. 
 
5.2.8.2 Role of purine availability in growth of JE2-pabA 
 
Growth of JE2-pabA and JE2 were compared on CDM agar with or without adenine and 
guanine (Figure 5.19). If low purine availability in the zebrafish embryo model and on 
human blood agar was the cause of the JE2-pabA phenotype, it was expected that lack 
of purines in CDM would mimic this. However, growth of JE2-pabA in the absence of 
purines, or an individual purine, was comparable to JE2. 
 
THF has a role in the synthesis of dTMP, methionine, vitamin B5, purines and the 
interconversion of serine/glycine (Figure 5.1). The absence of nucleobases was shown 
to have no impact on JE2-pabA growth relative to JE2 (Figure 5.19). Therefore, it was 
hypothesised that if the pabA mutant phenotype is the result of a nutritional deficiency 
then assessment of the role of glycine, serine, vitamin B5 and methionine on CDM 
should highlight this. As 5,10-methylene-THF is produced by conversion of serine to 
glycine (Figure 5.1A) and is required directly for pantothenate synthesis (Figure 5.1B) 
and indirectly for methionine biosynthesis (Figure 5.1D & E) it was hypothesised that 
serine/glycine interconversion would be the most active of the THF-dependent 
reactions. Therefore, the role of glycine and serine was assessed first on CDM agar. 
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Figure 5.18 Growth of JE2-pabA on CDM agar.  
 
Growth of JE2-pabA after 48 h incubation at 37
o
C was equivalent to JE2 in all 
conditions. Addition of folic acid did not enhance the growth of either strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDM Agar
Aerobic                             Microaerobic Anaerobic
CDM Agar + 50 µM Folic Acid
Aerobic                             Microaerobic Anaerobic
pabA
JE2
pabA
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Figure 5.19 Role of purines in the growth of JE2-pabA and JE2. 
 
Presence of purines in CDM did not alter the growth of JE2-pabA. Plates were incubated at 37
o
C for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
Anaerobic
+Guanine -Guanine -Guanine +Guanine
+Adenine                                -Adenine                         +Adenine               -Adenine
pabA
JE2
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5.2.8.3 The effect of glycine, serine & folic acid on JE2-pabA growth 
 
JE2-pabA growth was compared to JE2 on CDM plus or minus glycine and serine. 
CDM was prepared without purines, as it was shown in section 5.2.8.2 that purines are 
not essential for comparable growth of JE2-pabA to JE2. Folic acid was used to 
determine if it could complement the pabA mutant in vitro. Results are shown in Figure 
5.20 and Table 5.3. In the absence of serine, growth of JE2 was not affected, but growth 
of JE2-pabA was poor, suggesting that serine is important to the pabA mutant. In the 
absence of glycine, JE2 growth was poor, but JE2-pabA growth was very poor. This 
suggests that glycine is important for both strains. In the absence of serine and glycine 
both JE2 and the pabA mutant showed very poor growth with no apparent difference 
between them. However, in the presence of glycine, serine and folic acid growth of the 
pabA mutant appeared to be slightly reduced compared to JE2. Addition of folic acid 
did not restore JE2-pabA growth to that of JE2. 
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Figure 5.20 Role of glycine, serine, folic acid and purines (AG) in the growth of JE2-pabA and JE2. 
x indicates absence of supplement;  9  indicates presence of supplement, corresponding to the supplement key 
Plates were incubated at 37
o
C for 48 h. 
* AG = adenine & guanine, Ser = serine, Gly = glycine, FA = folic acid.
CDM agar in the presence or absence of nutrient supplements
Supplement Key*
AG x x x x x
Ser x x  9  9  9
Gly  9  9  9 x x
FA x  9  9 x  9
Supplement Key*
AG x x  9  9
Ser x x x x
Gly x x x x
FA x  9 x  9
JE2
pabA
Key
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Table 5.3 Analysis of the role of glycine, serine, folic acid and purines (AG) in the growth of JE2-pabA and JE2. 
Strain 
Key Nutrient supplements 
Adenine & 
Guanine 
x x x x x x x  9   9  
Serine x x  9   9   9  x x x x 
Glycine  9   9   9  x x x x x x 
Folic Acid x  9   9  x  9  x  9  x  9  
JE2  ++++ ++++ ++++ ++ ++ + + + + 
pabA  ++ ++ +++ + + + + + + 
+ Very poor growth 
++ Poor growth 
+++ Slightly reduced growth 
++++ Normal growth 
 9  indicates addition of supplement, corresponding to the key 
x indicates absence of supplement, corresponding to the key 
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5.2.8.4 The effect of 4-aminobenzoic acid (PABA) on growth of JE2-pabA 
 
Folic acid did not restore the growth of JE2-pabA to the level of JE2 in the absence of 
serine/glycine. Therefore, folic acid does not complement in vitro and could not be used 
as a positive control for complementation in further experiments. Hamilton-Miller, 
(1988) reported that folic acid, folinic acid, THF and DHF did not inhibit trimethoprim 
activity in S. aureus, whereas folinic acid, THF and DHF, but not folic acid, did inhibit 
trimethoprim activity in enterococci. Trimethoprim is an antifolate antibiotic that 
inhibits the DHFR enzyme (FolA in Figure 5.13) in THF synthesis downstream of 
PABA synthesis (Proctor, 2008). It has been reported that E. coli and Salmonella sp. are 
unable to transport folates into the cytoplasm, which is common to strains that can 
synthesise THF (Neidhardt et al., 1996; Tran & Nichols, 1991). However, 4-
aminobenzoate (PABA) has been used to complement a pabA mutant strain of E. coli, at 
5 ng ml
-1
 (Tran & Nichols, 1991). PABA concentrations up to 200 µg ml
-1
 have been 
used to determine the efficacy of folate inhibitors in S. aureus USA300 (Phetsang et al., 
2013). Therefore 50 µg ml
-1
 PABA was used as an alternative to folic acid in the 
complementation of JE2-pabA (Figure 5.21; Table 5.4). 
 
In the absence of serine and glycine, PABA slightly improves the growth of both JE2-
pabA and the parent. Addition of serine did not alter the very poor growth of both 
strains. The presence of glycine in the absence of serine restored JE2 growth, but JE2-
pabA growth was slightly reduced compared to JE2. This reduction in growth was 
complemented by PABA or serine. This suggested that PABA can be used to 
complement the pabA mutation. Serine does have a role, as the growth of JE2-pabA was 
slightly reduced in its absence and restored to JE2 levels when serine was added. The 
importance of glycine to both strains was clear, as both strains grew very poorly in its 
absence. Whether glycine has an increased importance to the pabA mutant relative to 
JE2 was not resolved in this experiment. The slight reduction in growth of the pabA 
mutant in CDM containing all components barring purines (Figure 5.20) was not seen in 
this experiment. 
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Figure 5.21 Role of glycine, serine, PABA and purines (AG) in the growth of JE2-
pabA and JE2. 
 
x indicates absence of supplement;  9  indicates presence of supplement, corresponding 
to the supplement key 
Plates were incubated at 37
o
C for 48 h. 
 
* AG = adenine & guanine, Ser = serine, Gly = glycine. 
CDM Agar Minus Purines Unless Stated
Supplement key*
AG x x x x
Ser x x  9  9
Gly x x x x
PABA x  9 x  9
Supplement key*
AG x x x x
Ser x x  9  9
Gly  9  9  9  9
PABA x  9 x  9
Supplement key*
AG  9  9
Ser x x
Gly x x
PABA x  9 Key
JE2
pabA
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Table 5.4 Analysis of the role of glycine, serine, PABA and purines (AG) in the growth of JE2-pabA and JE2. 
Strain 
Key Nutrient supplements 
Adenine & 
Guanine 
x x x x x x x x  9   9  
Serine x x  9   9  x x  9   9  x x 
Glycine x x x x  9   9   9   9  x x 
PABA x  9  x  9  x  9  x  9  x  9  
JE2  + ~+ + + ++++ ++++ ++++ ++++ + + 
pabA  + ~+ + + +++ ++++ ++++ ++++ + + 
+ Very poor growth 
~+ Very poor, but slightly better than previous condition 
++ Poor growth 
+++ Slightly reduced growth 
++++ Normal growth 
 9  indicates addition of supplement, corresponding to the key 
x indicates absence of supplement, corresponding to the key 
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5.2.8.5 Role of PABA, serine and glycine in SH-pabA pathogenicity 
 
CDM concentrations of glycine, serine and 7 µg ml
-1
 PABA were assessed in the 
zebrafish embryo model of systemic infection using SH-pabA. A lower concentration of 
PABA was used for the embryo model to minimise the influence of ethanol (used as the 
PABA diluent), as the CDM PABA concentration (50 µg ml
-1
) was found to be toxic to 
the embryos (data not shown).  When infected embryos were incubated in E3 solution 
SH-pabA remained attenuated (Figure 5.22A). Addition of CDM concentrations of 
glycine, serine and 7 µg ml
-1
 PABA restored the virulence of the pabA mutant (Figure 
5.22B).  
 
5.2.8.6 The role of glycine and serine in the growth of JE2-pabA 
 
To determine the relative importance of glycine and serine to the growth of JE2-pabA, 
different concentrations of these two amino acids were added to CDM. A hypothesis 
was developed based on serine/glycine interconversion shown in Figure 5.1A, shown 
diagrammatically in Figure 5.23. Glycine can be produced from threonine by threonine 
aldolase, however, the primary endogenous source of glycine is via THF-dependent 
serine conversion by the enzyme GlyA (Aller et al., 2015; Liu et al., 2015). As glycine 
is an important component of S. aureus peptidoglycan (Maidhof et al., 1991; Zhou & 
Cegelski, 2012), is required for biosynthesis of purines (Cheng et al., 1990) and is 
required as an amino acid in proteins, cutting off the primary source of endogenous 
glycine creates a need for exogenous glycine. The requirement for serine is less certain, 
as serine can be synthesised by JE2-pabA. This synthesis is subject to end product 
inhibition of the enzyme D-3-phosphoglycerate dehydrogenase (Ponce-de-Leon & 
Pizer, 1972). The hypothesis was that in JE2, conversion from serine provides a pool of 
glycine. Serine is important for the synthesis of other amino acids (Denk & Böck, 1987; 
Lane & Kirschner, 1983), the synthesis of phosphatidylserine and sphingolipids 
(Inuzuka et al., 2005) and for its role as an amino acid in proteins. Therefore, if the 
bacteria have to respond to a sudden need for lipids or certain amino acids, then glycine 
from the hypothetical glycine pool (shown in red in Figure 5.23) can be quickly 
converted to serine by GlyA and THF, bypassing the end product inhibition that slows 
the biosynthesis of serine. If the hypothesis was correct, then JE2-pabA would not have
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Figure 5.22 Effect of glycine, serine and PABA on SH-pabA virulence.  
 
A. SH-pabA pathogenesis was attenuated compared to SH1000 in embryos incubated in 
E3 solution, p < 0.0001.  
 
B. Pathogenesis was restored to SH-pabA in embryos incubates in E3 solution +1x 
CDM concentrations of glycine and serine and 7 µg ml
-1
 PABA compared to SH-pabA 
incubated in E3 solution p < 0.0001.  
 
 
 
E3 Solution 
E3 solution +Gly, +Ser (1x CDM), +PABA 7 µg ml
-1
 
A 
B 
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Figure 5.23 Diagrammatic representation of serine/glycine interconversion.  
 
Hypothetical aspects of the diagram are shown in red.  
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access to this serine/glycine pool and may require an excess of one over the other in 
order to respond to the changing needs of the bacteria during growth. 
 
Figure 5.24 and Table 5.5 show that excess serine in the absence of glycine resulted in 
poor growth of both strains. When glycine was added, JE2 growth was restored and 
JE2-pabA growth was only partially restored. In the presence of excess glycine, in the 
presence or absence of serine JE2 growth was completely restored, but growth of JE2-
pabA was poor. This suggested that addition of excess glycine had a negative impact on 
the pabA mutant. Where differences in growth could be resolved, PABA restored the 
growth of JE2-pabA to that of JE2. 
 
High concentrations of glycine have been associated with cell wall damage, lysis and 
accumulation of cell wall synthesis intermediates including nucleotides involved in cell 
wall synthesis in S. aureus (Parisi & Suling, 1968; Strominger & Birge, 1965). Bacteria 
avoid the toxic effects of glycine using the glycine cleavage system, which degrades 
glycine to CO2, NH4
+
 and a methylene group (Tezuka & Ohnishi, 2014). As THF is 
required for this process (Figure 5.1I), it is likely that the pabA mutant would be more 
susceptible to the effects of high glycine concentration than the wild-type. Furthermore, 
in the absence of serine/glycine interconversion, toxic levels of glycine cannot be 
converted to serine. As blood glycine levels have been shown to be 5x less than the 
standard CDM glycine concentration (shown to be non-toxic to S. aureus; De Vries et 
al., 1948), glycine toxicity on human blood agar was ruled out as a potential cause of 
the JE2-pabA phenotype. Based on these results the hypothesis shown in Figure 5.23 
was reasoned to be invalid, as low glycine concentrations need to be maintained to 
avoid glycine toxicity. 
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Figure 5.24 Role of 10x CDM concentration of glycine or serine, and 1x CDM 
concentration of glycine and serine in the growth of JE2-pabA and JE2. 
 
x indicates absence of supplement;  9  indicates presence of supplement, corresponding 
to the supplement key 
Plates were incubated at 37
o
C for 48 h. 
 
* 10x Ser = 1 mg ml
-1
 serine, 10x Gly = 1 mg ml
-1
 glycine, 1x Ser = 100 µg ml
-1
 Ser, 1x 
Gly = 100 µg ml
-1
 glycine. 
 
CDM agar in the presence or absence of nutrient supplements
Supplement key*
10x Ser  9  9  9  9
10x Gly x x x x
1x Ser x x x x
1x Gly x x  9  9
PABA x  9 x  9
pabA
JE2
pabA
JE2
Supplement key*
10x Ser x x x x
10x Gly  9  9  9  9
1x Ser x x  9  9
1x Gly x x x x
PABA x  9 x  9
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Table 5.5 Analysis of the role of 10x CDM concentration of glycine or serine, and 1x CDM concentration of glycine and serine in the growth 
of JE2-pabA and JE2. 
Strain 
Key* Nutrient supplements 
10x Ser  9   9   9   9  x x x x 
10x Gly x x x x  9   9   9   9  
1x Ser x x x x x x  9   9  
1x Gly x x  9   9  x x x x 
PABA x  9  x  9  x  9  x  9  
JE2  + + ++++ ++++ ++++ ++++ ++++ ++++ 
pabA  + + +++ ++++ ++ ++++ ++ ++++ 
+ Very poor growth 
++ Poor growth 
+++ Slightly reduced growth 
++++ Normal growth 
 9  indicates addition of supplement, corresponding to the key 
x indicates absence of supplement, corresponding to the key 
 
* 10x Ser = 1 mg ml
-1
 serine, 10x Gly = 1 mg ml
-1
 glycine, 1x Ser = 100 µg ml
-1
 Ser, 1x Gly = 100 µg ml
-1
 glycine. 
 
 
 
 
257 
 
5.2.8.7 Role of GlyA in virulence 
 
Serine/glycine interconversion is catalysed by the enzyme GlyA. To determine the 
importance of serine/glycine interconversion the transposon insertion from the NTML 
glyA mutant strain NE213 was transduced into SH1000 to give SH-glyA. Transduction 
was confirmed by PCR and analysis of PCR products on 1% (w/v) electrophoresis gel 
(data not shown). For transduction, PCR and electrophoresis methods see Chapter 
2.10.3, Chapter 2.12.1.2 and Chapter 2.12.5, respectively. SH-glyA was then assessed in 
vivo using the zebrafish embryo model of systemic infection (Figure 5.25). Disruption 
of glyA did not result in loss of virulence. This suggested that loss of serine/glycine 
interconversion due to loss of THF is not responsible for the JE2-pabA or the SH-pabA 
virulence phenotype in the zebrafish model. It was hypothesised that loss of 
serine/glycine interconversion may still relate to the JE2-pabA and SH-pabA phenotype, 
but the full effect (i.e. loss of virulence and poor growth on blood) may be due to the 
cumulative effect of the loss of all reactions requiring THF. 
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Figure 5.25 Role of glyA in S. aureus pathogenesis in the zebrafish embryo model.   
 
SH-glyA was not attenuated in the zebrafish embryo model compared to SH1000, p > 
0.05. 
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5.2.8.8 The role of serine, glycine, methionine & VitB5 on growth of JE2-pabA 
 
Table 5.1 shows that THF is involved in synthesis of methionine, VitB5 and 
glycine/serine interconversion. It was hypothesised that the JE2-pabA phenotype was 
the result of growth defects caused by the cumulative effect of the loss of these 
functions. The importance of serine, glycine, VitB5 and methionine to JE2-pabA growth 
was assessed in CDM (Figure 5.26; Table 5.6). In the absence of methionine growth of 
JE2 and the pabA mutant was very poor, therefore, no conclusion was drawn on the 
importance of methionine to JE2-pabA. The growth of JE2-pabA in the absence of 
VitB5 or glycine was slightly reduced relative to JE2. However, growth of JE2-pabA 
when all components were added to CDM was also slightly reduced relative to JE2. 
Only serine showed a clear effect when removed from CDM, resulting in JE2-pabA 
growing poorly in comparison to the growth of JE2.  
 
This suggested two things: firstly VitB5 and glycine may not be required by JE2-pabA 
for comparable growth to JE2, as their removal from CDM did not affect the relative 
growth of JE2-pabA to JE2 when compared to the addition of glycine and VitB5. 
Secondly that something not present in CDM is required by JE2-pabA as it shows 
slightly reduced growth in the presence of all CDM components, barring purines. 
Purines were found to not be required for comparable growth of JE2-pabA to JE2 
(Figure 5.19), therefore, they were not added to CDM. The lack of purines in the CDM 
may be responsible for the reduced growth of JE2-pabA in the CDM used for this 
experiment. Alternatively, THF has a role in conversion of dUMP to dTTP, via dTMP 
(Figure 5.1C). CDM does not contain any pyrimidines, which suggested that this may 
be the cause of the reduced growth of JE2-pabA compared to JE2 in CDM. 
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Figure 5.26 Role of glycine, serine, vitamin B5 and methionine in the growth of 
JE2-pabA and JE2. 
 
x indicates absence of supplement;  9  indicates presence of supplement, corresponding 
to the supplement key. 
Plates were incubated at 37
o
C for 48 h. 
 
* VitB5 = 400 ng ml
-1
 vitamin B5, 5x Met = 500 µg ml
-1
 methionine, 5x Ser = 500 µg 
ml
-1
 serine, 5x Gly = 500 µg ml
-1
 glycine, 1x Met = 100 µg ml
-1
 methionine. 
CDM agar in the presence or absence of nutrient supplements
Supplement key*
VitB5 x x  9  9
5x Met  9  9 x x
5x Ser  9  9  9  9
5x Gly  9  9  9  9
1x Met x x  9  9
PABA x  9 x  9
JE2
pabA
Supplement key*
VitB5  9  9  9  9
5x Met x x  9  9
5x Ser  9  9 x x
5x Gly  9  9  9  9
1x Met x x x x
PABA x  9 x  9
Supplement key*
VitB5  9  9
5x Met  9  9
5x Ser  9  9
5x Gly x x
1x Met x x
PABA x  9 Key
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Table 5.6 Analysis of the role of glycine, serine, vitamin B5 and methionine in the growth of JE2-pabA and JE2.  
Strain 
Key* Nutrient supplements 
VitB5 x x  9   9   9   9   9   9   9   9  
5x Met 
 9   9  x x x x  9   9   9   9  
5x Ser 
 9   9   9   9   9   9  x x  9   9  
5x Gly 
 9   9   9   9   9   9   9   9  x x 
1x Met x x 
 9   9  x x x x x x 
PABA x 
 9  x  9  x  9  x  9  x  9  
JE2  ++++ ++++ ++++ ++++ + + ++++ +++ +++ +++ 
pabA  +++ ++++ +++ ++++ + + ++ +++ ++ +++ 
+ Very poor growth 
++ Poor growth 
+++ Slightly reduced growth 
++++ Normal growth 
 9  indicates addition of supplement, corresponding to the key 
x indicates absence of supplement, corresponding to the key 
 
* VitB 5 = 400 ng ml-1 vitamin B5, 5x Met = 500 µ g ml-1 methionine, 5x Ser = 500 µ g ml-1 serine, 5x Gly = 500 µ g ml-1 glycine, 1x Met = 100 µ g 
ml-1 methionine. 
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5.2.8.9 The effect of methionine & thymine on JE2-pabA growth 
 
S. aureus uses THF as a cofactor in the synthesis of the pyrimidine biosynthesis 
pathway intermediate deoxythymidine monophosphate (dTMP; Figure 5.1C) and in the 
synthesis of the amino acid methionine (Figure 5.1E). As CDM does not contain 
pyrimidines and the role of methionine in the JE2-pabA phenotype was not resolved in 
the previous experiment (Figure 5.26), their impact on JE2-pabA growth was 
investigated in CDM. To assess the effect of methionine on JE2-pabA growth, low 
levels of methionine were added to determine if JE2-pabA had a greater methionine 
requirement than JE2 (i.e. to determine if growth of JE2 was restored at a lower 
concentration to the pabA mutant). The nucleobase thymine was also used to determine 
if it could restore growth of JE2-pabA to that of JE2 (i.e. to see if the absence of 
pyrimidines was the missing factor in CDM). Figure 5.27 and Table 5.7 show that the 
requirement for methionine of both strains was equivalent. Furthermore, in the presence 
of thymine growth of JE2-pabA remained slightly reduced compared to JE2. 
 
5.2.8.10 Role of serine, glycine, methionine & VitB5 in SH-pabA pathogenicity 
 
The role of serine, glycine, methionine and VitB5 in the pathogenicity of SH-pabA was 
assessed using the zebrafish embryo model of systemic infection. Embryos were 
injected with ~1,500 CFU of SH1000 or SH-pabA and incubated in E3 solution 
+glycine, serine, methionine and VitB5. Infected embryos incubated in E3 +PABA and 
E3 only were used as positive and negative controls, respectively. Experiments were 
repeated using 100 µg ml
-1
, 1 mg ml
-1
 or 2 mg ml
-1
 of the amino acids, and 290 ng ml
-1
, 
2.9 µg ml
-1
 or 5.8 µg ml
-1
 VitB5 (equivalent to 1x, 10x and 20x CDM concentrations; 
Figure 5.28), as higher levels may be required for complementation in the zebrafish 
model. SH-pabA was attenuated when embryos were incubated in E3. Addition of 
PABA to E3 restored virulence to SH-pabA. Addition of glycine, serine, methionine and 
VitB5 to E3, at all concentrations tested, did not restore virulence to SH-pabA. It 
remains uncertain as to whether glycine, serine, methionine and VitB5 have a role in 
SH-pabA pathogenicity, as the bacteria may not have access to the nutrients from within 
the embryos. The experiments did confirm that PABA can restore virulence of SH-pabA 
in vivo. 
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Figure 5.27 Role of methionine and thymine in the growth of JE2-pabA and JE2. 
 
x indicates absence of supplement;  9  indicates presence of supplement, corresponding 
to the supplement key. 
Plates were incubated at 37
o
C for 48 h. 
 
* 0.1x Met = 10 µg ml
-1
 methionine, 0.5x Met = 50 µg ml
-1
 methionine, Thymine = 40 
µg ml
-1
 thymine. 
 
 
 
 
 
 
 
 
 
 
 
 
CDM agar in the presence or absence of nutrient supplements
Supplement key*
0.1x Met  9  9 x
0.5x Met x x  9
Thymine x x x
PABA x  9 x
pabA
JE2
pabA
JE2
Supplement key*
0.1x Met x x x
0.5x Met  9 x x
Thymine x  9  9
PABA  9 x  9
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Table 5.7 Analysis of the role of methionine and thymine in the growth of JE2-pabA and JE2. 
Strain 
Key* Nutrient supplements 
0.1x Met  9   9  x x x x 
0.5x Met x x  9   9  x x 
Thymine x x x x  9   9  
PABA x  9  x  9  x  9  
JE2  + ++ ++ ++ ++++ ++++ 
pabA  + ++ ++ ++ +++ ++++ 
+ Very poor growth 
++ Poor growth 
+++ Slightly reduced growth 
++++ Normal growth 
 9  indicates addition of supplement, corresponding to the key 
x indicates absence of supplement, corresponding to the key 
 
* 0.1x Met = 10 µg ml
-1
 methionine, 0.5x Met = 50 µg ml
-1
 methionine, Thymine = 40 µg ml
-1
 thymine. 
 
 
 
 
 
 
 
 
 
 
 2
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A
B
C
E3 soln.                                                                                    E3 +PABA 7 µg ml -1 E3 +G,S,M 100 µg ml-1 & vitB5 290 ng ml
-1
E3 soln.                                                                                    E3 +PABA 7 µg ml -1 E3 +G,S,M 1 mg ml-1 & vitB5 2.9 µg ml
-1
E3 soln.                                                                                    E3 +PABA 7 µg ml -1 E3 +G,S,M 2 mg ml-1 & vitB5 5.8 µg ml
-1
 2
6
6
 
 
 
 
 
 
 
Figure 5.28 Effect of addition of glycine, serine, methionine and vitamin B5 on SH-pabA virulence.  
 
Survival of zebrafish embryos was assessed upon injection of embryos with 1,500 CFU SH-pabA or SH1000 and incubation in E3 soln. plus 100 µg 
ml
-1
, 1 mg ml
-1
 or 2 mg ml
-1
 of the amino acids, and 290 ng ml
-1
, 2.9 µg ml
-1
 or 5.8 µg ml
-1
 VitB5 (A, B and C, respectively). Incubation in E3 soln. 
and incubation in E3 soln. plus 7 µg ml
-1
 PABA were used as negative and positive controls respectively. Incubation in the presence of glycine, 
serine, methionine and VitB5 did not restore SH-pabA virulence compared to the SH1000 control, p < 0.0001. 
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5.2.8.11 PABA complementation is associated with the pab operon 
 
It is possible that addition of PABA improves the growth of SH-pabA in a way that is 
unrelated to the pab operon, allowing enough growth within embryos to restore killing. 
To confirm that the effect of PABA was associated with the pab operon, attempts were 
made to complement S. aureus  1 H Z + *ß pheP ßsaeR, which is highly attenuated in the 
zebrafish embryo model of systemic infection (Figure 5.29). This strain remained highly 
attenuated in the presence of PABA. 
 
5.2.9 Liquid CDM growth analysis of pabA 
 
Analysis of the relative growth of JE2-pabA on CDM agar is subjective and subtle 
differences in growth are difficult to resolve. This difficulty was thought to explain 
slight variation in previous experiments, in which growth between JE2 and the pabA 
mutant is comparable on CDM with or without purines (Figure 5.19), or the pabA 
mutant shows slightly reduced growth compared with JE2 in CDM without purines 
(Figure 5.26). The results on CDM agar highlighted the possibility that the phenotype 
(particularly the phenotype on human blood) is not related to a nutrient deficiency on 
blood, but rather an inhibitory effect, as the differences seen between JE2-pabA and JE2 
on CDM were slight, relative to the growth differences between the two strains on 
blood. However, phenotypic complementation by cross-feeding, caused by PABA 
diffusion, has been shown between pab
+ 
and pab
- 
strains on agar (Huang & Pittard, 
1967), allowing the growth of pabA and pabB mutants of E. coli on minimal media 
agar. This effect may well have diminished any growth difference between strains on 
CDM agar. It was thought essential to first confirm or deny that a nutrient deficiency 
was the cause of the JE2-pabA phenotype. 
 
A series of experiments were designed to determine if the results of the CDM agar 
analysis of the JE2-pabA phenotype remained the same in liquid CDM culture. All 
combinations of glycine, serine and VitB5 were to be assessed in the presence of 
adenine and guanine (Table 5.8), after confirmation that purines are required for 
comparable growth of JE2-pabA to JE2. 
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 ) L J X U H       ( I I H F W  R I  D G G L W L R Q  R I  3 $ % $  R Q  1 H Z + *ß phePßsaeR pathogenesis.  
* Data points overlap. 
 
A. S. aureus  1 H Z + *ß phePßsaeR is highly attenuated.  
 
B. Addition of PABA does not complement S. aureus  1 H Z + *ß phePßsaeR and it 
remains highly attenuated. 
 
 
 
 
E3 Solution 
E3 solution +PABA 7 µg ml -1 
A 
B 
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Table 5.8 Experimental plan for the liquid CDM analysis of glycine, serine and VitB5.  
 
Chemically Defined Media Plus Adenine & Guanine 
Expt. 1 Expt. 2 Expt. 3 Expt. 4 Expt. 5 Expt. 6 Expt. 7 Expt. 8 
VitB5 x  9  x x  9   9  x  9  
Serine x x 
 9  x  9  x  9   9  
Glycine x x x 
 9  x  9   9   9  
 9  indicates addition  
x indicates absence  
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5.2.9.1 Are purines required for full growth of JE2-pabA in CDM? 
 
To determine if purines were the missing components of CDM required by JE2-pabA 
for comparable growth to JE2, growth curves were carried out in CDM minus purines, 
CDM (i.e. with guanine and adenine added) and CDM plus inosine (Figure 5.30). For 
growth curve method and liquid CDM preparation see Chapter 2.8 and 2.1.4, 
respectively. In CDM minus purines the growth rate and maximum optical density at 
600nm (OD600) of JE2-pabA was reduced compared to JE2. Addition of purines restored 
the growth of JE2-pabA to that of JE2. 
 
5.2.9.2 Liquid CDM growth experiments 
 
To analyse growth of JE2-pabA in CDM with all combinations of purines, glycine, 
serine and VitB5, would require growth in 15 different conditions for both strains, with 
and without PABA in triplicate. Therefore, it was decided to carry out a series of 
individual growth experiments to determine the role of glycine, serine and VitB5 in 
CDM plus purines. The experiments would indicate whether glycine, serine or VitB5 
would complement the JE2-pabA phenotype. The analysis shows that serine and glycine 
are a requirement of JE2-pabA for comparable growth to JE2 and that VitB5 has a 
negative impact on JE2-pabA growth (Figure 5.31). The full growth curve method is 
given in section 2.8.  
 
Growth in CDM without glycine, serine and VitB5 resulted in a 10 h lag phase for both 
strains (Figure 5.31A). The growth rate of JE2-pabA was reduced, but both strains 
reached a similar maximum OD600 of 3. Addition of VitB5 did not reduce the 10 h lag 
phase and the growth rate of JE2-pabA remained less than that of JE2. Furthermore, the 
pabA mutant reached an OD600 of 1.76, whereas the maximum OD600 of JE2 was 3 
(Figure 5.31B). This suggested that VitB5 may be inhibitory to JE2-pabA growth rather 
than a requirement. Addition of glycine was beneficial to the growth of both strains; 
reducing the lag phase to 3-5 h and increasing their growth rate (Figure 5.31C). 
Furthermore, although the growth rate of JE2-pabA was still reduced in comparison to 
JE2, the time required for the pabA mutant to reach the same max OD600 of 4 was 
reduced when grown in the presence of glycine. This suggested that glycine may be a 
requirement for comparable growth of JE2-pabA to JE2. Addition of serine and VitB5 
restored the growth of JE2-pabA to a comparable level of growth to JE2 (Figure 5.31D). 
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Figure 5.30 Importance of purines to JE2-pabA growth.  
 
      - (   v     - (  -pabA  z     - (    3 $ % $  x     - (  -pabA+PABA.  
Purines are required by JE2-pabA to restore comparable growth to JE2. 
CDM  –Adenine & -Guanine A 
CDM +Adenine 20 µg ml 
-1
 & +Guanine 20 µg ml 
-1
 B 
CDM  –Adenine & -Guanine, +Inosine 20 µg ml 
-1
 C 
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      8 6 $     - (   v     - (  -pabA  z     8 6 $     - (    3 $ % $  x     - (  -pabA+PABA.
A B C
FD E
-Gly, -Ser, -VitB5 -Gly, -Ser, +VitB5 +Gly, -Ser, -VitB5
-Gly, +Ser, +VitB5 +Gly, -Ser, +VitB5 +Gly, +Ser, -VitB5
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Figure 5.31 Liquid CDM analysis of JE2-pabA growth. 
 
A. CDM minus serine, glycine and VitB5  
B. CDM minus serine and glycine 
C. CDM minus serine and VitB5  
D. CDM minus glycine 
E. CDM minus serine  
F. CDM minus VitB5 
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However, when glycine and VitB5 were added to CDM the VitB5 appeared to have a 
negative effect on JE2-pabA growth compared to when just glycine was added 
(Figure5.31E & Figure 5.31C, respectively). This again suggested a negative effect of 
VitB5 on the growth of JE2-pabA. Addition of glycine and serine in the absence of 
VitB5 gave comparable growth of JE2-pabA to JE2 (Figure 5.31F). 
 
5.2.9.3 Analysis of the relative importance of serine, glycine and purines to JE2- 
pabA growth 
 
Two experiments were carried out to determine the relative importance of glycine, 
serine and purines to the growth of JE2-pabA. In both experiments, JE2 and the pabA 
mutant were grown in base CDM (CDM minus purines, glycine and serine) in the 
presence or absence of PABA (VitB5 was no longer used in CDM preparations, due to 
its potentially negative impact on JE2-pabA). In experiment 1 growth was assessed in 
base CDM and base CDM plus glycine, serine or purines (Figure 5.32 A-D). In 
experiment 2 growth of both strains was assessed in base CDM plus all two or more 
member combinations of glycine, serine and purines (Figure 5.32 E-H).  
 
In experiment 1, no improvement in growth of JE2-pabA could be seen relative to JE2. 
Growth was improved for both strains by serine or glycine addition to base CDM, but 
the relative difference in growth remained the same (Figure 5.32 C & D).  
 
In experiment 2, the addition of two of the additives in any combination did not 
improve the growth rate of JE2-pabA relative to JE2, but the same max OD600 was 
reached (Figure 5.32E, F, G). The growth rate of JE2-pabA was improved relative to 
JE2 only in the presence of purines, glycine and serine. However, the growth rate of 
JE2-pabA was still not fully restored.  
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A B
C
G
FE
D
Base CDM                                                                     +Purines
+Glycine                                                                          +Serine
+Purines +Glycine                                                         +Purines +Serine
+Glycine +Serine                                                           +Purines +Glycine +SerineH
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Figure 5.32 Analysis of the JE2-pabA phenotype in liquid CDM.  
 
      - (   v     - (  -pabA  z     - (    3 $ % $  x     - (  -pabA+PABA,   = JE2 +additive labelled 
above graph, … = JE2-pabA +additive labelled above graph.  
Growth of JE2-pabA was compared with JE2 in CDM base with all combinations of 
glycine, serine and purines. Addition of all 3 components to the CDM base restored the 
growth of JE2-pabA to a comparable level to JE2. 
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5.2.9.4 Analysis of trimethoprim activity in the presence of VitB5 
 
Trimethoprim (TMP) is an antifolate antimicrobial that inhibits DHFR, the enzyme that 
converts DHF to THF downstream of PABA synthesis (Proctor, 2008). It was thought 
that addition of TMP to JE2 would lead to JE2-pabA-like growth of the wild-type, due 
to loss of THF. Therefore, as VitB5 appeared to inhibit the growth of JE2-pabA it was 
hypothesised that TMP activity would be enhanced in the presence of VitB5 as JE2 
would be inhibited by both TMP and the pabA phenotype associated impact of VitB5 on 
growth.  
 
TMP MIC experiments were carried out from 1000 - 0 µg ml
-1
, as in Chapter 2.17, in 
base CDM, which did not contain purines, glycine, serine or VitB5. The MIC 
experiment was repeated using 290ng ml
-1
 VitB5, 580 ng ml
-1
 VitB5 and 1.45 µg ml
-1
 
VitB5 (equivalent to 1x, 2x and 5x CDM concentrations, respectively). A baseline 
growth was determined, by growth of JE2 alongside MIC experiments in the absence of 
TMP. Increase in JE2 OD600 was determined as TMP levels were decreased. This 
increase was compared for MIC experiments with or without VitB5. The presence of 
higher levels of VitB5 did not alter the recovery of JE2 to the baseline OD600 as the 
TMP concentration was reduced (Figure 5.33). This suggested that VitB5 has no impact 
on TMP activity against JE2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
278 
 
 
 
 
Figure 5.33 Analysis of the effect of VitB5 concentration on trimethoprim activity.  
 
 ’ D V K H G   U H G   O L Q H   L Q G L F D W H V   E D V H O L Q H   J U R Z W K   Z L W K R X W   7 0 3           0 , &   L Q   E D V H   & ’ 0   z     
MIC in base CDM +VitB5. Addition of VitB5 at any concentration tested had no effect 
on the growth of JE2 exposed to TMP. 
290 ng ml 
-1
 VitB5 
580 ng ml 
-1
 VitB5 
1.45 µg ml 
-1
 VitB5 
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5.2.10 Effect of inosine on SH-pabA in vivo 
 
An unsuccessful attempt was made above to restore virulence to SH-pabA using serine, 
glycine, methionine and VitB5 in the zebrafish embryo model of systemic infection 
(Figure 5.28). The liquid CDM analysis showed that purines are a growth requirement 
of JE2-pabA. Therefore, the zebrafish embryo assay was used with the addition of 
inosine (Figure 5.34). Two concentrations of inosine were used, 150 µg ml
-1
 and 1 mg 
ml
-1
 (Figure 5.34 A & B respectively). SH-pabA remained attenuated at both 
concentrations compared to SH1000, p < 0.0001. 
 
5.2.11 Role of pabA in growth on human blood 
 
5.2.11.1 Analysis of JE2-pabA growth on human blood plus purines, glycine or  
serine 
 
A conclusion of the CDM experiments was that glycine, serine and purines were 
required in combination to enhance the growth of JE2-pabA to that of JE2. To confirm 
that a lack of purines, glycine and serine was the cause of the JE2-pabA phenotype, their 
effects on the growth of the pabA mutant was compared to JE2 on 30% (v/v) human 
blood agar (Figure 5.35). Neither purines, nor serine nor glycine restored the growth of 
JE2-pabA on human blood agar in any combination. Addition of 50 µg ml
-1
 PABA did 
restore the growth of the pabA mutant. Additionally chocolate agar was made by 
heating human blood to 70
o
C or 80
o
C. Lysis and release of nutrients caused by heating 
did not restore comparable growth of JE2-pabA to JE2. 
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Figure 5.34 Effect of inosine on SH-pabA virulence.  
 
A. 150 µg ml
-1 
inosine with 1x CDM concentration of serine, glycine, methionine and 
VitB5 did not restore SH-pabA pathogenicity, p < 0.0001.  
B. 1 mg ml
-1 
inosine with 1x CDM concentration of serine, glycine, methionine and 
VitB5 did not restore SH-pabA pathogenicity, p < 0.0001. 
 
 
CDM Conc. S,G,M & vitB5 
Inosine 150 µg ml 
-1
 
 
A 
B 
CDM Conc. S,G,M & vitB5 
Inosine 1 mg ml 
-1
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Figure 5.35 Analysis of the growth of JE2-pabA on human blood with various 
supplements.  
 
30% (v/v) human blood agar was supplemented with all combinations of glycine, serine 
and purines to determine their role in JE2-pabA growth. 30% (v/v) human blood agar 
was also heated to release nutrients and PABA was added as a positive control. 
Plates were incubated at 37
o
C for 48 h. 
 
 
 
 
JE2
pabA
30% (v/v) Citrated Whole Human Blood Agar Plates  – Additives Shown Above Plates
Whole blood only                             +PABA                                     +Glycine                           +Serine
+Glycine                                  +Glycine               +Serine
+Purines                                    +Serine                                   +Purines                      +Purines
+Glycine
+Serine
+Purines                            Heated to 70oC                         Heated to 80oC                                  Key
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5.2.11.2 Analysis of JE2-pabA growth on human blood plus methionine, VitB5 or  
thymine 
 
To confirm that the JE2-pabA phenotype was not the result of a lack of any of the CDM 
components assessed above, the effect of addition of methionine, VitB5 and thymine 
was assessed on 30% (v/v) human blood agar (Figure 5.36). Neither methionine nor 
VitB5 restored the growth of JE2-pabA. However, thymine at a concentration equivalent 
to that of purines in CDM (40 µg ml
-1
) did partially restore JE2-pabA growth on human 
blood. This suggested that increased pyrimidine synthesis may be required on blood, or 
that thymine is an antagonist of a factor that is inhibitory to the pabA mutant in human 
blood.  
 
5.2.12 Is the JE2-pabA phenotype on human blood the result of inhibition? 
 
Plasma extracted from RBC disrupted blood was used to assess inhibition of JE2-pabA. 
Blood from the same donation was pooled and separated into 2 aliquots. One aliquot 
was vortexed hard for 3min then plasma was extracted from both blood aliquots (for the 
plasma preparation method see Chapter 2.1.3.1.2). Figure 5.37A shows straw coloured 
plasma from non-vortexed blood on the left (NV plasma), and red coloured plasma from 
vortexed blood on the right (V plasma). The red colouration demonstrated lysis of 
RBCs. Plasma agar was prepared using NV and V plasma as shown in Table 5.9. 
Growth of JE2-pabA and JE2 was compared on each plasma agar ratio (Figure 5.37B). 
Growth of JE2-pabA was comparable to JE2 on 50% (v/v) NV plasma. Addition of just 
5% (v/v) V plasma resulted in highly reduced growth of the JE2-pabA mutant compared 
to JE2. This suggested that the JE2-pabA phenotype was the result of growth inhibition 
by an unidentified component of blood. 
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Figure 5.36 Analysis of methionine, VitB5 and thymine on JE2-pabA growth on 
human blood.  
 
Neither methionine nor VitB5 complemented JE2-pabA on human blood. 40 µg ml
-1
 
thymine (equivalent to the total purine concentration in CDM) partially complemented 
JE2-pabA growth. Plates were incubated at 37
o
C for 48 h. 
 
 
 
 
 
 
 
 
 
 
JE2
pabA
30% (v/v) Citrated Whole Human Blood Agar: Additives Shown Above Plates
Whole blood only                             +PABA                               +Methionine
+Vitamin B5 +Thymine                                     Key
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Table 5.9 Composition of vortexed and non-vortexed plasma agar plates (by 
volume). 
Non-vortexed (NV)  
Plasma (%) 
Vortexed (V) 
Plasma (%) 
2x Agar (%) 
50 0 50 
45 5 50 
37.5 12.5 50 
25 25 50 
12.5 37.5 50 
5 45 50 
0 50 50 
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Figure 5.37 Inhibition of JE2-pabA by plasma from vortexed blood.  
 
A. Straw coloured plasma from non-vortexed (NV) blood shown in the left tube. Red plasma 
from vortexed (V) blood shown in the right tube.  
B. Growth of JE2-pabA was comparable to JE2 on 50% (v/v) NV plasma, but increasing the 
ratio of V to NV plasma immediately inhibited JE2-pabA growth.  
Plates were incubated at 37
o
C for 48 h. 
JE2
pabA
50% (v/v) Plasma Plates Using Plasma from Vortexed (V) or 
Non-Vortexed (NV) Human Blood
45% (v/v) NV
50% (v/v) NV                                   5% (v/v)V
37.5% (v/v) NV                              25% (v/v) NV                             12.5% (v/v) NV
12.5% (v/v) V                                 25% (v/v) V                                37.5% (v/v) V
5% (v/v) NV                                         
45% (v/v) V                                  50% (v/v) V                                          Key
BA
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5.2.13 Genetic complementation of the pab operon 
5.2.13.1 Construction of the lipase integration plasmid pJC002 
 
The pGM073 plasmid was constructed by Gareth McVicker by insertion of the ezrA and 
PSmOrange genes into the pKasbar plasmid. Lysogenic bacteriophage DNA integrates 
into the S. aureus genome via its attP site and the bacterial genome encoded attB site, 
mediated by the integrase enzyme. In S. aureus the attB recognition site is located at the 
gene for glycerol ester hydrolase (geh) and incorporation of phage DNA leads to loss of 
lipase activity (Lee & Iandolo, 1986). The pGM073 plasmid encodes an attP site, 
allowing integration of the plasmid at lipase in the presence of integrase. Primers pab-F 
and pab-R were designed to amplify the pab operon and up and downstream control 
elements (for all primers and primer design method see Chapter 2.12.1.1). The primers 
were designed with an ApaI restriction site in the pab-F primer and an XhoI site in the 
pab-R primer. Primers and plasmid were cut with ApaI and XhoI and ligated (Chapter 
2.12.2 and Chapter 2.12.4, respectively). Cutting the plasmid with these enzymes 
removes the ezrA and PSmOrange genes. Ligation gives the plasmid pJC002, the 
pKasbar plasmid with the pab operon inserted (Figure 5.38A). The plasmid construct 
was then used to transform Escherichia coli strain Top10 (see Chapter 2.9.1.2 for 
transformation method). Successful construction was confirmed by purification of the 
plasmid from E. coli and digestion with ApaI and XhoI and analysis by 1% (w/v) 
electrophoresis. Bands corresponding in size to the plasmid and insert are indicated 
(Figure 5.38B). Plasmid DNA was sequenced by GATC Biotech, using primers pab1F, 
pab1R & pab2F, pab2R & pab3F, pab3R & pab4F, pab4R, to confirm that the correct 
sequence of the pab operon was inserted (for sequence data see Appendix 5.1).  
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Figure 5.38 Construction of the complementation plasmid pJC002.  
 
A. The pab operon with up and downstream control elements was amplified using 
primers with ApaI and XhoI restriction sites designed into them, giving a PCR product 
of 2,887bp. The pGM073 and amplified pab operon were then digested with ApaI and 
XhoI and purified. Digestion of the plasmid removes the PSmOrange and ezrA genes, 
reducing the plasmid size to 5,437bp. The pab operon was then ligated into the digested 
pGM073 plasmid to give pJC002.  
B. DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards 
(M) of sizes shown are in each panel. 
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5.2.13.2 Integration of pJC002 into S. aureus RN4220 
 
Integration of pJC002 into RN4220 is shown diagrammatically in Figure 5.39. The 
pJC002 was transformed into S. aureus  5 1       F R Q W D L Q L Q J   W K H   S < /    ß     S O D V P L G 
(Chapter 2.9.2.2). This plasmid encodes the integrase enzyme required for site-specific 
integration at geh. Integration of the pJC002 plasmid into geh results in loss of lipase 
activity. Lipase activity was compared with RN4220 to confirm insertion of pJC002 
(Figure 5.40A). The pJC002 plasmid was transferred from the RN4220 genome to JE2-
pabA, SH-pabA, JE2 and SH1000 by bacteriophage transduction (Chapter 2.10.3), 
allowing integration into the genome by homologous recombination. The pKasbar 
backbone was also transduced into JE2-pabA, SH-pabA, JE2 and SH1000 to give 
control strains for the integration of DNA at geh. PCR was carried out to confirm the 
successful integration of pJC002 or pKasbar into JE2-pabA, SH-pabA and the wild-type 
strains. Three sets of primers were used to determine correct insertion: NE821F and 
NE821R, which amplify the NE821 Tn insertion site, giving a fragment of the pabA 
gene from wild-type DNA, or the full Tn from pabA mutant DNA; pGM-F and pab1R, 
which amplify within pJC002 from outside the insertion site, to within the pab operon, 
confirming insertion of the pJC002 plasmid and pGM-F and pGM-R, which amplify 
within pKasbar from either side of the pab operon insertion site to confirm the 
integration of pKasbar and not pJC002 (primer sequences given in Chapter 2.12.1.1). 
Amplification products of expected sizes were found for all genetically complemented 
strains (Figure 5.40B). 
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Figure 5.39 Site specific integration of pJC002 at the geh gene of S. aureus 
RN4220. 
 
The pJC002 plasmid was transformed into RN4220 carrying the integrase gene within a 
separate plasmid. The integrase mediates site specific recombination between the 
plasmid encoded attP site and the attB site within the geh gene of RN4220. This leads 
to integration of the entire plasmid into geh, disrupting lipase activity. 
 
attB
S. aureus RN4220- S & /     ß    
chromosome carrying the int gene
geh  ¶ pabC pabB pabA ori bla tet-r geh  ¶
pJC002 Integration 
at attB site
geh
pJC002
8302 bp
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Figure 5.40 Confirming pJC002 integration into RN4220 by analysis of geh activity and 
confirmation of pJC002 & pKasbar transduction into the wild-type strains, SH-pabA and 
JE2-pabA by PCR.  
 
A. Arrows 1, 2 and 3 show loss of lipase activity from RN4220, due to disruption of geh caused 
by integration of pJC002. Arrow 4 shows RN4220 lipase activity.  
B. DNA fragments were separated by 1% (w/v) agarose gel electrophoresis. Standards (M) of 
sizes shown are in each panel. 
 
PCR confirmation of pJC002 or pKasbar integration into JE2-pabA, SH-pabA, JE2 and SH1000. 
All bands are of expected sizes.  
Lane 1: SH1000 or JE2 gDNA amplified with NE821F and NE821R. 
Lane 2: SH1000+pJC002 or JE2+pJC002 gDNA amplified with pGM-F and pab1R.  
Lane 3: SH1000+pKasbar or JE2+pKasbar gDNA amplified with pGM-F and pGM-R.  
Lane 4: SH-pabA or JE2-pabA gDNA amplified with NE821F and NE821R.  
Lane 5: (SH-pabA or JE2-pabA)+pJC002 gDNA amplified with pGM-F and pab1R.  
Lane 6: (SH-pabA or  JE2-pabA)+pJC002 gDNA amplified with NE821F and NE821R.  
Lane 7: (SH-pabA or JE2-pabA)+pKasbar gDNA amplified with pGM-F and pGM-R.  
Lane 8: (SH-pabA or JE2-pabA)+pKasbar gDNA amplified with NE821F and NE821R. 
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2
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5.2.13.3 Analysis of the genetically complemented JE2-pabA in vitro 
 
The growth of genetically complemented JE2-pabA was assessed on 30% (v/v) human 
blood agar (Figure 5.41). JE2-pabA showed highly reduced growth on human blood. 
Insertion of the pJC002 at lipase restored the growth of JE2-pabA on human blood, 
whereas insertion of pKasbar at lipase did not alter the reduced growth phenotype. 
Insertion of pJC002 or pKasbar at lipase did not alter the growth of JE2. 
 
5.2.13.4 Analysis of the genetically complemented SH-pabA in vivo 
 
The pathogenicity of the genetically complemented SH-pabA strains was assessed using 
the zebrafish embryo model of systemic infection. Approximately 1,500 CFU of each 
strain was injected into zebrafish embryos, which were then incubated in E3 solution for 
four days. SH-pabA was highly attenuated, as was SH-pabA+pKasbar (Figure 5.42). 
Integration of the pab operon encoding pJC002 plasmid restored the virulence of SH-
pabA to that of SH1000. 
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Figure 5.41 Growth of genetically complemented strains on 30% (v/v) human 
blood agar. 
 
Insertion of pJC002 into JE2-pabA restored growth to that of JE2 on human blood. 
Insertion of pKasbar did not alter the JE2-pabA phenotype on human blood. Insertion of 
pJC002 or pKasbar into JE2 did not alter the growth of the wild-type. Plates were 
incubated at 37
o
C for 48 h. 
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pJC002                                          pKasbar                                          Key
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Figure 5.42 In vivo analysis of the genetically complemented strains.  
 
Insertion of pJC002 carrying the pab operon restored the virulence of SH-pabA to that 
of SH1000, p > 0.05. SH-pabA+pKasbar remained attenuated compared to SH1000, p < 
0.0001. 
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5.2.14 Effect of thymidine on SH-pabA virulence 
 
The effect of thymidine on SH-pabA pathogenicity was assessed using the zebrafish 
embryo model of systemic infection. As thymine was found to partially complement the 
JE2-pabA phenotype on human blood agar (Figure 5.36) attempts were made to assess 
its role in pathogenicity. Initial attempts to replicate thymine complementation in vivo 
were frustrated by an inability to dissolve thymine in E3 solution. E3 has an ideal pH of 
7.4 for zebrafish embryos. Thymine dissolves in 1M NaOH or in E3 at pH 12 and 
adjusting the pH of E3 solution plus thymine toward pH 7.4 lead to thymine 
precipitation well above pH 7.4. Analysis of the pyrimidine biosynthesis pathways on 
the Kegg and Biocyc databases suggested that thymidine may provide an alternative to 
thymine (Figure 5.43). S. aureus conversion of dUMP to dTMP is THF-dependent 
(Chatterjee et al., 2008); however, there is an alternative means of producing dTMP, 
known as nucleotide salvage (Neidhardt et al., 1996; Zander et al., 2010). This is 
dependent on the conversion of thymine to thymidine by the enzyme pyrimidine-
nucleoside phosphorylase (Pdp), which can then be converted to dTMP by thymidine 
kinase (Tdk). Thymidine dissolved at a much lower pH and remained in solution in pH 
7.4 E3 solution.  
 
A high thymidine concentration of 800 µg ml
-1
, equivalent to 20x the total purine 
concentration of CDM, was used. Initially an effect was seen (data not shown), but this 
was not reproducible. Therefore, thymidine does not complement the virulence 
phenotype of SH-pabA in the zebrafish embryo model. Thymidine has since been 
shown to complement on whole human blood agar, which suggests that the inability of 
thymidine complementation in vivo, was the result of its poor diffusion into the 
zebrafish embryos. 
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Figure 5.43 Thymidine monophosphate biosynthesis in S. aureus.  
 
Conversion of dUMP to dTMP by ThyA (shown in green) is THF-dependent. Thymine 
can be converted to dTMP via thymidine by the sequential activity of the Pdp and Tdk 
enzymes (shown in green). Pathway information acquired from the Biocyc and Kegg 
databases. 
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5.2.15 The effect of homogenised RBCs on JE2-pabA growth 
 
Red blood cells (RBCs) are a by-product of leukocyte preparations carried out at The 
Royal Hallamshire Hosptital. Plasma and clotting factors are removed and the majority 
of white blood cells are separated from the RBCs, providing a source of primarily 
RBCs. The RBC preparation procedure is given in Chapter 2.18.1. The RBCs are 
normally discarded, but were frozen at -20
o
C for use in this study. After thawing, the 
RBCs were vortexed hard for 3 min. Freezing the RBCs was expected to cause lysis, but 
vortexing was still carried out. An equal volume of PPP was added, to give an RBC 
concentration equivalent to blood. After centrifugation there was no clear demarcation 
between RBCs and PPP. This was likely due to complete lysis of the RBCs from 
freezing resulting in RBC fragments that were too small to pellet at the centrifugation 
speed used and the release of all haemoglobin from the RBCs. The top 50% of the 
centrifuged RBC, PPP mixture was collected to give the RBC homogenate. 
 
Growth of JE2-pabA was assessed on 30% (v/v) RBC homogenate agar (Figure 5.44). 
Growth of JE2-pabA was inhibited on RBC homogenate agar. 50 µg ml
-1
 PABA 
completely restored growth of JE2-pabA and increasing the thymine concentration to 
400 µg ml
-1
, 10x the concentration that gave partial complementation in 30% (v/v) 
human blood agar (Figure 5.36), gave comparable growth to JE2 on RBC homogenate 
agar.  
 
The absence of thymine from CDM, which supports comparable growth of JE2-pabA to 
JE2, demonstrates that it is not an essential supplement for JE2-pabA growth. Figure 
5.43 shows that JE2 can synthesise dTMP from dUMP using ThyA and THF. The lack 
of THF in the pabA mutant means that dTMP can only be synthesised from thymidine 
by the enzyme Tdk. A low level of thymidine partially restored growth of JE2-pabA, 
whereas a higher level restored growth to that of JE2. This suggests that in CDM the 
pabA mutant can survive via the nucleotide salvage pathway, but cannot in blood. One 
possible explanation is that a component of blood competitively inhibits the Tdk 
enzyme, allowing partial complementation with low levels of thymidine and complete 
complementation at a higher concentration. Another possibility is that growth in human 
blood creates an increased demand for dTMP, which cannot be met by the THF 
deficient pabA mutant. 
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Figure 5.44 Analysis of the effect of RBC homogenate and thymine on the growth 
of JE2-pabA.  
 
RBC homogenate inhibits JE2-pabA growth. Increasing thymine concentration restores 
growth of JE2-pabA to equivalence with JE2. Plates were incubated at 37
o
C for 48 h. 
 
 
 
 
 
JE2
pabA
30% (v/v) Homogenised RBC Plates, Unless Stated Otherwise
50% (v/v) PPP                       RBC homogenate only                     +PABA 50 µg ml -1
Thymine 40 µg ml-1 Thymine 80 µg ml-1 Thymine 120 µg ml-1
Thymine 200 µg ml-1 Thymine 400 µg ml-1 Key
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5.2.16 Analysis of JE2-pabA inhibition by blood 
 
5.2.16.1 The effect of platelets on JE2-pabA growth 
 
The plasma produced up until this point was produced by a relatively high speed 
centrifugation of blood. At this speed, platelets would be removed from the resulting 
plasma, giving platelet poor plasma (PPP). A lower speed centrifugation procedure was 
used to produce plasma with a higher platelet concentration, platelet rich plasma (PRP; 
for PPP and PRP preparation see Chapter 2.1.3.1.2). Growth of JE2-pabA was 
compared to JE2 on PPP and PRP and PRP+PABA (Figure 5.45). JE2-pabA growth was 
comparable to JE2 in all conditions, which suggested that platelets are not the inhibitory 
factor in human blood. 
 
5.2.16.2 The effect of Fe
2+
 conc. on JE2-pabA growth 
 
Fe
2+
 was added to 30% (v/v) RBC homogenate agar to assess its role in inhibition of 
JE2-pabA. It was hypothesised that the poor growth of JE2-pabA on human blood may 
result from an inability to respond to a greater demand for dTMP, due to DNA damage 
caused by haem toxicity. The S. aureus iron regulated surface determinant system (Isd 
system) extracts haem from haemoglobin and transports it across the cell wall and 
membrane into the cytosol. The haem can be used intact or degraded to give free Fe 
(Anzaldi & Skaar, 2010; Hammer & Skaar, 2011). The Fur protein negatively regulates 
the isd genes when Fe levels are high, by binding to a consensus sequence (the Fur box) 
upstream of the isd operons inhibiting transcription. When Fe levels are low, Fur 
binding is alleviated and isd transcription can take place (Cassat & Skaar, 2012; Skaar, 
Gaspar, & Schneewind, 2004). It was hypothesised that addition of high levels of Fe to 
RBC homogenate agar would switch off the Isd system preventing acquisition of haem, 
thereby preventing haem toxicity (Figure 5.46). Addition of ammonium ferrous sulphate 
(AFS) at 6 µg ml
-1
, 12 µg ml
-1
, 30 µg ml
-1
 and 60 µg ml
-1
 (equivalent to 1x, 2x, 5x and 
10x CDM concentration) did not alter the JE2-pabA growth phenotype.  
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Figure 5.45 Analysis of the effect of clotting factors on JE2-pabA growth.  
 
Abbreviations: PPP, platelet poor plasma; PRP, platelet rich plasma (normal levels of 
clotting factors). The presence of clotting factors does not inhibit the growth of JE2-
pabA. Plates were incubated at 37
o
C for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pabA
JE2
50% (v/v) Plasma Plates
PRP
PPP                                                PRP                                             +PABA
300 
 
 
Figure 5.46 Analysis of Fe concentration on the growth of JE2-pabA on RBC 
homogenate.  
 
The presence of Fe
2+
 in the form of Ammonium ferrous sulphate at 1x, 2x, 5x and 10x 
CDM concentration does not alter the inhibition of JE2-pabA. Plates were incubated at 
37
o
C for 48 h. 
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pabA
30% (v/v) Homogenised RBC Agar Plates, Unless Stated Otherwise
50% (v/v) PPP                       RBC homogenate only                    +PABA 50 µg ml -1
AFS 6 µg ml-1 AFS 12 µg ml-1 AFS 30 µg ml-1
AFS 60 µg ml-1 Key
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5.2.16.3 The effect of bovine haemin on JE2-pabA growth 
 
Growth of JE2-pabA was assessed on 50% (v/v) plasma agar with addition of haemin. 
Haemin is a chlorinated form of haem used in laboratory analysis of haem toxicity. 
Bovine haemin has been demonstrated to cause haem toxicity in S. aureus strains at 
concentrations as low as 3 µg ml
-1
 (Nitzan et al., 1987). S. aureus Newman srtA
-
 was 
found to be more resistant to haemin, which was thought to be due to the role of SrtA in 
binding IsdABC & H to the S. aureus surface (Torres et al., 2007). It was hypothesised 
that if increased susceptibility to haem toxicity is the cause of the JE2-pabA phenotype 
then addition of haemin to plasma would replicate the JE2-pabA phenotype seen on 
human blood. Growth of JE2-pabA was found to be no different to JE2 on 50% (v/v) 
plasma agar with or without haemin (Figure 5.47). Unexpectedly both strains grew at 
the highest concentration (20 µg ml
-1
).  
 
5.2.16.4 The effect of bovine haemoglobin on JE2-pabA growth 
 
Growth of JE2-pabA was assessed on 50% (v/v) human plasma agar supplemented with 
bovine haemoglobin. S. aureus is able to grow utilising haemoglobin as its only Fe 
source at as low a concentration as 5 µg ml
-1
 (Pishchany et al., 2010). It was 
hypothesised that if increased susceptibility to haem toxicity is the cause of the JE2-
pabA phenotype then addition of bovine haemoglobin to plasma would replicate the 
JE2-pabA phenotype seen on human blood. Figure 5.48 shows that growth of JE2-pabA 
was not altered by bovine haemoglobin. The use of bovine haemin in section 5.2.16.3 
and the use of bovine haemoglobin above did not completely rule out the possibility that 
the JE2-pabA phenotype is the result of haem toxicity. Pishchany et al., (2010) showed 
that S. aureus has evolved specificity for human haemoglobin over murine 
haemoglobin. This specificity may result in poor acquisition of bovine haem minimising 
the effects of haem toxicity. However, if haem toxicity is not the cause of the JE2-pabA 
and SH-pabA phenotype, then the possibility that the cause is a Tdk inhibitory 
compound in human blood remains, as does the possibility that there is a greater 
demand for pyrimidines when growing on human blood. 
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Figure 5.47 Analysis of the effect of bovine haemin on the JE2-pabA growth 
phenotype.  
 
Increasing concentrations of bovine haemin does not inhibit growth of JE2-pabA on 
50% (v/v) human plasma. Plates were incubated at 37
o
C for 48 h. 
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Figure 5.48 Analysis of the effect of bovine haemoglobin on the JE2-pabA growth 
phenotype.  
 
Increasing bovine haemoglobin concentration did not alter the growth of JE2-pabA on 
50% (v/v) human plasma. Plates were incubated at 37
o
C for 48 h. 
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5.3 Discussion 
 
Nine strains, each with a separate gene disrupted by Tn insertion, were identified by 
screening the NTML on human blood agar (see Chapter 4). Characterising the 
phenotype caused by the loss of each of the nine genes was not a realistic possibility in 
the timeframe given for the analysis. Therefore, the zebrafish embryo model of systemic 
infection was employed to identify those strains whose phenotype resulted in reduced 
pathogenesis in this model. Of the nine, two strains with Tn disrupted genes involved in 
de novo purine biosynthesis and one strain with a Tn disrupted gene required for 
synthesis of folates were highly attenuated in the zebrafish embryo model. The 
phenotype of these three strains was then characterised. 
 
5.3.1 Analysis of purA & purB 
 
Analysis of the purine pathway mutants JE2-purA, SH-purA, JE2-purB and SH-purB 
followed the scheme of the flow diagram shown in Figure 5.49. When screened on 
bovine serum agar, human blood agar and sheep blood plus Columbia agar base, NE529 
and NE522 had reduced growth on human blood agar and bovine serum agar, but grew 
normally on sheep blood with the nutrient rich Columbia agar base. The phenotype was 
confirmed for the transduced strains, JE2-purA and JE2-purB, by growth curves in BHI 
and human or bovine serum. The ability to grow in nutrient rich media suggested that 
the purA and purB disrupted strains had a nutrient requirement missing from serum and 
blood. Analysis of the de novo purine biosynthesis pathway suggested that both strains 
could not synthesise AMP and the purB mutant had an additional requirement for GMP. 
 
The requirement for purines was not confirmed in the zebrafish model. This was likely 
the result of poor uptake of adenine and inosine to allow their use by the purA or purB 
mutant strains. However, since both strains required adenine, poor uptake could only be 
assumed for adenine. CDM analysis confirmed that the purine requirement of both 
strains matched the known roles of the purA and purB genes in S. aureus (Baxter-
Gabbard & Pattee, 1970). The analysis also suggested that purine availability in 
zebrafish embryos and in human blood is low. As the role of purA and purB in the de 
novo biosynthesis of purines by S. aureus is well characterised (Baxter-Gabbard & 
Pattee, 1970) and their importance to pathogenesis has been documented by other
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Figure 5.49 Diagram of the analysis of the purA and purB genes. 
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groups (McFarland & Stocker, 1987; Stocker, 1988) it was decided to centre all further 
effort on the folate pathway mutants JE2-pabA and SH-pabA. 
 
5.3.2 Analysis of pabA 
 
Analysis of the role of pabA followed the scheme of the flow diagram shown in Figure 
5.50. In the NTML screen (Chapter 4), strain NE821 showed an unusual phenotype, 
growing poorly on blood, but normally on bovine serum. The phenotype was confirmed 
above and shown to not be related to the different aeration conditions used in the screen, 
the low serum concentration in blood agar, or nutrient release during serum preparation. 
The phenotype was also found to be restricted to human blood when growth was 
assessed on 30% (v/v) horse, rabbit and sheep blood agar. The phenotype was thought 
to be the result of either inhibition by a human blood component or a nutrient that is 
more available in serum or plasma than in blood. The role of THF in the biosynthesis of 
some amino acids, nucleic acids and vitamins made it likely that the latter possibility 
was correct. 
 
The importance of purines, glycine, serine, vitamin B5, methionine and thymine in the 
growth and pathogenicity of JE2-pabA and SH-pabA was determined. Agar based and 
liquid CDM experiments were carried out and only glycine, serine and purines were 
found to complement the pabA mutant. However, in the absence of these components 
the difference in growth between the pabA mutant and JE2 was slight, relative to the 
difference seen on human blood agar. Furthermore, no combination of purines, glycine 
or serine restored JE2-pabA growth on human blood or restored virulence to SH-pabA 
in the zebrafish embryo model. Thymine was found to partially restore growth of JE2-
pabA on human blood at a concentration equivalent to the purine concentration in 
CDM. The CDM and whole human blood complementation results suggested that the 
pabA mutant phenotype was the result of inhibition in human blood and that this 
inhibition was antagonised by thymine, or that growth in human blood creates a greater 
demand for dTMP. 
 
Analysis of the inhibition of the pabA mutant demonstrated that the putative inhibitory 
factor was associated with the RBC component of blood and was likely to be found 
inside RBCs. Thymine or thymidine at high concentrations, relative to CDM purine 
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concentration, was found to complement on RBC homogenate agar. In the biosynthesis 
of dTTP, S. aureus converts dUMP to dTMP in a folate-dependent reaction. In the 
absence of folate, S. aureus depends on the nucleotide salvage pathway, in which the 
enzyme Pdp converts thymine to thymidine, which can then be converted to dTMP by 
thymidine kinase (Tdk; Figure 5.43). Complementation therefore suggested that 
conversion of thymidine to dTMP was possible in serum and plasma, but not in human 
blood and potentially that something in RBCs may competitively inhibit Tdk, leading to 
a requirement for a high thymidine or thymine concentration to overcome the inhibition.  
 
This did not explain how JE2-pabA could grow in chemically defined media, which 
does not contain thymine or thymidine. Wegkamp et al., (2007) demonstrated that trace 
amounts of PABA, folate, glycine, serine or nucleobases in CDM minus glycine, serine 
and nucleobases were able to sustain reduced but consistent growth of a pab operon 
deletion strain of Lactococcus lactis. Fresh inoculation of L. lactis pabA
 
into spent 
CDM minus glycine, serine and nucleobases with added glucose (i.e. CDM minus 
glycine, serine and nucleobases that has sustained the growth of L. lactis pabA to its 
maximum OD, filtered and supplemented with glucose) resulted in no growth of the pab 
operon mutant. Furthermore, the growth could be restored by addition of PABA. This 
suggested that trace amounts of PABA may have resulted in JE2-pabA growth in CDM.  
 
One possible explanation for CDM growth of the pabA mutant, but its lack of growth in 
human blood, was the presence of the thyX gene in S. aureus. ThyX allows for flavin-
dependent, folate-independent conversion of dUMP to dTMP (Myllykallio et al., 2002). 
If ThyX could be found amongst the S. aureus protein sequences, then it would suggest 
that ThyX conversion of dUMP to dTMP was possible in serum, plasma and CDM, but 
ThyX activity was inhibited in blood. The thyX gene is not commonly found in strains 
possessing the folate-dependent method of dTMP synthesis and there are no ThyX 
proteins reported on the Uniprot database for any S. aureus strains. Furthermore, a 
search of all USA300 protein sequences against the Pfam database found no protein 
containing a thy1 domain (the domain associated with the ThyX protein). Therefore, the 
presence of a thyX gene in the pabA mutant was ruled out. 
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Figure 5.50 Analysis of pabA shown diagrammatically. 
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Another possible explanation could be that the requirement for dTTP could be supplied 
by some other less effective means, which is enough to allow growth of JE2-pabA in 
CDM. When growing on human blood however, JE2-pabA may be more susceptible to 
haem toxicity or some other effect that results in increased demand for dTMP. 
Acquisition of haem primarily from host haemoglobin is a requirement for the 
pathogenicity of S. aureus, which uses haem as a cofactor in many reactions (Hammer 
& Skaar, 2011; Torres et al., 2006). Haem can be toxic at high levels leading to protein, 
lipid and DNA damage (Anzaldi & Skaar, 2010; Stauff et al., 2008). DNA damage 
caused by haem toxicity may result in a greater requirement for dTMP, which JE2-pabA 
cannot respond to in the absence of THF or thymine. 
 
Neither addition of increased Fe concentrations to downregulate haem acquisition in S. 
aureus, nor addition of bovine haemin or bovine haemoglobin altered the JE2-pabA 
phenotype. At the completion of the above analysis it remained possible that haem was 
the inhibitory factor, as S. aureus has been shown to favour acquisition of human haem 
as opposed to haem from other mammals (Pishchany et al., 2010). The lack of 
inhibition of JE2-pabA on rabbit, sheep and horse blood agar supports this possibility 
(Chapter 4). It also remained possible that something else in human blood drives a 
greater need for pyrimidines resulting in a requirement for exogenous thymine or 
thymidine or that something in blood interacts with the Tdk protein competitively 
inhibiting its function, which would also result in a greater requirement for thymine or 
thymidine. 
 
5.3.3 The ongoing analysis of pabA 
 
Dr Emma Johnson has followed up the above analysis, attempting to identify the cause 
of the JE2-pabA phenotype. Human haem was found to have no effect on the growth of 
JE2-pabA when added to human plasma agar and thymidine was found to complement 
JE2-pabA on 30% (v/v) human blood agar.  
 
Interestingly, growth of a tdk, pabA double mutant of S. aureus USA300 JE2 could not 
be restored by either thymine or thymidine on human blood agar. This demonstrates that 
the thymine and thymidine added to blood is being used by the pabA mutant to produce 
dTMP. It does not answer the question as to whether the requirement for high levels of 
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thymine or thymidine is to prevent competitive inhibition of Tdk or to complement an 
increased requirement for pyrimidines in human blood.  
 
5.3.4 Future work 
 
It is essential to genetically complement the tdk gene in the pabA/tdk mutant, thereby 
proving that the tdk gene is required for thymidine complementation. Complementing 
the pabA/tdk double mutant and the pabA mutant with the product of Tdk activity 
(deoxythymidine monophosphate; dTMP) would also demonstrate the importance of 
Tdk activity to the pabA mutant. 
 
To determine whether Tdk is able to function in plasma, but is inhibited in human 
blood, Tdk inhibitors could be employed. The enzyme dihydrofolate reductase (DHFR) 
reduces DHF to THF in the THF biosynthesis pathway. The antifolate trimethoprim 
binds to bacterial DHFR with 10
5
 times greater affinity than it binds to vertebrate 
DHFR (Hawser et al., 2006). Loss of DHFR activity leads to loss of THF and THF-
dependent functions, including folate-dependent synthesis of dTMP by thymidylate 
synthase (ThyA), as seen in the pabA mutant. Thymidine has been shown to reduce the 
potency of trimethoprim (Proctor, 2008), by allowing THF-independent conversion of 
thymidine to dTMP by Tdk. Tdk inhibitors have been used to restore the potency of 
trimethoprim in the presence of thymidine (Zander et al., 2010). Therefore, Tdk 
inhibition of the pabA mutant using a Tdk inhibitor may replicate the pabA mutant 
phenotype, seen on blood, on plasma. This would demonstrate that the phenotype on 
blood is the result of Tdk inhibition. If the phenotype is not replicated, then this would 
suggest that there is a greater need for dTMP when growing on human blood.  
 
An interesting experiment would be to compare the resistance of the wild-type and 
pabA mutant to trimethoprim. Long-term patient treatment with trimethoprim can result 
in small colony variant (SCV) strains of S. aureus, collected from many sites in the 
body including blood (Besier et al., 2008), all of which result from SNP changes in the 
thyA gene, producing slow growing trimethoprim resistant strains (Garcia et al., 2013). 
If the pabA mutant is found to be resistant to trimethoprim in CDM in the absence of 
serine, glycine and nucleic acids, this would suggest that pabA mutants resistant to 
trimethoprim are not commonly found in patients because of their inability to grow in 
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blood (i.e. they are resistant to trimethoprim, but they lack the ability to grow in blood 
and are therefore not found as resistant SCVs associated with patients). Also, it would 
suggest that the activity of sulphonamide drugs is the result of inhibition of THF 
coupled with the inhibition of Tdk in blood. It would be expected that the wild-type 
would be resistant to THF-inhibiting antimicrobials in rich media and susceptible to 
them on blood, where synthesis of dTMP is limited by the suspected inhibitor of Tdk 
and trimethoprim inhibition of THF-dependent synthesis of dTMP. If high thymidine 
concentration then restores wild-type growth on blood in the presence of trimethoprim, 
as it does with the pabA mutant, then this would suggest a role for Tdk inhibition by 
blood in the activity of antifolate antibiotics. 
 
As wild-type S. aureus can make dTMP via the THF-dependent route, Tdk inhibition 
has no evolutionary benefit unless natural inhibitors of THF biosynthesis exist, or if 
there are other pathogens that rely solely on nucleotide salvage for their dTMP. The 
genome of the human pathogen Ureaplasma urealyticum does not carry the genes 
required for de novo synthesis of dTMP and relies on Tdk activity for dTTP synthesis 
(Kosinska et al., 2005). Furthermore, a potent inhibitor of DHFR known as 10-formyl 
folic acid has been found in rat livers, which is thought to have a role in regulating 
folate levels   G ¶   8 U V R-Scott et al., 1974). Whether this or other folate regulators would 
recognise bacterial DHFR is uncertain. However, the existence of vertebrate DHFR 
regulation and pathogens reliant on Tdk activity does offer potential reasons for the 
evolution of Tdk inhibition. 
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CHAPTER 6 
 
GENERAL DISCUSSION 
 
 
6.1 Introduction 
 
The goal at the outset of this work was to identify and characterise a putative toxin that 
showed a dramatic necrotic effect on human neutrophils. Two independent publications 
allowed rapid identification of LukAB/GH as the putative toxin (Dumont et al., 2011; 
Ventura et al., 2010). Two methods were then employed to identify novel or 
uncharacterised virulence factors (VFs) required by S. aureus for pathogenesis. A 
bioinformatics approach was first used (Chapter 3), followed by screening of an ordered 
Tn mutagenesis library on human blood (Chapter 4). The genes isolated in the NTML 
screen were then characterised (Chapter 5). 
 
6.2 What is a virulence factor? 
 
When discussing virulence factors (VF), the standard texts focus primarily on adhesion 
& invasion proteins, toxins, immune evasion, biofilm and iron acquisition proteins 
(Atlas, 1997; Madigan, 2000; Prescott, 1999; Wu et al., 2008). Much less attention is 
given to essential metabolic functions and factors that allow the pathogen to respond to 
the host environment, which are key to S. aureus pathogenicity. Components essential 
for growth in any environment, such as cell wall synthesis, DNA replication, 
transcription and translation proteins cannot be classed as VFs, as they are required for 
growth not just during infection. A more meaningful definition would be factors that are 
non-essential for growth in vitro, but are essential for growth in the host. The purine and 
folate biosynthesis enzymes which were the subject of Chapter 5 are clearly required for 
growth in human blood. To categorise the purine pathway enzymes as VFs would likely 
be invalid, as full growth of the purA and purB mutants could only be supported in rich 
media, and are likely a requirement in all environments faced by S. aureus outside the 
laboratory. There is some justification for labelling the folate pathway enzyme PabA a 
VF, as growth was normal in a variety of conditions (i.e. serum, plasma, CDM and rich 
media) and only exhibited reduced growth in human blood. This demonstrated that 
PABA synthesis was not essential for growth in all environments and that pabA is 
required for the virulence of S. aureus. Although PabA does not have a direct role in 
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virulence, such as adhesion, tissue damage or immune evasion, it does meet the 
definition of a VF. 
 
       9 ) V  D U H  D  E D F W H U L X P ¶s response to its environment 
 
The versatility of S. aureus in its ability to respond to the hostile and nutritionally 
dynamic environment of the host is what makes it such an effective pathogen. A 
primary purpose of infection is the acquisition of nutrients; virulence determinants are 
produced to enable this acquisition. During the early stage of a S. aureus infection 
adhesins and immune evasion proteins are expressed, often regulated by the saeRS two-
component sensor regulator system (Geiger et al., 2008; Giraudo et al., 1996). This 
allows colonisation of the infection site, while protecting the bacteria from host 
defences. At this stage of infection the bacteria will be using the available nutrients and 
synthesising those nutrients that are sequestered by the host, such as purines. As the 
bacterial load at the site of infection increases, nutrient availability decreases. S. aureus 
constitutively secretes the octapeptide AIP, at a high bacterial load it reaches a threshold 
level resulting in activation of the AgrAC two-component sensor regulator system, 
which leads to expression of RNAIII (Chien et al., 1999; Wang et al., 2014). RNAIII 
promotes downregulation of adhesins allowing migration from the site of infection to 
other areas in the body and upregulation of exoenzymes promoting tissue damage. 
Toxins such as haemolysins and PSMs are also positively regulated by the agr system 
to combat leukocytes and liberate nutrients from non-immune cells (Cheung et al., 
2011; Chien et al., 1999; Wang et al., 2014). The agr system is normally repressed in 
the early stages of infection by CodY. However, if the nutrient levels are too low to 
support growth before the AIP threshold is reached, CodY derepresses agr allowing 
expression of exoenzymes and toxins for nutrient acquisition (Pohl et al., 2009). This 
response to reduced nutrients is not unique to S. aureus, for instance toxin expression in 
the pathogen Clostridium difficile is upregulated by the TdcR protein, due to CodY 
derepression, in the absence of a readily useable carbon source (Bouillaut et al., 2014; 
Dineen et al., 2010). 
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6.3 Success of S. aureus as a pathogen 
 
As well as disease, the success of a pathogen is also mediated by its ability to move 
between hosts and survive in the environment. S. aureus produces several proteins that 
allow it to do this. These factors cannot be classed as virulence factors, but their role is 
important for successful pathogenesis. The IsdA protein binds fibrinogen, fibronectin 
and is involved in nasal colonisation, allowing adhesion to squamous nasal epithelial 
cells, and has been shown to be important for colonisation of cotton rats (Clarke et al., 
2006; Clarke et al., 2004). As discussed in Chapter 1 & Chapter 5 the Isd system is 
controlled by the negative regulator Fur, leading to repression of the isd genes in high 
iron concentrations. The results of Clarke et al. (2004, 2006) suggest that the anterior 
nares of the human host are iron limited, leading to expression of IsdA to allow 
colonisation. This demonstrates adaptation by S. aureus to its environment allowing an 
appropriate response upon recognition of the appropriate signals. Although colonisation 
of the nares primarily leads to asymptomatic infection, S. aureus is an opportunistic 
pathogen, and nasal colonisation has been shown to increase the likelihood of invasive 
infections (Von Eiff et al., 2001). 
 
The KatA and AhpC enzymes contribute to S. aureus survival in aerobic environments 
such as the nares and resistance to desiccation (Cosgrove et al., 2007). The aerobic 
environment of the nares leads to endogenous H2O2 production that can damage 
bacterial DNA. The iron regulated PerR protein responds to the low iron levels in the 
nares, promoting expression of the H2O2 scavengers KatA and AhpC (Horsburgh et al., 
2001).  Furthermore, the intermittently dry environment of the nares can lead to 
desiccation of S. aureus. ClpX and the regulatory protein SigB have also been shown by 
Tn library screening to be required for desiccation survival (Chaibenjawong & Foster, 
2011). The ability to survive desiccation is not only important for survival in the nares, 
but also allows survival outside the host and has been implicated in the spread of S. 
aureus infection in the hospital environment (Farrington et al., 1992; Rountree, 1963).  
 
6.4 The bioinformatics toolbox 
 
Bioinformatics tools can be used to mine the vast amount of sequence data found on 
biological sequence databases, allowing for a comprehensive analysis of the VFs of 
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pathogens. The purpose of my bioinformatics study was to identify a component of 
interest relatively quickly, which could then be assessed in the laboratory. The 
bioinformatics of Chapter 3 broached only the standard definition of a VF (i.e. 
components directly involved in virulence, such as toxins, adhesins and immune 
evasion proteins). The methodology was similar to that used by Barh & Kumar (2009) 
to search for essential genes in Neisseria gonorrhoeae by blastp and blastx search of the 
N. gonorrhoeae protein sequences against the Database of Essential Genes (DEG).  
 
No novel VFs were found amongst the protein sequences of S. aureus, but that is not to 
say that there was no novel VFs to find. The methodology allowed for a relatively rapid 
analysis of the S. aureus genome, to identify targets that were potentially important 
virulence determinants. Certain aspects of the bioinformatics were employed to speed 
up the process, which likely reduced the sensitivity of the analysis. Limiting the 
hypothetical protein and database sequences to those containing N-terminal signal 
sequences improved the specificity, but likely had an impact on the sensitivity of the 
method. For instance, GAPDH is a metabolic protein that catalyses one step in 
glycolysis in the cytoplasm. It possesses no signal sequence, but is also found on the 
surface of S. aureus and other pathogens and has a role in plasmin binding (Modun & 
Williams, 1999; Taylor & Heinrichs, 2002). Therefore, this metabolic protein, absent of 
a recognisable signal sequence, could have a direct role in pathogenicity through tissue 
invasion. Similar VFs, possessing no signal sequence, would not have been found in the 
analysis. 
 
The analysis highlighted the level of incorrect/outdated annotation of the sequence 
databases. The 3 target proteins that were characterised in Chapter 3 (SSL12, SSL13 
and SSL14) were annotated as hypothetical proteins, but were in fact previously 
recognised SSLs. Little was known about the function of these SSLs, therefore the 
bioinformatics succeeded in isolating 3 targets for laboratory analysis. If this had not 
been the case, other approaches could have been used to isolate proteins of interest. 
Molecular mimicry is a common tactic employed by bacteria to subvert host functions 
during infection (Doxey & McConkey, 2013; Stebbins & Galán, 2001). Mimicry is 
either at the structural level or protein sequence level. Blastp comparison of the S. 
aureus protein sequences against all human protein sequences may reveal mimicry 
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strategies employed by S. aureus that benefit the pathogen during infection. This may 
identify novel VFs or indicate the function of VFs that have already been identified. 
 
6.5 Strain libraries as tools for virulence studies 
 
The results of the SSL characterisation suggested that they may be important for 
survival in human blood. However, the evidence for this was a relatively weak assay 
and no further support for a role in human blood could be found. It was decided to 
screen the NTML on human blood agar as an alternative method of identifying genes 
required for pathogenicity. Human blood agar was considered an ideal medium for 
assessing virulence, as survival in human blood is essential for S. aureus diseases such 
as septicaemia and endocarditis. Another benefit of analysing growth on human blood 
was that it had the potential to identify types of VF that were not likely to be found 
using the bioinformatics strategy employed in Chapter 3, such as metabolic proteins that 
are essential for growth on human blood, but not in other media. 
 
The merits and disadvantages of in vivo analysis of strain libraries (IVET & STM) or in 
vivo analysis of transcription (SCOTS) are discussed in Chapter 1. Arguably these 
methods are the most effective for the analysis of proteins important for virulence, as 
they rely on analysis of bacterial gene expression, or requirement, in the host 
environment over the course of infection, rather than in vitro. In reference to this work, 
the primary disadvantage discussed in Chapter 1 is the clonal expansion of S. aureus in 
the host leading to loss of many viable strains from the in vivo assay results (McVicker 
et al., 2014; Prajsnar et al., 2012). Screening the NTML on human blood agar was 
considered a rapid alternative to these methods, allowing identification of genes 
essential for survival of S. aureus in a close approximation of a key host environment. 
 
6.6 What is known about virulence determinants in vivo? 
 
Identification of VFs is an important step in understanding the interactions between host 
and pathogen that lead to disease. Virulence factors and their known functions were 
discussed in detail in Chapter 1. Clearly, much of what is known about the mechanism 
of VFs is from in vitro analyses (Abraham & Jefferson, 2012; Higgins et al., 2006). The 
use of isogenic VF mutants verifies the requirement of a specific VF for disease, but 
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does not address what the protein does in the host, which has to be inferred from in vitro 
data. IsdA has multiple functions as an adhesin (Clarke et al., 2004), haem acquisition 
protein (Torres et al., 2010) and is important for immune evasion of secreted immune 
factors on the skin surface (Clarke et al., 2007). What is it used for in vivo? If IsdA has 
multiple functions, which function is the most essential for virulence? Is the function of 
IsdA dependent on the site of infection, demonstrating the adaptability of S. aureus to 
its host? These are interesting questions that are not broached by simple identification of 
VFs. 
 
As an academic question it is interesting to know how a particular protein functions 
while in the host environment, where host proteins may interact with it blocking or 
enhancing its function. If academic curiosity towards these difficult problems leads to a 
greater understanding of the behaviour of VFs in vivo, this will have utilitarian benefits 
allowing for targeted drug design. A need rapidly becoming pressing, due to the 
evolution of resistance to many of the antibiotics used to treat important infections. 
 
6.7 Future directions 
 
This study used an in silico homology screen and a Tn mutant library screen on human 
blood to identify proteins important for the virulence of S. aureus. Proteins from a 
family with roles in immune evasion and nutrient biosynthesis proteins were found. 
Several methods could be employed to expand on this work. Comparison of S. aureus 
genomes to identify genes required for virulence cannot provide a complete 
understanding of why one strain is more virulent than another, as many S. aureus 
proteins have no designated function and slight sequence variations between strains may 
account for enhanced activity of individual proteins (Olivas et al., 2012). However, the 
genomes of subgroups of S. aureus associated with specific outbreaks or diseases could 
be compared to highlight subtle genomic differences, such as single nucleotide 
polymorphisms (SNPs) in order to determine their impact on virulence.  
 
The Nebraska Tn mutagenesis library (NTML) is a valuable resource for the analysis of 
virulence determinants. The role of each of the 1,920 strains in pathogenicity could be 
assessed using the zebrafish embryo model of systemic infection. This work has 
highlighted the specificity of S. aureus virulence determinants, having an effect only on 
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human or a specific subset of species. Therefore, this specificity would likely lead to 
false negative results using the zebrafish model. This could be overcome using ex vivo 
human material. Multiple affects towards human cell lines could be assessed for each 
Tn disrupted gene, for example superantigenic activity towards B and T-cells, leukocyte 
apoptosis, necrosis, activation and phagocytosis. 
 
It is by a combinatorial approach that a more comprehensive understanding of the role 
of individual virulence factors can be established. This in turn will identify components 
towards which novel control regimes can be directed to combat such an important 
human pathogen. 
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